{"id":2027,"date":"2021-06-21T11:05:11","date_gmt":"2021-06-21T09:05:11","guid":{"rendered":"https:\/\/www.crct-inserm.fr\/v2\/?page_id=2027"},"modified":"2024-01-08T14:31:35","modified_gmt":"2024-01-08T13:31:35","slug":"radopt","status":"publish","type":"page","link":"https:\/\/www.crct-inserm.fr\/radopt\/","title":{"rendered":"RADOPT"},"content":{"rendered":"

[et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”a00720d8-8e3f-4b20-83b7-6d54485f541c” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”694d3d5d-3e0a-4cd1-b2ba-4eea0d99d5b4″ background_image=”https:\/\/www.crct-inserm.fr\/wp-content\/uploads\/2021\/07\/image-1-1920_1080.jpg” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”8292df69-9d3c-4423-ab4f-a4755f6c1135″ text_text_color=”#ffffff” background_enable_image=”off” width_tablet=”85%” width_phone=”95%” width_last_edited=”on|phone” custom_padding_last_edited=”off|desktop” header_font_size_phone=”31px” global_colors_info=”{}”]<\/p>\n

\u00c9quipe
Elizabeth Cohen-Jonathan Moyal<\/h1>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”448e09ae-9652-4ead-bc5f-152c7adf1202″ header_2_font=”Open Sans||||||||” global_colors_info=”{}”]<\/p>\n

RADOPT : <\/strong><\/h2>\n

Optimisation de la radioth\u00e9rapie: des voies de signalisation mol\u00e9culaires aux essais cliniques<\/strong><\/h2>\n

[\/et_pb_text][et_pb_divider _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_divider][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_2,1_2″ disabled_on=”on|on|on” _builder_version=”4.16″ _module_preset=”default” width=”50%” disabled=”on” global_colors_info=”{}”][et_pb_column type=”1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/www.crct-inserm.fr\/wp-content\/uploads\/2021\/03\/LOGO-TOUCAN-Horizontal.png” title_text=”LOGO-TOUCAN-Horizontal” disabled_on=”off|off|off” _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” text_font_size=”22px” global_colors_info=”{}”]<\/p>\n

Optimiser la radioth\u00e9rapie dans la prise en charge des patients porteurs de glioblastomes (GBM)<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”default” use_background_color_gradient=”on” background_color_gradient_stops=”rgba(43,135,218,0) 50%|#f2efef 50%” background_color_gradient_start=”rgba(43,135,218,0)” background_color_gradient_start_position=”50%” background_color_gradient_end=”#f2efef” background_color_gradient_end_position=”0%” custom_padding=”0px|||||” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” custom_padding=”0px||0px|||” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_video src=”https:\/\/youtu.be\/sPoq8iwNidY” image_src=”https:\/\/www.crct-inserm.fr\/wp-content\/uploads\/2021\/03\/video.jpg” _builder_version=”4.16″ _module_preset=”default” width=”80%” module_alignment=”center” global_colors_info=”{}”][\/et_pb_video][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”default” background_color=”#f2efef” custom_padding=”0px||0px|||” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”448e09ae-9652-4ead-bc5f-152c7adf1202″ global_colors_info=”{}”]<\/p>\n

Les sp\u00e9cificit\u00e9s
<\/strong>de notre axe de recherche<\/h2>\n

[\/et_pb_text][et_pb_divider _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_divider][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_4,1_4,1_4,1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” text_font=”Open Sans|700|||||||” text_orientation=”center” custom_margin=”||15px||false|false” custom_padding=”15px||15px||false|false” border_color_bottom=”#F19532″ border_width_left=”5px” border_color_left=”#F19532″ global_colors_info=”{}”]<\/p>\n

Radioth\u00e9rapie<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” text_font=”Open Sans|700|||||||” text_orientation=”center” custom_margin=”||15px||false|false” custom_padding=”5px||5px||false|false” border_color_bottom=”#F19532″ border_width_left=”5px” border_color_left=”#F19532″ global_colors_info=”{}”]<\/p>\n

Tumor Treating Fields (TTF)<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” text_font=”Open Sans|700|||||||” text_orientation=”center” custom_margin=”||15px||false|false” custom_padding=”15px||15px||false|false” border_color_bottom=”#F19532″ border_width_left=”5px” border_color_left=”#F19532″ global_colors_info=”{}”]<\/p>\n

recherche translationnelle<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” text_font=”Open Sans|700|||||||” text_orientation=”center” custom_margin=”||15px||false|false” custom_padding=”15px||15px||false|false” border_color_bottom=”#F19532″ border_width_left=”5px” border_color_left=”#F19532″ global_colors_info=”{}”]<\/p>\n

Cellules souches<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_4,1_4,1_4,1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” text_font=”Open Sans|700|||||||” text_orientation=”center” custom_margin=”||15px||false|false” custom_padding=”15px||15px||false|false” border_color_bottom=”#F19532″ border_width_left=”5px” border_color_left=”#F19532″ global_colors_info=”{}”]<\/p>\n

Plasticit\u00e9<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” text_font=”Open Sans|700|||||||” text_orientation=”center” custom_margin=”||15px||false|false” custom_padding=”15px||15px||false|false” border_color_bottom=”#F19532″ border_width_left=”5px” border_color_left=”#F19532″ global_colors_info=”{}”]<\/p>\n

H\u00e9t\u00e9rog\u00e9n\u00e9it\u00e9<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” text_font=”Open Sans|700|||||||” text_orientation=”center” custom_margin=”||15px||false|false” custom_padding=”15px||15px||false|false” border_color_bottom=”#F19532″ border_width_left=”5px” border_color_left=”#F19532″ global_colors_info=”{}”]<\/p>\n

M\u00e9tabolisme<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” text_font=”Open Sans|700|||||||” text_orientation=”center” custom_margin=”||15px||false|false” custom_padding=”15px||15px||false|false” border_color_bottom=”#F19532″ border_width_left=”5px” border_color_left=”#F19532″ global_colors_info=”{}”]<\/p>\n

R\u00e9sistance<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_4,1_4,1_4,1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” text_font=”Open Sans|700|||||||” text_orientation=”center” custom_margin=”||15px||false|false” custom_padding=”15px||15px||false|false” border_color_bottom=”#F19532″ border_width_left=”5px” border_color_left=”#F19532″ global_colors_info=”{}”]<\/p>\n

Traitement de l’image<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” text_font=”Open Sans|700|||||||” text_orientation=”center” custom_margin=”||15px||false|false” custom_padding=”15px||15px||false|false” border_color_bottom=”#F19532″ border_width_left=”5px” border_color_left=”#F19532″ global_colors_info=”{}”]<\/p>\n

Math\u00e9matiques et physique<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” text_font=”Open Sans|700|||||||” text_orientation=”center” custom_margin=”||15px||false|false” custom_padding=”15px||15px||false|false” border_color_bottom=”#F19532″ border_width_left=”5px” border_color_left=”#F19532″ global_colors_info=”{}”]<\/p>\n

Mod\u00e9lisation<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” text_font=”Open Sans|700|||||||” text_orientation=”center” custom_margin=”||15px||false|false” custom_padding=”15px||15px||false|false” border_color_bottom=”#F19532″ border_width_left=”5px” border_color_left=”#F19532″ global_colors_info=”{}”]<\/p>\n

Intelligence artificielle<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”448e09ae-9652-4ead-bc5f-152c7adf1202″ global_colors_info=”{}”]<\/p>\n

DES PROJETS<\/strong>
DE RECHERCHE<\/h2>\n

[\/et_pb_text][et_pb_divider _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_divider][\/et_pb_column][\/et_pb_row][et_pb_row use_custom_gutter=”on” gutter_width=”2″ _builder_version=”4.16″ _module_preset=”default” custom_padding=”||0px|||” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_blog fullwidth=”off” include_categories=”96″ use_manual_excerpt=”off” show_more=”on” show_author=”off” show_date=”off” show_categories=”off” masonry_tile_background_color=”#f2efef” _builder_version=”4.16″ _module_preset=”default” header_level=”h3″ header_font=”|800|||||||” header_font_size=”20px” body_font_size=”20px” read_more_text_color=”#5EC7ED” read_more_font_size=”20px” read_more_line_height=”3em” background_enable_color=”off” border_width_all=”0px” global_colors_info=”{}”][\/et_pb_blog][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”off|off|off” _builder_version=”4.16″ _module_preset=”default” custom_padding=”||0px|||” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”448e09ae-9652-4ead-bc5f-152c7adf1202″ global_colors_info=”{}”]<\/p>\n

LES FOCUS<\/strong>
DE L\u2019\u00c9QUIPE<\/h2>\n

[\/et_pb_text][et_pb_divider _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_divider][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”off|off|off” _builder_version=”4.16″ _module_preset=”default” use_background_color_gradient=”on” background_color_gradient_stops=”#ffffff 50%|rgba(174,227,246,0) 50%” background_color_gradient_overlays_image=”on” background_color_gradient_start=”#ffffff” background_color_gradient_start_position=”50%” background_color_gradient_end=”rgba(174,227,246,0)” background_color_gradient_end_position=”0%” background_image=”https:\/\/www.crct-inserm.fr\/wp-content\/uploads\/2021\/03\/Filets-bleu-actu.png” background_size=”contain” background_position=”bottom_center” custom_padding=”0px|||||” saved_tabs=”all” global_colors_info=”{}”][et_pb_row column_structure=”1_3,1_3,1_3″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_3″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”4ae3b26e-eab0-4b6f-bd7b-05f173fca79b” custom_margin=”||-4px||false|false” header_font_size_tablet=”” header_font_size_phone=”” header_font_size_last_edited=”on|desktop” header_2_font_size_tablet=”” header_2_font_size_phone=”” header_2_font_size_last_edited=”on|desktop” header_4_font_size_tablet=”” header_4_font_size_phone=”” header_4_font_size_last_edited=”on|desktop” global_colors_info=”{}”]<\/p>\n

D\u00e9couvrir<\/h4>\n

[\/et_pb_text][et_pb_post_slider posts_number=”5″ include_categories=”1002″ show_arrows=”off” use_manual_excerpt=”off” excerpt_length=”0″ show_meta=”off” image_placement=”top” use_bg_overlay=”off” use_text_overlay=”off” dot_nav_custom_color=”#5EC7ED” _builder_version=”4.16″ _module_preset=”412cf9f9-c22e-468d-92e3-f93d454642a9″ header_font=”Open Sans|600|||||||” header_text_color=”#5EC7ED” header_font_size=”20px” header_line_height=”1.2em” body_font=”Open Sans||||||||” body_text_align=”left” body_text_color=”#505659″ body_font_size=”18px” background_color=”#FFFFFF” custom_button=”on” button_text_size=”18px” button_bg_color=”#5EC7ED” button_border_width=”0px” button_border_radius=”0px” button_use_icon=”off” button_alignment=”center” button_custom_margin=”20px||0px||false|false” button_custom_padding=”10px|50px|10px|50px|true|true” custom_padding=”0px|||||” header_font_size_tablet=”” header_font_size_phone=”22px” header_font_size_last_edited=”on|phone” body_font_size_tablet=”” body_font_size_phone=”18px” body_font_size_last_edited=”on|phone” border_color_all_image=”#ffffff” border_width_bottom_image=”15px” text_shadow_style=”preset4″ text_shadow_vertical_length=”0em” global_colors_info=”{}”][\/et_pb_post_slider][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text disabled_on=”off|off|off” _builder_version=”4.16″ _module_preset=”4ae3b26e-eab0-4b6f-bd7b-05f173fca79b” custom_margin=”||-3px||false|false” global_colors_info=”{}”]<\/p>\n

Comprendre<\/h4>\n

[\/et_pb_text][et_pb_post_slider posts_number=”5″ include_categories=”1188,1216″ show_arrows=”off” use_manual_excerpt=”off” excerpt_length=”0″ show_meta=”off” image_placement=”top” use_bg_overlay=”off” use_text_overlay=”off” dot_nav_custom_color=”#5EC7ED” show_image_tablet=”” show_image_phone=”” show_image_last_edited=”on|phone” disabled_on=”off|off|off” _builder_version=”4.19.0″ _module_preset=”default” header_font=”Open Sans|600|||||||” header_text_color=”#5EC7ED” header_font_size=”20px” header_line_height=”1.2em” body_font=”Open Sans||||||||” body_text_align=”left” body_text_color=”#505659″ body_font_size=”18px” background_color=”#FFFFFF” custom_button=”on” button_text_size=”18px” button_bg_color=”#5EC7ED” button_border_width=”0px” button_border_radius=”0px” button_use_icon=”off” button_alignment=”center” button_custom_margin=”20px||0px||false|false” button_custom_padding=”10px|50px|10px|50px|true|true” custom_padding=”0px|||||” header_font_size_tablet=”” header_font_size_phone=”22px” header_font_size_last_edited=”on|phone” border_width_bottom_image=”15px” border_color_bottom_image=”#ffffff” text_shadow_style=”preset4″ text_shadow_vertical_length=”0em” global_colors_info=”{}”][\/et_pb_post_slider][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text disabled_on=”off|off|off” _builder_version=”4.16″ _module_preset=”4ae3b26e-eab0-4b6f-bd7b-05f173fca79b” custom_margin=”||-4px||false|false” global_colors_info=”{}”]<\/p>\n

Participer<\/h4>\n

[\/et_pb_text][et_pb_post_slider posts_number=”5″ include_categories=”1261,1319″ show_arrows=”off” use_manual_excerpt=”off” excerpt_length=”0″ show_meta=”off” image_placement=”top” use_bg_overlay=”off” use_text_overlay=”off” dot_nav_custom_color=”#5EC7ED” disabled_on=”off|off|off” _builder_version=”4.21.0″ _module_preset=”default” header_font=”Open Sans|600|||||||” header_text_color=”#5EC7ED” header_font_size=”20px” header_line_height=”1.2em” body_font=”Open Sans||||||||” body_text_align=”left” body_text_color=”#505659″ body_font_size=”18px” background_color=”#FFFFFF” custom_button=”on” button_text_size=”18px” button_bg_color=”#5EC7ED” button_border_width=”0px” button_border_radius=”0px” button_use_icon=”off” button_alignment=”center” button_custom_margin=”20px||0px||false|false” button_custom_padding=”10px|50px|10px|50px|true|true” custom_padding=”0px|||||” header_font_size_tablet=”” header_font_size_phone=”22px” header_font_size_last_edited=”on|phone” body_font_size_tablet=”” body_font_size_phone=”18px” body_font_size_last_edited=”on|phone” border_width_bottom_image=”15px” border_color_bottom_image=”#ffffff” text_shadow_style=”preset4″ text_shadow_vertical_length=”0em” global_colors_info=”{}”][\/et_pb_post_slider][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”off|off|off” _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”448e09ae-9652-4ead-bc5f-152c7adf1202″ global_colors_info=”{}”]<\/p>\n

En live<\/h2>\n

[\/et_pb_text][et_pb_divider _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_divider][et_pb_code _builder_version=”4.22.1″ _module_preset=”default” global_colors_info=”{}”]\n\n

\n\t
\n
\n
\n\t\t\t\t\tLe flux Twitter n\u2019est pas disponible pour le moment. <\/div>\n <\/div>\n <\/div>\n\t\t\n \n
\n <\/div>\n\n <\/span>\n<\/div>\n[\/et_pb_code][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”default” background_color=”#f2efef” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”448e09ae-9652-4ead-bc5f-152c7adf1202″ global_colors_info=”{}”]<\/p>\n

PRODUCTIONS SCIENTIFIQUES<\/strong><\/h2>\n

[\/et_pb_text][et_pb_divider _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_divider][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_toggle title=”PUBLICATIONS 2024″ open=”on” open_toggle_text_color=”#5EC7ED” open_toggle_background_color=”#ffffff” closed_toggle_text_color=”#505659″ closed_toggle_background_color=”#AEE3F6″ icon_color=”#505659″ open_icon_color=”#505659″ _builder_version=”4.22.1″ _module_preset=”default” title_text_color=”#ffffff” title_font=”|600||on|||||” title_text_align=”center” title_font_size=”22px” closed_title_font=”|600|||||||” closed_title_font_size=”22px” body_text_align=”left” body_text_color=”#505659″ body_font_size=”16px” text_orientation=”center” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n

\n\n\t\t7813506<\/span>\n\t\t<\/span>\n\t\tMCWU4QSQ<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t2024<\/span>\n <\/span>\n items<\/span>\n\t\t1<\/span>\n\t\tchicago-fullnote-bibliography<\/span>\n\t\t0<\/span>\n\t\tdefault<\/span>\n\t\tasc<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n <\/span>\n 2027<\/span>\n\t\thttps:\/\/www.crct-inserm.fr\/wp-content\/plugins\/zotpress\/<\/span>\n\n\t\t
\n\t\t\t
\n\t\t\t\t%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-0fe2be5da59c01a39baa9b6c369981e7%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22E3VUJ9NV%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Tauzi%5Cu00e8de-Espariat%20et%20al.%22%2C%22parsedDate%22%3A%222024-04-05%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ETauzi%26%23xE8%3Bde-Espariat%2C%20Arnault%2C%20Yvan%20Nicaise%2C%20Philipp%20Sievers%2C%20Felix%20Sahm%2C%20Andreas%20von%20Deimling%2C%20Delphine%20Guillemot%2C%20Ga%26%23xEB%3Blle%20Pierron%2C%20et%20al.%20%26%23x201C%3BCNS%20Tumors%20with%20PLAGL1-Fusion%3A%20Beyond%20ZFTA%20and%20YAP1%20in%20the%20Genetic%20Spectrum%20of%20Supratentorial%20Ependymomas.%26%23x201D%3B%20%3Ci%3EActa%20Neuropathologica%20Communications%3C%5C%2Fi%3E%2012%2C%20no.%201%20%28April%205%2C%202024%29%3A%2055.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs40478-023-01695-7%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs40478-023-01695-7%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22CNS%20tumors%20with%20PLAGL1-fusion%3A%20beyond%20ZFTA%20and%20YAP1%20in%20the%20genetic%20spectrum%20of%20supratentorial%20ependymomas%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnault%22%2C%22lastName%22%3A%22Tauzi%5Cu00e8de-Espariat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yvan%22%2C%22lastName%22%3A%22Nicaise%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philipp%22%2C%22lastName%22%3A%22Sievers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Felix%22%2C%22lastName%22%3A%22Sahm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andreas%22%2C%22lastName%22%3A%22von%20Deimling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Delphine%22%2C%22lastName%22%3A%22Guillemot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ga%5Cu00eblle%22%2C%22lastName%22%3A%22Pierron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Duchesne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Myriam%22%2C%22lastName%22%3A%22Edjlali%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Volodia%22%2C%22lastName%22%3A%22Dangouloff-Ros%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Boddaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandre%22%2C%22lastName%22%3A%22Roux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edouard%22%2C%22lastName%22%3A%22Dezamis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lauren%22%2C%22lastName%22%3A%22Hasty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beno%5Cu00eet%22%2C%22lastName%22%3A%22Lhermitte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edouard%22%2C%22lastName%22%3A%22Hirsch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20Paola%20Valenti%22%2C%22lastName%22%3A%22Hirsch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois-Daniel%22%2C%22lastName%22%3A%22Ardellier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%5Cu00e9lodie-Anne%22%2C%22lastName%22%3A%22Karnoub%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Csanyi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claude-Alain%22%2C%22lastName%22%3A%22Maurage%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karima%22%2C%22lastName%22%3A%22Mokhtari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franck%22%2C%22lastName%22%3A%22Bielle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Rigau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Roujeau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marine%22%2C%22lastName%22%3A%22Abad%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%5Cu00e9bastien%22%2C%22lastName%22%3A%22Klein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mich%5Cu00e8le%22%2C%22lastName%22%3A%22Bernier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Horodyckid%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clovis%22%2C%22lastName%22%3A%22Adam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Petter%22%2C%22lastName%22%3A%22Brandal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pitt%22%2C%22lastName%22%3A%22Niehusmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Quentin%22%2C%22lastName%22%3A%22Vannod-Michel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corentin%22%2C%22lastName%22%3A%22Provost%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%20Menjot%22%2C%22lastName%22%3A%22de%20Champfleur%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucia%22%2C%22lastName%22%3A%22Nichelli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alice%22%2C%22lastName%22%3A%22M%5Cu00e9tais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cassandra%22%2C%22lastName%22%3A%22Mariet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrice%22%2C%22lastName%22%3A%22Chr%5Cu00e9tien%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Blauwblomme%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%5Cu00e9vin%22%2C%22lastName%22%3A%22Beccaria%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Johan%22%2C%22lastName%22%3A%22Pallud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Puget%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Uro-Coste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascale%22%2C%22lastName%22%3A%22Varlet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22RENOCLIP-LOC%22%7D%5D%2C%22abstractNote%22%3A%22A%20novel%20methylation%20class%2C%20%5C%22neuroepithelial%20tumor%2C%20with%20PLAGL1%20fusion%5C%22%20%28NET-PLAGL1%29%2C%20has%20recently%20been%20described%2C%20based%20on%20epigenetic%20features%2C%20as%20a%20supratentorial%20pediatric%20brain%20tumor%20with%20recurrent%20histopathological%20features%20suggesting%20an%20ependymal%20differentiation.%20Because%20of%20the%20recent%20identification%20of%20this%20neoplastic%20entity%2C%20few%20histopathological%2C%20radiological%20and%20clinical%20data%20are%20available.%20Herein%2C%20we%20present%20a%20detailed%20series%20of%20nine%20cases%20of%20PLAGL1-fused%20supratentorial%20tumors%2C%20reclassified%20from%20a%20series%20of%20supratentorial%20ependymomas%2C%20non-ZFTA%5C%2Fnon-YAP1%20fusion-positive%20and%20subependymomas%20of%20the%20young.%20This%20study%20included%20extensive%20clinical%2C%20radiological%2C%20histopathological%2C%20ultrastructural%2C%20immunohistochemical%2C%20genetic%20and%20epigenetic%20%28DNA%20methylation%20profiling%29%20data%20for%20characterization.%20An%20important%20aim%20of%20this%20work%20was%20to%20evaluate%20the%20sensitivity%20and%20specificity%20of%20a%20novel%20fluorescent%20in%20situ%20hybridization%20%28FISH%29%20targeting%20the%20PLAGL1%20gene.%20Using%20histopathology%2C%20immunohistochemistry%20and%20electron%20microscopy%2C%20we%20confirmed%20the%20ependymal%20differentiation%20of%20this%20new%20neoplastic%20entity.%20Indeed%2C%20the%20cases%20histopathologically%20presented%20as%20%5C%22mixed%20subependymomas-ependymomas%5C%22%20with%20well-circumscribed%20tumors%20exhibiting%20a%20diffuse%20immunoreactivity%20for%20GFAP%2C%20without%20expression%20of%20Olig2%20or%20SOX10.%20Ultrastructurally%2C%20they%20also%20harbored%20features%20reminiscent%20of%20ependymal%20differentiation%2C%20such%20as%20cilia.%20Different%20gene%20partners%20were%20fused%20with%20PLAGL1%3A%20FOXO1%2C%20EWSR1%20and%20for%20the%20first%20time%20MAML2.%20The%20PLAGL1%20FISH%20presented%20a%20100%25%20sensitivity%20and%20specificity%20according%20to%20RNA%20sequencing%20and%20DNA%20methylation%20profiling%20results.%20This%20cohort%20of%20supratentorial%20PLAGL1-fused%20tumors%20highlights%3A%201%5C%2F%20the%20ependymal%20cell%20origin%20of%20this%20new%20neoplastic%20entity%3B%202%5C%2F%20benefit%20of%20looking%20for%20a%20PLAGL1%20fusion%20in%20supratentorial%20cases%20of%20non-ZFTA%5C%2Fnon-YAP1%20ependymomas%3B%20and%203%5C%2F%20the%20usefulness%20of%20PLAGL1%20FISH.%22%2C%22date%22%3A%222024-04-05%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs40478-023-01695-7%22%2C%22ISSN%22%3A%222051-5960%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222024-04-09T10%3A27%3A00Z%22%7D%7D%2C%7B%22key%22%3A%22A4KZUU2B%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Picca%20et%20al.%22%2C%22parsedDate%22%3A%222024-03-22%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EPicca%2C%20Alberto%2C%20Mehdi%20Touat%2C%20Lisa%20Belin%2C%20Carole%20Gourmelon%2C%20Vincent%20Harlay%2C%20Stefania%20Cuzzubbo%2C%20Elizabeth%20Cohen-Jonathan%20Moyal%2C%20et%20al.%20%26%23x201C%3BREVOLUMAB%3A%20A%20Phase%20II%20Trial%20of%20Nivolumab%20in%20Recurrent%20IDH%20Mutant%20High-Grade%20Gliomas.%26%23x201D%3B%20%3Ci%3EEuropean%20Journal%20of%20Cancer%20%28Oxford%2C%20England%3A%201990%29%3C%5C%2Fi%3E%20202%20%28March%2022%2C%202024%29%3A%20114034.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ejca.2024.114034%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ejca.2024.114034%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22REVOLUMAB%3A%20A%20phase%20II%20trial%20of%20nivolumab%20in%20recurrent%20IDH%20mutant%20high-grade%20gliomas%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alberto%22%2C%22lastName%22%3A%22Picca%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mehdi%22%2C%22lastName%22%3A%22Touat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lisa%22%2C%22lastName%22%3A%22Belin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carole%22%2C%22lastName%22%3A%22Gourmelon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Harlay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefania%22%2C%22lastName%22%3A%22Cuzzubbo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Cohen-Jonathan%20Moyal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Bronnimann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%20Luisa%22%2C%22lastName%22%3A%22Di%20Stefano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isaura%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Lerond%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Carpentier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franck%22%2C%22lastName%22%3A%22Bielle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Ducray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Dehais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22POLA%20Network%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Novel%20effective%20treatments%20are%20needed%20for%20recurrent%20IDH%20mutant%20high-grade%20gliomas%20%28IDHm%20HGGs%29.%20The%20aim%20of%20the%20multicentric%2C%20single-arm%2C%20phase%20II%20REVOLUMAB%20trial%20%28NCT03925246%29%20was%20to%20assess%20the%20efficacy%20and%20safety%20of%20the%20anti-PD1%20Nivolumab%20in%20patients%20with%20recurrent%20IDHm%20HGGs.%5CnPATIENTS%20AND%20METHODS%3A%20Adult%20patients%20with%20IDHm%20WHO%20grade%203-4%20gliomas%20recurring%20after%20radiotherapy%20and%20%5Cu2265%5Cu00a01%20line%20of%20alkylating%20chemotherapy%20were%20treated%20with%20intravenous%20Nivolumab%20until%20end%20of%20treatment%20%2812%20months%29%2C%20progression%2C%20unacceptable%20toxicity%2C%20or%20death.%20The%20primary%20endpoint%20was%20the%2024-week%20progression-free%20survival%20rate%20%2824w-PFS%29%20according%20to%20RANO%20criteria.%5CnRESULTS%3A%20From%20July%202019%20to%20June%202020%2C%2039%20patients%20with%20recurrent%20IDHm%20HGGs%20%28twenty-one%20grade%203%2C%20thirteen%20grade%204%2C%20five%20grade%202%20with%20radiological%20evidence%20of%20anaplastic%20transformation%3B%2039%25%201p%5C%2F19q%20codeleted%29%20were%20enrolled.%20Median%20time%20since%20diagnosis%20was%205.7%20years%2C%20and%20the%20median%20number%20of%20previous%20systemic%20treatments%20was%20two.%20The%2024w-PFS%20was%2028.2%25%20%2811%5C%2F39%2C%20CI95%25%2015-44.9%25%29.%20Median%20PFS%20and%20OS%20were%201.84%20%28CI95%25%201.81-5.89%29%20and%2014.7%20months%20%28CI95%25%209.18-NR%29%2C%20respectively.%20Four%20patients%20%2810.3%25%29%20achieved%20partial%20response%20according%20to%20RANO%20criteria.%20There%20were%20no%20significant%20differences%20in%20clinical%20or%20histomolecular%20features%20between%20responders%20and%20non-responders.%20The%20safety%20profile%20of%20Nivolumab%20was%20consistent%20with%20prior%20studies.%5CnCONCLUSIONS%3A%20We%20report%20the%20results%20of%20the%20first%20trial%20of%20immune%20checkpoint%20inhibitors%20in%20IDHm%20gliomas.%20Nivolumab%20failed%20to%20achieve%20its%20primary%20endpoint.%20However%2C%20treatment%20was%20well%20tolerated%2C%20and%20long-lasting%20responses%20were%20observed%20in%20a%20subset%20of%20patients%2C%20supporting%20further%20evaluation%20in%20combination%20with%20other%20agents%20%28e.g.%20IDH%20inhibitors%29.%22%2C%22date%22%3A%222024-03-22%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ejca.2024.114034%22%2C%22ISSN%22%3A%221879-0852%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222024-03-28T10%3A34%3A43Z%22%7D%7D%2C%7B%22key%22%3A%22VDTBISRD%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Laprie%20et%20al.%22%2C%22parsedDate%22%3A%222024-01-05%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELaprie%2C%20Anne%2C%20Georges%20Noel%2C%20Leonor%20Chaltiel%2C%20Gilles%20Truc%2C%20Marie-Pierre%20Sunyach%2C%20Marie%20Charissoux%2C%20Nicolas%20Magne%2C%20et%20al.%20%26%23x201C%3BRandomized%20Phase%20III%20Trial%20of%20Metabolic%20Imaging-Guided%20Dose%20Escalation%20of%20Radio-Chemotherapy%20in%20Patients%20with%20Newly%20Diagnosed%20Glioblastoma%20%28SPECTRO%20GLIO%20Trial%29.%26%23x201D%3B%20%3Ci%3ENeuro-Oncology%3C%5C%2Fi%3E%2026%2C%20no.%201%20%28January%205%2C%202024%29%3A%20153%26%23x2013%3B63.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fneuonc%5C%2Fnoad119%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fneuonc%5C%2Fnoad119%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Randomized%20phase%20III%20trial%20of%20metabolic%20imaging-guided%20dose%20escalation%20of%20radio-chemotherapy%20in%20patients%20with%20newly%20diagnosed%20glioblastoma%20%28SPECTRO%20GLIO%20trial%29%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Laprie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Georges%22%2C%22lastName%22%3A%22Noel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leonor%22%2C%22lastName%22%3A%22Chaltiel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Truc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Pierre%22%2C%22lastName%22%3A%22Sunyach%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Charissoux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Magne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Auberdiac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julian%22%2C%22lastName%22%3A%22Biau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sol%5Cu00e9akh%5Cu00e9na%22%2C%22lastName%22%3A%22Ken%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fatima%22%2C%22lastName%22%3A%22Tensaouti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Khalifa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ingrid%22%2C%22lastName%22%3A%22Sidibe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franck-Emmanuel%22%2C%22lastName%22%3A%22Roux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Vieillevigne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Catalaa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sergio%22%2C%22lastName%22%3A%22Boetto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Uro-Coste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phane%22%2C%22lastName%22%3A%22Supiot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Bernier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Filleron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Muriel%22%2C%22lastName%22%3A%22Mounier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Muriel%22%2C%22lastName%22%3A%22Poublanc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascale%22%2C%22lastName%22%3A%22Olivier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Pierre%22%2C%22lastName%22%3A%22Delord%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Cohen-Jonathan-Moyal%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Glioblastoma%20%28GBM%29%20systematically%20recurs%20after%20a%20standard%2060%20Gy%20radio-chemotherapy%20regimen.%20Since%20magnetic%20resonance%20spectroscopic%20imaging%20%28MRSI%29%20has%20been%20shown%20to%20predict%20the%20site%20of%20relapse%2C%20we%20analyzed%20the%20effect%20of%20MRSI-guided%20dose%20escalation%20on%20overall%20survival%20%28OS%29%20of%20patients%20with%20newly%20diagnosed%20GBM.%5CnMETHODS%3A%20In%20this%20multicentric%20prospective%20phase%20III%20trial%2C%20patients%20who%20had%20undergone%20biopsy%20or%20surgery%20for%20a%20GBM%20were%20randomly%20assigned%20to%20a%20standard%20dose%20%28SD%29%20of%2060%20Gy%20or%20a%20high%20dose%20%28HD%29%20of%2060%20Gy%20with%20an%20additional%20simultaneous%20integrated%20boost%20totaling%2072%20Gy%20to%20MRSI%20metabolic%20abnormalities%2C%20the%20tumor%20bed%20and%20residual%20contrast%20enhancements.%20Temozolomide%20was%20administered%20concomitantly%20and%20maintained%20for%206%20months%20thereafter.%5CnRESULTS%3A%20One%20hundred%20and%20eighty%20patients%20were%20included%20in%20the%20study%20between%20March%202011%20and%20March%202018.%20After%20a%20median%20follow-up%20of%2043.9%20months%20%2895%25%20CI%20%5B42.5%3B%2045.5%5D%29%2C%20median%20OS%20was%2022.6%20months%20%2895%25%20CI%20%5B18.9%3B%2025.4%5D%29%20versus%2022.2%20months%20%2895%25%20CI%20%5B18.3%3B%2027.8%5D%29%20for%20HD%2C%20and%20median%20progression-free%20survival%20was%208.6%20%2895%25%20CI%20%5B6.8%3B%2010.8%5D%29%20versus%207.8%20months%20%2895%25%20CI%20%5B6.3%3B%208.6%5D%29%2C%20in%20SD%20versus%20HD%2C%20respectively.%20No%20increase%20in%20toxicity%20rate%20was%20observed%20in%20the%20study%20arm.%20The%20pseudoprogression%20rate%20was%20similar%20across%20the%20SD%20%2814.4%25%29%20and%20HD%20%2816.7%25%29%20groups.%20For%20O%286%29-methylguanine-DNA%20methyltransferase%20%28MGMT%29%20methylated%20patients%2C%20the%20median%20OS%20was%2038%20months%20%2895%25%20CI%20%5B23.2%3B%20NR%5D%29%20for%20HD%20patients%20versus%2028.5%20months%20%2895%25%20CI%20%5B21.1%3B%2035.7%5D%29%20for%20SD%20patients.%5CnCONCLUSION%3A%20The%20additional%20MRSI-guided%20irradiation%20dose%20totaling%2072%20Gy%20was%20well%20tolerated%20but%20did%20not%20improve%20OS%20in%20newly%20diagnosed%20GBM.%5CnTRIAL%20REGISTRATION%3A%20NCT01507506%3B%20registration%20date%3A%20December%2020%2C%202011.%20https%3A%5C%2F%5C%2Fclinicaltrials.gov%5C%2Fct2%5C%2Fshow%5C%2FNCT01507506%3Fcond%3DNCT01507506%26rank%3D1.%22%2C%22date%22%3A%222024-01-05%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1093%5C%2Fneuonc%5C%2Fnoad119%22%2C%22ISSN%22%3A%221523-5866%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222024-02-06T14%3A01%3A40Z%22%7D%7D%5D%7D<\/span>\n\n\t\t\t\t
\n
\n
Tauziède-Espariat, Arnault, Yvan Nicaise, Philipp Sievers, Felix Sahm, Andreas von Deimling, Delphine Guillemot, Gaëlle Pierron, et al. “CNS Tumors with PLAGL1-Fusion: Beyond ZFTA and YAP1 in the Genetic Spectrum of Supratentorial Ependymomas.” Acta Neuropathologica Communications<\/i> 12, no. 1 (April 5, 2024): 55. https:\/\/doi.org\/10.1186\/s40478-023-01695-7<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Picca, Alberto, Mehdi Touat, Lisa Belin, Carole Gourmelon, Vincent Harlay, Stefania Cuzzubbo, Elizabeth Cohen-Jonathan Moyal, et al. “REVOLUMAB: A Phase II Trial of Nivolumab in Recurrent IDH Mutant High-Grade Gliomas.” European Journal of Cancer (Oxford, England: 1990)<\/i> 202 (March 22, 2024): 114034. https:\/\/doi.org\/10.1016\/j.ejca.2024.114034<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Laprie, Anne, Georges Noel, Leonor Chaltiel, Gilles Truc, Marie-Pierre Sunyach, Marie Charissoux, Nicolas Magne, et al. “Randomized Phase III Trial of Metabolic Imaging-Guided Dose Escalation of Radio-Chemotherapy in Patients with Newly Diagnosed Glioblastoma (SPECTRO GLIO Trial).” Neuro-Oncology<\/i> 26, no. 1 (January 5, 2024): 153–63. https:\/\/doi.org\/10.1093\/neuonc\/noad119<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n\n\n

[\/et_pb_toggle][et_pb_toggle title=”PUBLICATIONS 2023″ open_toggle_text_color=”#5EC7ED” open_toggle_background_color=”#ffffff” closed_toggle_text_color=”#505659″ closed_toggle_background_color=”#AEE3F6″ icon_color=”#505659″ open_icon_color=”#505659″ _builder_version=”4.22.1″ _module_preset=”default” title_text_color=”#ffffff” title_font=”|600||on|||||” title_text_align=”center” title_font_size=”22px” closed_title_font=”|600|||||||” closed_title_font_size=”22px” body_text_align=”left” body_text_color=”#505659″ body_font_size=”16px” text_orientation=”center” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n

\n\n\t\t7813506<\/span>\n\t\t<\/span>\n\t\tMCWU4QSQ<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t2023<\/span>\n <\/span>\n items<\/span>\n\t\t1<\/span>\n\t\tchicago-fullnote-bibliography<\/span>\n\t\t0<\/span>\n\t\tdefault<\/span>\n\t\tasc<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n <\/span>\n 2027<\/span>\n\t\thttps:\/\/www.crct-inserm.fr\/wp-content\/plugins\/zotpress\/<\/span>\n\n\t\t
\n\t\t\t
\n\t\t\t\t%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-2ca659fbfa5e20ed8544776a67b747e7%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22L36EP2C6%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Uro-Coste%20et%20al.%22%2C%22parsedDate%22%3A%222023-11-23%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EUro-Coste%2C%20Emmanuelle%2C%20Arnault%20Tauziede-Espariat%2C%20Charlotte%20Dubucs%2C%20Dan%20Christian%20Chiforeanu%2C%20Aurore%20Siegfried%2C%20Yvan%20Nicaise%2C%20Luc%20Bauchet%2C%20et%20al.%20%26%23x201C%3BTwo%20Novel%20Tumours%20with%20NTRK2%20Fusion%20in%20the%20Methylation%20Class%20of%20Extraventricular%20Neurocytomas%2C%20Including%20One%20Intraventricular.%26%23x201D%3B%20%3Ci%3EBrain%20Pathology%20%28Zurich%2C%20Switzerland%29%3C%5C%2Fi%3E%2C%20November%2023%2C%202023%2C%20e13223.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fbpa.13223%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fbpa.13223%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Two%20novel%20tumours%20with%20NTRK2%20fusion%20in%20the%20methylation%20class%20of%20extraventricular%20neurocytomas%2C%20including%20one%20intraventricular%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Uro-Coste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnault%22%2C%22lastName%22%3A%22Tauziede-Espariat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Dubucs%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dan%20Christian%22%2C%22lastName%22%3A%22Chiforeanu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aurore%22%2C%22lastName%22%3A%22Siegfried%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yvan%22%2C%22lastName%22%3A%22Nicaise%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luc%22%2C%22lastName%22%3A%22Bauchet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Riffaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franck%22%2C%22lastName%22%3A%22Bielle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandre%22%2C%22lastName%22%3A%22Vasiljevic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Appay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sol%5Cu00e8ne%22%2C%22lastName%22%3A%22Evrard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascale%22%2C%22lastName%22%3A%22Varlet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Rigau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Biopathology%20RENOCLIP-LOC%20network%22%7D%5D%2C%22abstractNote%22%3A%22We%20report%20here%20about%20two%20novel%20tumours%20classified%20as%20extraventricular%20neurocytomas%20%28EVN%29%20using%20DNA-methylation%20profiling%2C%20associated%20with%20NTRK2%20fusions%20instead%20of%20the%20usual%20FGFR1%20alterations%20so%20far%20attributed%20to%20this%20tumoural%20entity.%20We%20present%20the%20second%20detailed%20case%20of%20an%20intraventricular%20presentation%20in%20the%20MC%20EVN.%20Our%20findings%20broaden%20the%20spectrum%20of%20MC%20EVN%20and%20have%20implications%20in%20terms%20of%20diagnosis%2C%20therapy%20and%20terminology.%22%2C%22date%22%3A%222023-11-23%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1111%5C%2Fbpa.13223%22%2C%22ISSN%22%3A%221750-3639%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222024-04-16T10%3A23%3A19Z%22%7D%7D%2C%7B%22key%22%3A%22T34NA8CX%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Younes%20et%20al.%22%2C%22parsedDate%22%3A%222023-10%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EYounes%2C%20Tony%2C%20Fr%26%23xE9%3Bd%26%23xE9%3Bric%20Chatrie%2C%20Marianne%20Zinutti%2C%20Luc%20Simon%2C%20Georges%20Fares%2C%20and%20Laure%20Vieillevigne.%20%26%23x201C%3BOptimization%20of%20the%20Eclipse%20TPS%20Beam%20Configuration%20Parameters%20for%20Small%20Field%20Dosimetry%20Using%20Monte%20Carlo%20Simulations%20and%20Experimental%20Measurements.%26%23x201D%3B%20%3Ci%3EPhysica%20Medica%3A%20PM%3A%20An%20International%20Journal%20Devoted%20to%20the%20Applications%20of%20Physics%20to%20Medicine%20and%20Biology%3A%20Official%20Journal%20of%20the%20Italian%20Association%20of%20Biomedical%20Physics%20%28AIFB%29%3C%5C%2Fi%3E%20114%20%28October%202023%29%3A%20103141.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ejmp.2023.103141%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ejmp.2023.103141%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Optimization%20of%20the%20Eclipse%20TPS%20beam%20configuration%20parameters%20for%20small%20field%20dosimetry%20using%20Monte%20Carlo%20simulations%20and%20experimental%20measurements%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tony%22%2C%22lastName%22%3A%22Younes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Chatrie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marianne%22%2C%22lastName%22%3A%22Zinutti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luc%22%2C%22lastName%22%3A%22Simon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Georges%22%2C%22lastName%22%3A%22Fares%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Vieillevigne%22%7D%5D%2C%22abstractNote%22%3A%22PURPOSE%3A%20To%20evaluate%20the%20impact%20of%20tuning%20the%20beam%20configurations%20parameters%20on%20the%20Analytical%20Anisotropic%20Algorithm%20%28AAA%29%20and%20the%20Acuros%20XB%20%28AXB%29%20algorithm%20for%20small%20fields%20using%20Monte%20Carlo%20simulations%20and%20measurements.%5CnMETHODS%3A%20The%20TrueBeam%20STx%20with%20the%20high-definition%20120%20multi-leaf%20collimator%20%28HD120-MLC%29%20was%20modeled%20with%20Geant4%20application%20for%20emission%20tomography%20%28GATE%29%20Monte%20Carlo%20platform%20and%20validated%20against%20measurements.%20The%20impact%20of%20varying%20the%20effective%20spot%20size%20%28ESS%29%20and%20dosimetric%20leaf%20gap%20%28DLG%29%20on%20AAA%20and%20AXB%20calculations%20was%20carried%20out%20for%20small%20MLC-fields%20ranging%20from%200.5%5Cu00d70.5%20cm2%20to%203%20%5Cu00d7%203%20cm2.%20Beam%20penumbras%2C%20field%20sizes%20and%20output%20factors%20calculated%20by%20AAA%20and%20AXB%20were%20compared%20to%20GATE%20calculations%20and%20measurements.%5CnRESULTS%3A%20The%20beam%20penumbra%20comparisons%20showed%20that%20the%20best%20ESS%20value%20for%20AXB%20was%20about%201.0%20mm%20in%20the%20crossplane%20direction%20and%200.5%20mm%20in%20the%20inplane%20direction.%20By%20optimizing%20the%20ESS%20values%2C%20AXB%20could%20provide%20output%20factor%20results%20almost%20within%202%25%20of%20GATE%20calculations%20and%20measurements%20for%20fields%20down%20to%200.5%5Cu00d70.5%20cm2.%20For%20AAA%2C%20significant%20output%20factor%20differences%20were%20observed%20for%20all%20ESS%20values%20and%20tuning%20the%20DLG%20in%20addition%20to%20the%20ESS%20optimization%20resulted%20in%20an%20absorbed%20dose%20difference%20of%20less%20than%202.5%25%20for%20MLC-fields%20down%20to%201%20%5Cu00d7%201%20cm2.%5CnCONCLUSION%3A%20By%20optimizing%20the%20ESS%20values%2C%20AXB%20can%20achieve%20accurate%20output%20factors%20in%20the%20case%20of%20small%20MLC-fields%20without%20the%20need%20of%20DLG%20tuning.%20Nevertheless%2C%20compromises%20between%20the%20output%20factor%2C%20DLG%20and%20ESS%20values%20were%20found%20necessary%20for%20AAA%20calculations.%20A%20MLC%20model%20improvement%20would%20allow%20to%20avoid%20the%20complexity%20related%20to%20tuning%20the%20configuration%20parameters.%22%2C%22date%22%3A%222023-10%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ejmp.2023.103141%22%2C%22ISSN%22%3A%221724-191X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222024-02-06T14%3A00%3A35Z%22%7D%7D%2C%7B%22key%22%3A%22YAGFQN3P%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Hardcastle%20et%20al.%22%2C%22parsedDate%22%3A%222023-12-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EHardcastle%2C%20Nicholas%2C%20Mirjana%20Josipovic%2C%20Enrico%20Clementel%2C%20Victor%20Hernandez%2C%20Gregory%20Smyth%2C%20Manuela%20Gober%2C%20Lotte%20Wilke%2C%20et%20al.%20%26%23x201C%3BRecommendation%20on%20the%20Technical%20and%20Dosimetric%20Data%20to%20Be%20Included%20in%20Stereotactic%20Body%20Radiation%20Therapy%20Clinical%20Trial%20Publications%20Based%20on%20a%20Systematic%20Review.%26%23x201D%3B%20%3Ci%3ERadiotherapy%20and%20Oncology%3A%20Journal%20of%20the%20European%20Society%20for%20Therapeutic%20Radiology%20and%20Oncology%3C%5C%2Fi%3E%20190%20%28December%201%2C%202023%29%3A%20110042.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.radonc.2023.110042%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.radonc.2023.110042%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Recommendation%20on%20the%20technical%20and%20dosimetric%20data%20to%20be%20included%20in%20stereotactic%20body%20radiation%20therapy%20clinical%20trial%20publications%20based%20on%20a%20systematic%20review%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicholas%22%2C%22lastName%22%3A%22Hardcastle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mirjana%22%2C%22lastName%22%3A%22Josipovic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Enrico%22%2C%22lastName%22%3A%22Clementel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Victor%22%2C%22lastName%22%3A%22Hernandez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregory%22%2C%22lastName%22%3A%22Smyth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manuela%22%2C%22lastName%22%3A%22Gober%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lotte%22%2C%22lastName%22%3A%22Wilke%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Eaton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Josset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Smaro%22%2C%22lastName%22%3A%22Lazarakis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jordi%22%2C%22lastName%22%3A%22Saez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Vieillevigne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%5Cu00faria%22%2C%22lastName%22%3A%22Jornet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pietro%22%2C%22lastName%22%3A%22Mancosu%22%7D%5D%2C%22abstractNote%22%3A%22The%20results%20of%20phase%20II%20and%20III%20trials%20on%20Stereotactic%20Body%20Radiation%20Therapy%20%28SBRT%29%20increased%20adoption%20of%20SBRT%20worldwide.%20The%20ability%20to%20replicate%20clinical%20trial%20outcomes%20in%20routine%20practice%20depends%20on%20the%20capability%20to%20reproduce%20technical%20and%20dosimetric%20procedures%20used%20in%20the%20clinical%20trial.%20In%20this%20systematic%20review%2C%20we%20evaluated%20if%20peer-reviewed%20publications%20of%20clinical%20trials%20in%20SBRT%20reported%20sufficient%20technical%20data%20to%20ensure%20safe%20and%20robust%20implementation%20in%20real%20world%20clinics.%20Twenty%20papers%20were%20selected%20for%20inclusion%2C%20and%20data%20was%20extracted%20by%20a%20working%20group%20of%20medical%20physicists%20created%20following%20the%20ESTRO%202021%20physics%20workshop.%20A%20large%20variability%20in%20technical%20and%20dosimetric%20data%20were%20observed%2C%20with%20frequent%20lack%20of%20required%20information%20for%20reproducing%20trial%20procedures.%20None%20of%20the%20evaluated%20studies%20were%20judged%20completely%20reproducible%20from%20a%20technical%20perspective.%20A%20list%20of%20recommendations%20has%20been%20provided%20by%20the%20group%2C%20based%20on%20the%20analysis%20and%20consensus%20process%2C%20to%20ensure%20an%20adequate%20reproducibility%20of%20technical%20parameters%20in%20primary%20SBRT%20clinical%20trials.%20Future%20publications%20should%20consider%20these%20recommendations%20to%20assist%20transferability%20of%20the%20clinical%20trial%20in%20real%20world%20practice.%22%2C%22date%22%3A%222023-12-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.radonc.2023.110042%22%2C%22ISSN%22%3A%221879-0887%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222024-02-06T14%3A00%3A23Z%22%7D%7D%2C%7B%22key%22%3A%226S6SAPAK%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Tauzi%5Cu00e8de-Espariat%20et%20al.%22%2C%22parsedDate%22%3A%222023-10-24%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ETauzi%26%23xE8%3Bde-Espariat%2C%20Arnault%2C%20Emmanuelle%20Uro-Coste%2C%20Yvan%20Nicaise%2C%20Philipp%20Sievers%2C%20Andreas%20von%20Deimling%2C%20Felix%20Sahm%2C%20Oumaima%20Aboubakr%2C%20Alice%20M%26%23xE9%3Btais%2C%20Fabrice%20Chr%26%23xE9%3Btien%2C%20and%20Pascale%20Varlet.%20%26%23x201C%3BRefinement%20of%20Diagnostic%20Criteria%20for%20Pediatric-Type%20Diffuse%20High-Grade%20Glioma%2C%20IDH-%20and%20H3-Wildtype%2C%20MYCN-Subtype%20Including%20Histopathology%2C%20TP53%2C%20MYCN%20and%20ID2%20Status.%26%23x201D%3B%20%3Ci%3EActa%20Neuropathologica%20Communications%3C%5C%2Fi%3E%2011%2C%20no.%201%20%28October%2024%2C%202023%29%3A%20170.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs40478-023-01667-x%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs40478-023-01667-x%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Refinement%20of%20diagnostic%20criteria%20for%20pediatric-type%20diffuse%20high-grade%20glioma%2C%20IDH-%20and%20H3-wildtype%2C%20MYCN-subtype%20including%20histopathology%2C%20TP53%2C%20MYCN%20and%20ID2%20status%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnault%22%2C%22lastName%22%3A%22Tauzi%5Cu00e8de-Espariat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Uro-Coste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yvan%22%2C%22lastName%22%3A%22Nicaise%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philipp%22%2C%22lastName%22%3A%22Sievers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andreas%22%2C%22lastName%22%3A%22von%20Deimling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Felix%22%2C%22lastName%22%3A%22Sahm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Oumaima%22%2C%22lastName%22%3A%22Aboubakr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alice%22%2C%22lastName%22%3A%22M%5Cu00e9tais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrice%22%2C%22lastName%22%3A%22Chr%5Cu00e9tien%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascale%22%2C%22lastName%22%3A%22Varlet%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222023-10-24%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs40478-023-01667-x%22%2C%22ISSN%22%3A%222051-5960%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222024-02-06T14%3A00%3A08Z%22%7D%7D%2C%7B%22key%22%3A%224HFIISK3%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Modesto%20et%20al.%22%2C%22parsedDate%22%3A%222023-10-12%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EModesto%2C%20Anouchka%2C%20David%20Tougeron%2C%20Pierre%20Tremoli%26%23xE8%3Bres%2C%20Philippe%20Ronchin%2C%20Ariane%20Darut%20Jouve%2C%20Delphine%20Argo%20Leignel%2C%20V%26%23xE9%3Bronique%20Vendrely%2C%20et%20al.%20%26%23x201C%3BAssociation%20of%20Radiochemotherapy%20to%20Immunotherapy%20in%20Unresectable%20Locally%20Advanced%20Oesophageal%20CarciNoma-Randomized%20Phase%202%20Trial%20ARION%20UCGI%2033%5C%2FPRODIGE%2067%3A%20The%20Study%20Protocol.%26%23x201D%3B%20%3Ci%3EBMC%20Cancer%3C%5C%2Fi%3E%2023%2C%20no.%201%20%28October%2012%2C%202023%29%3A%20966.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12885-023-11227-0%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12885-023-11227-0%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Association%20of%20Radiochemotherapy%20to%20Immunotherapy%20in%20unresectable%20locally%20advanced%20Oesophageal%20carciNoma-randomized%20phase%202%20trial%20ARION%20UCGI%2033%5C%2FPRODIGE%2067%3A%20the%20study%20protocol%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anouchka%22%2C%22lastName%22%3A%22Modesto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Tougeron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Tremoli%5Cu00e8res%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Ronchin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ariane%20Darut%22%2C%22lastName%22%3A%22Jouve%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Delphine%20Argo%22%2C%22lastName%22%3A%22Leignel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%5Cu00e9ronique%22%2C%22lastName%22%3A%22Vendrely%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Riou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Martin-Babau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samuel%22%2C%22lastName%22%3A%22Le%20Sourd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Mirabel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Leroy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Huguet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucile%22%2C%22lastName%22%3A%22Montaigne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Baumgaertner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marion%22%2C%22lastName%22%3A%22Deslandres%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Moyal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Seva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Janick%22%2C%22lastName%22%3A%22Selves%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Otal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Veronica%22%2C%22lastName%22%3A%22Pezzella%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rosine%22%2C%22lastName%22%3A%22Guimbaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Filleron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Qu%5Cu00e9ro%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20In%20case%20of%20locally%20advanced%20and%5C%2For%20non-metastatic%20unresectable%20esophageal%20cancer%2C%20definitive%20chemoradiotherapy%20%28CRT%29%20delivering%2050%5Cu00a0Gy%20in%2025%20daily%20fractions%20in%20combination%20with%20platinum-based%20regimen%20remains%20the%20standard%20of%20care%20resulting%20in%20a%202-year%20disease-free%20survival%20of%2025%25%20which%20deserves%20to%20be%20associated%20with%20new%20systemic%20strategies.%20In%20recent%20years%2C%20several%20immune%20checkpoint%20inhibitors%20%28anti-PD1%5C%2Fanti-PD-L1%2C%20anti-Program-Death%201%5C%2Fanti-Program-Death%20ligand%201%29%20have%20been%20approved%20for%20the%20treatment%20of%20various%20solid%20malignancies%20including%20metastatic%20esophageal%20cancer.%20As%20such%2C%20we%20hypothesized%20that%20the%20addition%20of%20an%20anti-PD-L1%20to%20CRT%20would%20provide%20clinical%20benefit%20for%20patients%20with%20locally%20advanced%20oesophageal%20cancer.%20To%20assess%20the%20efficacy%20of%20the%20anti-PD-L1%20durvalumab%20in%20combination%20with%20CRT%20and%20then%20as%20maintenance%20therapy%20we%20designed%20the%20randomized%20phase%20II%20ARION%20%28Association%20of%20Radiochemotherapy%20with%20Immunotherapy%20in%20unresectable%20Oesophageal%20carciNoma-%20UCGI%2033%5C%2FPRODIGE%2067%29.%5CnMETHODS%3A%20ARION%20is%20a%20multicenter%2C%20open-label%2C%20randomized%2C%20comparative%20phase%20II%20trial.%20Patients%20are%20randomly%20assigned%20in%20a%201%3A1%20ratio%20in%20each%20arm%20with%20a%20stratification%20according%20to%20tumor%20stage%2C%20histology%20and%20centre.%20Experimental%20arm%20relies%20on%20CRT%20with%2050%5Cu00a0Gy%20in%2025%20daily%20fractions%20in%20combination%20with%20FOLFOX%20regimen%20administrated%20during%20and%20after%20radiotherapy%20every%20two%20weeks%20for%20a%20total%20of%206%20cycles%20and%20durvalumab%20starting%20with%20CRT%20for%20a%20total%20of%2012%20infusions.%20Standard%20arm%20is%20CRT%20alone.%20Use%20of%20Intensity%20Modulated%20radiotherapy%20is%20mandatory.%20The%20primary%20endpoint%20is%20to%20increase%20progression-free%20survival%20at%2012%5Cu00a0months%20from%2050%20to%2068%25%20%28HR%5Cu2009%3D%5Cu20090.55%29%20%28power%2090%25%3B%20one-sided%20alpha-risk%2C%2010%25%29.%20Progression%20will%20be%20defined%20with%20central%20external%20review%20of%20imaging.%5CnANCILLARY%20STUDIES%20ARE%20PLANNED%3A%20PD-L1%20Combined%20Positivity%20Score%20on%20carcinoma%20cells%20and%20stromal%20immune%20cells%20of%20diagnostic%20biopsy%20specimen%20will%20be%20correlated%20to%20disease%20free%20survival.%20The%20study%20of%20gut%20microbiota%20will%20aim%20to%20determine%20if%20baseline%20intestinal%20bacteria%20correlates%20with%20tumor%20response.%20Proteomic%20analysis%20on%20blood%20samples%20will%20compare%20long-term%20responder%20after%20CRT%20with%20durvalumab%20to%20non-responder%20to%20identify%20biomarkers.%5CnCONCLUSION%3A%20Results%20of%20the%20present%20study%20will%20be%20of%20great%20importance%20to%20evaluate%20the%20impact%20of%20immunotherapy%20in%20combination%20with%20CRT%20and%20decipher%20immune%20response%20in%20this%20unmet%20need%20clinical%20situation.%5CnTRIAL%20REGISTRATION%3A%20ClinicalTrials.gov%2C%20NCT%3A%2003777813.Trial%20registration%20date%3A%205th%20December%202018.%22%2C%22date%22%3A%222023-10-12%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12885-023-11227-0%22%2C%22ISSN%22%3A%221471-2407%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222024-02-06T13%3A59%3A34Z%22%7D%7D%2C%7B%22key%22%3A%22N4XDTTWW%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Robinet%20et%20al.%22%2C%22parsedDate%22%3A%222023-04-12%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ERobinet%2C%20Lucas%2C%20Aurore%20Siegfried%2C%20Margaux%20Roques%2C%20Ahmad%20Berjaoui%2C%20and%20Elizabeth%20Cohen-Jonathan%20Moyal.%20%26%23x201C%3BMRI-Based%20Deep%20Learning%20Tools%20for%20MGMT%20Promoter%20Methylation%20Detection%3A%20A%20Thorough%20Evaluation.%26%23x201D%3B%20%3Ci%3ECancers%3C%5C%2Fi%3E%2015%2C%20no.%208%20%28April%2012%2C%202023%29%3A%202253.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers15082253%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers15082253%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22MRI-Based%20Deep%20Learning%20Tools%20for%20MGMT%20Promoter%20Methylation%20Detection%3A%20A%20Thorough%20Evaluation%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucas%22%2C%22lastName%22%3A%22Robinet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aurore%22%2C%22lastName%22%3A%22Siegfried%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Margaux%22%2C%22lastName%22%3A%22Roques%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ahmad%22%2C%22lastName%22%3A%22Berjaoui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Cohen-Jonathan%20Moyal%22%7D%5D%2C%22abstractNote%22%3A%22Glioblastoma%20is%20the%20most%20aggressive%20primary%20brain%20tumor%2C%20which%20almost%20systematically%20relapses%20despite%20surgery%20%28when%20possible%29%20followed%20by%20radio-chemotherapy%20temozolomide-based%20treatment.%20Upon%20relapse%2C%20one%20option%20for%20treatment%20is%20another%20chemotherapy%2C%20lomustine.%20The%20efficacy%20of%20these%20chemotherapy%20regimens%20depends%20on%20the%20methylation%20of%20a%20specific%20gene%20promoter%20known%20as%20MGMT%2C%20which%20is%20the%20main%20prognosis%20factor%20for%20glioblastoma.%20Knowing%20this%20biomarker%20is%20a%20key%20issue%20for%20the%20clinician%20to%20personalize%20and%20adapt%20treatment%20to%20the%20patient%20at%20primary%20diagnosis%20for%20elderly%20patients%2C%20in%20particular%2C%20and%20also%20upon%20relapse.%20The%20association%20between%20MRI-derived%20information%20and%20the%20prediction%20of%20MGMT%20promoter%20status%20has%20been%20discussed%20in%20many%20studies%2C%20and%20some%2C%20more%20recently%2C%20have%20proposed%20the%20use%20of%20deep%20learning%20algorithms%20on%20multimodal%20scans%20to%20extract%20this%20information%2C%20but%20they%20have%20failed%20to%20reach%20a%20consensus.%20Therefore%2C%20in%20this%20work%2C%20beyond%20the%20classical%20performance%20figures%20usually%20displayed%2C%20we%20seek%20to%20compute%20confidence%20scores%20to%20see%20if%20a%20clinical%20application%20of%20such%20methods%20can%20be%20seriously%20considered.%20The%20systematic%20approach%20carried%20out%2C%20using%20different%20input%20configurations%20and%20algorithms%20as%20well%20as%20the%20exact%20methylation%20percentage%2C%20led%20to%20the%20following%20conclusion%3A%20current%20deep%20learning%20methods%20are%20unable%20to%20determine%20MGMT%20promoter%20methylation%20from%20MRI%20data.%22%2C%22date%22%3A%222023-04-12%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3390%5C%2Fcancers15082253%22%2C%22ISSN%22%3A%222072-6694%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222024-02-06T13%3A59%3A18Z%22%7D%7D%2C%7B%22key%22%3A%22WFHZ5E8S%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Gilhodes%20et%20al.%22%2C%22parsedDate%22%3A%222023-06-06%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGilhodes%2C%20Julia%2C%20Ad%26%23xE8%3Ble%20Meola%2C%20Bastien%20Cabarrou%2C%20Guillaume%20Peyraga%2C%20Caroline%20Dehais%2C%20Dominique%20Figarella-Branger%2C%20Fran%26%23xE7%3Bois%20Ducray%2C%20et%20al.%20%26%23x201C%3BA%20Multigene%20Signature%20Associated%20with%20Progression-Free%20Survival%20after%20Treatment%20for%20IDH%20Mutant%20and%201p%5C%2F19q%20Codeleted%20Oligodendrogliomas.%26%23x201D%3B%20%3Ci%3ECancers%3C%5C%2Fi%3E%2015%2C%20no.%2012%20%28June%206%2C%202023%29%3A%203067.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers15123067%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers15123067%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22A%20Multigene%20Signature%20Associated%20with%20Progression-Free%20Survival%20after%20Treatment%20for%20IDH%20Mutant%20and%201p%5C%2F19q%20Codeleted%20Oligodendrogliomas%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julia%22%2C%22lastName%22%3A%22Gilhodes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ad%5Cu00e8le%22%2C%22lastName%22%3A%22Meola%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bastien%22%2C%22lastName%22%3A%22Cabarrou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Peyraga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Dehais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%22%2C%22lastName%22%3A%22Figarella-Branger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Ducray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claude-Alain%22%2C%22lastName%22%3A%22Maurage%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Delphine%22%2C%22lastName%22%3A%22Loussouarn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Uro-Coste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Cohen-Jonathan%20Moyal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22null%22%2C%22lastName%22%3A%22Pola%20Network%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20IDH%20mutant%20and%201p%5C%2F19q%20codeleted%20oligodendrogliomas%20are%20the%20gliomas%20associated%20with%20the%20best%20prognosis.%20However%2C%20despite%20their%20sensitivity%20to%20treatment%2C%20patient%20survival%20remains%20heterogeneous.%20We%20aimed%20to%20identify%20gene%20expressions%20associated%20with%20response%20to%20treatment%20from%20a%20national%20cohort%20of%20patients%20with%20oligodendrogliomas%2C%20all%20treated%20with%20radiotherapy%20%2B%5C%2F-%20chemotherapy.%5CnMETHODS%3A%20We%20extracted%20total%20RNA%20from%20frozen%20tumor%20samples%20and%20investigated%20enriched%20pathways%20using%20KEGG%20and%20Reactome%20databases.%20We%20applied%20a%20stability%20selection%20approach%20based%20on%20subsampling%20combined%20with%20the%20lasso-pcvl%20algorithm%20to%20identify%20genes%20associated%20with%20progression-free%20survival%20and%20calculate%20a%20risk%20score.%5CnRESULTS%3A%20We%20included%2068%20patients%20with%20oligodendrogliomas%20treated%20with%20radiotherapy%20%2B%5C%2F-%20chemotherapy.%20After%20filtering%2C%201697%20genes%20were%20obtained%2C%20including%20134%20associated%20with%20progression-free%20survival%3A%2035%20with%20a%20better%20prognosis%20and%2099%20with%20a%20poorer%20one.%20Eight%20genes%20%28ST3GAL6%2C%20QPCT%2C%20NQO1%2C%20EPHX1%2C%20CST3%2C%20S100A8%2C%20CHI3L1%2C%20and%20OSBPL3%29%20whose%20risk%20score%20remained%20statistically%20significant%20after%20adjustment%20for%20prognostic%20factors%20in%20multivariate%20analysis%20were%20selected%20in%20more%20than%2060%25%20of%20cases%20were%20associated%20with%20shorter%20progression-free%20survival.%5CnCONCLUSIONS%3A%20We%20found%20an%20eight-gene%20signature%20associated%20with%20a%20higher%20risk%20of%20rapid%20relapse%20after%20treatment%20in%20patients%20with%20oligodendrogliomas.%20This%20finding%20could%20help%20clinicians%20identify%20patients%20who%20need%20more%20intensive%20treatment.%22%2C%22date%22%3A%222023-06-06%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3390%5C%2Fcancers15123067%22%2C%22ISSN%22%3A%222072-6694%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222024-02-06T13%3A59%3A00Z%22%7D%7D%2C%7B%22key%22%3A%22WE6KWC82%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Khalifa%20et%20al.%22%2C%22parsedDate%22%3A%222023%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EKhalifa%2C%20Jonathan%2C%20No%26%23xE9%3Bmie%20Th%26%23xE9%3Bbault%2C%20Clara-Maria%20Scarlata%2C%20Emma%20Norkowski%2C%20Carole%20Massabeau%2C%20Laurent%20Brouchet%2C%20Sophie%20Peries%20Bataille%2C%20et%20al.%20%26%23x201C%3BImmune%20Changes%20in%20Hilar%20Tumor%20Draining%20Lymph%20Nodes%20Following%20Node%20Sparing%20Neoadjuvant%20Chemoradiotherapy%20of%20Localized%20CN0%20Non-Small%20Cell%20Lung%20Cancer.%26%23x201D%3B%20%3Ci%3EFrontiers%20in%20Oncology%3C%5C%2Fi%3E%2013%20%282023%29%3A%201269166.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffonc.2023.1269166%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffonc.2023.1269166%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Immune%20changes%20in%20hilar%20tumor%20draining%20lymph%20nodes%20following%20node%20sparing%20neoadjuvant%20chemoradiotherapy%20of%20localized%20cN0%20non-small%20cell%20lung%20cancer%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Khalifa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22No%5Cu00e9mie%22%2C%22lastName%22%3A%22Th%5Cu00e9bault%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clara-Maria%22%2C%22lastName%22%3A%22Scarlata%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emma%22%2C%22lastName%22%3A%22Norkowski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carole%22%2C%22lastName%22%3A%22Massabeau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Brouchet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Peries%20Bataille%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christelle%22%2C%22lastName%22%3A%22Casaroli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Liza%22%2C%22lastName%22%3A%22Vaz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carine%22%2C%22lastName%22%3A%22Valle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emeline%22%2C%22lastName%22%3A%22Sarot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Saint-Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Martin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre-Beno%5Cu00eet%22%2C%22lastName%22%3A%22Pages%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alice%22%2C%22lastName%22%3A%22Milli%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Mazi%5Cu00e8res%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Cohen-Jonathan%20Moyal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Lauz%5Cu00e9ral-Vizca%5Cu00efno%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maha%22%2C%22lastName%22%3A%22Ayyoub%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20While%20much%20progress%20has%20been%20accomplished%20in%20the%20understanding%20of%20radiation-induced%20immune%20effects%20in%20tumors%2C%20little%20is%20known%20regarding%20the%20mechanisms%20involved%20at%20the%20tumor%20draining%20lymph%20node%20%28TDLN%29%20level.%20The%20objective%20of%20this%20retrospective%20study%20was%20to%20assess%20the%20immune%20and%20biological%20changes%20arising%20in%20non-involved%20TDLNs%20upon%20node%20sparing%20concurrent%20chemoradiotherapy%20%28CRT%29%20of%20non-small%20cell%20lung%20cancer%20%28NSCLC%29%20tumors.%5CnMETHODS%3A%20Patients%20with%20proven%20localized%20%28cN0M0%29%20NSCLC%2C%20treated%20by%20radical%20surgery%20plus%20lymph%20node%20dissection%20with%20%28CRT%2B%29%20or%20without%20%28CRT-%29%20neoadjuvant%20chemoradiotherapy%2C%20whereby%20radiotherapy%20was%20targeted%20on%20the%20primary%20tumor%20with%20no%20significant%20incidental%20irradiation%20of%20the%20non-involved%20TDLN%20station%20%28stations%20XI%29%2C%20were%20identified.%20Bulk%20RNA%20sequencing%20of%20TDLNs%20was%20performed%20and%20data%20were%20analyzed%20based%20on%20differential%20gene%20expression%20%28DGE%29%20and%20gene%20sets%20enrichment.%5CnRESULTS%3A%20Sixteen%20patients%20were%20included%20and%2025%20TDLNs%20were%20analyzed%3A%206%20patients%20in%20the%20CRT%2B%20group%20%2812%20samples%29%20and%2010%20patients%20in%20the%20CRT-%20group%20%2813%20samples%29.%20Overall%2C%201001%20genes%20were%20differentially%20expressed%20between%20the%20two%20groups%20%28CRT%2B%20and%20CRT-%29.%20Analysis%20with%20g-profiler%20revealed%20that%20gene%20sets%20associated%20with%20antitumor%20immune%20response%2C%20inflammatory%20response%2C%20hypoxia%2C%20angiogenesis%2C%20epithelial%20mesenchymal%20transition%20and%20extra-cellular%20matrix%20remodeling%20were%20enriched%20in%20the%20CRT%2B%20group%2C%20whereas%20only%20gene%20sets%20associated%20with%20B%20cells%20and%20B-cell%20receptor%20signaling%20were%20enriched%20in%20the%20CRT-%20group.%20Unsupervised%20dimensionality%20reduction%20identified%20two%20clusters%20of%20TDLNs%20from%20CRT%2B%20patients%2C%20of%20which%20one%20cluster%20%28cluster%201%29%20exhibited%20higher%20expression%20of%20pathways%20identified%20as%20enriched%20in%20the%20overall%20CRT%2B%20group%20in%20comparison%20to%20the%20CRT-%20group.%20In%20CRT%2B%20cluster%201%2C%203%20out%20of%203%20patients%20had%20pathological%20complete%20response%20%28pCR%29%20or%20major%20pathological%20response%20%28MPR%29%20to%20neoadjuvant%20CRT%2C%20whereas%20only%201%20out%20of%203%20patients%20in%20the%20other%20CRT%2B%20cluster%20%28cluster%202%29%20experienced%20MPR%20and%20none%20exhibited%20pCR.%5CnCONCLUSION%3A%20Neoadjuvant%20node%20sparing%20concurrent%20CRT%20of%20NSCLC%20patients%20is%20associated%20with%20distinct%20microenvironment%20and%20immunological%20patterns%20in%20non-involved%20TDLNs%20as%20compared%20to%20non-involved%20TDLNs%20from%20patients%20with%20non-irradiated%20tumors.%20Our%20data%20are%20in%20line%20with%20studies%20showing%20superiority%20of%20lymph%20node%20sparing%20irradiation%20of%20the%20primary%20tumor%20in%20the%20induction%20of%20antitumor%20immunity.%22%2C%22date%22%3A%222023%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3389%5C%2Ffonc.2023.1269166%22%2C%22ISSN%22%3A%222234-943X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222024-02-06T13%3A58%3A03Z%22%7D%7D%2C%7B%22key%22%3A%22J5U6MX4D%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Cartiaux%20et%20al.%22%2C%22parsedDate%22%3A%222023%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ECartiaux%2C%20Benjamin%2C%20Alexandra%20Deviers%2C%20Caroline%20Delmas%2C%20J%26%23xE9%3Br%26%23xF4%3Bme%20Abadie%2C%20Mart%26%23xED%3B%20Pumarola%20Battle%2C%20Elizabeth%20Cohen-Jonathan%20Moyal%2C%20and%20Giovanni%20Mogicato.%20%26%23x201C%3BEvaluation%20of%20in%20Vitro%20Intrinsic%20Radiosensitivity%20and%20Characterization%20of%20Five%20Canine%20High-Grade%20Glioma%20Cell%20Lines.%26%23x201D%3B%20%3Ci%3EFrontiers%20in%20Veterinary%20Science%3C%5C%2Fi%3E%2010%20%282023%29%3A%201253074.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffvets.2023.1253074%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffvets.2023.1253074%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Evaluation%20of%20in%20vitro%20intrinsic%20radiosensitivity%20and%20characterization%20of%20five%20canine%20high-grade%20glioma%20cell%20lines%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benjamin%22%2C%22lastName%22%3A%22Cartiaux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Deviers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Delmas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Abadie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mart%5Cu00ed%22%2C%22lastName%22%3A%22Pumarola%20Battle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Cohen-Jonathan%20Moyal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giovanni%22%2C%22lastName%22%3A%22Mogicato%22%7D%5D%2C%22abstractNote%22%3A%22Glioma%20is%20the%20most%20common%20primary%20brain%20tumor%20in%20dogs%20and%20predominantly%20affects%20brachycephalic%20breeds.%20Diagnosis%20relies%20on%20CT%20or%20MRI%20imaging%2C%20and%20the%20proposed%20treatments%20include%20surgical%20resection%2C%20chemotherapy%2C%20and%20radiotherapy%20depending%20on%20the%20tumor%27s%20location.%20Canine%20glioma%20from%20domestic%20dogs%20could%20be%20used%20as%20a%20more%20powerful%20model%20to%20study%20radiotherapy%20for%20human%20glioma%20than%20the%20murine%20model.%20Indeed%2C%20%28i%29%20contrary%20to%20mice%2C%20immunocompetent%20dogs%20develop%20spontaneous%20glioma%2C%20%28ii%29%20the%20canine%20brain%20structure%20is%20closer%20to%20human%20than%20mice%2C%20and%20%28iii%29%20domestic%20dogs%20are%20exposed%20to%20the%20same%20environmental%20factors%20than%20humans.%20Moreover%2C%20imaging%20techniques%20and%20radiation%20therapy%20used%20in%20human%20medicine%20can%20be%20applied%20to%20dogs%2C%20facilitating%20the%20direct%20transposition%20of%20results.%20The%20objective%20of%20this%20study%20is%20to%20fully%20characterize%205%20canine%20glioma%20cell%20lines%20and%20to%20evaluate%20their%20intrinsic%20radiosensitivity.%20Canine%20cell%20lines%20present%20numerous%20analogies%20between%20the%20data%20obtained%20during%20this%20study%20on%20different%20glioma%20cell%20lines%20in%20dogs.%20Cell%20morphology%20is%20identical%2C%20such%20as%20doubling%20time%2C%20clonality%20test%20and%20karyotype.%20Immunohistochemical%20study%20of%20surface%20proteins%2C%20directly%20on%20cell%20lines%20and%20after%20stereotaxic%20injection%20in%20mice%20also%20reveals%20close%20similarity.%20Radiosensitivity%20profile%20of%20canine%20glial%20cells%20present%20high%20profile%20of%20radioresistance.%22%2C%22date%22%3A%222023%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3389%5C%2Ffvets.2023.1253074%22%2C%22ISSN%22%3A%222297-1769%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222024-02-06T13%3A57%3A41Z%22%7D%7D%2C%7B%22key%22%3A%224GZEPV2C%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bentaberry-Rosa%20et%20al.%22%2C%22parsedDate%22%3A%222023-12-20%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBentaberry-Rosa%2C%20Alexandre%2C%20Yvan%20Nicaise%2C%20Caroline%20Delmas%2C%20Val%26%23xE9%3Brie%20Gouaz%26%23xE9%3B-Andersson%2C%20Elizabeth%20Cohen-Jonathan-Moyal%2C%20and%20Catherine%20Seva.%20%26%23x201C%3BOverexpression%20of%20Growth%20Differentiation%20Factor%2015%20in%20Glioblastoma%20Stem%20Cells%20Promotes%20Their%20Radioresistance.%26%23x201D%3B%20%3Ci%3ECancers%3C%5C%2Fi%3E%2016%2C%20no.%201%20%28December%2020%2C%202023%29%3A%2027.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers16010027%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers16010027%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Overexpression%20of%20Growth%20Differentiation%20Factor%2015%20in%20Glioblastoma%20Stem%20Cells%20Promotes%20Their%20Radioresistance%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandre%22%2C%22lastName%22%3A%22Bentaberry-Rosa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yvan%22%2C%22lastName%22%3A%22Nicaise%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Delmas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Gouaz%5Cu00e9-Andersson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Cohen-Jonathan-Moyal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Seva%22%7D%5D%2C%22abstractNote%22%3A%22GSCs%20play%20an%20important%20role%20in%20GBM%20recurrence.%20Understanding%20the%20resistance%20mechanisms%20in%20these%20cells%20is%20therefore%20crucial%20for%20radiation%20therapy%20optimization.%20In%20this%20study%2C%20using%20patient-derived%20GSCs%2C%20we%20demonstrate%20that%20GDF15%2C%20a%20cytokine%20belonging%20to%20the%20TGF-%5Cu03b2%20superfamily%2C%20is%20regulated%20by%20irradiation%20%28IR%29%20and%20the%20transcription%20factor%20WWTR1%5C%2FTAZ.%20Blocking%20WWTR1%5C%2FTAZ%20using%20specific%20siRNAs%20significantly%20reduces%20GDF15%20basal%20expression%20and%20reverses%20the%20upregulation%20of%20this%20cytokine%20induced%20by%20IR.%20Furthermore%2C%20we%20demonstrate%20that%20GDF15%20plays%20an%20important%20role%20in%20GSC%20radioresistance.%20Targeting%20GDF15%20expression%20by%20siRNA%20in%20GSCs%20expressing%20high%20levels%20of%20GDF15%20sensitizes%20the%20cells%20to%20IR.%20In%20addition%2C%20we%20also%20found%20that%20GDF15%20expression%20is%20critical%20for%20GSC%20spheroid%20formation%2C%20as%20GDF15%20knockdown%20significantly%20reduces%20the%20number%20of%20GSC%20neurospheres.%20This%20study%20suggests%20that%20GDF15%20targeting%20in%20combination%20with%20radiotherapy%20may%20be%20a%20feasible%20approach%20in%20patients%20with%20GBM.%22%2C%22date%22%3A%222023-12-20%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3390%5C%2Fcancers16010027%22%2C%22ISSN%22%3A%222072-6694%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222024-02-06T13%3A57%3A28Z%22%7D%7D%2C%7B%22key%22%3A%224ZHJ6KEB%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Huguet%20et%20al.%22%2C%22parsedDate%22%3A%222023-10-06%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EHuguet%2C%20F.%2C%20O.%20Riou%2C%20D.%20Pasquier%2C%20A.%20Modesto%2C%20L.%20Qu%26%23xE9%3Bro%2C%20M.%20Michalet%2C%20A.%20Bordron%2C%20et%20al.%20%26%23x201C%3BRadiation%20Therapy%20of%20the%20Primary%20Tumour%20and%5C%2For%20Metastases%20of%20Digestive%20Metastatic%20Cancers.%26%23x201D%3B%20%3Ci%3ECancer%20Radiotherapie%3A%20Journal%20De%20La%20Societe%20Francaise%20De%20Radiotherapie%20Oncologique%3C%5C%2Fi%3E%2C%20October%206%2C%202023%2C%20S1278-3218%2823%2900209-3.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.canrad.2023.04.007%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.canrad.2023.04.007%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Radiation%20therapy%20of%20the%20primary%20tumour%20and%5C%2For%20metastases%20of%20digestive%20metastatic%20cancers%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Huguet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%22%2C%22lastName%22%3A%22Riou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Pasquier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Modesto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Qu%5Cu00e9ro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Michalet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Bordron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Schipman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Orthuon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Lisbona%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Vendrely%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Jaksic%22%7D%5D%2C%22abstractNote%22%3A%22Metastatic%20gastrointestinal%20cancer%20is%20not%20an%20uncommon%20situation%2C%20especially%20for%20pancreatic%2C%20gastric%2C%20and%20colorectal%20cancers.%20In%20this%20setting%2C%20few%20data%20are%20available%20on%20the%20impact%20of%20the%20treatment%20of%20the%20primary%20tumour.%20Oligometastatic%20disease%20is%20associated%20with%20longer%20survival%20in%20comparison%20with%20more%20advanced%20disease.%20Metastasis-directed%20therapy%2C%20such%20as%20stereotactic%20body%20radiotherapy%2C%20seems%20related%20to%20better%20outcomes%2C%20but%20the%20level%20of%20evidence%20is%20low.%20In%20most%20tumour%20locations%2C%20prospective%20data%20are%20very%20scarce%20and%20inclusion%20in%20ongoing%20trials%20is%20strongly%20recommended.%22%2C%22date%22%3A%222023-10-06%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.canrad.2023.04.007%22%2C%22ISSN%22%3A%221769-6658%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222024-02-06T12%3A48%3A02Z%22%7D%7D%2C%7B%22key%22%3A%22AJB8YII5%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lemari%5Cu00e9%20et%20al.%22%2C%22parsedDate%22%3A%222023-11-03%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELemari%26%23xE9%3B%2C%20Anthony%2C%20Vincent%20Lubrano%2C%20Caroline%20Delmas%2C%20Am%26%23xE9%3Blie%20Lusque%2C%20Juan-Pablo%20Cerapio%2C%20Marion%20Perrier%2C%20Aurore%20Siegfried%2C%20et%20al.%20%26%23x201C%3BThe%20STEMRI%20Trial%3A%20Magnetic%20Resonance%20Spectroscopy%20Imaging%20Can%20Define%20Tumor%20Areas%20Enriched%20in%20Glioblastoma%20Stem-like%20Cells.%26%23x201D%3B%20%3Ci%3EScience%20Advances%3C%5C%2Fi%3E%209%2C%20no.%2044%20%28November%203%2C%202023%29%3A%20eadi0114.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1126%5C%2Fsciadv.adi0114%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1126%5C%2Fsciadv.adi0114%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20STEMRI%20trial%3A%20Magnetic%20resonance%20spectroscopy%20imaging%20can%20define%20tumor%20areas%20enriched%20in%20glioblastoma%20stem-like%20cells%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anthony%22%2C%22lastName%22%3A%22Lemari%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Lubrano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Delmas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Am%5Cu00e9lie%22%2C%22lastName%22%3A%22Lusque%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan-Pablo%22%2C%22lastName%22%3A%22Cerapio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marion%22%2C%22lastName%22%3A%22Perrier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aurore%22%2C%22lastName%22%3A%22Siegfried%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florent%22%2C%22lastName%22%3A%22Arnauduc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yvan%22%2C%22lastName%22%3A%22Nicaise%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Perrine%22%2C%22lastName%22%3A%22Dahan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Filleron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Muriel%22%2C%22lastName%22%3A%22Mounier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Toulas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Cohen-Jonathan%20Moyal%22%7D%5D%2C%22abstractNote%22%3A%22Despite%20maximally%20safe%20resection%20of%20the%20magnetic%20resonance%20imaging%20%28MRI%29-defined%20contrast-enhanced%20%28CE%29%20central%20tumor%20area%20and%20chemoradiotherapy%2C%20most%20patients%20with%20glioblastoma%20%28GBM%29%20relapse%20within%20a%20year%20in%20peritumoral%20FLAIR%20regions.%20Magnetic%20resonance%20spectroscopy%20imaging%20%28MRSI%29%20can%20discriminate%20metabolic%20tumor%20areas%20with%20higher%20recurrence%20potential%20as%20CNI%2B%20regions%20%28choline%5C%2FN-acetyl-aspartate%20index%20%3E2%29%20can%20predict%20relapse%20sites.%20As%20relapses%20are%20mainly%20imputed%20to%20glioblastoma%20stem-like%20cells%20%28GSCs%29%2C%20CNI%2B%20areas%20might%20be%20GSC%20enriched.%20In%20this%20prospective%20trial%2C%2016%20patients%20with%20GBM%20underwent%20MRSI%5C%2FMRI%20before%20surgery%5C%2Fchemoradiotherapy%20to%20investigate%20GSC%20content%20in%20CNI-%5C%2F%2B%20biopsies%20from%20CE%5C%2FFLAIR.%20Biopsy%20and%20derived-GSC%20characterization%20revealed%20a%20FLAIR%5C%2FCNI%2B%20sample%20enrichment%20in%20GSC%20and%20in%20gene%20signatures%20related%20to%20stemness%2C%20DNA%20repair%2C%20adhesion%5C%2Fmigration%2C%20and%20mitochondrial%20bioenergetics.%20FLAIR%5C%2FCNI%2B%20samples%20generate%20GSC-enriched%20neurospheres%20faster%20than%20FLAIR%5C%2FCNI-.%20Parameters%20assessing%20biopsy%20GSC%20content%20and%20time-to-neurosphere%20formation%20in%20FLAIR%5C%2FCNI%2B%20were%20associated%20with%20worse%20patient%20outcome.%20Preoperative%20MRI%5C%2FMRSI%20would%20certainly%20allow%20better%20resection%20and%20targeting%20of%20FLAIR%5C%2FCNI%2B%20areas%2C%20as%20their%20GSC%20enrichment%20can%20predict%20worse%20outcomes.%22%2C%22date%22%3A%222023-11-03%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1126%5C%2Fsciadv.adi0114%22%2C%22ISSN%22%3A%222375-2548%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222023-11-06T10%3A38%3A54Z%22%7D%7D%2C%7B%22key%22%3A%22A5VLIIWB%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Darr%5Cu00e9on%20et%20al.%22%2C%22parsedDate%22%3A%222023-09%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDarr%26%23xE9%3Bon%2C%20J.%2C%20C.%20Massabeau%2C%20C.%20Geffroy%2C%20P.%20Maroun%2C%20and%20L.%20Simon.%20%26%23x201C%3BSurface-Guided%20Radiotherapy%20Overview%3A%20Technical%20Aspects%20and%20Clinical%20Applications.%26%23x201D%3B%20%3Ci%3ECancer%20Radiotherapie%3A%20Journal%20De%20La%20Societe%20Francaise%20De%20Radiotherapie%20Oncologique%3C%5C%2Fi%3E%2027%2C%20no.%206%26%23x2013%3B7%20%28September%202023%29%3A%20504%26%23x2013%3B10.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.canrad.2023.07.003%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.canrad.2023.07.003%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Surface-guided%20radiotherapy%20overview%3A%20Technical%20aspects%20and%20clinical%20applications%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Darr%5Cu00e9on%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Massabeau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Geffroy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Maroun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Simon%22%7D%5D%2C%22abstractNote%22%3A%22In%20radiotherapy%2C%20patient%20positioning%20has%20long%20been%20ensured%20by%20ionizing%20imaging%20%28kV%20or%20MV%29.%20Over%20the%20past%20ten%20years%2C%20surface-guided%20radiotherapy%20has%20appeared%20in%20radiotherapy%20departments.%20It%20is%20a%20continuous%20three-dimensional%20acquisition%20of%20the%20surface%20of%20the%20patient%2C%20based%20on%20the%20use%20of%20several%20optical%20cameras.%20The%20acquired%20surface%20is%20compared%20to%20an%20expected%20surface%20%28usually%20taken%20from%20the%20planning%20scanner%29.%20Operators%20can%20constantly%20appreciate%20poor%20position%2C%20anatomical%20deformity%20or%20patient%20shift.%20Thus%2C%20the%20system%20allows%20an%20aid%20to%20the%20positioning%20of%20the%20patient%2C%20possibly%20without%20tattooing%2C%20but%20also%20a%20follow-up%20of%20the%20patient%20during%20the%20duration%20of%20the%20session.%20The%20most%20obvious%20contribution%20of%20the%20system%20concerns%20the%20treatment%20of%20the%20breast.%20In%20fact%2C%20for%20this%20location%2C%20the%20bone%20registration%20is%20not%20ideal%20and%20the%20target%20is%20visible%20in%20surface-guided%20radiotherapy.%20These%20systems%20also%20make%20it%20possible%20to%20treat%20in%20deep%20inspiration%20breath%20hold.%20But%20several%20other%20locations%20can%20benefit%20from%20it%20%28pelvis%2C%20thorax%2C%20etc.%29.%22%2C%22date%22%3A%222023-09%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.canrad.2023.07.003%22%2C%22ISSN%22%3A%221769-6658%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222023-09-13T11%3A39%3A07Z%22%7D%7D%2C%7B%22key%22%3A%22J7XETLYB%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Pouessel%20et%20al.%22%2C%22parsedDate%22%3A%222023-09-07%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EPouessel%2C%20Damien%2C%20Sol%26%23xE9%3Bakh%26%23xE9%3Bna%20Ken%2C%20Val%26%23xE9%3Brie%20Gouaze-Andersson%2C%20Lucie%20Piram%2C%20Augustin%20Mervoyer%2C%20Delphine%20Larrieu-Ciron%2C%20Bastien%20Cabarrou%2C%20et%20al.%20%26%23x201C%3BHypofractionated%20Stereotactic%20Re-Irradiation%20and%26%23xA0%3B%20Anti-PDL1%20Durvalumab%20Combination%20in%20Recurrent%20Glioblastoma%3A%20STERIMGLI%20Phase%20I%20Results.%26%23x201D%3B%20%3Ci%3EThe%20Oncologist%3C%5C%2Fi%3E%2028%2C%20no.%209%20%28September%207%2C%202023%29%3A%20825-e817.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Foncolo%5C%2Foyad095%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Foncolo%5C%2Foyad095%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Hypofractionated%20Stereotactic%20Re-irradiation%20and%20%5Cu2028Anti-PDL1%20Durvalumab%20Combination%20in%20Recurrent%20Glioblastoma%3A%20STERIMGLI%20Phase%20I%20Results%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damien%22%2C%22lastName%22%3A%22Pouessel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sol%5Cu00e9akh%5Cu00e9na%22%2C%22lastName%22%3A%22Ken%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Gouaze-Andersson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucie%22%2C%22lastName%22%3A%22Piram%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Augustin%22%2C%22lastName%22%3A%22Mervoyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Delphine%22%2C%22lastName%22%3A%22Larrieu-Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bastien%22%2C%22lastName%22%3A%22Cabarrou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Am%5Cu00e9lie%22%2C%22lastName%22%3A%22Lusque%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Sebastien%22%2C%22lastName%22%3A%22Frenel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Uro-Coste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascale%22%2C%22lastName%22%3A%22Olivier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Muriel%22%2C%22lastName%22%3A%22Mounier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Umberto%22%2C%22lastName%22%3A%22Sabatini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eduardo%20Hugo%22%2C%22lastName%22%3A%22Sanchez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mehdi%22%2C%22lastName%22%3A%22Zouitine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ahmad%22%2C%22lastName%22%3A%22Berjaoui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Cohen-Jonathan%20Moyal%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Hypofractionated%20stereotactic%20radiotherapy%20%28hFSRT%29%20is%20a%20salvage%20option%20for%20recurrent%20glioblastoma%20%28GB%29%20which%20may%20synergize%20anti-PDL1%20treatment.%20This%20phase%20I%20study%20evaluated%20the%20safety%20and%20the%20recommended%20phase%20II%20dose%20of%20anti-PDL1%20durvalumab%20combined%20with%20hFSRT%20in%20patients%20with%20recurrent%20GB.%5CnMETHODS%3A%20Patients%20were%20treated%20with%2024%20Gy%2C%208%20Gy%20per%20fraction%20on%20days%201%2C%203%2C%20and%205%20combined%20with%20the%20first%201500%20mg%20Durvalumab%20dose%20on%20day%205%2C%20followed%20by%20infusions%20q4weeks%20until%20progression%20or%20for%20a%20maximum%20of%2012%20months.%20A%20standard%203%20%2B%203%20Durvalumab%20dose%20de-escalation%20design%20was%20used.%20Longitudinal%20lymphocytes%20count%2C%20cytokines%20analyses%20on%20plasma%20samples%2C%20and%20magnetic%20resonance%20imaging%20%28MRI%29%20were%20collected.%5CnRESULTS%3A%20Six%20patients%20were%20included.%20One%20dose%20limiting%20toxicity%2C%20an%20immune-related%20grade%203%20vestibular%20neuritis%20related%20to%20Durvalumab%2C%20was%20reported.%20Median%20progression-free%20interval%20%28PFI%29%20and%20overall%20survival%20%28OS%29%20were%202.3%20and%2016.7%20months%2C%20respectively.%20Multi-modal%20deep%20%5Cu2028learning-based%20analysis%20including%20MRI%2C%20cytokines%2C%20and%20lymphocytes%5C%2Fneutrophil%20ratio%20isolated%20the%20patients%20presenting%20pseudoprogression%2C%20the%20longest%20PFI%20and%20those%20with%20the%20longest%20OS%2C%20but%20statistical%20significance%20cannot%20be%20established%20considering%20phase%20I%20data%20only.%5CnCONCLUSION%3A%20Combination%20of%20hFSRT%20and%20Durvalumab%20in%20recurrent%20GB%20was%20well%20tolerated%20in%20this%20phase%20I%20study.%20These%20encouraging%20results%20led%20to%20an%20ongoing%20randomized%20phase%20II.%20%28ClinicalTrials.gov%20Identifier%3A%20NCT02866747%29.%22%2C%22date%22%3A%222023-09-07%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1093%5C%2Foncolo%5C%2Foyad095%22%2C%22ISSN%22%3A%221549-490X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222023-09-11T12%3A48%3A30Z%22%7D%7D%2C%7B%22key%22%3A%22YNU7BTVY%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Prat%20et%20al.%22%2C%22parsedDate%22%3A%222023-08%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EPrat%2C%20M%26%23xE9%3Blissa%2C%20Kimberley%20Coulson%2C%20Cl%26%23xE9%3Bment%20Blot%2C%20Godefroy%20Jacquemin%2C%20Mathilde%20Romano%2C%20Marie-Laure%20Renoud%2C%20Mohamad%20AlaEddine%2C%20et%20al.%20%26%23x201C%3BPPAR%26%23x3B3%3B%20Activation%20Modulates%20the%20Balance%20of%20Peritoneal%20Macrophage%20Populations%20to%20Suppress%20Ovarian%20Tumor%20Growth%20and%20Tumor-Induced%20Immunosuppression.%26%23x201D%3B%20%3Ci%3EJournal%20for%20Immunotherapy%20of%20Cancer%3C%5C%2Fi%3E%2011%2C%20no.%208%20%28August%202023%29%3A%20e007031.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fjitc-2023-007031%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fjitc-2023-007031%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22PPAR%5Cu03b3%20activation%20modulates%20the%20balance%20of%20peritoneal%20macrophage%20populations%20to%20suppress%20ovarian%20tumor%20growth%20and%20tumor-induced%20immunosuppression%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%5Cu00e9lissa%22%2C%22lastName%22%3A%22Prat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kimberley%22%2C%22lastName%22%3A%22Coulson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9ment%22%2C%22lastName%22%3A%22Blot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Godefroy%22%2C%22lastName%22%3A%22Jacquemin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Romano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Laure%22%2C%22lastName%22%3A%22Renoud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mohamad%22%2C%22lastName%22%3A%22AlaEddine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Augustin%22%2C%22lastName%22%3A%22Le%20Naour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Authier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mouna%20Chirine%22%2C%22lastName%22%3A%22Rahabi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Khaddouj%22%2C%22lastName%22%3A%22Benmoussa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Salon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%5Cu00e9lissa%22%2C%22lastName%22%3A%22Parny%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Pierre%22%2C%22lastName%22%3A%22Delord%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gwena%5Cu00ebl%22%2C%22lastName%22%3A%22Ferron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lise%22%2C%22lastName%22%3A%22Lef%5Cu00e8vre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bettina%22%2C%22lastName%22%3A%22Couderc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agn%5Cu00e8s%22%2C%22lastName%22%3A%22Coste%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Ovarian%20adenocarcinoma%20%28OVAD%29%20frequently%20metastasizes%20to%20the%20peritoneal%20cavity%20and%20manifests%20by%20the%20formation%20of%20ascites%2C%20which%20constitutes%20a%20tumor-promoting%20microenvironment.%20In%20the%20peritoneal%20cavity%2C%20two%20developmentally%2C%20phenotypically%20and%20functionally%20distinct%20macrophage%20subsets%2C%20immunocompetent%20large%20peritoneal%20macrophages%20%28LPM%29%20and%20immunosuppressive%20small%20peritoneal%20macrophages%20%28SPM%29%2C%20coexist.%20Because%20peroxisome%20proliferator-activated%20receptor%20%5Cu03b3%20%28PPAR%5Cu03b3%29%20is%20a%20critical%20factor%20participating%20in%20macrophage%20differentiation%20and%20cooperates%20with%20CCAAT%5C%2Fenhancer%20binding%20protein%20%5Cu03b2%20%28C%5C%2FEBP%5Cu03b2%29%2C%20a%20transcription%20factor%20essential%20for%20SPM-to-LPM%20differentiation%2C%20PPAR%5Cu03b3%20could%20be%20also%20involved%20in%20the%20regulation%20of%20SPM%5C%2FLPM%20balance%20and%20could%20be%20a%20promising%20therapeutic%20target.%5CnMETHODS%3A%20To%20evaluate%20the%2015%28S%29-hydroxyeicosatetraenoic%20acid%20%28HETE%29%2C%20a%20PPAR%5Cu03b3%20endogenous%20ligand%2C%20impact%20on%20ovarian%20tumor%20growth%2C%20we%20intraperitoneally%20injected%2015%28S%29-HETE%20into%20a%20murine%20ovarian%20cancer%20model.%20This%20experimental%20model%20consists%20in%20the%20intraperitoneally%20injection%20of%20ID8%20cells%20expressing%20luciferase%20into%20syngeneic%20C57BL%5C%2F6%20female%20mice.%20This%20ID8%20orthotopic%20mouse%20model%20is%20a%20well-established%20experimental%20model%20of%20end-stage%20epithelial%20OVAD.%20Tumor%20progression%20was%20monitored%20using%20an%20in%20vivo%20imaging%20system.%20Peritoneal%20immune%20cells%20in%20ascites%20were%20analyzed%20by%20flow%20cytometry%20and%20cell%20sorting.%20To%20determine%20whether%20the%20impact%20of%2015%28S%29-HETE%20in%20tumor%20development%20is%20mediated%20through%20the%20macrophages%2C%20these%20cells%20were%20depleted%20by%20injection%20of%20liposomal%20clodronate.%20To%20further%20dissect%20how%2015%28S%29-HETE%20mediated%20its%20antitumor%20effect%2C%20we%20assessed%20the%20tumor%20burden%20in%20tumor-bearing%20mice%20in%20which%20the%20PPAR%5Cu03b3%20gene%20was%20selectively%20disrupted%20in%20myeloid-derived%20cells%20and%20in%20mice%20deficient%20of%20the%20recombination-activating%20gene%20Rag2.%20Finally%2C%20to%20validate%20our%20data%20in%20humans%2C%20we%20isolated%20and%20treated%20macrophages%20from%20ascites%20of%20individuals%20with%20OVAD.%5CnRESULTS%3A%20Here%20we%20show%2C%20in%20the%20murine%20experimental%20model%20of%20OVAD%2C%20that%2015%28S%29-HETE%20treatment%20significantly%20suppresses%20the%20tumor%20growth%2C%20which%20is%20associated%20with%20the%20differentiation%20of%20SPM%20into%20LPM%20and%20the%20LPM%20residency%20in%20the%20peritoneal%20cavity.%20We%20demonstrate%20that%20C%5C%2FEBP%5Cu03b2%20and%20GATA6%20play%20a%20central%20role%20in%20SPM-to-LPM%20differentiation%20and%20in%20LPM%20peritoneal%20residence%20through%20PPAR%5Cu03b3%20activation%20during%20OVAD.%20Moreover%2C%20this%20SPM-to-LPM%20switch%20is%20associated%20with%20the%20increase%20of%20the%20effector%5C%2Fregulatory%20T-cell%20ratio.%20Finally%2C%20we%20report%20that%2015%28S%29-HETE%20attenuates%20immunosuppressive%20properties%20of%20human%20ovarian%20tumor-associated%20macrophages%20from%20ascites.%5CnCONCLUSION%3A%20Altogether%2C%20these%20results%20promote%20PPAR%5Cu03b3%20as%20a%20potential%20therapeutic%20target%20to%20restrain%20OVAD%20development%20and%20strengthen%20the%20use%20of%20PPAR%5Cu03b3%20agonists%20in%20anticancer%20therapy.%22%2C%22date%22%3A%222023-08%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1136%5C%2Fjitc-2023-007031%22%2C%22ISSN%22%3A%222051-1426%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222023-08-21T09%3A26%3A57Z%22%7D%7D%2C%7B%22key%22%3A%22YL28TN9P%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Tensaouti%20et%20al.%22%2C%22parsedDate%22%3A%222023-06%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ETensaouti%2C%20Fatima%2C%20Franck%20Desmoulin%2C%20Julia%20Gilhodes%2C%20Margaux%20Roques%2C%20Soleakhena%20Ken%2C%20Jean-Albert%20Lotterie%2C%20Georges%20No%26%23xEB%3Bl%2C%20et%20al.%20%26%23x201C%3BIs%20Pre-Radiotherapy%20Metabolic%20Heterogeneity%20of%20Glioblastoma%20Predictive%20of%20Progression-Free%20Survival%3F%26%23x201D%3B%20%3Ci%3ERadiotherapy%20and%20Oncology%3A%20Journal%20of%20the%20European%20Society%20for%20Therapeutic%20Radiology%20and%20Oncology%3C%5C%2Fi%3E%20183%20%28June%202023%29%3A%20109665.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.radonc.2023.109665%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.radonc.2023.109665%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Is%20pre-radiotherapy%20metabolic%20heterogeneity%20of%20glioblastoma%20predictive%20of%20progression-free%20survival%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fatima%22%2C%22lastName%22%3A%22Tensaouti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franck%22%2C%22lastName%22%3A%22Desmoulin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julia%22%2C%22lastName%22%3A%22Gilhodes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Margaux%22%2C%22lastName%22%3A%22Roques%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Soleakhena%22%2C%22lastName%22%3A%22Ken%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Albert%22%2C%22lastName%22%3A%22Lotterie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Georges%22%2C%22lastName%22%3A%22No%5Cu00ebl%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Truc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Pierre%22%2C%22lastName%22%3A%22Sunyach%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Charissoux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Magn%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Lubrano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrice%22%2C%22lastName%22%3A%22P%5Cu00e9ran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Cohen-Jonathan%20Moyal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Laprie%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%20AND%20PURPOSE%3A%20All%20glioblastoma%20subtypes%20share%20the%20hallmark%20of%20aggressive%20invasion%2C%20meaning%20that%20it%20is%20crucial%20to%20identify%20their%20different%20components%20if%20we%20are%20to%20ensure%20effective%20treatment%20and%20improve%20survival.%20Proton%20MR%20spectroscopic%20imaging%20%28MRSI%29%20is%20a%20noninvasive%20technique%20that%20yields%20metabolic%20information%20and%20is%20able%20to%20identify%20pathological%20tissue%20with%20high%20accuracy.%20The%20aim%20of%20the%20present%20study%20was%20to%20identify%20clusters%20of%20metabolic%20heterogeneity%2C%20using%20a%20large%20MRSI%20dataset%2C%20and%20determine%20which%20of%20these%20clusters%20are%20predictive%20of%20progression-free%20survival%20%28PFS%29.%5CnMATERIALS%20AND%20METHODS%3A%20MRSI%20data%20of%20180%20patients%20acquired%20in%20a%20pre-radiotherapy%20examination%20were%20included%20in%20the%20prospective%20SPECTRO-GLIO%20trial.%20Eight%20features%20were%20extracted%20for%20each%20spectrum%3A%20Cho%5C%2FNAA%2C%20NAA%5C%2FCr%2C%20Cho%5C%2FCr%2C%20Lac%5C%2FNAA%2C%20and%20the%20ratio%20of%20each%20metabolite%20to%20the%20sum%20of%20all%20the%20metabolites.%20Clustering%20of%20data%20was%20performed%20using%20a%20mini-batch%20k-means%20algorithm.%20The%20Cox%20model%20and%20logrank%20test%20were%20used%20for%20PFS%20analysis.%5CnRESULTS%3A%20Five%20clusters%20were%20identified%20as%20sharing%20similar%20metabolic%20information%20and%20being%20predictive%20of%20PFS.%20Two%20clusters%20revealed%20metabolic%20abnormalities.%20PFS%20was%20lower%20when%20Cluster%202%20was%20the%20dominant%20cluster%20in%20patients%27%20MRSI%20data.%20Among%20the%20metabolites%2C%20lactate%20%28present%20in%20this%20cluster%20and%20in%20Cluster%205%29%20was%20the%20most%20statistically%20significant%20predictor%20of%20poor%20outcome.%5CnCONCLUSION%3A%20Results%20showed%20that%20pre-radiotherapy%20MRSI%20can%20be%20used%20to%20reveal%20tumor%20heterogeneity.%20Groups%20of%20spectra%2C%20which%20have%20the%20same%20metabolic%20information%2C%20reflect%20the%20different%20tissue%20components%20representative%20of%20tumor%20burden%20proliferation%20and%20hypoxia.%20Clusters%20with%20metabolic%20abnormalities%20and%20high%20lactate%20are%20predictive%20of%20PFS.%22%2C%22date%22%3A%222023-06%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.radonc.2023.109665%22%2C%22ISSN%22%3A%221879-0887%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222023-06-05T13%3A59%3A39Z%22%7D%7D%2C%7B%22key%22%3A%22HKLPF9I3%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Hern%5Cu00e1ndez-Verdin%20et%20al.%22%2C%22parsedDate%22%3A%222023-02%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EHern%26%23xE1%3Bndez-Verdin%2C%20I.%2C%20E.%20Kirasic%2C%20K.%20Wienand%2C%20K.%20Mokhtari%2C%20S.%20Eimer%2C%20H.%20Loiseau%2C%20A.%20Rousseau%2C%20et%20al.%20%26%23x201C%3BMolecular%20and%20Clinical%20Diversity%20in%20Primary%20Central%20Nervous%20System%20Lymphoma.%26%23x201D%3B%20%3Ci%3EAnnals%20of%20Oncology%3A%20Official%20Journal%20of%20the%20European%20Society%20for%20Medical%20Oncology%3C%5C%2Fi%3E%2034%2C%20no.%202%20%28February%202023%29%3A%20186%26%23x2013%3B99.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.annonc.2022.11.002%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.annonc.2022.11.002%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Molecular%20and%20clinical%20diversity%20in%20primary%20central%20nervous%20system%20lymphoma%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.%22%2C%22lastName%22%3A%22Hern%5Cu00e1ndez-Verdin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Kirasic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Wienand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Mokhtari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Eimer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Loiseau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Rousseau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Paillassa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Ahle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Lerintiu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Uro-Coste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Oberic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Figarella-Branger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%22%2C%22lastName%22%3A%22Chinot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Gauchotte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Taillandier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.-P.%22%2C%22lastName%22%3A%22Marolleau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Polivka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Adam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Ursu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Schmitt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Barillot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Nichelli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Lozano-S%5Cu00e1nchez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.-J.%22%2C%22lastName%22%3A%22Iba%5Cu00f1ez-Juli%5Cu00e1%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Peyre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Mathon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%22%2C%22lastName%22%3A%22Abada%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Charlotte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Davi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Stewart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22de%20Reyni%5Cu00e8s%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Choquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Soussain%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Houillier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Chapuy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Hoang-Xuan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Alentorn%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Primary%20central%20nervous%20system%20lymphoma%20%28PCNSL%29%20is%20a%20rare%20and%20distinct%20entity%20within%20diffuse%20large%20B-cell%20lymphoma%20presenting%20with%20variable%20response%20rates%20probably%20to%20underlying%20molecular%20heterogeneity.%5CnPATIENTS%20AND%20METHODS%3A%20To%20identify%20and%20characterize%20PCNSL%20heterogeneity%20and%20facilitate%20clinical%20translation%2C%20we%20carried%20out%20a%20comprehensive%20multi-omic%20analysis%20%5Bwhole-exome%20sequencing%2C%20RNA%20sequencing%20%28RNA-seq%29%2C%20methylation%20sequencing%2C%20and%20clinical%20features%5D%20in%20a%20discovery%20cohort%20of%20147%20fresh-frozen%20%28FF%29%20immunocompetent%20PCNSLs%20and%20a%20validation%20cohort%20of%20formalin-fixed%2C%20paraffin-embedded%20%28FFPE%29%2093%20PCNSLs%20with%20RNA-seq%20and%20clinico-radiological%20data.%5CnRESULTS%3A%20Consensus%20clustering%20of%20multi-omic%20data%20uncovered%20concordant%20classification%20of%20four%20robust%2C%20non-overlapping%2C%20prognostically%20significant%20clusters%20%28CS%29.%20The%20CS1%20and%20CS2%20groups%20presented%20an%20immune-cold%20hypermethylated%20profile%20but%20a%20distinct%20clinical%20behavior.%20The%20%27immune-hot%27%20CS4%20group%2C%20enriched%20with%20mutations%20increasing%20the%20Janus%20kinase%20%28JAK%29-signal%20transducer%20and%20activator%20of%20transcription%20%28STAT%29%20and%20nuclear%20factor-%5Cu03baB%20activity%2C%20had%20the%20most%20favorable%20clinical%20outcome%2C%20while%20the%20heterogeneous-immune%20CS3%20group%20had%20the%20worse%20prognosis%20probably%20due%20to%20its%20association%20with%20meningeal%20infiltration%20and%20enriched%20HIST1H1E%20mutations.%20CS1%20was%20characterized%20by%20high%20Polycomb%20repressive%20complex%202%20activity%20and%20CDKN2A%5C%2FB%20loss%20leading%20to%20higher%20proliferation%20activity.%20Integrated%20analysis%20on%20proposed%20targets%20suggests%20potential%20use%20of%20immune%20checkpoint%20inhibitors%5C%2FJAK1%20inhibitors%20for%20CS4%2C%20cyclin%20D-Cdk4%2C6%20plus%20phosphoinositide%203-kinase%20%28PI3K%29%20inhibitors%20for%20CS1%2C%20lenalidomide%5C%2Fdemethylating%20drugs%20for%20CS2%2C%20and%20enhancer%20of%20zeste%202%20polycomb%20repressive%20complex%202%20subunit%20%28EZH2%29%20inhibitors%20for%20CS3.%20We%20developed%20an%20algorithm%20to%20identify%20the%20PCNSL%20subtypes%20using%20RNA-seq%20data%20from%20either%20FFPE%20or%20FF%20tissue.%5CnCONCLUSIONS%3A%20The%20integration%20of%20genome-wide%20data%20from%20multi-omic%20data%20revealed%20four%20molecular%20patterns%20in%20PCNSL%20with%20a%20distinctive%20prognostic%20impact%20that%20provides%20a%20basis%20for%20future%20clinical%20stratification%20and%20subtype-based%20targeted%20interventions.%22%2C%22date%22%3A%222023-02%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.annonc.2022.11.002%22%2C%22ISSN%22%3A%221569-8041%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222023-03-21T14%3A41%3A19Z%22%7D%7D%2C%7B%22key%22%3A%22E54W9ELZ%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Tauzi%5Cu00e8de-Espariat%20et%20al.%22%2C%22parsedDate%22%3A%222023-02-13%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ETauzi%26%23xE8%3Bde-Espariat%2C%20Arnault%2C%20Emmanuelle%20Uro-Coste%2C%20Philipp%20Sievers%2C%20Yvan%20Nicaise%2C%20Cassandra%20Mariet%2C%20Aurore%20Siegfried%2C%20Ga%26%23xEB%3Blle%20Pierron%2C%20et%20al.%20%26%23x201C%3BCNS%20Tumor%20with%20EP300%3A%3ABCOR%20Fusion%3A%20Discussing%20Its%20Prevalence%20in%20Adult%20Population.%26%23x201D%3B%20%3Ci%3EActa%20Neuropathologica%20Communications%3C%5C%2Fi%3E%2011%2C%20no.%201%20%28February%2013%2C%202023%29%3A%2026.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs40478-023-01523-y%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs40478-023-01523-y%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22CNS%20tumor%20with%20EP300%3A%3ABCOR%20fusion%3A%20discussing%20its%20prevalence%20in%20adult%20population%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnault%22%2C%22lastName%22%3A%22Tauzi%5Cu00e8de-Espariat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Uro-Coste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philipp%22%2C%22lastName%22%3A%22Sievers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yvan%22%2C%22lastName%22%3A%22Nicaise%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cassandra%22%2C%22lastName%22%3A%22Mariet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aurore%22%2C%22lastName%22%3A%22Siegfried%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ga%5Cu00eblle%22%2C%22lastName%22%3A%22Pierron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Delphine%22%2C%22lastName%22%3A%22Guillemot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%22%2C%22lastName%22%3A%22Benzakoun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Johan%22%2C%22lastName%22%3A%22Pallud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Margaux%22%2C%22lastName%22%3A%22Roques%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrice%22%2C%22lastName%22%3A%22Bonneville%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Delphine%22%2C%22lastName%22%3A%22Larrieu-Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%22%2C%22lastName%22%3A%22Chaynes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rapha%5Cu00ebl%22%2C%22lastName%22%3A%22Saffroy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jocelyne%22%2C%22lastName%22%3A%22Hamelin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lauren%22%2C%22lastName%22%3A%22Hasty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alice%22%2C%22lastName%22%3A%22M%5Cu00e9tais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrice%22%2C%22lastName%22%3A%22Chr%5Cu00e9tien%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcel%22%2C%22lastName%22%3A%22Kool%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Johannes%22%2C%22lastName%22%3A%22Gojo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascale%22%2C%22lastName%22%3A%22Varlet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22RENOCLIP-LOC%22%7D%5D%2C%22abstractNote%22%3A%22The%20Central%20Nervous%20System%20%28CNS%29%20tumor%20with%20BCOR%20internal%20tandem%20duplication%20%28ITD%29%20has%20recently%20been%20added%20as%20a%20novel%20embryonal%20histomolecular%20tumor%20type%20to%20the%202021%20World%20Health%20Organization%20%28WHO%29%20Classification%20of%20CNS%20Tumors.%20In%20addition%2C%20other%20CNS%20tumors%20harboring%20a%20BCOR%5C%2FBCORL1%20fusion%2C%20which%20are%20defined%20by%20a%20distinct%20DNA-methylation%20profile%2C%20have%20been%20recently%20identified%20in%20the%20literature%20but%20clinical%2C%20radiological%20and%20histopathological%20data%20remain%20scarce.%20Herein%2C%20we%20present%20two%20adult%20cases%20of%20CNS%20tumors%20with%20EP300%3A%3ABCOR%20fusion.%20These%20two%20cases%20presented%20radiological%2C%20histopathological%2C%20and%20immunohistochemical%20homologies%20with%20CNS%20tumors%20having%20BCOR%20ITD%20in%20children.%20To%20compare%20these%20tumors%20with%20different%20BCOR%20alterations%2C%20we%20performed%20a%20literature%20review%20with%20a%20meta-analysis.%20CNS%20tumors%20with%20EP300%3A%3ABCOR%20fusion%20seem%20to%20be%20distinct%20from%20their%20BCOR%20ITD%20counterparts%20in%20terms%20of%20age%2C%20location%2C%20progression-free%20survival%2C%20tumor%20growth%20pattern%2C%20and%20immunopositivity%20for%20the%20BCOR%20protein.%20CNS%20tumors%20from%20the%20EP300%3A%3ABCOR%20fusion%20methylation%20class%20in%20adults%20may%20be%20added%20to%20the%20future%20WHO%20classification.%22%2C%22date%22%3A%222023-02-13%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs40478-023-01523-y%22%2C%22ISSN%22%3A%222051-5960%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222023-03-21T14%3A40%3A23Z%22%7D%7D%2C%7B%22key%22%3A%22XHV74XPY%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Aboudaram%20et%20al.%22%2C%22parsedDate%22%3A%222023-02-11%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EAboudaram%2C%20Am%26%23xE9%3Blie%2C%20L%26%23xE9%3Bonor%20Chaltiel%2C%20Damien%20Pouessel%2C%20Pierre%20Graff-Cailleaud%2C%20Nicolas%20Benziane-Ouaritini%2C%20Paul%20Sargos%2C%20Ulrike%20Schick%2C%20et%20al.%20%26%23x201C%3BConsolidative%20Radiotherapy%20for%20Metastatic%20Urothelial%20Bladder%20Cancer%20Patients%20with%20No%20Progression%20and%20with%20No%20More%20than%20Five%20Residual%20Metastatic%20Lesions%20Following%20First-Line%20Systemic%20Therapy%3A%20A%20Retrospective%20Analysis.%26%23x201D%3B%20%3Ci%3ECancers%3C%5C%2Fi%3E%2015%2C%20no.%204%20%28February%2011%2C%202023%29%3A%201161.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers15041161%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers15041161%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Consolidative%20Radiotherapy%20for%20Metastatic%20Urothelial%20Bladder%20Cancer%20Patients%20with%20No%20Progression%20and%20with%20No%20More%20than%20Five%20Residual%20Metastatic%20Lesions%20Following%20First-Line%20Systemic%20Therapy%3A%20A%20Retrospective%20Analysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Am%5Cu00e9lie%22%2C%22lastName%22%3A%22Aboudaram%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%5Cu00e9onor%22%2C%22lastName%22%3A%22Chaltiel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damien%22%2C%22lastName%22%3A%22Pouessel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Graff-Cailleaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Benziane-Ouaritini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%22%2C%22lastName%22%3A%22Sargos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ulrike%22%2C%22lastName%22%3A%22Schick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Cr%5Cu00e9hange%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Cohen-Jonathan%20Moyal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Chevreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Khalifa%22%7D%5D%2C%22abstractNote%22%3A%22Local%20consolidative%20radiotherapy%20in%20the%20treatment%20of%20metastatic%20malignancies%20has%20shown%20promising%20results%20in%20several%20types%20of%20tumors.%20The%20objective%20of%20this%20study%20was%20to%20assess%20consolidative%20radiotherapy%20to%20the%20bladder%20and%20to%20residual%20metastases%20in%20metastatic%20urothelial%20bladder%20cancer%20with%20no%20progression%20following%20first-line%20systemic%20therapy.%5CnMATERIALS%5C%2FMETHODS%3A%20Patients%20who%20received%20first-line%20therapy%20for%20the%20treatment%20of%20metastatic%20urothelial%20bladder%20cancer%20%28mUBC%29%20and%20who%20were%20progression-free%20following%20treatment%20with%20no%20more%20than%20five%20residual%20metastases%20were%20retrospectively%20identified%20through%20the%20database%20of%20four%20Comprehensive%20Cancer%20Centers%2C%20between%20January%202005%20and%20December%202018.%20Among%20them%2C%20patients%20who%20received%20subsequent%20definitive%20radiotherapy%20%28of%20EQD2Gy%20%3E%2045Gy%29%20to%20the%20bladder%20and%20residual%20metastases%20were%20included%20in%20the%20consolidative%20group%20%28irradiated%20%28IR%29%20group%29%2C%20and%20the%20other%20patients%20were%20included%20in%20the%20observation%20group%20%28NIR%20group%29.%20Progression-free%20survival%20%28PFS%29%20and%20overall%20survival%20%28OS%29%20were%20determined%20from%20the%20start%20of%20the%20first-line%20chemotherapy%20using%20the%20Kaplan-Meier%20method.%20To%20prevent%20immortal%20time%20bias%2C%20a%20Cox%20model%20with%20time-dependent%20covariates%20and%206-month%20landmark%20analyses%20were%20performed%20to%20examine%20OS%20and%20PFS.%5CnRESULTS%3A%20A%20total%20of%2091%20patients%20with%20at%20least%20stable%20disease%20following%20first-line%20therapy%20and%20with%20no%20more%20than%20five%20residual%20metastases%20were%20analyzed%3A%2051%20in%20the%20IR%20group%20and%2040%20in%20the%20NIR%20group.%20Metachronous%20metastatic%20disease%20was%20more%20frequent%20in%20the%20NIR%20group%20%2819%25%20vs.%205%25%2C%20p%20%3D%200.02%29%3B%20the%20median%20number%20of%20metastases%20in%20the%20IR%20group%20vs.%20in%20the%20NIR%20group%20was%202%20%281-9%29%20vs.%203%20%281-5%29%20%28p%20%3D%200.04%29%20at%20metastatic%20presentation%2C%20and%201%20%280-5%29%20vs.%202%20%280-5%29%20%28p%20%3D%200.18%29%20after%20completion%20of%20chemotherapy%20%28residual%20lesions%29%2C%20respectively.%20Two%20grade%203%20toxicities%20%283.9%25%29%20and%20no%20grade%204%20toxicity%20were%20reported%20in%20the%20IR%20group%20related%20to%20radiotherapy.%20With%20a%20median%20follow%20up%20of%2085.9%20months%20%2895%25%20IC%20%2836.7%3B%20101.6%29%29%2C%20median%20OS%20and%20PFS%20were%2021.7%20months%20%2895%25%20IC%20%2817.1%3B%2029.7%29%29%20and%2011.1%20months%20%2895%25%20IC%20%289.9%3B%2014.1%29%29%20for%20the%20whole%20cohort%2C%20respectively.%20In%20multivariable%20analysis%2C%20consolidative%20radiotherapy%20conferred%20a%20benefit%20in%20both%20PFS%20%28HR%20%3D%200.49%2C%20p%20%3D%200.007%29%20and%20OS%20%28HR%20%3D%200.47%2C%20p%20%3D%200.015%29%20in%20the%20whole%20population%3B%20in%20the%20landmark%20analysis%20at%206%20months%2C%20radiotherapy%20was%20associated%20with%20improved%20OS%20%28HR%20%3D%200.48%2C%20p%20%3D%200.026%29%2C%20with%20a%20trend%20for%20PFS%20%28HR%20%3D%200.57%2C%20p%20%3D%200.082%29.%5CnCONCLUSION%3A%20Consolidative%20radiotherapy%20for%20mUBC%20patients%20who%20have%20not%20progressed%20after%20first-line%20therapy%20and%20with%20limited%20residual%20disease%20seems%20to%20confer%20both%20OS%20and%20PFS%20benefits.%20The%20role%20of%20consolidative%20radiotherapy%20in%20the%20context%20of%20avelumab%20maintenance%20should%20be%20addressed%20prospectively.%22%2C%22date%22%3A%222023-02-11%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3390%5C%2Fcancers15041161%22%2C%22ISSN%22%3A%222072-6694%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222023-03-21T14%3A39%3A47Z%22%7D%7D%2C%7B%22key%22%3A%22GE65ESNX%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Sakata%20et%20al.%22%2C%22parsedDate%22%3A%222023-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ESakata%2C%20Dousatsu%2C%20Ryoichi%20Hirayama%2C%20Wook-Geun%20Shin%2C%20Mauro%20Belli%2C%20Maria%20A.%20Tabocchini%2C%20Robert%20D.%20Stewart%2C%20Oleg%20Belov%2C%20et%20al.%20%26%23x201C%3BPrediction%20of%20DNA%20Rejoining%20Kinetics%20and%20Cell%20Survival%20after%20Proton%20Irradiation%20for%20V79%20Cells%20Using%20Geant4-DNA.%26%23x201D%3B%20%3Ci%3EPhysica%20Medica%3A%20PM%3A%20An%20International%20Journal%20Devoted%20to%20the%20Applications%20of%20Physics%20to%20Medicine%20and%20Biology%3A%20Official%20Journal%20of%20the%20Italian%20Association%20of%20Biomedical%20Physics%20%28AIFB%29%3C%5C%2Fi%3E%20105%20%28January%202023%29%3A%20102508.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ejmp.2022.11.012%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ejmp.2022.11.012%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Prediction%20of%20DNA%20rejoining%20kinetics%20and%20cell%20survival%20after%20proton%20irradiation%20for%20V79%20cells%20using%20Geant4-DNA%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dousatsu%22%2C%22lastName%22%3A%22Sakata%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ryoichi%22%2C%22lastName%22%3A%22Hirayama%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wook-Geun%22%2C%22lastName%22%3A%22Shin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mauro%22%2C%22lastName%22%3A%22Belli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20A.%22%2C%22lastName%22%3A%22Tabocchini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20D.%22%2C%22lastName%22%3A%22Stewart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Oleg%22%2C%22lastName%22%3A%22Belov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mario%20A.%22%2C%22lastName%22%3A%22Bernal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Claude%22%2C%22lastName%22%3A%22Bordage%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeremy%20M.%20C.%22%2C%22lastName%22%3A%22Brown%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Milos%22%2C%22lastName%22%3A%22Dordevic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dimitris%22%2C%22lastName%22%3A%22Emfietzoglou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ziad%22%2C%22lastName%22%3A%22Francis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Susanna%22%2C%22lastName%22%3A%22Guatelli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Taku%22%2C%22lastName%22%3A%22Inaniwa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vladimir%22%2C%22lastName%22%3A%22Ivanchenko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathieu%22%2C%22lastName%22%3A%22Karamitros%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ioanna%22%2C%22lastName%22%3A%22Kyriakou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathanael%22%2C%22lastName%22%3A%22Lampe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zhuxin%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvain%22%2C%22lastName%22%3A%22Meylan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Michelet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Petteri%22%2C%22lastName%22%3A%22Nieminen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yann%22%2C%22lastName%22%3A%22Perrot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ivan%22%2C%22lastName%22%3A%22Petrovic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jose%22%2C%22lastName%22%3A%22Ramos-Mendez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aleksandra%22%2C%22lastName%22%3A%22Ristic-Fira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giovanni%22%2C%22lastName%22%3A%22Santin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan%22%2C%22lastName%22%3A%22Schuemann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hoang%20N.%22%2C%22lastName%22%3A%22Tran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carmen%22%2C%22lastName%22%3A%22Villagrasa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sebastien%22%2C%22lastName%22%3A%22Incerti%22%7D%5D%2C%22abstractNote%22%3A%22PURPOSE%3A%20Track%20structure%20Monte%20Carlo%20%28MC%29%20codes%20have%20achieved%20successful%20outcomes%20in%20the%20quantitative%20investigation%20of%20radiation-induced%20initial%20DNA%20damage.%20The%20aim%20of%20the%20present%20study%20is%20to%20extend%20a%20Geant4-DNA%20radiobiological%20application%20by%20incorporating%20a%20feature%20allowing%20for%20the%20prediction%20of%20DNA%20rejoining%20kinetics%20and%20corresponding%20cell%20surviving%20fraction%20along%20time%20after%20irradiation%2C%20for%20a%20Chinese%20hamster%20V79%20cell%20line%2C%20which%20is%20one%20of%20the%20most%20popular%20and%20widely%20investigated%20cell%20lines%20in%20radiobiology.%5CnMETHODS%3A%20We%20implemented%20the%20Two-Lesion%20Kinetics%20%28TLK%29%20model%2C%20originally%20proposed%20by%20Stewart%2C%20which%20allows%20for%20simulations%20to%20calculate%20residual%20DNA%20damage%20and%20surviving%20fraction%20along%20time%20via%20the%20number%20of%20initial%20DNA%20damage%20and%20its%20complexity%20as%20inputs.%5CnRESULTS%3A%20By%20optimizing%20the%20model%20parameters%20of%20the%20TLK%20model%20in%20accordance%20to%20the%20experimental%20data%20on%20V79%2C%20we%20were%20able%20to%20predict%20both%20DNA%20rejoining%20kinetics%20at%20low%20linear%20energy%20transfers%20%28LET%29%20and%20cell%20surviving%20fraction.%5CnCONCLUSION%3A%20This%20is%20the%20first%20study%20to%20demonstrate%20the%20implementation%20of%20both%20the%20cell%20surviving%20fraction%20and%20the%20DNA%20rejoining%20kinetics%20with%20the%20estimated%20initial%20DNA%20damage%2C%20in%20a%20realistic%20cell%20geometrical%20model%20simulated%20by%20full%20track%20structure%20MC%20simulations%20at%20DNA%20level%20and%20for%20various%20LET.%20These%20simulation%20and%20model%20make%20the%20link%20between%20mechanistic%20physical%5C%2Fchemical%20damage%20processes%20and%20these%20two%20specific%20biological%20endpoints.%22%2C%22date%22%3A%222023-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ejmp.2022.11.012%22%2C%22ISSN%22%3A%221724-191X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222023-01-23T11%3A56%3A00Z%22%7D%7D%2C%7B%22key%22%3A%22PVB59UJW%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22M%5Cu00e9tais%20et%20al.%22%2C%22parsedDate%22%3A%222023-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EM%26%23xE9%3Btais%2C%20Alice%2C%20Yassine%20Bouchoucha%2C%20Thomas%20Kergrohen%2C%20Volodia%20Dangouloff-Ros%2C%20Xavier%20Maynadier%2C%20Yassine%20Ajlil%2C%20Matthieu%20Carton%2C%20et%20al.%20%26%23x201C%3BPediatric%20Spinal%20Pilocytic%20Astrocytomas%20Form%20a%20Distinct%20Epigenetic%20Subclass%20from%20Pilocytic%20Astrocytomas%20of%20Other%20Locations%20and%20Diffuse%20Leptomeningeal%20Glioneuronal%20Tumours.%26%23x201D%3B%20%3Ci%3EActa%20Neuropathologica%3C%5C%2Fi%3E%20145%2C%20no.%201%20%28January%202023%29%3A%2083%26%23x2013%3B95.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00401-022-02512-6%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00401-022-02512-6%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Pediatric%20spinal%20pilocytic%20astrocytomas%20form%20a%20distinct%20epigenetic%20subclass%20from%20pilocytic%20astrocytomas%20of%20other%20locations%20and%20diffuse%20leptomeningeal%20glioneuronal%20tumours%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alice%22%2C%22lastName%22%3A%22M%5Cu00e9tais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yassine%22%2C%22lastName%22%3A%22Bouchoucha%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Kergrohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Volodia%22%2C%22lastName%22%3A%22Dangouloff-Ros%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Maynadier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yassine%22%2C%22lastName%22%3A%22Ajlil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthieu%22%2C%22lastName%22%3A%22Carton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wael%22%2C%22lastName%22%3A%22Yacoub%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raphael%22%2C%22lastName%22%3A%22Saffroy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%22%2C%22lastName%22%3A%22Figarella-Branger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Uro-Coste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Annick%22%2C%22lastName%22%3A%22Sevely%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Delphine%22%2C%22lastName%22%3A%22Larrieu-Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Faisant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Christine%22%2C%22lastName%22%3A%22Machet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ellen%22%2C%22lastName%22%3A%22Wahler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandre%22%2C%22lastName%22%3A%22Roux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandro%22%2C%22lastName%22%3A%22Benichi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kevin%22%2C%22lastName%22%3A%22Beccaria%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Blauwblomme%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Boddaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrice%22%2C%22lastName%22%3A%22Chr%5Cu00e9tien%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Doz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christelle%22%2C%22lastName%22%3A%22Dufour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacques%22%2C%22lastName%22%3A%22Grill%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%20Anne%22%2C%22lastName%22%3A%22Debily%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascale%22%2C%22lastName%22%3A%22Varlet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnault%22%2C%22lastName%22%3A%22Tauzi%5Cu00e8de-Espariat%22%7D%5D%2C%22abstractNote%22%3A%22Pediatric%20spinal%20low-grade%20glioma%20%28LGG%29%20and%20glioneuronal%20tumours%20are%20rare%2C%20accounting%20for%20less%202.8-5.2%25%20of%20pediatric%20LGG.%20New%20tumour%20types%20frequently%20found%20in%20spinal%20location%20such%20as%20diffuse%20leptomeningeal%20glioneuronal%20tumours%20%28DLGNT%29%20have%20been%20added%20to%20the%20World%20Health%20Organization%20%28WHO%29%20classification%20of%20tumours%20of%20the%20central%20nervous%20system%20since%202016%2C%20but%20their%20distinction%20from%20others%20gliomas%20and%20particularly%20from%20pilocytic%20astrocytoma%20%28PA%29%20are%20poorly%20defined.%20Most%20large%20studies%20on%20this%20subject%20were%20published%20before%20the%20era%20of%20the%20molecular%20diagnosis%20and%20did%20not%20address%20the%20differential%20diagnosis%20between%20PAs%20and%20DLGNTs%20in%20this%20peculiar%20location.%20Our%20study%20retrospectively%20examined%20a%20cohort%20of%2028%20children%20with%20LGGs%20and%20glioneuronal%20intramedullary%20tumours%20using%20detailed%20radiological%2C%20clinico-pathological%20and%20molecular%20analysis.%2025%25%20of%20spinal%20PAs%20were%20reclassified%20as%20DLGNTs.%20PA%20and%20DLGNT%20are%20nearly%20indistinguishable%20in%20histopathology%20or%20neuroradiology.%2083%25%20of%20spinal%20DLGNTs%20presented%20first%20without%20leptomeningeal%20contrast%20enhancement.%20Unsupervised%20t-distributed%20stochastic%20neighbor%20embedding%20%28t-SNE%29%20analysis%20of%20DNA%20methylation%20profiles%20showed%20that%20spinal%20PAs%20formed%20a%20unique%20methylation%20cluster%20distinct%20from%20reference%20midline%20and%20posterior%20fossa%20PAs%2C%20whereas%20spinal%20DLGNTs%20clustered%20with%20reference%20DLGNT%20cohort.%20FGFR1%20alterations%20were%20found%20in%2036%25%20of%20spinal%20tumours%20and%20were%20restricted%20to%20PAs.%20Spinal%20PAs%20affected%20significantly%20younger%20patients%20%28median%20age%202%5Cu00a0years%20old%29%20than%20DLGNTs%20%28median%20age%208.2%5Cu00a0years%20old%29.%20Progression-free%20survival%20was%20similar%20among%20the%20two%20groups.%20In%20this%20location%2C%20histopathology%20and%20radiology%20are%20of%20limited%20interest%2C%20but%20molecular%20data%20%28methyloma%2C%201p%20and%20FGFR1%20status%29%20represent%20important%20tools%20differentiating%20these%20two%20mitogen-activated%20protein%20kinase%20%28MAPK%29%20altered%20tumour%20types%2C%20PA%20and%20DLGNT.%20Thus%2C%20these%20molecular%20alterations%20should%20systematically%20be%20explored%20in%20this%20type%20of%20tumour%20in%20a%20spinal%20location.%22%2C%22date%22%3A%222023-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs00401-022-02512-6%22%2C%22ISSN%22%3A%221432-0533%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222023-01-03T10%3A23%3A27Z%22%7D%7D%5D%7D<\/span>\n\n\t\t\t\t
\n
\n
Uro-Coste, Emmanuelle, Arnault Tauziede-Espariat, Charlotte Dubucs, Dan Christian Chiforeanu, Aurore Siegfried, Yvan Nicaise, Luc Bauchet, et al. “Two Novel Tumours with NTRK2 Fusion in the Methylation Class of Extraventricular Neurocytomas, Including One Intraventricular.” Brain Pathology (Zurich, Switzerland)<\/i>, November 23, 2023, e13223. https:\/\/doi.org\/10.1111\/bpa.13223<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Younes, Tony, Frédéric Chatrie, Marianne Zinutti, Luc Simon, Georges Fares, and Laure Vieillevigne. “Optimization of the Eclipse TPS Beam Configuration Parameters for Small Field Dosimetry Using Monte Carlo Simulations and Experimental Measurements.” Physica Medica: PM: An International Journal Devoted to the Applications of Physics to Medicine and Biology: Official Journal of the Italian Association of Biomedical Physics (AIFB)<\/i> 114 (October 2023): 103141. https:\/\/doi.org\/10.1016\/j.ejmp.2023.103141<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Hardcastle, Nicholas, Mirjana Josipovic, Enrico Clementel, Victor Hernandez, Gregory Smyth, Manuela Gober, Lotte Wilke, et al. “Recommendation on the Technical and Dosimetric Data to Be Included in Stereotactic Body Radiation Therapy Clinical Trial Publications Based on a Systematic Review.” Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology<\/i> 190 (December 1, 2023): 110042. https:\/\/doi.org\/10.1016\/j.radonc.2023.110042<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Tauziède-Espariat, Arnault, Emmanuelle Uro-Coste, Yvan Nicaise, Philipp Sievers, Andreas von Deimling, Felix Sahm, Oumaima Aboubakr, Alice Métais, Fabrice Chrétien, and Pascale Varlet. “Refinement of Diagnostic Criteria for Pediatric-Type Diffuse High-Grade Glioma, IDH- and H3-Wildtype, MYCN-Subtype Including Histopathology, TP53, MYCN and ID2 Status.” Acta Neuropathologica Communications<\/i> 11, no. 1 (October 24, 2023): 170. https:\/\/doi.org\/10.1186\/s40478-023-01667-x<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Modesto, Anouchka, David Tougeron, Pierre Tremolières, Philippe Ronchin, Ariane Darut Jouve, Delphine Argo Leignel, Véronique Vendrely, et al. “Association of Radiochemotherapy to Immunotherapy in Unresectable Locally Advanced Oesophageal CarciNoma-Randomized Phase 2 Trial ARION UCGI 33\/PRODIGE 67: The Study Protocol.” BMC Cancer<\/i> 23, no. 1 (October 12, 2023): 966. https:\/\/doi.org\/10.1186\/s12885-023-11227-0<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Robinet, Lucas, Aurore Siegfried, Margaux Roques, Ahmad Berjaoui, and Elizabeth Cohen-Jonathan Moyal. “MRI-Based Deep Learning Tools for MGMT Promoter Methylation Detection: A Thorough Evaluation.” Cancers<\/i> 15, no. 8 (April 12, 2023): 2253. https:\/\/doi.org\/10.3390\/cancers15082253<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Gilhodes, Julia, Adèle Meola, Bastien Cabarrou, Guillaume Peyraga, Caroline Dehais, Dominique Figarella-Branger, François Ducray, et al. “A Multigene Signature Associated with Progression-Free Survival after Treatment for IDH Mutant and 1p\/19q Codeleted Oligodendrogliomas.” Cancers<\/i> 15, no. 12 (June 6, 2023): 3067. https:\/\/doi.org\/10.3390\/cancers15123067<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Khalifa, Jonathan, Noémie Thébault, Clara-Maria Scarlata, Emma Norkowski, Carole Massabeau, Laurent Brouchet, Sophie Peries Bataille, et al. “Immune Changes in Hilar Tumor Draining Lymph Nodes Following Node Sparing Neoadjuvant Chemoradiotherapy of Localized CN0 Non-Small Cell Lung Cancer.” Frontiers in Oncology<\/i> 13 (2023): 1269166. https:\/\/doi.org\/10.3389\/fonc.2023.1269166<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Cartiaux, Benjamin, Alexandra Deviers, Caroline Delmas, Jérôme Abadie, Martí Pumarola Battle, Elizabeth Cohen-Jonathan Moyal, and Giovanni Mogicato. “Evaluation of in Vitro Intrinsic Radiosensitivity and Characterization of Five Canine High-Grade Glioma Cell Lines.” Frontiers in Veterinary Science<\/i> 10 (2023): 1253074. https:\/\/doi.org\/10.3389\/fvets.2023.1253074<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Bentaberry-Rosa, Alexandre, Yvan Nicaise, Caroline Delmas, Valérie Gouazé-Andersson, Elizabeth Cohen-Jonathan-Moyal, and Catherine Seva. “Overexpression of Growth Differentiation Factor 15 in Glioblastoma Stem Cells Promotes Their Radioresistance.” Cancers<\/i> 16, no. 1 (December 20, 2023): 27. https:\/\/doi.org\/10.3390\/cancers16010027<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Huguet, F., O. Riou, D. Pasquier, A. Modesto, L. Quéro, M. Michalet, A. Bordron, et al. “Radiation Therapy of the Primary Tumour and\/or Metastases of Digestive Metastatic Cancers.” Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique<\/i>, October 6, 2023, S1278-3218(23)00209-3. https:\/\/doi.org\/10.1016\/j.canrad.2023.04.007<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Lemarié, Anthony, Vincent Lubrano, Caroline Delmas, Amélie Lusque, Juan-Pablo Cerapio, Marion Perrier, Aurore Siegfried, et al. “The STEMRI Trial: Magnetic Resonance Spectroscopy Imaging Can Define Tumor Areas Enriched in Glioblastoma Stem-like Cells.” Science Advances<\/i> 9, no. 44 (November 3, 2023): eadi0114. https:\/\/doi.org\/10.1126\/sciadv.adi0114<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Darréon, J., C. Massabeau, C. Geffroy, P. Maroun, and L. Simon. “Surface-Guided Radiotherapy Overview: Technical Aspects and Clinical Applications.” Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique<\/i> 27, no. 6–7 (September 2023): 504–10. https:\/\/doi.org\/10.1016\/j.canrad.2023.07.003<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Pouessel, Damien, Soléakhéna Ken, Valérie Gouaze-Andersson, Lucie Piram, Augustin Mervoyer, Delphine Larrieu-Ciron, Bastien Cabarrou, et al. “Hypofractionated Stereotactic Re-Irradiation and  Anti-PDL1 Durvalumab Combination in Recurrent Glioblastoma: STERIMGLI Phase I Results.” The Oncologist<\/i> 28, no. 9 (September 7, 2023): 825-e817. https:\/\/doi.org\/10.1093\/oncolo\/oyad095<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Prat, Mélissa, Kimberley Coulson, Clément Blot, Godefroy Jacquemin, Mathilde Romano, Marie-Laure Renoud, Mohamad AlaEddine, et al. “PPARγ Activation Modulates the Balance of Peritoneal Macrophage Populations to Suppress Ovarian Tumor Growth and Tumor-Induced Immunosuppression.” Journal for Immunotherapy of Cancer<\/i> 11, no. 8 (August 2023): e007031. https:\/\/doi.org\/10.1136\/jitc-2023-007031<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Tensaouti, Fatima, Franck Desmoulin, Julia Gilhodes, Margaux Roques, Soleakhena Ken, Jean-Albert Lotterie, Georges Noël, et al. “Is Pre-Radiotherapy Metabolic Heterogeneity of Glioblastoma Predictive of Progression-Free Survival?” Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology<\/i> 183 (June 2023): 109665. https:\/\/doi.org\/10.1016\/j.radonc.2023.109665<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Hernández-Verdin, I., E. Kirasic, K. Wienand, K. Mokhtari, S. Eimer, H. Loiseau, A. Rousseau, et al. “Molecular and Clinical Diversity in Primary Central Nervous System Lymphoma.” Annals of Oncology: Official Journal of the European Society for Medical Oncology<\/i> 34, no. 2 (February 2023): 186–99. https:\/\/doi.org\/10.1016\/j.annonc.2022.11.002<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Tauziède-Espariat, Arnault, Emmanuelle Uro-Coste, Philipp Sievers, Yvan Nicaise, Cassandra Mariet, Aurore Siegfried, Gaëlle Pierron, et al. “CNS Tumor with EP300::BCOR Fusion: Discussing Its Prevalence in Adult Population.” Acta Neuropathologica Communications<\/i> 11, no. 1 (February 13, 2023): 26. https:\/\/doi.org\/10.1186\/s40478-023-01523-y<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Aboudaram, Amélie, Léonor Chaltiel, Damien Pouessel, Pierre Graff-Cailleaud, Nicolas Benziane-Ouaritini, Paul Sargos, Ulrike Schick, et al. “Consolidative Radiotherapy for Metastatic Urothelial Bladder Cancer Patients with No Progression and with No More than Five Residual Metastatic Lesions Following First-Line Systemic Therapy: A Retrospective Analysis.” Cancers<\/i> 15, no. 4 (February 11, 2023): 1161. https:\/\/doi.org\/10.3390\/cancers15041161<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Sakata, Dousatsu, Ryoichi Hirayama, Wook-Geun Shin, Mauro Belli, Maria A. Tabocchini, Robert D. Stewart, Oleg Belov, et al. “Prediction of DNA Rejoining Kinetics and Cell Survival after Proton Irradiation for V79 Cells Using Geant4-DNA.” Physica Medica: PM: An International Journal Devoted to the Applications of Physics to Medicine and Biology: Official Journal of the Italian Association of Biomedical Physics (AIFB)<\/i> 105 (January 2023): 102508. https:\/\/doi.org\/10.1016\/j.ejmp.2022.11.012<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Métais, Alice, Yassine Bouchoucha, Thomas Kergrohen, Volodia Dangouloff-Ros, Xavier Maynadier, Yassine Ajlil, Matthieu Carton, et al. “Pediatric Spinal Pilocytic Astrocytomas Form a Distinct Epigenetic Subclass from Pilocytic Astrocytomas of Other Locations and Diffuse Leptomeningeal Glioneuronal Tumours.” Acta Neuropathologica<\/i> 145, no. 1 (January 2023): 83–95. https:\/\/doi.org\/10.1007\/s00401-022-02512-6<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n\n\n

[\/et_pb_toggle][et_pb_toggle title=”PUBLICATIONS 2022″ open_toggle_text_color=”#5EC7ED” open_toggle_background_color=”#ffffff” closed_toggle_text_color=”#505659″ closed_toggle_background_color=”#AEE3F6″ icon_color=”#505659″ open_icon_color=”#505659″ _builder_version=”4.19.0″ _module_preset=”default” title_text_color=”#ffffff” title_font=”|600||on|||||” title_text_align=”center” title_font_size=”22px” closed_title_font=”|600|||||||” closed_title_font_size=”22px” body_text_align=”left” body_text_color=”#505659″ body_font_size=”16px” text_orientation=”center” global_colors_info=”{}”]<\/p>\n

\n\n\t\t7813506<\/span>\n\t\t<\/span>\n\t\tMCWU4QSQ<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t2022<\/span>\n <\/span>\n items<\/span>\n\t\t1<\/span>\n\t\tchicago-fullnote-bibliography<\/span>\n\t\t0<\/span>\n\t\tdefault<\/span>\n\t\tasc<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n <\/span>\n 2027<\/span>\n\t\thttps:\/\/www.crct-inserm.fr\/wp-content\/plugins\/zotpress\/<\/span>\n\n\t\t
\n\t\t\t
\n\t\t\t\t%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-234c6e3e6ad67ebfe8f76e9013ea5b93%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22YS46ZKI9%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Modesto%20et%20al.%22%2C%22parsedDate%22%3A%222022-10%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EModesto%2C%20A.%2C%20P.%20Graff%20Cailleaud%2C%20P.%20Blanchard%2C%20P.%20Boisselier%2C%20and%20Y.%20Pointreau.%20%26%23x201C%3B%5BChallenges%20and%20limits%20of%20therapeutic%20de-escalation%20for%20papillomavirus-related%20oropharyngeal%20cancer%5D.%26%23x201D%3B%20%3Ci%3ECancer%20Radiotherapie%3A%20Journal%20De%20La%20Societe%20Francaise%20De%20Radiotherapie%20Oncologique%3C%5C%2Fi%3E%2026%2C%20no.%206%26%23x2013%3B7%20%28October%202022%29%3A%20921%26%23x2013%3B24.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.canrad.2022.06.018%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.canrad.2022.06.018%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22%5BChallenges%20and%20limits%20of%20therapeutic%20de-escalation%20for%20papillomavirus-related%20oropharyngeal%20cancer%5D%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Modesto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Graff%20Cailleaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Blanchard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Boisselier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%22%2C%22lastName%22%3A%22Pointreau%22%7D%5D%2C%22abstractNote%22%3A%22The%20incidence%20of%20HPV-related%20oropharyngeal%20cancers%20has%20been%20increasing%20in%20Western%20countries%20for%20several%20decades.%20If%20they%20are%20individualized%20within%20the%20latest%20TNM%20classification%2C%20the%20current%20standards%20of%20management%20do%20not%20authorize%20the%20management%20of%20these%20patients%20to%20be%20singled%20out.%20However%2C%20their%20distinct%20oncogenesis%20and%20their%20excellent%20prognosis%20compared%20to%20other%20patients%20has%20allowed%20the%20development%20of%20several%20clinical%20trials%20based%20on%20the%20question%20of%20therapeutic%20de-escalation.%20This%20review%20of%20the%20literature%20aims%20to%20take%20stock%20of%20the%20elements%20provided%20by%20clinical%20research%20in%20recent%20years.%22%2C%22date%22%3A%222022-10%22%2C%22language%22%3A%22fre%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.canrad.2022.06.018%22%2C%22ISSN%22%3A%221769-6658%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222023-01-03T10%3A27%3A03Z%22%7D%7D%2C%7B%22key%22%3A%227LQYLPAG%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bikfalvi%20et%20al.%22%2C%22parsedDate%22%3A%222022-11-15%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBikfalvi%2C%20Andreas%2C%20Cristine%20Alves%20da%20Costa%2C%20Tony%20Avril%2C%20Jean-Vianney%20Barnier%2C%20Luc%20Bauchet%2C%20Lucie%20Brisson%2C%20Pierre%20Francois%20Cartron%2C%20et%20al.%20%26%23x201C%3BChallenges%20in%20Glioblastoma%20Research%3A%20Focus%20on%20the%20Tumor%20Microenvironment.%26%23x201D%3B%20%3Ci%3ETrends%20in%20Cancer%3C%5C%2Fi%3E%2C%20November%2015%2C%202022%2C%20S2405-8033%2822%2900220-5.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.trecan.2022.09.005%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.trecan.2022.09.005%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Challenges%20in%20glioblastoma%20research%3A%20focus%20on%20the%20tumor%20microenvironment%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andreas%22%2C%22lastName%22%3A%22Bikfalvi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cristine%20Alves%22%2C%22lastName%22%3A%22da%20Costa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tony%22%2C%22lastName%22%3A%22Avril%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Vianney%22%2C%22lastName%22%3A%22Barnier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luc%22%2C%22lastName%22%3A%22Bauchet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucie%22%2C%22lastName%22%3A%22Brisson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%20Francois%22%2C%22lastName%22%3A%22Cartron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Castel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Chevet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Herv%5Cu00e9%22%2C%22lastName%22%3A%22Chneiweiss%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Clavreul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Constantin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Coronas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Daubon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Monique%22%2C%22lastName%22%3A%22Dontenwill%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francois%22%2C%22lastName%22%3A%22Ducray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Natacha%22%2C%22lastName%22%3A%22Enz-Werle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%22%2C%22lastName%22%3A%22Figarella-Branger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Fournier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-S%5Cu00e9bastien%22%2C%22lastName%22%3A%22Frenel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathieu%22%2C%22lastName%22%3A%22Gabut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Galli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Gavard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Huberfeld%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Hugnot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ahmed%22%2C%22lastName%22%3A%22Idbaih%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Pierre%22%2C%22lastName%22%3A%22Junier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Mathivet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Menei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Meyronet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Mirjolet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrice%22%2C%22lastName%22%3A%22Morin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Mosser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%20Cohen-Jonathan%22%2C%22lastName%22%3A%22Moyal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%5Cu00e9ronique%22%2C%22lastName%22%3A%22Rousseau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michel%22%2C%22lastName%22%3A%22Salzet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Sanson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giorgio%22%2C%22lastName%22%3A%22Seano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emeline%22%2C%22lastName%22%3A%22Tabouret%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Tchoghandjian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Turchi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francois%20M.%22%2C%22lastName%22%3A%22Vallette%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Somya%22%2C%22lastName%22%3A%22Vats%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mait%5Cu00e9%22%2C%22lastName%22%3A%22Verreault%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Virolle%22%7D%5D%2C%22abstractNote%22%3A%22Glioblastoma%20%28GBM%29%20is%20the%20most%20deadly%20type%20of%20malignant%20brain%20tumor%2C%20despite%20extensive%20molecular%20analyses%20of%20GBM%20cells.%20In%20recent%20years%2C%20the%20tumor%20microenvironment%20%28TME%29%20has%20been%20recognized%20as%20an%20important%20player%20and%20therapeutic%20target%20in%20GBM.%20However%2C%20there%20is%20a%20need%20for%20a%20full%20and%20integrated%20understanding%20of%20the%20different%20cellular%20and%20molecular%20components%20involved%20in%20the%20GBM%20TME%20and%20their%20interactions%20for%20the%20development%20of%20more%20efficient%20therapies.%20In%20this%20review%2C%20we%20provide%20a%20comprehensive%20report%20of%20the%20GBM%20TME%2C%20which%20assembles%20the%20contributions%20of%20physicians%20and%20translational%20researchers%20working%20on%20brain%20tumor%20pathology%20and%20therapy%20in%20France.%20We%20propose%20a%20holistic%20view%20of%20the%20subject%20by%20delineating%20the%20specific%20features%20of%20the%20GBM%20TME%20at%20the%20cellular%2C%20molecular%2C%20and%20therapeutic%20levels.%22%2C%22date%22%3A%222022-11-15%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.trecan.2022.09.005%22%2C%22ISSN%22%3A%222405-8025%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222023-01-02T14%3A40%3A01Z%22%7D%7D%2C%7B%22key%22%3A%22F2AFHPD4%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ouvrard%20et%20al.%22%2C%22parsedDate%22%3A%222022-12%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EOuvrard%2C%20Chlo%26%23xE9%3B%2C%20Alice%20M%26%23xE9%3Btais%2C%20Enola%20Brigot%2C%20Charlotte%20Berthaud%2C%20No%26%23xE9%3Bmie%20Pucelle%2C%20Jo%26%23xEB%3Blle%20Lacombe%2C%20Lauren%20Hasty%2C%20et%20al.%20%26%23x201C%3BETV4%20Immunohistostaining%20Is%20a%20Sensitive%20and%20Specific%20Diagnostic%20Biomarker%20for%20CIC-Rearranged%20Sarcoma%20of%20the%20Central%20Nervous%20System.%26%23x201D%3B%20%3Ci%3EHistopathology%3C%5C%2Fi%3E%2081%2C%20no.%206%20%28December%202022%29%3A%20852%26%23x2013%3B55.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fhis.14796%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fhis.14796%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22ETV4%20immunohistostaining%20is%20a%20sensitive%20and%20specific%20diagnostic%20biomarker%20for%20CIC-rearranged%20sarcoma%20of%20the%20central%20nervous%20system%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chlo%5Cu00e9%22%2C%22lastName%22%3A%22Ouvrard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alice%22%2C%22lastName%22%3A%22M%5Cu00e9tais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Enola%22%2C%22lastName%22%3A%22Brigot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Berthaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22No%5Cu00e9mie%22%2C%22lastName%22%3A%22Pucelle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jo%5Cu00eblle%22%2C%22lastName%22%3A%22Lacombe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lauren%22%2C%22lastName%22%3A%22Hasty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrice%22%2C%22lastName%22%3A%22Chr%5Cu00e9tien%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franck%22%2C%22lastName%22%3A%22Bielle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karima%22%2C%22lastName%22%3A%22Mokhtari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%22%2C%22lastName%22%3A%22Cazals-Hatem%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beno%5Cu00eet%22%2C%22lastName%22%3A%22Lhermitte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Uro-Coste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascale%22%2C%22lastName%22%3A%22Varlet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnault%22%2C%22lastName%22%3A%22Tauzi%5Cu00e8de-Espariat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22RENOCLIP-LOC%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222022-12%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1111%5C%2Fhis.14796%22%2C%22ISSN%22%3A%221365-2559%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222022-11-14T11%3A51%3A35Z%22%7D%7D%2C%7B%22key%22%3A%22PKVSIVLI%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Tauzi%5Cu00e8de-Espariat%20et%20al.%22%2C%22parsedDate%22%3A%222022-12%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ETauzi%26%23xE8%3Bde-Espariat%2C%20Arnault%2C%20null%20Volodia-Dangouloff-Ros%2C%20Dominique%20Figarella-Branger%2C%20Emmanuelle%20Uro-Coste%2C%20Yvan%20Nicaise%2C%20Nicolas%20Andr%26%23xE9%3B%2C%20Didier%20Scavarda%2C%20et%20al.%20%26%23x201C%3BClinicopathological%20and%20Molecular%20Characterization%20of%20Three%20Cases%20Classified%20by%20DNA-Methylation%20Profiling%20as%20%26%23x2018%3BGlioneuronal%20Tumors%2C%20NOS%2C%20Subtype%20A.%26%23x2019%3B%26%23x201D%3B%20%3Ci%3EActa%20Neuropathologica%3C%5C%2Fi%3E%20144%2C%20no.%206%20%28December%202022%29%3A%201179%26%23x2013%3B83.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00401-022-02490-9%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00401-022-02490-9%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Clinicopathological%20and%20molecular%20characterization%20of%20three%20cases%20classified%20by%20DNA-methylation%20profiling%20as%20%5C%22Glioneuronal%20Tumors%2C%20NOS%2C%20Subtype%20A%5C%22%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnault%22%2C%22lastName%22%3A%22Tauzi%5Cu00e8de-Espariat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22null%22%2C%22lastName%22%3A%22Volodia-Dangouloff-Ros%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%22%2C%22lastName%22%3A%22Figarella-Branger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Uro-Coste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yvan%22%2C%22lastName%22%3A%22Nicaise%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Andr%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Didier%22%2C%22lastName%22%3A%22Scavarda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beno%5Cu00eet%22%2C%22lastName%22%3A%22Testud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadine%22%2C%22lastName%22%3A%22Girard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rousseau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laetitia%22%2C%22lastName%22%3A%22Basset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Chotard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Jecko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22le%20Loarer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Hostein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Christine%22%2C%22lastName%22%3A%22Machet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%22%2C%22lastName%22%3A%22Tallegas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Listrat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lauren%22%2C%22lastName%22%3A%22Hasty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alice%22%2C%22lastName%22%3A%22M%5Cu00e9tais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrice%22%2C%22lastName%22%3A%22Chr%5Cu00e9tien%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Boddaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascale%22%2C%22lastName%22%3A%22Varlet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22RENOCLIP-LOC%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222022-12%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs00401-022-02490-9%22%2C%22ISSN%22%3A%221432-0533%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222022-11-14T11%3A50%3A11Z%22%7D%7D%2C%7B%22key%22%3A%223PZ2YNL2%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Tauzi%5Cu00e8de-Espariat%20et%20al.%22%2C%22parsedDate%22%3A%222022-10%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ETauzi%26%23xE8%3Bde-Espariat%2C%20Arnault%2C%20Aurore%20Siegfried%2C%20Yvan%20Nicaise%2C%20Dominique%20Figarella-Branger%2C%20Romain%20Appay%2C%20Suhan%20Senova%2C%20Dorian%20Bochaton%2C%20et%20al.%20%26%23x201C%3BA%20Novel%20YAP1-MAML2%20Fusion%20in%20an%20Adult%20Supra-Tentorial%20Ependymoma%2C%20YAP1-Fused.%26%23x201D%3B%20%3Ci%3EBrain%20Tumor%20Pathology%3C%5C%2Fi%3E%2C%20October%202022.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs10014-022-00439-0%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs10014-022-00439-0%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22A%20novel%20YAP1-MAML2%20fusion%20in%20an%20adult%20supra-tentorial%20ependymoma%2C%20YAP1-fused%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnault%22%2C%22lastName%22%3A%22Tauzi%5Cu00e8de-Espariat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aurore%22%2C%22lastName%22%3A%22Siegfried%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yvan%22%2C%22lastName%22%3A%22Nicaise%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%22%2C%22lastName%22%3A%22Figarella-Branger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Appay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Suhan%22%2C%22lastName%22%3A%22Senova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dorian%22%2C%22lastName%22%3A%22Bochaton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lauren%22%2C%22lastName%22%3A%22Hasty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%22%2C%22lastName%22%3A%22Martin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrice%22%2C%22lastName%22%3A%22Chr%5Cu00e9tien%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alice%22%2C%22lastName%22%3A%22M%5Cu00e9tais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascale%22%2C%22lastName%22%3A%22Varlet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Uro-Coste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22RENOCLIP-LOC%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222022-10%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs10014-022-00439-0%22%2C%22ISSN%22%3A%221861-387X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222022-11-03T12%3A54%3A39Z%22%7D%7D%2C%7B%22key%22%3A%22L22AGPBP%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Laprie%20et%20al.%22%2C%22parsedDate%22%3A%222022-10%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELaprie%2C%20A.%2C%20F.%20Tensaouti%2C%20and%20E.%20Cohen-Jonathan%20Moyal.%20%26%23x201C%3B%5BRadiation%20dose%20intensification%20for%20glioblastoma%5D.%26%23x201D%3B%20%3Ci%3ECancer%20Radiotherapie%3A%20Journal%20De%20La%20Societe%20Francaise%20De%20Radiotherapie%20Oncologique%3C%5C%2Fi%3E%2026%2C%20no.%206%26%23x2013%3B7%20%28October%202022%29%3A%20894%26%23x2013%3B98.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.canrad.2022.07.007%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.canrad.2022.07.007%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22%5BRadiation%20dose%20intensification%20for%20glioblastoma%5D%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Laprie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Tensaouti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Cohen-Jonathan%20Moyal%22%7D%5D%2C%22abstractNote%22%3A%22Glioblastoma%20is%20the%20most%20common%20brain%20tumor%20in%20adults%3B%20its%20treatment%20includes%20surgical%20excision%20or%20biopsy%20followed%20by%20radio-chemotherapy.%20Even%20if%20radiotherapy%20increases%20the%20survival%20of%20all%20patients%20regardless%20of%20their%20age%20or%20their%20general%20condition%2C%20there%20are%20always%20sources%20of%20radioresistance%2C%20where%20relapses%20occur%20and%20therefore%20treatment%20fails.%20Indeed%2C%20these%20foci%20result%20in%20a%20local%20relapse%2C%20which%20is%20observed%20in%2095%25%20of%20cases%20in%20the%20irradiation%20fields.%20We%20will%20describe%20here%20the%20current%20approaches%20to%20overcome%20this%20radioresistance%20by%20dose%20escalation%2C%20without%20or%20with%20guidance%20by%20metabolic%20and%20functional%20imaging%20%28dose-painting%29.%20We%20will%20detail%20several%20prospective%20trials%20including%20the%20French%20phase%20III%20trial%2C%20SPECTRO-GLIO%2C%20randomizing%20the%20use%20of%20an%20integrated%20boost%20guided%20by%20spectrometric%20magnetic%20resonance%20imaging%20and%20similar%20trials%20developed%20across%20the%20Atlantic.%20We%20will%20also%20discuss%20approaches%20using%20different%20PET%20markers%20as%20well%20as%20diffusion%20or%20perfusion%20magnetic%20resonance%20imaging.%22%2C%22date%22%3A%222022-10%22%2C%22language%22%3A%22fre%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.canrad.2022.07.007%22%2C%22ISSN%22%3A%221769-6658%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222022-10-25T10%3A36%3A51Z%22%7D%7D%2C%7B%22key%22%3A%228N43PMKS%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Appay%20et%20al.%22%2C%22parsedDate%22%3A%222022-03-16%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EAppay%2C%20Romain%2C%20Franck%20Bielle%2C%20Philipp%20Sievers%2C%20Doriane%20Barets%2C%20Fr%26%23xE9%3Bd%26%23xE9%3Bric%20Fina%2C%20Jean%20Boutonnat%2C%20Adam%20Clovis%2C%20et%20al.%20%26%23x201C%3BRosette-Forming%20Glioneuronal%20Tumours%20Are%20Midline%2C%20FGFR1-Mutated%20Tumours.%26%23x201D%3B%20%3Ci%3ENeuropathology%20and%20Applied%20Neurobiology%3C%5C%2Fi%3E%2C%20March%2016%2C%202022%2C%20e12813.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fnan.12813%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fnan.12813%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Rosette-forming%20glioneuronal%20tumours%20are%20midline%2C%20FGFR1-mutated%20tumours%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Appay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franck%22%2C%22lastName%22%3A%22Bielle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philipp%22%2C%22lastName%22%3A%22Sievers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Doriane%22%2C%22lastName%22%3A%22Barets%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Fina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Boutonnat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adam%22%2C%22lastName%22%3A%22Clovis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Gauchotte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Godfraind%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beno%5Cu00eet%22%2C%22lastName%22%3A%22Lhermitte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claude-Alain%22%2C%22lastName%22%3A%22Maurage%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Meyronet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karima%22%2C%22lastName%22%3A%22Mokhtari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rousseau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnault%22%2C%22lastName%22%3A%22Tauzi%5Cu00e8de-Espariat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Claire%22%2C%22lastName%22%3A%22Tortel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Uro-Coste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fanny%22%2C%22lastName%22%3A%22Burel-Vandenbos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Chotard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florian%22%2C%22lastName%22%3A%22Pesce%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascale%22%2C%22lastName%22%3A%22Varlet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carole%22%2C%22lastName%22%3A%22Colin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%22%2C%22lastName%22%3A%22Figarella-Branger%22%7D%5D%2C%22abstractNote%22%3A%22Rosette-forming%20glioneuronal%20tumour%20%28RGNT%29%20is%20a%20rare%20CNS%20WHO%20grade%201%20brain%20neoplasm.%20According%20to%20WHO%202021%2C%20essential%20diagnostic%20criteria%20are%20a%20%5C%22biphasic%20histomorphology%20with%20neurocytic%20and%20a%20glial%20component%2C%20and%20uniform%20neurocytes%20forming%20rosettes%20and%5C%2For%20perivascular%20pseudorosettes%20associated%20with%20synaptophysin%20expression%5C%22%20and%5C%2For%20DNA%20methylation%20profile%20of%20RGNT%20whereas%20%5C%22FGFR1%20mutation%20with%20co-occurring%20PIK3CA%20and%5C%2For%20NF1%20mutation%5C%22%20are%20desirable%20criteria.%5CnMATERIAL%20AND%20METHODS%3A%20We%20report%20a%20series%20of%2046%20cases%20fulfilling%20the%20essential%20pathological%20diagnostic%20criteria%20for%20RGNT.%20FGFR1%20and%20PIK3CA%20hotspot%20mutations%20were%20searched%20for%20by%20multiplex%20digital%20PCR%20in%20all%20cases%20whereas%20DNA%20methylation%20profiling%20and%5C%2For%20PIK3R1%20and%20NF1%20alterations%20were%20analysed%20in%20a%20subset%20of%20cases.%5CnRESULTS%3A%20Three%20groups%20were%20observed.%20The%20first%20one%20included%2021%20intracranial%20midline%20tumours%20demonstrating%20FGFR1%20mutation%20associated%20with%20PIK3CA%20or%20PIK3R1%20%28n%3D19%29%20or%20NF1%20%28n%3D1%29%20or%20PIK3CA%20and%20NF1%20%28n%3D1%29%20mutation.%20By%20DNA%20methylation%20profiling%2C%208%20cases%20were%20classified%20as%20RGNT%20%28they%20demonstrated%20FGFR1%20and%20PIK3CA%20or%20PIK3R1%20mutations%29.%20Group%202%20comprised%2011%20cases%20associated%20with%20one%20single%20FGFR1%20mutation.%20Group%203%20included%206%20cases%20classified%20as%20LGG%20other%20than%20RGNT%20%281%5C%2F6%20showed%20FGFR1%20mutation%20and%20one%20a%20FGFR1%20and%20NF1%20mutation%29%20and%208%20cases%20without%20FGFR1%20mutation.%20Groups%202%20and%203%20were%20enriched%20in%20lateral%20and%20spinal%20cases.%5CnCONCLUSIONS%3A%20We%20suggest%20adding%20FGFR1%20mutation%20and%20intracranial%20midline%20location%20as%20essential%20diagnostic%20criteria.%20When%20DNA%20methylation%20profiling%20is%20not%20available%2C%20a%20RGNT%20diagnosis%20remains%20certain%20in%20cases%20demonstrating%20characteristic%20pathological%20features%20and%20FGFR1%20mutation%20associated%20with%20either%20PIK3CA%20or%20PIK3R1%20mutation.%22%2C%22date%22%3A%222022-03-16%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1111%5C%2Fnan.12813%22%2C%22ISSN%22%3A%221365-2990%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222022-10-04T08%3A12%3A50Z%22%7D%7D%2C%7B%22key%22%3A%2239TU7CD2%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Maingon%20et%20al.%22%2C%22parsedDate%22%3A%222022-04%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMaingon%2C%20P.%2C%20V.%20Marchesi%2C%20D.%20Azria%2C%20J.%20Balosso%2C%20%26%23xC9%3B%20Deutsch%2C%20%26%23xC9%3B%20Cohen%20Jonathan-Moyal%2C%20P.%20Giraud%2C%20and%20%26%23xC9%3B%20Bayart.%20%26%23x201C%3BRadioTransNet%3A%20Preclinical%20Research%20Network%20Coordinated%20at%20the%20SFRO%20and%20SFPM.%26%23x201D%3B%20%3Ci%3ECancer%20Radiotherapie%3A%20Journal%20De%20La%20Societe%20Francaise%20De%20Radiotherapie%20Oncologique%3C%5C%2Fi%3E%2026%2C%20no.%201%26%23x2013%3B2%20%28April%202022%29%3A%20108%26%23x2013%3B15.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.canrad.2021.08.003%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.canrad.2021.08.003%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22RadioTransNet%3A%20Preclinical%20research%20network%20coordinated%20at%20the%20SFRO%20and%20SFPM%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Maingon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Marchesi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Azria%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Balosso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%5Cu00c9%22%2C%22lastName%22%3A%22Deutsch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%5Cu00c9%22%2C%22lastName%22%3A%22Cohen%20Jonathan-Moyal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Giraud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%5Cu00c9%22%2C%22lastName%22%3A%22Bayart%22%7D%5D%2C%22abstractNote%22%3A%22The%20RadioTransNet%20programme%20launched%20under%20the%20auspices%20of%20French%20societies%20for%20radiation%20oncology%20%28SFRO%29%20and%20medical%20physics%20%28SFPM%29%20was%20approved%20by%20the%20French%20national%20cancer%20institute%20%28INCa%29%20in%20December%202018%20and%20is%20dedicated%20to%20proposing%20a%20relevant%20national%20and%20transversal%20structure%20for%20preclinical%20research%20including%20translational%20research%20in%20radiation%20oncology%20with%20well-defined%20priority%20areas%20of%20research.%20Its%20activities%2C%20coordinated%20by%20a%20scientific%20committee%20that%20includes%20radiation%20oncologists%2C%20medical%20physicists%2C%20academic%20biologists%2C%20are%20structured%20around%20several%20main%20areas%2C%20i.e.%3A%20target%20volume%20definition%2C%20interaction%20of%20radiation%20with%20normal%20tissues%2C%20combined%20treatments%20and%20modern%20dose%20calculation%20approaches.%20Four%20work%20packages%20have%20been%20created%20in%20these%20areas%20and%20are%20associated%20with%20other%20objectives%20pertaining%20to%20fundamental%20radiobiology%2C%20early%20implementation%20of%20new%20drugs%20in%20a%20preclinical%20setting%2C%20contribution%20of%20imaging%20in%20this%20task%2C%20research%20in%20medical%20physics%20including%20transversal%20components%20such%20as%20medical%20oncology%2C%20radiology%2C%20nuclear%20medicine%20and%20also%20cost%5C%2Fefficiency%20evaluation.%20All%20these%20tasks%20will%20be%20included%20in%20a%20national%20network%20that%20uses%20the%20complementary%20expertise%20provided%20by%20partners%20involved%20in%20the%20scheme.%20Calls%20for%20proposals%20will%20be%20selected%20by%20the%20scientific%20council%20to%20be%20submitted%20to%20INCa%20and%20the%20various%20academic%20associations%20to%20obtain%20funding%20for%20the%20human%20and%20technical%20resources%20required%20to%20conduct%20under%20optimal%20conditions%20projects%20in%20preclinical%20and%20translational%20research%20in%20radiation-oncology.%22%2C%22date%22%3A%222022-04%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.canrad.2021.08.003%22%2C%22ISSN%22%3A%221769-6658%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222022-10-04T08%3A12%3A43Z%22%7D%7D%2C%7B%22key%22%3A%22I97PGZFR%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Sidibe%20et%20al.%22%2C%22parsedDate%22%3A%222022-01-26%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ESidibe%2C%20Ingrid%2C%20Fatima%20Tensaouti%2C%20Margaux%20Roques%2C%20Elizabeth%20Cohen-Jonathan-Moyal%2C%20and%20Anne%20Laprie.%20%26%23x201C%3BPseudoprogression%20in%20Glioblastoma%3A%20Role%20of%20Metabolic%20and%20Functional%20MRI-Systematic%20Review.%26%23x201D%3B%20%3Ci%3EBiomedicines%3C%5C%2Fi%3E%2010%2C%20no.%202%20%28January%2026%2C%202022%29%3A%20285.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fbiomedicines10020285%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fbiomedicines10020285%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Pseudoprogression%20in%20Glioblastoma%3A%20Role%20of%20Metabolic%20and%20Functional%20MRI-Systematic%20Review%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ingrid%22%2C%22lastName%22%3A%22Sidibe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fatima%22%2C%22lastName%22%3A%22Tensaouti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Margaux%22%2C%22lastName%22%3A%22Roques%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Cohen-Jonathan-Moyal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Laprie%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Glioblastoma%20is%20the%20most%20frequent%20malignant%20primitive%20brain%20tumor%20in%20adults.%20The%20treatment%20includes%20surgery%2C%20radiotherapy%2C%20and%20chemotherapy.%20During%20follow-up%2C%20combined%20chemoradiotherapy%20can%20induce%20treatment-related%20changes%20mimicking%20tumor%20progression%20on%20medical%20imaging%2C%20such%20as%20pseudoprogression%20%28PsP%29.%20Differentiating%20PsP%20from%20true%20progression%20%28TP%29%20remains%20a%20challenge%20for%20radiologists%20and%20oncologists%2C%20who%20need%20to%20promptly%20start%20a%20second-line%20treatment%20in%20the%20case%20of%20TP.%20Advanced%20magnetic%20resonance%20imaging%20%28MRI%29%20techniques%20such%20as%20diffusion-weighted%20imaging%2C%20perfusion%20MRI%2C%20and%20proton%20magnetic%20resonance%20spectroscopic%20imaging%20are%20more%20efficient%20than%20conventional%20MRI%20in%20differentiating%20PsP%20from%20TP.%20None%20of%20these%20techniques%20are%20fully%20effective%2C%20but%20current%20advances%20in%20computer%20science%20and%20the%20advent%20of%20artificial%20intelligence%20are%20opening%20up%20new%20possibilities%20in%20the%20imaging%20field%20with%20radiomics%20%28i.e.%2C%20extraction%20of%20a%20large%20number%20of%20quantitative%20MRI%20features%20describing%20tumor%20density%2C%20texture%2C%20and%20geometry%29.%20These%20features%20are%20used%20to%20build%20predictive%20models%20for%20diagnosis%2C%20prognosis%2C%20and%20therapeutic%20response.%5CnMETHOD%3A%20Out%20of%207350%20records%20for%20MR%20spectroscopy%2C%20GBM%2C%20glioma%2C%20recurrence%2C%20diffusion%2C%20perfusion%2C%20pseudoprogression%2C%20radiomics%2C%20and%20advanced%20imaging%2C%20we%20screened%20574%20papers.%20A%20total%20of%20228%20were%20eligible%2C%20and%20we%20analyzed%2072%20of%20them%2C%20in%20order%20to%20establish%20the%20role%20of%20each%20imaging%20modality%20and%20the%20usefulness%20and%20limitations%20of%20radiomics%20analysis.%22%2C%22date%22%3A%222022-01-26%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3390%5C%2Fbiomedicines10020285%22%2C%22ISSN%22%3A%222227-9059%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222022-10-04T08%3A12%3A38Z%22%7D%7D%2C%7B%22key%22%3A%22ABB2YKUU%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22M%5Cu00e9tais%20et%20al.%22%2C%22parsedDate%22%3A%222022-02%22%2C%22numChildren%22%3A6%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EM%26%23xE9%3Btais%2C%20Alice%2C%20Romain%20Appay%2C%20M%26%23xE9%3Blanie%20Pag%26%23xE8%3Bs%2C%20Catherine%20Gallardo%2C%20Karen%20Silva%2C%20Aurore%20Siegfried%2C%20Romain%20Perbet%2C%20et%20al.%20%26%23x201C%3BLow-Grade%20Epilepsy-Associated%20Neuroepithelial%20Tumours%20with%20a%20Prominent%20Oligodendroglioma-like%20Component%3A%20The%20Diagnostic%20Challenges.%26%23x201D%3B%20%3Ci%3ENeuropathology%20and%20Applied%20Neurobiology%3C%5C%2Fi%3E%2048%2C%20no.%202%20%28February%202022%29%3A%20e12769.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fnan.12769%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fnan.12769%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Low-grade%20epilepsy-associated%20neuroepithelial%20tumours%20with%20a%20prominent%20oligodendroglioma-like%20component%3A%20The%20diagnostic%20challenges%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alice%22%2C%22lastName%22%3A%22M%5Cu00e9tais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Appay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%5Cu00e9lanie%22%2C%22lastName%22%3A%22Pag%5Cu00e8s%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Gallardo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karen%22%2C%22lastName%22%3A%22Silva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aurore%22%2C%22lastName%22%3A%22Siegfried%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Perbet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claude-Alain%22%2C%22lastName%22%3A%22Maurage%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Didier%22%2C%22lastName%22%3A%22Scavarda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Fina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Uro-Coste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Riffaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carole%22%2C%22lastName%22%3A%22Colin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%22%2C%22lastName%22%3A%22Figarella-Branger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22contributors%20of%20the%20Biopathology%20RENOCLIP-LOC%20network%22%7D%5D%2C%22abstractNote%22%3A%22AIMS%3A%20We%20searched%20for%20recurrent%20pathological%20features%20and%20molecular%20alterations%20in%20a%20retrospective%20series%20of%2072%20low-grade%20epilepsy-associated%20neuroepithelial%20tumours%20%28LEATs%29%20with%20a%20prominent%20oligodendroglioma-like%20component%2C%20in%20order%20to%20classify%20them%20according%20to%20the%202021%20World%20Health%20Organization%20%28WHO%29%20classification%20of%20central%20nervous%20system%20%28CNS%29%20tumours.%5CnMETHODS%3A%20Centralised%20pathological%20examination%20was%20performed%20as%20well%20as%20targeted%20molecular%20analysis%20of%20v-Raf%20murine%20sarcoma%20viral%20oncogene%20homologue%20B%20%28BRAF%29%20and%20fibroblast%20growth%20factor%20receptor%201%20%28FGFR1%29%20by%20multiplexed%20digital%20polymerase%20chain%20reaction%20%28mdPCR%29.%20DNA%20methylation%20profiling%20was%20performed%20in%20cases%20with%20sufficient%20DNA.%20In%20cases%20with%20no%20genetic%20alteration%20by%20mdPCR%20and%20sufficient%20material%2C%20RNA%20sequencing%20was%20done.%5CnRESULTS%3A%20We%20first%20reclassified%20our%20cohort%20into%20three%20groups%3A%20ganglioglioma%20%28GG%2C%20n%5Cu2009%3D%5Cu200914%29%2C%20dysembryoplastic%20neuroepithelial%20tumours%20%28DNTs%2C%20n%5Cu2009%3D%5Cu200919%29%20and%20glioneuronal%20tumours%5C%2Fpaediatric-type%20low-grade%20glioma%20%28LGG%29%20not%20otherwise%20specified%20%28GNT%5C%2FPLGG%20NOS%2C%20n%5Cu2009%3D%5Cu200939%29.%20mdPCR%20found%20an%20alteration%20in%2038%5C%2F72%20cases.%20Subsequent%20RNA%20sequencing%20revealed%20a%20fusion%20transcript%20involving%20BRAF%2C%20FGFR1%5C%2F2%5C%2F3%20or%20neurotrophic%20tyrosine%20kinase%20receptor%20type%202%20%5BNTRK2%5D%20in%209%5C%2F25%20cases.%20DNA%20methylation%20profiling%20found%2012%5C%2F46%20cases%20with%20a%20calibrated%20score%20%5Cu22650.9.%20Unsupervised%20hierarchical%20clustering%20revealed%20two%20clusters%3A%20Cluster%201%20was%20enriched%20with%20cases%20classified%20as%20DNT%20at%20histology%2C%20belonging%20to%20the%20LGG-DNT%20methylation%20class%20%28MC%29%2C%20with%20haematopoietic%20progenitor%20cell%20antigen%20%28CD34%29%20negativity%20and%20FGRF1%20alterations%3B%20Cluster%202%20was%20enriched%20with%20cases%20classified%20at%20histology%20as%20GG%2C%20belonging%20to%20the%20LGG-GG%20MC%20MC%2C%20with%20BRAF%20V600E%20mutation%20and%20CD34%20positivity.%20The%20tumours%20reclassified%20as%20GNT%5C%2FPLGG%20NOS%20were%20equally%20distributed%20across%20both%20clusters.%20Interestingly%2C%20all%20polymorphous%20low-grade%20neuroepithelial%20tumour%20of%20the%20young%20belonged%20to%20Cluster%202%2C%20whereas%20diffuse%20LGG%20mitogen-activated%20protein%20kinase%20%28MAPK%29%20pathway-altered%20were%20equally%20distributed%20among%20the%20two%20clusters.%20This%20led%20us%20to%20build%20an%20algorithm%20to%20classify%20LEATs%20with%20a%20prominent%20oligodendroglioma-like%20component.%5CnCONCLUSIONS%3A%20Integrated%20histomolecular%20diagnosis%20of%20LEATs%20with%20a%20prominent%20oligodendroglioma-like%20component%20remains%20challenging.%20Because%20these%20tumours%20can%20be%20split%20into%20two%20major%20clusters%20of%20biological%20significance%2C%20the%20clinicopathological%20relevance%20of%20the%20four%20types%20recognised%20by%20the%20WHO%20CNS5%20within%20this%20spectrum%20of%20tumours%20is%20questionable.%22%2C%22date%22%3A%222022-02%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1111%5C%2Fnan.12769%22%2C%22ISSN%22%3A%221365-2990%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222022-10-04T08%3A11%3A46Z%22%7D%7D%2C%7B%22key%22%3A%22YVFPA7Q6%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Hennequin%20et%20al.%22%2C%22parsedDate%22%3A%222022-04%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EHennequin%2C%20C.%2C%20D.%20Azria%2C%20P.%20Blanchard%2C%20G.%20Cr%26%23xE9%3Bhange%2C%20%26%23xC9%3B%20Deutsch%2C%20A.%20Lisbona%2C%20%26%23xC9%3B%20Moyal%2C%20et%20al.%20%26%23x201C%3BSpecificities%20of%20Clinical%20Research%20in%20Radiotherapy.%26%23x201D%3B%20%3Ci%3ECancer%20Radiotherapie%3A%20Journal%20De%20La%20Societe%20Francaise%20De%20Radiotherapie%20Oncologique%3C%5C%2Fi%3E%2026%2C%20no.%201%26%23x2013%3B2%20%28April%202022%29%3A%20104%26%23x2013%3B7.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.canrad.2021.11.011%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.canrad.2021.11.011%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Specificities%20of%20clinical%20research%20in%20radiotherapy%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Hennequin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Azria%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Blanchard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Cr%5Cu00e9hange%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%5Cu00c9%22%2C%22lastName%22%3A%22Deutsch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Lisbona%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%5Cu00c9%22%2C%22lastName%22%3A%22Moyal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Pasquier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Roca%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Supiot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Giraud%22%7D%5D%2C%22abstractNote%22%3A%22The%20aim%20of%20this%20review%20is%20to%20present%20the%20specificities%20of%20clinical%20research%20in%20radiation%20oncology.%20Objectives%20are%20similar%20to%20all%20research%20in%20oncology%3A%20to%20improve%20the%20efficacy%20and%20to%20decrease%20toxic%20effects.%20Phase%20III%20trials%20remain%20the%20main%20methodology%20to%20demonstrate%20an%20improvement%20in%20efficiency%2C%20but%20phase%20I-II%20and%20registers%20are%20also%20important%20tools%20to%20validate%20an%20improvement%20in%20the%20therapeutic%20index%20with%20new%20technologies.%20In%20this%20article%20we%20discuss%20the%20special%20features%20of%20end-points%2C%20selection%20of%20population%2C%20and%20design%20for%20radiation%20oncology%20clinical%20trials.%20Quality%20control%20of%20delivered%20treatments%20is%20an%20important%20component%20of%20these%20protocols.%20Financial%20issues%20are%20also%20discussed%2C%20in%20the%20particular%20context%20of%20France.%22%2C%22date%22%3A%222022-04%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.canrad.2021.11.011%22%2C%22ISSN%22%3A%221769-6658%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222022-10-04T08%3A10%3A57Z%22%7D%7D%2C%7B%22key%22%3A%22D6A3VGUB%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Monteiro%20et%20al.%22%2C%22parsedDate%22%3A%222022-04-11%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMonteiro%2C%20C%26%23xE1%3Btia%2C%20Lauritz%20Miarka%2C%20Mar%26%23xED%3Ba%20Perea-Garc%26%23xED%3Ba%2C%20Neibla%20Priego%2C%20Pedro%20Garc%26%23xED%3Ba-G%26%23xF3%3Bmez%2C%20Laura%20%26%23xC1%3Blvaro-Espinosa%2C%20Ana%20de%20Pablos-Aragoneses%2C%20et%20al.%20%26%23x201C%3BStratification%20of%20Radiosensitive%20Brain%20Metastases%20Based%20on%20an%20Actionable%20S100A9%5C%2FRAGE%20Resistance%20Mechanism.%26%23x201D%3B%20%3Ci%3ENature%20Medicine%3C%5C%2Fi%3E%2C%20April%2011%2C%202022.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41591-022-01749-8%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41591-022-01749-8%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Stratification%20of%20radiosensitive%20brain%20metastases%20based%20on%20an%20actionable%20S100A9%5C%2FRAGE%20resistance%20mechanism%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e1tia%22%2C%22lastName%22%3A%22Monteiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lauritz%22%2C%22lastName%22%3A%22Miarka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mar%5Cu00eda%22%2C%22lastName%22%3A%22Perea-Garc%5Cu00eda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Neibla%22%2C%22lastName%22%3A%22Priego%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pedro%22%2C%22lastName%22%3A%22Garc%5Cu00eda-G%5Cu00f3mez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%22%2C%22lastName%22%3A%22%5Cu00c1lvaro-Espinosa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ana%22%2C%22lastName%22%3A%22de%20Pablos-Aragoneses%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Natalia%22%2C%22lastName%22%3A%22Yebra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diana%22%2C%22lastName%22%3A%22Retana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patricia%22%2C%22lastName%22%3A%22Baena%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Coral%22%2C%22lastName%22%3A%22Fustero-Torre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Osvaldo%22%2C%22lastName%22%3A%22Gra%5Cu00f1a-Castro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kevin%22%2C%22lastName%22%3A%22Troul%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eduardo%22%2C%22lastName%22%3A%22Caleiras%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patricia%22%2C%22lastName%22%3A%22Tezanos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pablo%22%2C%22lastName%22%3A%22Muela%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisa%22%2C%22lastName%22%3A%22Cintado%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jos%5Cu00e9%20Luis%22%2C%22lastName%22%3A%22Trejo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%20Manuel%22%2C%22lastName%22%3A%22Sep%5Cu00falveda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pedro%22%2C%22lastName%22%3A%22Gonz%5Cu00e1lez-Le%5Cu00f3n%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luis%22%2C%22lastName%22%3A%22Jim%5Cu00e9nez-Rold%5Cu00e1n%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luis%20Miguel%22%2C%22lastName%22%3A%22Moreno%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olga%22%2C%22lastName%22%3A%22Esteban%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%5Cu00c1ngel%22%2C%22lastName%22%3A%22P%5Cu00e9rez-N%5Cu00fa%5Cu00f1ez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aurelio%22%2C%22lastName%22%3A%22Hern%5Cu00e1ndez-Lain%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jos%5Cu00e9%22%2C%22lastName%22%3A%22Mazarico%20Gallego%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Irene%22%2C%22lastName%22%3A%22Ferrer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roc%5Cu00edo%22%2C%22lastName%22%3A%22Su%5Cu00e1rez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eva%20M.%22%2C%22lastName%22%3A%22Garrido-Mart%5Cu00edn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luis%22%2C%22lastName%22%3A%22Paz-Ares%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Celine%22%2C%22lastName%22%3A%22Dalmasso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Cohen-Jonathan%20Moyal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aurore%22%2C%22lastName%22%3A%22Siegfried%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aisling%22%2C%22lastName%22%3A%22Hegarty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephen%22%2C%22lastName%22%3A%22Keelan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damir%22%2C%22lastName%22%3A%22Vare%5Cu0161lija%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leonie%20S.%22%2C%22lastName%22%3A%22Young%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Malte%22%2C%22lastName%22%3A%22Mohme%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yvonne%22%2C%22lastName%22%3A%22Goy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harriet%22%2C%22lastName%22%3A%22Wikman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jose%22%2C%22lastName%22%3A%22Fern%5Cu00e1ndez-Al%5Cu00e9n%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillermo%22%2C%22lastName%22%3A%22Blasco%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luc%5Cu00eda%22%2C%22lastName%22%3A%22Alc%5Cu00e1zar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clara%22%2C%22lastName%22%3A%22Caba%5Cu00f1uz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sergei%20I.%22%2C%22lastName%22%3A%22Grivennikov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrada%22%2C%22lastName%22%3A%22Ianus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Noam%22%2C%22lastName%22%3A%22Shemesh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudia%20C.%22%2C%22lastName%22%3A%22Faria%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rebecca%22%2C%22lastName%22%3A%22Lee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%22%2C%22lastName%22%3A%22Lorigan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilie%22%2C%22lastName%22%3A%22Le%20Rhun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Weller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Riccardo%22%2C%22lastName%22%3A%22Soffietti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luca%22%2C%22lastName%22%3A%22Bertero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Umberto%22%2C%22lastName%22%3A%22Ricardi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joaquim%22%2C%22lastName%22%3A%22Bosch-Barrera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elia%22%2C%22lastName%22%3A%22Sais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eduard%22%2C%22lastName%22%3A%22Teixidor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alejandro%22%2C%22lastName%22%3A%22Hern%5Cu00e1ndez-Mart%5Cu00ednez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alfonso%22%2C%22lastName%22%3A%22Calvo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Javier%22%2C%22lastName%22%3A%22Aristu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Santiago%20M.%22%2C%22lastName%22%3A%22Martin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alvaro%22%2C%22lastName%22%3A%22Gonzalez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Omer%22%2C%22lastName%22%3A%22Adler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Neta%22%2C%22lastName%22%3A%22Erez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22RENACER%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manuel%22%2C%22lastName%22%3A%22Valiente%22%7D%5D%2C%22abstractNote%22%3A%22Whole-brain%20radiotherapy%20%28WBRT%29%20is%20the%20treatment%20backbone%20for%20many%20patients%20with%20brain%20metastasis%3B%20however%2C%20its%20efficacy%20in%20preventing%20disease%20progression%20and%20the%20associated%20toxicity%20have%20questioned%20the%20clinical%20impact%20of%20this%20approach%20and%20emphasized%20the%20need%20for%20alternative%20treatments.%20Given%20the%20limited%20therapeutic%20options%20available%20for%20these%20patients%20and%20the%20poor%20understanding%20of%20the%20molecular%20mechanisms%20underlying%20the%20resistance%20of%20metastatic%20lesions%20to%20WBRT%2C%20we%20sought%20to%20uncover%20actionable%20targets%20and%20biomarkers%20that%20could%20help%20to%20refine%20patient%20selection.%20Through%20an%20unbiased%20analysis%20of%20experimental%20in%20vivo%20models%20of%20brain%20metastasis%20resistant%20to%20WBRT%2C%20we%20identified%20activation%20of%20the%20S100A9-RAGE-NF-%5Cu03baB-JunB%20pathway%20in%20brain%20metastases%20as%20a%20potential%20mediator%20of%20resistance%20in%20this%20organ.%20Targeting%20this%20pathway%20genetically%20or%20pharmacologically%20was%20sufficient%20to%20revert%20the%20WBRT%20resistance%20and%20increase%20therapeutic%20benefits%20in%20vivo%20at%20lower%20doses%20of%20radiation.%20In%20patients%20with%20primary%20melanoma%2C%20lung%20or%20breast%20adenocarcinoma%20developing%20brain%20metastasis%2C%20endogenous%20S100A9%20levels%20in%20brain%20lesions%20correlated%20with%20clinical%20response%20to%20WBRT%20and%20underscored%20the%20potential%20of%20S100A9%20levels%20in%20the%20blood%20as%20a%20noninvasive%20biomarker.%20Collectively%2C%20we%20provide%20a%20molecular%20framework%20to%20personalize%20WBRT%20and%20improve%20its%20efficacy%20through%20combination%20with%20a%20radiosensitizer%20that%20balances%20therapeutic%20benefit%20and%20toxicity.%22%2C%22date%22%3A%222022-04-11%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41591-022-01749-8%22%2C%22ISSN%22%3A%221546-170X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222022-10-04T08%3A10%3A43Z%22%7D%7D%2C%7B%22key%22%3A%22X93TB33E%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Garnier%20et%20al.%22%2C%22parsedDate%22%3A%222022-05-06%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGarnier%2C%20Louis%2C%20Chrystelle%20Vidal%2C%20Olivier%20Chinot%2C%20Elisabeth%20Cohen-Jonathan%20Moyal%2C%20Apolline%20Djelad%2C%20Charlotte%20Bronnimann%2C%20Lien%20Bekaert%2C%20et%20al.%20%26%23x201C%3BCharacteristics%20of%20Anaplastic%20Oligodendrogliomas%20Short-Term%20Survivors%3A%20A%20POLA%20Network%20Study.%26%23x201D%3B%20%3Ci%3EThe%20Oncologist%3C%5C%2Fi%3E%2027%2C%20no.%205%20%28May%206%2C%202022%29%3A%20414%26%23x2013%3B23.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Foncolo%5C%2Foyac023%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Foncolo%5C%2Foyac023%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Characteristics%20of%20Anaplastic%20Oligodendrogliomas%20Short-Term%20Survivors%3A%20A%20POLA%20Network%20Study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Louis%22%2C%22lastName%22%3A%22Garnier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chrystelle%22%2C%22lastName%22%3A%22Vidal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Chinot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Cohen-Jonathan%20Moyal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Apolline%22%2C%22lastName%22%3A%22Djelad%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Bronnimann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lien%22%2C%22lastName%22%3A%22Bekaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luc%22%2C%22lastName%22%3A%22Taillandier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-S%5Cu00e9bastien%22%2C%22lastName%22%3A%22Frenel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Langlois%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Colin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Menei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Dhermain%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Carpentier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Gerazime%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elsa%22%2C%22lastName%22%3A%22Curtit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%22%2C%22lastName%22%3A%22Figarella-Branger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Dehais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Ducray%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Anaplastic%20oligodendrogliomas%20IDH-mutant%20and%201p%5C%2F19q%20codeleted%20%28AO%29%20occasionally%20have%20a%20poor%20outcome.%20Herein%20we%20aimed%20at%20analyzing%20their%20characteristics.%5CnMETHODS%3A%20We%20retrospectively%20analyzed%20the%20characteristics%20of%2044%20AO%20patients%20with%20a%20cancer-specific%20survival%20%3C5%20years%20%28short-term%20survivors%2C%20STS%29%20and%20compared%20them%20with%20those%20of%20146%20AO%20patients%20with%20a%20survival%20%5Cu22655%20years%20%28classical%20survivors%2C%20CS%29%20included%20in%20the%20POLA%20network.%5CnRESULTS%3A%20Compared%20to%20CS%2C%20STS%20were%20older%20%28P%20%3D%20.0001%29%2C%20less%20frequently%20presented%20with%20isolated%20seizures%20%28P%20%3C%20.0001%29%2C%20more%20frequently%20presented%20with%20cognitive%20dysfunction%20%28P%20%3C%20.0001%29%2C%20had%20larger%20tumors%20%28P%20%3D%20.%3D%20.003%29%2C%20a%20higher%20proliferative%20index%20%28P%20%3D%20.%3D%20.0003%29%2C%20and%20a%20higher%20number%20of%20chromosomal%20arm%20abnormalities%20%28P%20%3D%20.%3D%20.02%29.%20Regarding%20treatment%2C%20STS%20less%20frequently%20underwent%20a%20surgical%20resection%20than%20CS%20%28P%20%3D%20.%3D%20.0001%29%20and%20were%20more%20frequently%20treated%20with%20chemotherapy%20alone%20%28P%20%3D%20.%3D%20.009%29%20or%20with%20radiotherapy%20plus%20temozolomide%20%28P%20%3D%20.%3D%20.05%29.%20Characteristics%20independently%20associated%20with%20STS%20in%20multivariate%20analysis%20were%20cognitive%20dysfunction%2C%20a%20number%20of%20mitosis%20%3E%208%2C%20and%20the%20absence%20of%20tumor%20resection.%20Based%20on%20cognitive%20dysfunction%2C%20type%20of%20surgery%2C%20and%20number%20of%20mitosis%2C%20patients%20could%20be%20classified%20into%20groups%20of%20standard%20%2818%25%29%20and%20high%20%2862%25%29%20risk%20of%20%3C5%20year%20survival.%5CnCONCLUSION%3A%20The%20present%20study%20suggests%20that%20although%20STS%20poor%20outcome%20appears%20to%20largely%20result%20from%20a%20more%20advanced%20disease%20at%20diagnosis%2C%20surgical%20resection%20may%20be%20particularly%20important%20in%20this%20population.%22%2C%22date%22%3A%222022-05-06%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1093%5C%2Foncolo%5C%2Foyac023%22%2C%22ISSN%22%3A%221549-490X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222022-10-04T08%3A09%3A48Z%22%7D%7D%2C%7B%22key%22%3A%228ZI8U5XV%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Tauzi%5Cu00e8de-Espariat%20et%20al.%22%2C%22parsedDate%22%3A%222022-01%22%2C%22numChildren%22%3A12%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ETauzi%26%23xE8%3Bde-Espariat%2C%20Arnault%2C%20Philipp%20Sievers%2C%20Fr%26%23xE9%3Bd%26%23xE9%3Brique%20Larousserie%2C%20Joseph%20Benzakoun%2C%20Delphine%20Guillemot%2C%20Ga%26%23xEB%3Blle%20Pierron%2C%20Mathilde%20Duchesne%2C%20et%20al.%20%26%23x201C%3BAn%20Integrative%20Histopathological%20and%20Epigenetic%20Characterization%20of%20Primary%20Intracranial%20Mesenchymal%20Tumors%2C%20FET%3ACREB-Fused%20Broadening%20the%20Spectrum%20of%20Tumor%20Entities%20in%20Comparison%20with%20Their%20Soft%20Tissue%20Counterparts.%26%23x201D%3B%20%3Ci%3EBrain%20Pathology%20%28Zurich%2C%20Switzerland%29%3C%5C%2Fi%3E%2032%2C%20no.%201%20%28January%202022%29%3A%20e13010.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fbpa.13010%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fbpa.13010%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22An%20integrative%20histopathological%20and%20epigenetic%20characterization%20of%20primary%20intracranial%20mesenchymal%20tumors%2C%20FET%3ACREB-fused%20broadening%20the%20spectrum%20of%20tumor%20entities%20in%20comparison%20with%20their%20soft%20tissue%20counterparts%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnault%22%2C%22lastName%22%3A%22Tauzi%5Cu00e8de-Espariat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philipp%22%2C%22lastName%22%3A%22Sievers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9rique%22%2C%22lastName%22%3A%22Larousserie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%22%2C%22lastName%22%3A%22Benzakoun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Delphine%22%2C%22lastName%22%3A%22Guillemot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ga%5Cu00eblle%22%2C%22lastName%22%3A%22Pierron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Duchesne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Uro-Coste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandre%22%2C%22lastName%22%3A%22Roux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandre%22%2C%22lastName%22%3A%22Vasiljevic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tanguy%22%2C%22lastName%22%3A%22Fenouil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Meyronet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karima%22%2C%22lastName%22%3A%22Mokhtari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Polivka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rousseau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9rique%22%2C%22lastName%22%3A%22Bost-Bezeaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samir%22%2C%22lastName%22%3A%22Akoury%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Johan%22%2C%22lastName%22%3A%22Pallud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chiara%22%2C%22lastName%22%3A%22Benevello%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lauren%22%2C%22lastName%22%3A%22Hasty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Albane%22%2C%22lastName%22%3A%22Gareton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanu%5Cu00e8le%22%2C%22lastName%22%3A%22Lechapt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrice%22%2C%22lastName%22%3A%22Chr%5Cu00e9tien%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Blauwblomme%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%5Cu00e9vin%22%2C%22lastName%22%3A%22Beccaria%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Puget%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Felix%22%2C%22lastName%22%3A%22Sahm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascale%22%2C%22lastName%22%3A%22Varlet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22RENOCLIP-LOC%22%7D%5D%2C%22abstractNote%22%3A%22FET%3ACREB%20fusions%20have%20been%20described%20in%20a%20variety%20of%20tumors%20from%20various%20phenotypes.%20Recently%2C%20these%20fusion%20transcripts%20were%20reported%20in%20intracranial%20tumors%2C%20variably%20named%20intracranial%20mesenchymal%20myxoid%20tumors%20or%20angiomatoid%20fibrous%20histiocytomas.%20Controversy%20remains%20concerning%20the%20terminology%20for%20these%20tumors.%20Here%2C%20we%20report%2011%20cases%20of%20central%20nervous%20system%20mesenchymal%20tumors%20with%20proven%20FET%3ACREB%20fusion.%20Most%20DNA%20methylation%20profiles%20were%20not%20classifiable%20using%20the%20Heidelberg%20Brain%20Tumor%20or%20Sarcoma%20Classifier%20%28v11b4%5C%2Fv12.2%29.%20However%2C%20by%20using%20unsupervised%20t-SNE%20and%20hierarchical%20clustering%20analyses%2C%20six%20of%20the%20cases%20constituted%20a%20distinct%20cluster.%20The%20remaining%20four%20tumors%20showed%20no%20obvious%20relation%20to%20any%20of%20the%20other%20referenced%20classes%20but%20were%20close%20to%20the%20clusters%20of%20extra-CNS%20angiomatoid%20fibrous%20histiocytomas%20%28n%5Cu00a0%3D%5Cu00a01%29%2C%20clear%20cell%20sarcomas%20%28n%5Cu00a0%3D%5Cu00a01%29%2C%20or%20solitary%20fibrous%20tumors%20%28n%5Cu00a0%3D%5Cu00a02%29.%20Our%20findings%20confirm%20that%20intracranial%20FET%3ACREB-fused%20tumors%20do%20not%20represent%20a%20single%20molecular%20tumor%20entity%2C%20although%20most%20samples%20clustered%20close%20to%20each%20other%2C%20indicating%20the%20existence%20of%20a%20distinct%20epigenetic%20group%20that%20could%20potentially%20be%20partially%20masked%20by%20the%20low%20number%20of%20cases%20included.%20Further%20analyses%20are%20needed%20to%20characterize%20intracranial%20FET%3ACREB%20fused-defined%20tumors%20in%20more%20detail.%22%2C%22date%22%3A%222022-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1111%5C%2Fbpa.13010%22%2C%22ISSN%22%3A%221750-3639%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%2C%223U3NWA3K%22%5D%2C%22dateModified%22%3A%222022-10-04T08%3A09%3A22Z%22%7D%7D%2C%7B%22key%22%3A%223TZ6QS6E%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lacore%20et%20al.%22%2C%22parsedDate%22%3A%222022-07-06%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELacore%2C%20Marie%20Geraldine%2C%20Caroline%20Delmas%2C%20Yvan%20Nicaise%2C%20Aline%20Kowalski-Chauvel%2C%20Elizabeth%20Cohen-Jonathan-Moyal%2C%20and%20Catherine%20Seva.%20%26%23x201C%3BThe%20Glycoprotein%20M6a%20Is%20Associated%20with%20Invasiveness%20and%20Radioresistance%20of%20Glioblastoma%20Stem%20Cells.%26%23x201D%3B%20%3Ci%3ECells%3C%5C%2Fi%3E%2011%2C%20no.%2014%20%28July%206%2C%202022%29%3A%202128.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcells11142128%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcells11142128%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20Glycoprotein%20M6a%20Is%20Associated%20with%20Invasiveness%20and%20Radioresistance%20of%20Glioblastoma%20Stem%20Cells%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%20Geraldine%22%2C%22lastName%22%3A%22Lacore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Delmas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yvan%22%2C%22lastName%22%3A%22Nicaise%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aline%22%2C%22lastName%22%3A%22Kowalski-Chauvel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Cohen-Jonathan-Moyal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Seva%22%7D%5D%2C%22abstractNote%22%3A%22Systematic%20recurrence%20of%20glioblastoma%20%28GB%29%20despite%20surgery%20and%20chemo-radiotherapy%20is%20due%20to%20GB%20stem%20cells%20%28GBSC%29%2C%20which%20are%20particularly%20invasive%20and%20radioresistant.%20Therefore%2C%20there%20is%20a%20need%20to%20identify%20new%20factors%20that%20might%20be%20targeted%20to%20decrease%20GBSC%20invasive%20capabilities%20as%20well%20as%20radioresistance.%20Patient-derived%20GBSC%20were%20used%20in%20this%20study%20to%20demonstrate%20a%20higher%20expression%20of%20the%20glycoprotein%20M6a%20%28GPM6A%29%20in%20invasive%20GBSC%20compared%20to%20non-invasive%20cells.%20In%203D%20invasion%20assays%20performed%20on%20primary%20neurospheres%20of%20GBSC%2C%20we%20showed%20that%20blocking%20GPM6A%20expression%20by%20siRNA%20significantly%20reduced%20cell%20invasion.%20We%20also%20demonstrated%20a%20high%20correlation%20of%20GPM6A%20with%20the%20oncogenic%20protein%20tyrosine%20phosphatase%2C%20PTPRZ1%2C%20which%20regulates%20GPM6A%20expression%20and%20cell%20invasion.%20The%20results%20of%20our%20study%20also%20show%20that%20GPM6A%20and%20PTPRZ1%20are%20crucial%20for%20GBSC%20sphere%20formation.%20Finally%2C%20we%20demonstrated%20that%20targeting%20GPM6A%20or%20PTPRZ1%20in%20GBSC%20increases%20the%20radiosensitivity%20of%20GBSC.%20Our%20results%20suggest%20that%20blocking%20GPM6A%20or%20PTPRZ1%20could%20represent%20an%20interesting%20approach%20in%20the%20treatment%20of%20glioblastoma%20since%20it%20would%20simultaneously%20target%20proliferation%2C%20invasion%2C%20and%20radioresistance.%22%2C%22date%22%3A%222022-07-06%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3390%5C%2Fcells11142128%22%2C%22ISSN%22%3A%222073-4409%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222022-08-25T07%3A37%3A28Z%22%7D%7D%2C%7B%22key%22%3A%228PV55NM9%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Tauzi%5Cu00e8de-Espariat%20et%20al.%22%2C%22parsedDate%22%3A%222022-08-19%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ETauzi%26%23xE8%3Bde-Espariat%2C%20Arnault%2C%20Aurore%20Siegfried%2C%20Emmanuelle%20Uro-Coste%2C%20Yvan%20Nicaise%2C%20David%20Castel%2C%20Annick%20Sevely%2C%20Marion%20Gambart%2C%20et%20al.%20%26%23x201C%3BDisseminated%20Diffuse%20Midline%20Gliomas%2C%20H3K27-Altered%20Mimicking%20Diffuse%20Leptomeningeal%20Glioneuronal%20Tumors%3A%20A%20Diagnostical%20Challenge%21%26%23x201D%3B%20%3Ci%3EActa%20Neuropathologica%20Communications%3C%5C%2Fi%3E%2010%2C%20no.%201%20%28August%2019%2C%202022%29%3A%20119.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs40478-022-01419-3%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs40478-022-01419-3%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Disseminated%20diffuse%20midline%20gliomas%2C%20H3K27-altered%20mimicking%20diffuse%20leptomeningeal%20glioneuronal%20tumors%3A%20a%20diagnostical%20challenge%21%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnault%22%2C%22lastName%22%3A%22Tauzi%5Cu00e8de-Espariat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aurore%22%2C%22lastName%22%3A%22Siegfried%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Uro-Coste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yvan%22%2C%22lastName%22%3A%22Nicaise%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Castel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Annick%22%2C%22lastName%22%3A%22Sevely%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marion%22%2C%22lastName%22%3A%22Gambart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sergio%22%2C%22lastName%22%3A%22Boetto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lauren%22%2C%22lastName%22%3A%22Hasty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alice%22%2C%22lastName%22%3A%22M%5Cu00e9tais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrice%22%2C%22lastName%22%3A%22Chr%5Cu00e9tien%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%22%2C%22lastName%22%3A%22Benzakoun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Puget%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacques%22%2C%22lastName%22%3A%22Grill%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Volodia%22%2C%22lastName%22%3A%22Dangouloff-Ros%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Boddaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Azadeh%22%2C%22lastName%22%3A%22Ebrahimi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascale%22%2C%22lastName%22%3A%22Varlet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22RENOCLIP-LOC%20Network%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222022-08-19%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs40478-022-01419-3%22%2C%22ISSN%22%3A%222051-5960%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222022-08-22T13%3A23%3A22Z%22%7D%7D%2C%7B%22key%22%3A%225EQ9LSWQ%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Duval%20et%20al.%22%2C%22parsedDate%22%3A%222022-06-04%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDuval%2C%20Tanguy%2C%20Jean-Albert%20Lotterie%2C%20Anthony%20Lemarie%2C%20Caroline%20Delmas%2C%20Fatima%20Tensaouti%2C%20Elizabeth%20Cohen-Jonathan%20Moyal%2C%20and%20Vincent%20Lubrano.%20%26%23x201C%3BGlioblastoma%20Stem-like%20Cell%20Detection%20Using%20Perfusion%20and%20Diffusion%20MRI.%26%23x201D%3B%20%3Ci%3ECancers%3C%5C%2Fi%3E%2014%2C%20no.%2011%20%28June%204%2C%202022%29%3A%202803.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers14112803%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers14112803%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Glioblastoma%20Stem-like%20Cell%20Detection%20Using%20Perfusion%20and%20Diffusion%20MRI%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tanguy%22%2C%22lastName%22%3A%22Duval%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Albert%22%2C%22lastName%22%3A%22Lotterie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anthony%22%2C%22lastName%22%3A%22Lemarie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Delmas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fatima%22%2C%22lastName%22%3A%22Tensaouti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%20Cohen-Jonathan%22%2C%22lastName%22%3A%22Moyal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Lubrano%22%7D%5D%2C%22abstractNote%22%3A%22PURPOSE%3A%20With%20current%20gold%20standard%20treatment%2C%20which%20associates%20maximum%20safe%20surgery%20and%20chemo-radiation%2C%20the%20large%20majority%20of%20glioblastoma%20patients%20relapse%20within%20a%20year%20in%20the%20peritumoral%20non%20contrast-enhanced%20region%20%28NCE%29.%20A%20subpopulation%20of%20glioblastoma%20stem-like%20cells%20%28GSC%29%20are%20known%20to%20be%20particularly%20radio-resistant%20and%20aggressive%2C%20and%20are%20thus%20suspected%20to%20be%20the%20cause%20of%20these%20relapses.%20Previous%20studies%20have%20shown%20that%20their%20distribution%20is%20heterogeneous%20in%20the%20NCE%20compartment%2C%20but%20no%20study%20exists%20on%20the%20sensitivity%20of%20medical%20imaging%20for%20localizing%20these%20cells.%20In%20this%20work%2C%20we%20propose%20to%20study%20the%20magnetic%20resonance%20%28MR%29%20signature%20of%20these%20infiltrative%20cells.%5CnMETHODS%3A%20In%20the%20context%20of%20a%20clinical%20trial%20on%2016%20glioblastoma%20patients%2C%20relative%20Cerebral%20Blood%20Volume%20%28rCBV%29%20and%20Apparent%20Diffusion%20Coefficient%20%28ADC%29%20were%20measured%20in%20a%20preoperative%20diffusion%20and%20perfusion%20MRI%20examination.%20During%20surgery%2C%20two%20biopsies%20were%20extracted%20using%20image-guidance%20in%20the%20hyperintensities-FLAIR%20region.%20GSC%20subpopulation%20was%20quantified%20within%20the%20biopsies%20and%20then%20cultivated%20in%20selective%20conditions%20to%20determine%20their%20density%20and%20aggressiveness.%5CnRESULTS%3A%20Low%20ADC%20was%20found%20to%20be%20a%20good%20predictor%20of%20the%20time%20to%20GSC%20neurospheres%20formation%20in%20vitro.%20In%20addition%2C%20GSCs%20were%20found%20in%20higher%20concentrations%20in%20areas%20with%20high%20rCBV.%5CnCONCLUSIONS%3A%20This%20study%20confirms%20that%20GSCs%20have%20a%20critical%20role%20for%20glioblastoma%20aggressiveness%20and%20supports%20the%20idea%20that%20peritumoral%20sites%20with%20low%20ADC%20or%20high%20rCBV%20should%20be%20preferably%20removed%20when%20possible%20during%20surgery%20and%20targeted%20by%20radiotherapy.%22%2C%22date%22%3A%222022-06-04%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3390%5C%2Fcancers14112803%22%2C%22ISSN%22%3A%222072-6694%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222022-06-16T13%3A19%3A08Z%22%7D%7D%2C%7B%22key%22%3A%22GIPMK5SN%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Tensaouti%20et%20al.%22%2C%22parsedDate%22%3A%222022-04%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ETensaouti%2C%20Fatima%2C%20Franck%20Desmoulin%2C%20Julia%20Gilhodes%2C%20Elodie%20Martin%2C%20Soleakhena%20Ken%2C%20Jean-Albert%20Lotterie%2C%20Georges%20No%26%23xEB%3Bl%2C%20et%20al.%20%26%23x201C%3BQuality%20Control%20of%203D%20MRSI%20Data%20in%20Glioblastoma%3A%20Can%20We%20Do%20without%20the%20Experts%3F%26%23x201D%3B%20%3Ci%3EMagnetic%20Resonance%20in%20Medicine%3C%5C%2Fi%3E%2087%2C%20no.%204%20%28April%202022%29%3A%201688%26%23x2013%3B99.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fmrm.29098%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fmrm.29098%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Quality%20control%20of%203D%20MRSI%20data%20in%20glioblastoma%3A%20Can%20we%20do%20without%20the%20experts%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fatima%22%2C%22lastName%22%3A%22Tensaouti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franck%22%2C%22lastName%22%3A%22Desmoulin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julia%22%2C%22lastName%22%3A%22Gilhodes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elodie%22%2C%22lastName%22%3A%22Martin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Soleakhena%22%2C%22lastName%22%3A%22Ken%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Albert%22%2C%22lastName%22%3A%22Lotterie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Georges%22%2C%22lastName%22%3A%22No%5Cu00ebl%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Truc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Pierre%22%2C%22lastName%22%3A%22Sunyach%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Charissoux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Magn%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Lubrano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrice%22%2C%22lastName%22%3A%22P%5Cu00e9ran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Cohen-Jonathan%20Moyal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Laprie%22%7D%5D%2C%22abstractNote%22%3A%22PURPOSE%3A%20Proton%20magnetic%20resonance%20spectroscopic%20imaging%20%281H%20MRSI%29%20is%20a%20noninvasive%20technique%20for%20assessing%20tumor%20metabolism.%20Manual%20inspection%20is%20still%20the%20gold%20standard%20for%20quality%20control%20%28QC%29%20of%20spectra%2C%20but%20it%20is%20both%20time-consuming%20and%20subjective.%20The%20aim%20of%20the%20present%20study%20was%20to%20assess%20automatic%20QC%20of%20glioblastoma%20MRSI%20data%20using%20random%20forest%20analysis.%5CnMETHODS%3A%20Data%20for%2025%20patients%2C%20acquired%20prospectively%20in%20a%20preradiotherapy%20examination%2C%20were%20submitted%20to%20postprocessing%20with%20syngo.MR%20Spectro%20%28VB40A%3B%20Siemens%29%20or%20Java-based%20magnetic%20resonance%20user%20interface%20%28jMRUI%29%20software.%20A%20total%20of%2028%20features%20were%20extracted%20from%20each%20spectrum%20for%20the%20automatic%20QC.%20Three%20spectroscopists%20also%20performed%20manual%20inspections%2C%20labeling%20each%20spectrum%20as%20good%20or%20poor%20quality.%20All%20statistical%20analyses%2C%20with%20addressing%20unbalanced%20data%2C%20were%20conducted%20with%20R%203.6.1%20%28R%20Foundation%20for%20Statistical%20Computing%3B%20https%3A%5C%2F%5C%2Fwww.r-project.org%29.%5CnRESULTS%3A%20The%20random%20forest%20method%20classified%20the%20spectra%20with%20an%20area%20under%20the%20curve%20of%2095.5%25%2C%20sensitivity%20of%2095.8%25%2C%20and%20specificity%20of%2081.7%25.%20The%20most%20important%20feature%20for%20the%20classification%20was%20Residuum_Lipids_Versus_Fit%2C%20obtained%20with%20syngo.MR%20Spectro.%5CnCONCLUSION%3A%20The%20automatic%20QC%20method%20was%20able%20to%20distinguish%20between%20good-%20and%20poor-quality%20spectra%2C%20and%20can%20be%20used%20by%20radiation%20oncologists%20who%20are%20not%20spectroscopy%20experts.%20This%20study%20revealed%20a%20novel%20set%20of%20MRSI%20signal%20features%20that%20are%20closely%20correlated%20with%20spectral%20quality.%22%2C%22date%22%3A%222022-04%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fmrm.29098%22%2C%22ISSN%22%3A%221522-2594%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222022-05-31T07%3A57%3A26Z%22%7D%7D%2C%7B%22key%22%3A%224FAAGIXD%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Acquitter%20et%20al.%22%2C%22parsedDate%22%3A%222022-01-07%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EAcquitter%2C%20Cl%26%23xE9%3Bment%2C%20Lucie%20Piram%2C%20Umberto%20Sabatini%2C%20Julia%20Gilhodes%2C%20Elizabeth%20Moyal%20Cohen-Jonathan%2C%20Soleakhena%20Ken%2C%20and%20Benjamin%20Lemasson.%20%26%23x201C%3BRadiomics-Based%20Detection%20of%20Radionecrosis%20Using%20Harmonized%20Multiparametric%20MRI.%26%23x201D%3B%20%3Ci%3ECancers%3C%5C%2Fi%3E%2014%2C%20no.%202%20%28January%207%2C%202022%29%3A%20286.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers14020286%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers14020286%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Radiomics-Based%20Detection%20of%20Radionecrosis%20Using%20Harmonized%20Multiparametric%20MRI%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9ment%22%2C%22lastName%22%3A%22Acquitter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucie%22%2C%22lastName%22%3A%22Piram%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Umberto%22%2C%22lastName%22%3A%22Sabatini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julia%22%2C%22lastName%22%3A%22Gilhodes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Moyal%20Cohen-Jonathan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Soleakhena%22%2C%22lastName%22%3A%22Ken%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benjamin%22%2C%22lastName%22%3A%22Lemasson%22%7D%5D%2C%22abstractNote%22%3A%22In%20this%20study%2C%20a%20radiomics%20analysis%20was%20conducted%20to%20provide%20insights%20into%20the%20differentiation%20of%20radionecrosis%20and%20tumor%20progression%20in%20multiparametric%20MRI%20in%20the%20context%20of%20a%20multicentric%20clinical%20trial.%20First%2C%20the%20sensitivity%20of%20radiomic%20features%20to%20the%20unwanted%20variability%20caused%20by%20different%20protocol%20settings%20was%20assessed%20for%20each%20modality.%20Then%2C%20the%20ability%20of%20image%20normalization%20and%20ComBat-based%20harmonization%20to%20reduce%20the%20scanner-related%20variability%20was%20evaluated.%20Finally%2C%20the%20performances%20of%20several%20radiomic%20models%20dedicated%20to%20the%20classification%20of%20MRI%20examinations%20were%20measured.%20Our%20results%20showed%20that%20using%20radiomic%20models%20trained%20on%20harmonized%20data%20achieved%20better%20predictive%20performance%20for%20the%20investigated%20clinical%20outcome%20%28balanced%20accuracy%20of%200.61%20with%20the%20model%20based%20on%20raw%20data%20and%200.72%20with%20ComBat%20harmonization%29.%20A%20comparison%20of%20several%20models%20based%20on%20information%20extracted%20from%20different%20MR%20modalities%20showed%20that%20the%20best%20classification%20accuracy%20was%20achieved%20with%20a%20model%20based%20on%20MR%20perfusion%20features%20in%20conjunction%20with%20clinical%20observation%20%28balanced%20accuracy%20of%200.76%20using%20LASSO%20feature%20selection%20and%20a%20Random%20Forest%20classifier%29.%20Although%20multimodality%20did%20not%20provide%20additional%20benefit%20in%20predictive%20power%2C%20the%20model%20based%20on%20T1-weighted%20MRI%20before%20injection%20provided%20an%20accuracy%20close%20to%20the%20performance%20achieved%20with%20perfusion.%22%2C%22date%22%3A%222022-01-07%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3390%5C%2Fcancers14020286%22%2C%22ISSN%22%3A%222072-6694%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222022-05-31T07%3A56%3A39Z%22%7D%7D%2C%7B%22key%22%3A%223H3WKH7E%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Balosso%20et%20al.%22%2C%22parsedDate%22%3A%222022%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBalosso%2C%20J.%2C%20F.%20Missohou%2C%20D.%20Antoni%2C%20C.%20Hennequin%2C%20M.-A.%20Mah%26%23xE9%3B%2C%20L.%20Simon%2C%20and%20C.%20Demoor-Goldschmidt.%20%26%23x201C%3BRadiotherapy%20of%20Lymphomas.%26%23x201D%3B%20%3Ci%3ECancer%5C%2FRadioth%26%23xE9%3Brapie%3C%5C%2Fi%3E%2026%2C%20no.%201%26%23x2013%3B2%20%282022%29%3A%20388%26%23x2013%3B96.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.canrad.2021.11.007%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.canrad.2021.11.007%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Radiotherapy%20of%20lymphomas%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Balosso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Missohou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Antoni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Hennequin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.-A.%22%2C%22lastName%22%3A%22Mah%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Simon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Demoor-Goldschmidt%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2202%5C%2F2022%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.canrad.2021.11.007%22%2C%22ISSN%22%3A%2212783218%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Flinkinghub.elsevier.com%5C%2Fretrieve%5C%2Fpii%5C%2FS1278321821002961%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222022-05-31T07%3A46%3A37Z%22%7D%7D%2C%7B%22key%22%3A%229BBUXEZU%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Darr%5Cu00e9on%20et%20al.%22%2C%22parsedDate%22%3A%222022%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDarr%26%23xE9%3Bon%2C%20J.%2C%20G.%20Bouilhol%2C%20N.%20Ailli%26%23xE8%3Bres%2C%20H.%20Bouscayrol%2C%20L.%20Simon%2C%20and%20M.%20Ayadi.%20%26%23x201C%3BRespiratory%20Motion%20Management%20for%20External%20Radiotherapy%20Treatment.%26%23x201D%3B%20%3Ci%3ECancer%5C%2FRadioth%26%23xE9%3Brapie%3C%5C%2Fi%3E%2026%2C%20no.%201%26%23x2013%3B2%20%282022%29%3A%2050%26%23x2013%3B58.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.canrad.2021.09.006%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.canrad.2021.09.006%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Respiratory%20motion%20management%20for%20external%20radiotherapy%20treatment%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Darr%5Cu00e9on%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Bouilhol%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Ailli%5Cu00e8res%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Bouscayrol%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Simon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Ayadi%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2202%5C%2F2022%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.canrad.2021.09.006%22%2C%22ISSN%22%3A%2212783218%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Flinkinghub.elsevier.com%5C%2Fretrieve%5C%2Fpii%5C%2FS127832182100247X%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222022-05-31T07%3A45%3A41Z%22%7D%7D%2C%7B%22key%22%3A%22E38JSYXC%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Gr%5Cu00e9goire%20et%20al.%22%2C%22parsedDate%22%3A%222022-04%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGr%26%23xE9%3Bgoire%2C%20V.%2C%20P.%20Giraud%2C%20L.%20Vieillevigne%2C%20and%20P.%20Maingon.%20%26%23x201C%3BManagement%20of%20Oropharyngeal%20Squamous%20Cell%20Carcinoma.%26%23x201D%3B%20%3Ci%3ECancer%20Radiotherapie%3A%20Journal%20De%20La%20Societe%20Francaise%20De%20Radiotherapie%20Oncologique%3C%5C%2Fi%3E%2026%2C%20no.%201%26%23x2013%3B2%20%28April%202022%29%3A%20174%26%23x2013%3B88.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.canrad.2021.10.002%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.canrad.2021.10.002%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Management%20of%20oropharyngeal%20squamous%20cell%20carcinoma%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Gr%5Cu00e9goire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Giraud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Vieillevigne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Maingon%22%7D%5D%2C%22abstractNote%22%3A%22This%20article%20reviews%20the%20various%20treatment%20options%2C%20by%20primary%20or%20postoperative%20external%20radiotherapy%20and%20by%20brachytherapy%20for%20the%20p16-negative%20oropharyngeal%20squamous%20cell%20carcinoma.%20Dose%20levels%2C%20fractionation%20and%20association%20with%20systemic%20treatments%20are%20presented.%20The%20need%20for%20neck%20node%20dissection%20post%20local%20treatment%20is%20discussed%2C%20as%20well%20as%20specificities%20for%20the%20management%20of%20p16-positive%20tumours.%20Guidelines%20for%20target%20volume%20selection%20and%20delineation%20are%20thoroughly%20elaborated.%20Last%2C%20the%20management%20by%20radiotherapy%20of%20locoregional%20recurrences%20is%20discussed.%22%2C%22date%22%3A%222022%20Feb-Apr%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.canrad.2021.10.002%22%2C%22ISSN%22%3A%221769-6658%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222022-05-31T07%3A43%3A21Z%22%7D%7D%2C%7B%22key%22%3A%22PRM5KPXZ%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Gr%5Cu00e9goire%20et%20al.%22%2C%22parsedDate%22%3A%222022-04%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGr%26%23xE9%3Bgoire%2C%20V.%2C%20S.%20Boisbouvier%2C%20P.%20Giraud%2C%20P.%20Maingon%2C%20Y.%20Pointreau%2C%20and%20L.%20Vieillevigne.%20%26%23x201C%3BManagement%20and%20Work-up%20Procedures%20of%20Patients%20with%20Head%20and%20Neck%20Malignancies%20Treated%20by%20Radiation.%26%23x201D%3B%20%3Ci%3ECancer%20Radiotherapie%3A%20Journal%20De%20La%20Societe%20Francaise%20De%20Radiotherapie%20Oncologique%3C%5C%2Fi%3E%2026%2C%20no.%201%26%23x2013%3B2%20%28April%202022%29%3A%20147%26%23x2013%3B55.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.canrad.2021.10.005%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.canrad.2021.10.005%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Management%20and%20work-up%20procedures%20of%20patients%20with%20head%20and%20neck%20malignancies%20treated%20by%20radiation%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Gr%5Cu00e9goire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Boisbouvier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Giraud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Maingon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%22%2C%22lastName%22%3A%22Pointreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Vieillevigne%22%7D%5D%2C%22abstractNote%22%3A%22Radiotherapy%20alone%20or%20in%20association%20with%20systemic%20treatment%20plays%20a%20major%20role%20in%20the%20treatment%20of%20head%20and%20neck%20tumours%2C%20either%20as%20a%20primary%20treatment%20or%20as%20a%20postoperative%20modality.%20The%20management%20of%20these%20tumours%20is%20multidisciplinary%2C%20requiring%20particular%20care%20at%20every%20treatment%20step.%20We%20present%20the%20update%20of%20the%20recommendations%20of%20the%20French%20Society%20of%20Radiation%20Oncology%20on%20the%20radiotherapy%20of%20head%20and%20neck%20tumours%20from%20the%20imaging%20work-up%20needed%20for%20optimal%20selection%20of%20treatment%20volume%2C%20to%20optimization%20of%20the%20dose%20distribution%20and%20delivery.%22%2C%22date%22%3A%222022%20Feb-Apr%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.canrad.2021.10.005%22%2C%22ISSN%22%3A%221769-6658%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222022-05-31T07%3A42%3A51Z%22%7D%7D%2C%7B%22key%22%3A%22TJSJX6XX%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Delbaere%20et%20al.%22%2C%22parsedDate%22%3A%222022-04-07%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDelbaere%2C%20Alexia%2C%20Tony%20Younes%2C%20Luc%20Simon%2C%20Catherine%20Khamphan%2C%20and%20Laure%20Vieillevigne.%20%26%23x201C%3BField%20Output%20Correction%20Factors%20and%20Electron%20Fluence%20Perturbation%20of%20the%20MicroSilicon%20and%20MicroSilicon%20X%20Detectors.%26%23x201D%3B%20%3Ci%3EPhysics%20in%20Medicine%20and%20Biology%3C%5C%2Fi%3E%2067%2C%20no.%208%20%28April%207%2C%202022%29.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1088%5C%2F1361-6560%5C%2Fac5e5e%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1088%5C%2F1361-6560%5C%2Fac5e5e%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Field%20output%20correction%20factors%20and%20electron%20fluence%20perturbation%20of%20the%20microSilicon%20and%20microSilicon%20X%20detectors%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexia%22%2C%22lastName%22%3A%22Delbaere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tony%22%2C%22lastName%22%3A%22Younes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luc%22%2C%22lastName%22%3A%22Simon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Khamphan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Vieillevigne%22%7D%5D%2C%22abstractNote%22%3A%22Objective.The%20aim%20of%20this%20study%20was%20to%20determine%20field%20output%20correction%20factorskQclin%2CQreffclin%2Cfrefand%20electron%20fluence%20perturbation%20for%20new%20PTW%20unshielded%20microSilicon%20and%20shielded%20microSilicon%20X%20detectors.Approach.kQclin%2CQreffclin%2Cfreffactors%20were%20calculated%20for%206%20and%2010%20MV%20with%20and%20without%20flattening%20filter%20beams%20delivered%20by%20a%20TrueBeam%20STx.%20Correction%20factors%20were%20determined%20for%20field%20sizes%20ranging%20from%200.5%20%5Cu00d7%200.5%20cm2to%203%20%5Cu00d7%203%20cm2using%20both%20experimental%20and%20numerical%20methods.%20To%20better%20understand%20the%20underlying%20physics%20of%20their%20response%2C%20total%20electron%20%28%2Bpositron%29%20fluence%20spectra%20were%20scored%20in%20the%20sensitive%20volume%20considering%20the%20various%20component-dependent%20perturbations.Main%20results.The%20microSilicon%20and%20microSilicon%20X%20detectors%20can%20be%20used%20down%20to%20the%20smallest%20studied%20field%20size%20by%20applying%20corrections%20factors%20fulfilling%20the%20tolerance%20of%205%25%20recommended%20by%20the%20IAEA%20TRS483.%20Electron%20fluence%20perturbation%20in%20both%20microSilicon%20detectors%20was%20greater%20than%20that%20in%20water%20but%20to%20a%20lesser%20extent%20than%20their%20predecessors.%20The%20main%20contribution%20of%20the%20overall%20perturbation%20of%20the%20detectors%20comes%20from%20the%20materials%20surrounding%20their%20sensitive%20volume%2C%20especially%20the%20epoxy%20in%20the%20case%20of%20unshielded%20diodes%20and%20the%20shielding%20for%20shielded%20diodes.%20This%20work%20demonstrated%20that%20the%20decrease%20in%20the%20density%20of%20the%20epoxy%20for%20the%20microSilicon%20led%20to%20a%20decrease%20in%20the%20electron%20fluence%20perturbation.Significance.A%20real%20improvement%20was%20observed%20regarding%20the%20design%20of%20the%20microSilicon%20and%20microSilicon%20X%20detectors%20compared%20to%20their%20predecessors.%22%2C%22date%22%3A%222022-04-07%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1088%5C%2F1361-6560%5C%2Fac5e5e%22%2C%22ISSN%22%3A%221361-6560%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222022-05-31T07%3A42%3A33Z%22%7D%7D%2C%7B%22key%22%3A%22XPNDTR4I%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Deshors%20et%20al.%22%2C%22parsedDate%22%3A%222022-03-18%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDeshors%2C%20Pauline%2C%20Florent%20Arnauduc%2C%20Betty%20Bo%26%23xEB%3Blle%2C%20Elizabeth%20Cohen-Jonathan%20Moyal%2C%20Monique%20Courtade-Sa%26%23xEF%3Bdi%2C%20and%20Sol%26%23xE8%3Bne%20M.%20Evrard.%20%26%23x201C%3BImpact%20of%20Regorafenib%20on%20Endothelial%20Transdifferentiation%20of%20Glioblastoma%20Stem-like%20Cells.%26%23x201D%3B%20%3Ci%3ECancers%3C%5C%2Fi%3E%2014%2C%20no.%206%20%28March%2018%2C%202022%29%3A%201551.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers14061551%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers14061551%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Impact%20of%20Regorafenib%20on%20Endothelial%20Transdifferentiation%20of%20Glioblastoma%20Stem-like%20Cells%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pauline%22%2C%22lastName%22%3A%22Deshors%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florent%22%2C%22lastName%22%3A%22Arnauduc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Betty%22%2C%22lastName%22%3A%22Bo%5Cu00eblle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Cohen-Jonathan%20Moyal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Monique%22%2C%22lastName%22%3A%22Courtade-Sa%5Cu00efdi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sol%5Cu00e8ne%20M.%22%2C%22lastName%22%3A%22Evrard%22%7D%5D%2C%22abstractNote%22%3A%22Glioblastomas%20%28GBM%29%20are%20aggressive%20brain%20tumours%20with%20a%20poor%20prognosis%20despite%20heavy%20therapy%20that%20combines%20surgical%20resection%20and%20radio-chemotherapy.%20The%20presence%20of%20a%20subpopulation%20of%20GBM%20stem%20cells%20%28GSC%29%20contributes%20to%20tumour%20aggressiveness%2C%20resistance%20and%20recurrence.%20Moreover%2C%20GBM%20are%20characterised%20by%20abnormal%2C%20abundant%20vascularisation.%20Previous%20studies%20have%20shown%20that%20GSC%20are%20directly%20involved%20in%20new%20vessel%20formation%20via%20their%20transdifferentiation%20into%20tumour-derived%20endothelial%20cells%20%28TDEC%29%20and%20that%20irradiation%20%28IR%29%20potentiates%20the%20pro-angiogenic%20capacity%20of%20TDEC%20via%20the%20Tie2%20signalling%20pathway.%20We%20therefore%20investigated%20the%20impact%20of%20regorafenib%2C%20a%20multikinase%20inhibitor%20with%20anti-angiogenic%20and%20anti-tumourigenic%20activity%2C%20on%20GSC%20and%20TDEC%20obtained%20from%20irradiated%20GSC%20%28TDEC%20IR%2B%29%20or%20non-irradiated%20GSC%20%28TDEC%29.%20Regorafenib%20significantly%20decreases%20GSC%20neurosphere%20formation%20in%20vitro%20and%20inhibits%20tumour%20formation%20in%20the%20orthotopic%20xenograft%20model.%20Regorafenib%20also%20inhibits%20transdifferentiation%20by%20decreasing%20CD31%20expression%2C%20CD31%2B%20cell%20count%2C%20pseudotube%20formation%20in%20vitro%20and%20the%20formation%20of%20functional%20blood%20vessels%20in%20vivo%20of%20TDEC%20and%20TDEC%20IR%2B.%20All%20of%20these%20results%20confirm%20that%20regorafenib%20clearly%20impacts%20GSC%20tumour%20formation%20and%20transdifferentiation%20and%20may%20therefore%20be%20a%20promising%20therapeutic%20option%20in%20combination%20with%20chemo%5C%2Fradiotherapy%20for%20the%20treatment%20of%20highly%20aggressive%20brain%20tumours.%22%2C%22date%22%3A%222022-03-18%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3390%5C%2Fcancers14061551%22%2C%22ISSN%22%3A%222072-6694%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222022-05-31T07%3A40%3A30Z%22%7D%7D%5D%7D<\/span>\n\n\t\t\t\t
\n
\n
Modesto, A., P. Graff Cailleaud, P. Blanchard, P. Boisselier, and Y. Pointreau. “[Challenges and limits of therapeutic de-escalation for papillomavirus-related oropharyngeal cancer].” Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique<\/i> 26, no. 6–7 (October 2022): 921–24. https:\/\/doi.org\/10.1016\/j.canrad.2022.06.018<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Bikfalvi, Andreas, Cristine Alves da Costa, Tony Avril, Jean-Vianney Barnier, Luc Bauchet, Lucie Brisson, Pierre Francois Cartron, et al. “Challenges in Glioblastoma Research: Focus on the Tumor Microenvironment.” Trends in Cancer<\/i>, November 15, 2022, S2405-8033(22)00220-5. https:\/\/doi.org\/10.1016\/j.trecan.2022.09.005<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Ouvrard, Chloé, Alice Métais, Enola Brigot, Charlotte Berthaud, Noémie Pucelle, Joëlle Lacombe, Lauren Hasty, et al. “ETV4 Immunohistostaining Is a Sensitive and Specific Diagnostic Biomarker for CIC-Rearranged Sarcoma of the Central Nervous System.” Histopathology<\/i> 81, no. 6 (December 2022): 852–55. https:\/\/doi.org\/10.1111\/his.14796<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Tauziède-Espariat, Arnault, null Volodia-Dangouloff-Ros, Dominique Figarella-Branger, Emmanuelle Uro-Coste, Yvan Nicaise, Nicolas André, Didier Scavarda, et al. “Clinicopathological and Molecular Characterization of Three Cases Classified by DNA-Methylation Profiling as ‘Glioneuronal Tumors, NOS, Subtype A.’” Acta Neuropathologica<\/i> 144, no. 6 (December 2022): 1179–83. https:\/\/doi.org\/10.1007\/s00401-022-02490-9<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Tauziède-Espariat, Arnault, Aurore Siegfried, Yvan Nicaise, Dominique Figarella-Branger, Romain Appay, Suhan Senova, Dorian Bochaton, et al. “A Novel YAP1-MAML2 Fusion in an Adult Supra-Tentorial Ependymoma, YAP1-Fused.” Brain Tumor Pathology<\/i>, October 2022. https:\/\/doi.org\/10.1007\/s10014-022-00439-0<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Laprie, A., F. Tensaouti, and E. Cohen-Jonathan Moyal. “[Radiation dose intensification for glioblastoma].” Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique<\/i> 26, no. 6–7 (October 2022): 894–98. https:\/\/doi.org\/10.1016\/j.canrad.2022.07.007<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Appay, Romain, Franck Bielle, Philipp Sievers, Doriane Barets, Frédéric Fina, Jean Boutonnat, Adam Clovis, et al. “Rosette-Forming Glioneuronal Tumours Are Midline, FGFR1-Mutated Tumours.” Neuropathology and Applied Neurobiology<\/i>, March 16, 2022, e12813. https:\/\/doi.org\/10.1111\/nan.12813<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Maingon, P., V. Marchesi, D. Azria, J. Balosso, É Deutsch, É Cohen Jonathan-Moyal, P. Giraud, and É Bayart. “RadioTransNet: Preclinical Research Network Coordinated at the SFRO and SFPM.” Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique<\/i> 26, no. 1–2 (April 2022): 108–15. https:\/\/doi.org\/10.1016\/j.canrad.2021.08.003<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Sidibe, Ingrid, Fatima Tensaouti, Margaux Roques, Elizabeth Cohen-Jonathan-Moyal, and Anne Laprie. “Pseudoprogression in Glioblastoma: Role of Metabolic and Functional MRI-Systematic Review.” Biomedicines<\/i> 10, no. 2 (January 26, 2022): 285. https:\/\/doi.org\/10.3390\/biomedicines10020285<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Métais, Alice, Romain Appay, Mélanie Pagès, Catherine Gallardo, Karen Silva, Aurore Siegfried, Romain Perbet, et al. “Low-Grade Epilepsy-Associated Neuroepithelial Tumours with a Prominent Oligodendroglioma-like Component: The Diagnostic Challenges.” Neuropathology and Applied Neurobiology<\/i> 48, no. 2 (February 2022): e12769. https:\/\/doi.org\/10.1111\/nan.12769<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Hennequin, C., D. Azria, P. Blanchard, G. Créhange, É Deutsch, A. Lisbona, É Moyal, et al. “Specificities of Clinical Research in Radiotherapy.” Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique<\/i> 26, no. 1–2 (April 2022): 104–7. https:\/\/doi.org\/10.1016\/j.canrad.2021.11.011<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Monteiro, Cátia, Lauritz Miarka, María Perea-García, Neibla Priego, Pedro García-Gómez, Laura Álvaro-Espinosa, Ana de Pablos-Aragoneses, et al. “Stratification of Radiosensitive Brain Metastases Based on an Actionable S100A9\/RAGE Resistance Mechanism.” Nature Medicine<\/i>, April 11, 2022. https:\/\/doi.org\/10.1038\/s41591-022-01749-8<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Garnier, Louis, Chrystelle Vidal, Olivier Chinot, Elisabeth Cohen-Jonathan Moyal, Apolline Djelad, Charlotte Bronnimann, Lien Bekaert, et al. “Characteristics of Anaplastic Oligodendrogliomas Short-Term Survivors: A POLA Network Study.” The Oncologist<\/i> 27, no. 5 (May 6, 2022): 414–23. https:\/\/doi.org\/10.1093\/oncolo\/oyac023<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Tauziède-Espariat, Arnault, Philipp Sievers, Frédérique Larousserie, Joseph Benzakoun, Delphine Guillemot, Gaëlle Pierron, Mathilde Duchesne, et al. “An Integrative Histopathological and Epigenetic Characterization of Primary Intracranial Mesenchymal Tumors, FET:CREB-Fused Broadening the Spectrum of Tumor Entities in Comparison with Their Soft Tissue Counterparts.” Brain Pathology (Zurich, Switzerland)<\/i> 32, no. 1 (January 2022): e13010. https:\/\/doi.org\/10.1111\/bpa.13010<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Lacore, Marie Geraldine, Caroline Delmas, Yvan Nicaise, Aline Kowalski-Chauvel, Elizabeth Cohen-Jonathan-Moyal, and Catherine Seva. “The Glycoprotein M6a Is Associated with Invasiveness and Radioresistance of Glioblastoma Stem Cells.” Cells<\/i> 11, no. 14 (July 6, 2022): 2128. https:\/\/doi.org\/10.3390\/cells11142128<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Tauziède-Espariat, Arnault, Aurore Siegfried, Emmanuelle Uro-Coste, Yvan Nicaise, David Castel, Annick Sevely, Marion Gambart, et al. “Disseminated Diffuse Midline Gliomas, H3K27-Altered Mimicking Diffuse Leptomeningeal Glioneuronal Tumors: A Diagnostical Challenge!” Acta Neuropathologica Communications<\/i> 10, no. 1 (August 19, 2022): 119. https:\/\/doi.org\/10.1186\/s40478-022-01419-3<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Duval, Tanguy, Jean-Albert Lotterie, Anthony Lemarie, Caroline Delmas, Fatima Tensaouti, Elizabeth Cohen-Jonathan Moyal, and Vincent Lubrano. “Glioblastoma Stem-like Cell Detection Using Perfusion and Diffusion MRI.” Cancers<\/i> 14, no. 11 (June 4, 2022): 2803. https:\/\/doi.org\/10.3390\/cancers14112803<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Tensaouti, Fatima, Franck Desmoulin, Julia Gilhodes, Elodie Martin, Soleakhena Ken, Jean-Albert Lotterie, Georges Noël, et al. “Quality Control of 3D MRSI Data in Glioblastoma: Can We Do without the Experts?” Magnetic Resonance in Medicine<\/i> 87, no. 4 (April 2022): 1688–99. https:\/\/doi.org\/10.1002\/mrm.29098<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Acquitter, Clément, Lucie Piram, Umberto Sabatini, Julia Gilhodes, Elizabeth Moyal Cohen-Jonathan, Soleakhena Ken, and Benjamin Lemasson. “Radiomics-Based Detection of Radionecrosis Using Harmonized Multiparametric MRI.” Cancers<\/i> 14, no. 2 (January 7, 2022): 286. https:\/\/doi.org\/10.3390\/cancers14020286<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Balosso, J., F. Missohou, D. Antoni, C. Hennequin, M.-A. Mahé, L. Simon, and C. Demoor-Goldschmidt. “Radiotherapy of Lymphomas.” Cancer\/Radiothérapie<\/i> 26, no. 1–2 (2022): 388–96. https:\/\/doi.org\/10.1016\/j.canrad.2021.11.007<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Darréon, J., G. Bouilhol, N. Aillières, H. Bouscayrol, L. Simon, and M. Ayadi. “Respiratory Motion Management for External Radiotherapy Treatment.” Cancer\/Radiothérapie<\/i> 26, no. 1–2 (2022): 50–58. https:\/\/doi.org\/10.1016\/j.canrad.2021.09.006<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Grégoire, V., P. Giraud, L. Vieillevigne, and P. Maingon. “Management of Oropharyngeal Squamous Cell Carcinoma.” Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique<\/i> 26, no. 1–2 (April 2022): 174–88. https:\/\/doi.org\/10.1016\/j.canrad.2021.10.002<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Grégoire, V., S. Boisbouvier, P. Giraud, P. Maingon, Y. Pointreau, and L. Vieillevigne. “Management and Work-up Procedures of Patients with Head and Neck Malignancies Treated by Radiation.” Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique<\/i> 26, no. 1–2 (April 2022): 147–55. https:\/\/doi.org\/10.1016\/j.canrad.2021.10.005<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Delbaere, Alexia, Tony Younes, Luc Simon, Catherine Khamphan, and Laure Vieillevigne. “Field Output Correction Factors and Electron Fluence Perturbation of the MicroSilicon and MicroSilicon X Detectors.” Physics in Medicine and Biology<\/i> 67, no. 8 (April 7, 2022). https:\/\/doi.org\/10.1088\/1361-6560\/ac5e5e<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Deshors, Pauline, Florent Arnauduc, Betty Boëlle, Elizabeth Cohen-Jonathan Moyal, Monique Courtade-Saïdi, and Solène M. Evrard. “Impact of Regorafenib on Endothelial Transdifferentiation of Glioblastoma Stem-like Cells.” Cancers<\/i> 14, no. 6 (March 18, 2022): 1551. https:\/\/doi.org\/10.3390\/cancers14061551<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n\n\n

[\/et_pb_toggle][et_pb_toggle title=”PUBLICATIONS 2021″ open_toggle_text_color=”#5EC7ED” open_toggle_background_color=”#ffffff” closed_toggle_text_color=”#505659″ closed_toggle_background_color=”#AEE3F6″ icon_color=”#505659″ open_icon_color=”#505659″ _builder_version=”4.16″ _module_preset=”default” title_text_color=”#ffffff” title_font=”|600||on|||||” title_text_align=”center” title_font_size=”22px” closed_title_font=”|600|||||||” closed_title_font_size=”22px” body_text_align=”left” body_text_color=”#505659″ body_font_size=”16px” text_orientation=”center” global_colors_info=”{}”]<\/p>\n

\n\n\t\t7813506<\/span>\n\t\t<\/span>\n\t\tMCWU4QSQ<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t2021<\/span>\n <\/span>\n items<\/span>\n\t\t1<\/span>\n\t\tchicago-fullnote-bibliography<\/span>\n\t\t0<\/span>\n\t\tdefault<\/span>\n\t\tasc<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n <\/span>\n 2027<\/span>\n\t\thttps:\/\/www.crct-inserm.fr\/wp-content\/plugins\/zotpress\/<\/span>\n\n\t\t
\n\t\t\t
\n\t\t\t\t%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-9eb710963004929a21ca7b28b782ca2f%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22FFALPFAM%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Zanca%20et%20al.%22%2C%22parsedDate%22%3A%222021-03%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EZanca%2C%20F.%2C%20I.%20Hernandez-Giron%2C%20M.%20Avanzo%2C%20G.%20Guidi%2C%20W.%20Crijns%2C%20O.%20Diaz%2C%20G.%20C.%20Kagadis%2C%20et%20al.%20%26%23x201C%3BExpanding%20the%20Medical%20Physicist%20Curricular%20and%20Professional%20Programme%20to%20Include%20Artificial%20Intelligence.%26%23x201D%3B%20%3Ci%3EPhysica%20Medica%3A%20PM%3A%20An%20International%20Journal%20Devoted%20to%20the%20Applications%20of%20Physics%20to%20Medicine%20and%20Biology%3A%20Official%20Journal%20of%20the%20Italian%20Association%20of%20Biomedical%20Physics%20%28AIFB%29%3C%5C%2Fi%3E%2083%20%28March%202021%29%3A%20174%26%23x2013%3B83.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ejmp.2021.01.069%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ejmp.2021.01.069%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Expanding%20the%20medical%20physicist%20curricular%20and%20professional%20programme%20to%20include%20Artificial%20Intelligence%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Zanca%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.%22%2C%22lastName%22%3A%22Hernandez-Giron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Avanzo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Guidi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%22%2C%22lastName%22%3A%22Crijns%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%22%2C%22lastName%22%3A%22Diaz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%20C.%22%2C%22lastName%22%3A%22Kagadis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%22%2C%22lastName%22%3A%22Rampado%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20I.%22%2C%22lastName%22%3A%22L%5Cu00f8nne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Ken%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Colgan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Zaidi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%20A.%22%2C%22lastName%22%3A%22Zakaria%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Kortesniemi%22%7D%5D%2C%22abstractNote%22%3A%22PURPOSE%3A%20To%20provide%20a%20guideline%20curriculum%20related%20to%20Artificial%20Intelligence%20%28AI%29%2C%20for%20the%20education%20and%20training%20of%20European%20Medical%20Physicists%20%28MPs%29.%5CnMATERIALS%20AND%20METHODS%3A%20The%20proposed%20curriculum%20consists%20of%20two%20levels%3A%20Basic%20%28introducing%20MPs%20to%20the%20pillars%20of%20knowledge%2C%20development%20and%20applications%20of%20AI%2C%20in%20the%20context%20of%20medical%20imaging%20and%20radiation%20therapy%29%20and%20Advanced.%20Both%20are%20common%20to%20the%20subspecialties%20%28diagnostic%20and%20interventional%20radiology%2C%20nuclear%20medicine%2C%20and%20radiation%20oncology%29.%20The%20learning%20outcomes%20of%20the%20training%20are%20presented%20as%20knowledge%2C%20skills%20and%20competences%20%28KSC%20approach%29.%5CnRESULTS%3A%20For%20the%20Basic%20section%2C%20KSCs%20were%20stratified%20in%20four%20subsections%3A%20%281%29%20Medical%20imaging%20analysis%20and%20AI%20Basics%3B%20%282%29%20Implementation%20of%20AI%20applications%20in%20clinical%20practice%3B%20%283%29%20Big%20data%20and%20enterprise%20imaging%2C%20and%20%284%29%20Quality%2C%20Regulatory%20and%20Ethical%20Issues%20of%20AI%20processes.%20For%20the%20Advanced%20section%20instead%2C%20a%20common%20block%20was%20proposed%20to%20be%20further%20elaborated%20by%20each%20subspecialty%20core%20curriculum.%20The%20learning%20outcomes%20were%20also%20translated%20into%20a%20syllabus%20of%20a%20more%20traditional%20format%2C%20including%20practical%20applications.%5CnCONCLUSIONS%3A%20This%20AI%20curriculum%20is%20the%20first%20attempt%20to%20create%20a%20guideline%20expanding%20the%20current%20educational%20framework%20for%20Medical%20Physicists%20in%20Europe.%20It%20should%20be%20considered%20as%20a%20document%20to%20top%20the%20sub-specialties%27%20curriculums%20and%20adapted%20by%20national%20training%20and%20regulatory%20bodies.%20The%20proposed%20educational%20program%20can%20be%20implemented%20via%20the%20European%20School%20of%20Medical%20Physics%20Expert%20%28ESMPE%29%20course%20modules%20and%20-%20to%20some%20extent%20-%20also%20by%20the%20national%20competent%20EFOMP%20organizations%2C%20to%20reach%20widely%20the%20medical%20physicist%20community%20in%20Europe.%22%2C%22date%22%3A%222021-03%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ejmp.2021.01.069%22%2C%22ISSN%22%3A%221724-191X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222023-03-21T12%3A53%3A34Z%22%7D%7D%2C%7B%22key%22%3A%22UWXLTAB3%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Robert%20et%20al.%22%2C%22parsedDate%22%3A%222021%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ERobert%2C%20C.%2C%20A.%20Munoz%2C%20D.%20Moreau%2C%20J.%20Mazurier%2C%20G.%20Sidorski%2C%20A.%20Gasnier%2C%20G.%20Beldjoudi%2C%20et%20al.%20%26%23x201C%3BClinical%20Implementation%20of%20Deep-Learning%20Based%20Auto-Contouring%20Tools%26%23x2013%3BExperience%20of%20Three%20French%20Radiotherapy%20Centers.%26%23x201D%3B%20%3Ci%3ECancer%5C%2FRadioth%26%23xE9%3Brapie%3C%5C%2Fi%3E%2025%2C%20no.%206%26%23x2013%3B7%20%282021%29%3A%20607%26%23x2013%3B16.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.canrad.2021.06.023%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.canrad.2021.06.023%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Clinical%20implementation%20of%20deep-learning%20based%20auto-contouring%20tools%5Cu2013Experience%20of%20three%20French%20radiotherapy%20centers%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Munoz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Mazurier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Sidorski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Gasnier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Beldjoudi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Gr%5Cu00e9goire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Deutsch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Meyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Simon%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2210%5C%2F2021%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.canrad.2021.06.023%22%2C%22ISSN%22%3A%2212783218%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Flinkinghub.elsevier.com%5C%2Fretrieve%5C%2Fpii%5C%2FS1278321821001220%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222022-05-31T07%3A49%3A13Z%22%7D%7D%2C%7B%22key%22%3A%22L2QVCWVQ%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Meyer%20et%20al.%22%2C%22parsedDate%22%3A%222021%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMeyer%2C%20P.%2C%20M.-C.%20Biston%2C%20C.%20Khamphan%2C%20T.%20Marghani%2C%20J.%20Mazurier%2C%20V.%20Bodez%2C%20L.%20Fezzani%2C%20et%20al.%20%26%23x201C%3BAutomation%20in%20Radiotherapy%20Treatment%20Planning%3A%20Examples%20of%20Use%20in%20Clinical%20Practice%20and%20Future%20Trends%20for%20a%20Complete%20Automated%20Workflow.%26%23x201D%3B%20%3Ci%3ECancer%5C%2FRadioth%26%23xE9%3Brapie%3C%5C%2Fi%3E%2025%2C%20no.%206%26%23x2013%3B7%20%282021%29%3A%20617%26%23x2013%3B22.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.canrad.2021.06.006%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.canrad.2021.06.006%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Automation%20in%20radiotherapy%20treatment%20planning%3A%20Examples%20of%20use%20in%20clinical%20practice%20and%20future%20trends%20for%20a%20complete%20automated%20workflow%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Meyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.-C.%22%2C%22lastName%22%3A%22Biston%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Khamphan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Marghani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Mazurier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Bodez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Fezzani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.A.%22%2C%22lastName%22%3A%22Rigaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Sidorski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Simon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Robert%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2210%5C%2F2021%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.canrad.2021.06.006%22%2C%22ISSN%22%3A%2212783218%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Flinkinghub.elsevier.com%5C%2Fretrieve%5C%2Fpii%5C%2FS1278321821001037%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222022-05-31T07%3A48%3A49Z%22%7D%7D%2C%7B%22key%22%3A%22ASXVAQQ2%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Simon%20et%20al.%22%2C%22parsedDate%22%3A%222021%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ESimon%2C%20L.%2C%20C.%20Robert%2C%20and%20P.%20Meyer.%20%26%23x201C%3BArtificial%20Intelligence%20for%20Quality%20Assurance%20in%20Radiotherapy.%26%23x201D%3B%20%3Ci%3ECancer%5C%2FRadioth%26%23xE9%3Brapie%3C%5C%2Fi%3E%2025%2C%20no.%206%26%23x2013%3B7%20%282021%29%3A%20623%26%23x2013%3B26.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.canrad.2021.06.012%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.canrad.2021.06.012%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Artificial%20intelligence%20for%20quality%20assurance%20in%20radiotherapy%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Simon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Meyer%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2210%5C%2F2021%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.canrad.2021.06.012%22%2C%22ISSN%22%3A%2212783218%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Flinkinghub.elsevier.com%5C%2Fretrieve%5C%2Fpii%5C%2FS1278321821001104%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222022-05-31T07%3A48%3A29Z%22%7D%7D%2C%7B%22key%22%3A%229UKZKSDD%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Leste%20et%20al.%22%2C%22parsedDate%22%3A%222021%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELeste%2C%20Jeremy%2C%20Tony%20Younes%2C%20Maxime%20Chauvin%2C%20Xavier%20Franceries%2C%20Alexia%20Delbaere%2C%20Laure%20Vieillevigne%2C%20Regis%20Ferrand%2C%20Manuel%20Bardies%2C%20and%20Luc%20Simon.%20%26%23x201C%3BTechnical%20Note%3A%20GAMMORA%2C%20a%20Free%2C%20Open-Source%2C%20and%20Validated%20GATE-Based%20Model%20for%20Monte-Carlo%20Simulations%20of%20the%20Varian%20TrueBeam.%26%23x201D%3B%20%3Ci%3EPhysica%20Medica%3C%5C%2Fi%3E%2089%20%282021%29%3A%20211%26%23x2013%3B18.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ejmp.2021.07.037%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ejmp.2021.07.037%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Technical%20note%3A%20GAMMORA%2C%20a%20free%2C%20open-source%2C%20and%20validated%20GATE-based%20model%20for%20Monte-Carlo%20simulations%20of%20the%20Varian%20TrueBeam%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeremy%22%2C%22lastName%22%3A%22Leste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tony%22%2C%22lastName%22%3A%22Younes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Chauvin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Franceries%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexia%22%2C%22lastName%22%3A%22Delbaere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Vieillevigne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Regis%22%2C%22lastName%22%3A%22Ferrand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manuel%22%2C%22lastName%22%3A%22Bardies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luc%22%2C%22lastName%22%3A%22Simon%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2209%5C%2F2021%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ejmp.2021.07.037%22%2C%22ISSN%22%3A%2211201797%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Flinkinghub.elsevier.com%5C%2Fretrieve%5C%2Fpii%5C%2FS1120179721002817%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222022-05-31T07%3A47%3A49Z%22%7D%7D%2C%7B%22key%22%3A%22I7LWYC49%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Attal%20et%20al.%22%2C%22parsedDate%22%3A%222021-12%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EAttal%2C%20J.%2C%20B.%20Cabarrou%2C%20T.%20Valentin%2C%20J.%20P.%20Nesseler%2C%20E.%20Stoeckle%2C%20A.%20Ducassou%2C%20T.%20Filleron%2C%20et%20al.%20%26%23x201C%3BEvaluation%20of%20Two%20Modalities%20of%20Perioperative%20Treatment%20in%20the%20Management%20of%26%23xA0%3BExtremity%20and%26%23xA0%3BTruncal%26%23xA0%3BSoft%20Tissue%20Sarcomas%3A%20Neoadjuvant%20Concurrent%20Chemoradiotherapy%20and%20Sequential%20Treatment.%26%23x201D%3B%20%3Ci%3EStrahlentherapie%20Und%20Onkologie%3A%20Organ%20Der%20Deutschen%20Rontgengesellschaft%20...%20%5Bet%20Al%5D%3C%5C%2Fi%3E%20197%2C%20no.%2012%20%28December%202021%29%3A%201051%26%23x2013%3B62.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00066-021-01847-5%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00066-021-01847-5%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Evaluation%20of%20two%20modalities%20of%20perioperative%20treatment%20in%20the%20management%20of%5Cu00a0extremity%20and%5Cu00a0truncal%5Cu00a0soft%20tissue%20sarcomas%3A%20neoadjuvant%20concurrent%20chemoradiotherapy%20and%20sequential%20treatment%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Attal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Cabarrou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Valentin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20P.%22%2C%22lastName%22%3A%22Nesseler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Stoeckle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Ducassou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Filleron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Le%20Guellec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Boulet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Vogin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Ferron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20Cohen-Jonathan%22%2C%22lastName%22%3A%22Moyal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Delannes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Chevreau%22%7D%5D%2C%22abstractNote%22%3A%22PURPOSE%3A%20Patients%20with%20locally%20advanced%20grade%202-3%20extremity%5C%2Ftruncal%20soft%20tissue%20sarcomas%20%28STS%29%20are%20at%20high%20risk%20of%20recurrence.%20The%20objective%20of%20this%20study%20was%20to%20assess%20the%20efficacy%20and%20feasibility%20of%20neoadjuvant%20concurrent%20chemoradiotherapy%20%28cCRT%29%20in%20selected%20grade%202-3%5Cu00a0patients%20with%20limb%20or%20trunk%20wall%20STS%2C%20and%20to%20compare%20this%20schedule%20to%20a%5Cu00a0sequential%20approach%20combining%20neoadjuvant%20chemotherapy%20and%20adjuvant%20radiotherapy.%5CnMETHODS%3A%20We%20retrospectively%20included%20patients%20who%20underwent%20neoadjuvant%20cCRT%20at%20two%20comprehensive%20cancer%20centers%20from%201992-2016.%20We%20then%20compared%20these%20results%20to%20those%20of%20patients%20treated%20with%20preoperative%20chemotherapy%20and%20postoperative%20radiotherapy%20from%20a%5Cu00a0third%20comprehensive%20cancer%20center%20with%20a%5Cu00a0propensity%20score%20matched%20analysis.%5CnRESULTS%3A%20A%5Cu00a0total%20of%2053%5Cu00a0patients%20were%20treated%5Cu00a0by%20neoadjuvant%20cCRT%3B%2058%5Cu00a0patients%20could%20be%20matched%20with%2029%5Cu00a0patients%20in%20each%20treatment%20group%20after%20propensity%20score%20matching.%20Disease-free%20survival%20and%20overall%20survival%20at%205%5Cu00a0years%20were%2054.9%20and%2063.5%25%2C%20respectively%20with%20neoadjuvant%20cCRT%2C%20with%20no%20significant%20difference%20when%20compared%20to%20the%20sequential%20treatment%20group.%20R0%5Cu00a0resection%20rate%20was%20higher%20%2890.9%20vs%2044.8%25%2C%20p%5Cu202f%3C%5Cu20090.01%29%20in%20the%20cCRT%20group%20than%20in%20the%20sequential%20treatment%20group%20during%20a%5Cu00a0shorter%20therapeutic%20sequence%20%28118%20vs%20210.5%5Cu00a0days%2C%20p%5Cu202f%3C%5Cu20090.01%29%2C%20with%20no%20impact%20on%20the%20surgical%20procedure%20or%20postoperative%20complications.%5CnCONCLUSION%3A%20cCRT%20is%20feasible%20with%20acceptable%20immediate%20and%20late%20toxicities.%20It%20could%20facilitate%20surgery%20by%20increasing%20the%20R0%5Cu00a0resection%20rate%20and%20improve%20patient%20compliance%20by%20shortening%20the%20therapeutic%20sequence.%22%2C%22date%22%3A%222021-12%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs00066-021-01847-5%22%2C%22ISSN%22%3A%221439-099X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222022-04-11T13%3A46%3A30Z%22%7D%7D%2C%7B%22key%22%3A%227Q3MIT37%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Alhalabi%20et%20al.%22%2C%22parsedDate%22%3A%222021-11%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EAlhalabi%2C%20Karam%20T.%2C%20Damian%20Stichel%2C%20Philipp%20Sievers%2C%20Heike%20Peterziel%2C%20Alexander%20C.%20Sommerkamp%2C%20Dominik%20Sturm%2C%20Andrea%20Wittmann%2C%20et%20al.%20%26%23x201C%3BPATZ1%20Fusions%20Define%20a%20Novel%20Molecularly%20Distinct%20Neuroepithelial%20Tumor%20Entity%20with%20a%20Broad%20Histological%20Spectrum.%26%23x201D%3B%20%3Ci%3EActa%20Neuropathologica%3C%5C%2Fi%3E%20142%2C%20no.%205%20%28November%202021%29%3A%20841%26%23x2013%3B57.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00401-021-02354-8%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00401-021-02354-8%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22PATZ1%20fusions%20define%20a%20novel%20molecularly%20distinct%20neuroepithelial%20tumor%20entity%20with%20a%20broad%20histological%20spectrum%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karam%20T.%22%2C%22lastName%22%3A%22Alhalabi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damian%22%2C%22lastName%22%3A%22Stichel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philipp%22%2C%22lastName%22%3A%22Sievers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Heike%22%2C%22lastName%22%3A%22Peterziel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexander%20C.%22%2C%22lastName%22%3A%22Sommerkamp%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominik%22%2C%22lastName%22%3A%22Sturm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrea%22%2C%22lastName%22%3A%22Wittmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%22%2C%22lastName%22%3A%22Sill%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Natalie%22%2C%22lastName%22%3A%22J%5Cu00e4ger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pengbo%22%2C%22lastName%22%3A%22Beck%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kristian%20W.%22%2C%22lastName%22%3A%22Pajtler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matija%22%2C%22lastName%22%3A%22Snuderl%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22George%22%2C%22lastName%22%3A%22Jour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Delorenzo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Allison%20M.%22%2C%22lastName%22%3A%22Martin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adam%22%2C%22lastName%22%3A%22Levy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nagma%22%2C%22lastName%22%3A%22Dalvi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jordan%20R.%22%2C%22lastName%22%3A%22Hansford%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicholas%20G.%22%2C%22lastName%22%3A%22Gottardo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Uro-Coste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claude-Alain%22%2C%22lastName%22%3A%22Maurage%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Godfraind%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fanny%22%2C%22lastName%22%3A%22Vandenbos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Torsten%22%2C%22lastName%22%3A%22Pietsch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christof%22%2C%22lastName%22%3A%22Kramm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%22%2C%22lastName%22%3A%22Filippidou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antonis%22%2C%22lastName%22%3A%22Kattamis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chris%22%2C%22lastName%22%3A%22Jones%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ingrid%22%2C%22lastName%22%3A%22%5Cu00d8ra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Torben%20Stamm%22%2C%22lastName%22%3A%22Mikkelsen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michal%22%2C%22lastName%22%3A%22Zapotocky%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Sumerauer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Scheie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%22%2C%22lastName%22%3A%22McCabe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pieter%22%2C%22lastName%22%3A%22Wesseling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bastiaan%20B.%20J.%22%2C%22lastName%22%3A%22Tops%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mari%5Cu00ebtte%20E.%20G.%22%2C%22lastName%22%3A%22Kranendonk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%20A.%22%2C%22lastName%22%3A%22Karajannis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nancy%22%2C%22lastName%22%3A%22Bouvier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elli%22%2C%22lastName%22%3A%22Papaemmanuil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hildegard%22%2C%22lastName%22%3A%22Dohmen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Till%22%2C%22lastName%22%3A%22Acker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katja%22%2C%22lastName%22%3A%22von%20Hoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simone%22%2C%22lastName%22%3A%22Schmid%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Evelina%22%2C%22lastName%22%3A%22Miele%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katharina%22%2C%22lastName%22%3A%22Filipski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lidija%22%2C%22lastName%22%3A%22Kitanovski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lenka%22%2C%22lastName%22%3A%22Krskova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Johannes%22%2C%22lastName%22%3A%22Gojo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Haberler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frank%22%2C%22lastName%22%3A%22Alvaro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonas%22%2C%22lastName%22%3A%22Ecker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florian%22%2C%22lastName%22%3A%22Selt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Till%22%2C%22lastName%22%3A%22Milde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olaf%22%2C%22lastName%22%3A%22Witt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ina%22%2C%22lastName%22%3A%22Oehme%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcel%22%2C%22lastName%22%3A%22Kool%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andreas%22%2C%22lastName%22%3A%22von%20Deimling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrey%22%2C%22lastName%22%3A%22Korshunov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefan%20M.%22%2C%22lastName%22%3A%22Pfister%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Felix%22%2C%22lastName%22%3A%22Sahm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20T.%20W.%22%2C%22lastName%22%3A%22Jones%22%7D%5D%2C%22abstractNote%22%3A%22Large-scale%20molecular%20profiling%20studies%20in%20recent%20years%20have%20shown%20that%20central%20nervous%20system%20%28CNS%29%20tumors%20display%20a%20much%20greater%20heterogeneity%20in%20terms%20of%20molecularly%20distinct%20entities%2C%20cellular%20origins%20and%20genetic%20drivers%20than%20anticipated%20from%20histological%20assessment.%20DNA%20methylation%20profiling%20has%20emerged%20as%20a%20useful%20tool%20for%20robust%20tumor%20classification%2C%20providing%20new%20insights%20into%20these%20heterogeneous%20molecular%20classes.%20This%20is%20particularly%20true%20for%20rare%20CNS%20tumors%20with%20a%20broad%20morphological%20spectrum%2C%20which%20are%20not%20possible%20to%20assign%20as%20separate%20entities%20based%20on%20histological%20similarity%20alone.%20Here%2C%20we%20describe%20a%20molecularly%20distinct%20subset%20of%20predominantly%20pediatric%20CNS%20neoplasms%20%28n%5Cu2009%3D%5Cu200960%29%20that%20harbor%20PATZ1%20fusions.%20The%20original%20histological%20diagnoses%20of%20these%20tumors%20covered%20a%20wide%20spectrum%20of%20tumor%20types%20and%20malignancy%20grades.%20While%20the%20single%20most%20common%20diagnosis%20was%20glioblastoma%20%28GBM%29%2C%20clinical%20data%20of%20the%20PATZ1-fused%20tumors%20showed%20a%20better%20prognosis%20than%20typical%20GBM%2C%20despite%20frequent%20relapses.%20RNA%20sequencing%20revealed%20recurrent%20MN1%3APATZ1%20or%20EWSR1%3APATZ1%20fusions%20related%20to%20%28often%20extensive%29%20copy%20number%20variations%20on%20chromosome%2022%2C%20where%20PATZ1%20and%20the%20two%20fusion%20partners%20are%20located.%20These%20fusions%20have%20individually%20been%20reported%20in%20a%20number%20of%20glial%5C%2Fglioneuronal%20tumors%2C%20as%20well%20as%20extracranial%20sarcomas.%20We%20show%20here%20that%20they%20are%20more%20common%20than%20previously%20acknowledged%2C%20and%20together%20define%20a%20biologically%20distinct%20CNS%20tumor%20type%20with%20high%20expression%20of%20neural%20development%20markers%20such%20as%20PAX2%2C%20GATA2%20and%20IGF2.%20Drug%20screening%20performed%20on%20the%20MN1%3APATZ1%20fusion-bearing%20KS-1%20brain%20tumor%20cell%20line%20revealed%20preliminary%20candidates%20for%20further%20study.%20In%20summary%2C%20PATZ1%20fusions%20define%20a%20molecular%20class%20of%20histologically%20polyphenotypic%20neuroepithelial%20tumors%2C%20which%20show%20an%20intermediate%20prognosis%20under%20current%20treatment%20regimens.%22%2C%22date%22%3A%222021-11%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs00401-021-02354-8%22%2C%22ISSN%22%3A%221432-0533%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222022-02-23T12%3A53%3A48Z%22%7D%7D%2C%7B%22key%22%3A%22V4INCKSR%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Sacko%20et%20al.%22%2C%22parsedDate%22%3A%222021%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ESacko%2C%20Oumar%2C%20Alexandra%20Benouaich-Amiel%2C%20Pierre%20Brandicourt%2C%20Mahamadou%20Niar%26%23xE9%3B%2C%20Saloua%20Charni%2C%20Clarissa%20Cavandoli%2C%20David%20Brauge%2C%20et%20al.%20%26%23x201C%3BThe%20Impact%20of%20Surgery%20on%20the%20Survival%20of%20Patients%20with%20Recurrent%20Glioblastoma.%26%23x201D%3B%20%3Ci%3EAsian%20Journal%20of%20Neurosurgery%3C%5C%2Fi%3E%2016%2C%20no.%201%20%282021%29%3A%201%26%23x2013%3B7.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.4103%5C%2Fajns.AJNS_180_20%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.4103%5C%2Fajns.AJNS_180_20%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20Impact%20of%20Surgery%20on%20the%20Survival%20of%20Patients%20with%20Recurrent%20Glioblastoma%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Oumar%22%2C%22lastName%22%3A%22Sacko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Benouaich-Amiel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Brandicourt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mahamadou%22%2C%22lastName%22%3A%22Niar%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Saloua%22%2C%22lastName%22%3A%22Charni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clarissa%22%2C%22lastName%22%3A%22Cavandoli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Brauge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Catalaa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adam%22%2C%22lastName%22%3A%22Brenner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%20Cohen-Jonathan%22%2C%22lastName%22%3A%22Moyal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franck-Emmanuel%22%2C%22lastName%22%3A%22Roux%22%7D%5D%2C%22abstractNote%22%3A%22Objective%3A%20The%20purpose%20of%20this%20study%20was%20to%20investigate%20the%20possible%20benefit%20of%20repeat%20surgery%20on%20overall%20survival%20for%20patients%20with%20recurrent%20glioblastoma%20multiforme%20%28GBM%29.%5CnMethods%3A%20We%20performed%20a%20retrospective%20analysis%20of%20data%20from%20patients%20who%20presented%20with%20recurrent%20GBM%20over%20a%205-year%20period%20%28n%20%3D%20157%29%2C%20comparing%20baseline%20characteristics%20and%20survival%20for%20patients%20who%20had%20at%20least%201%20new%20tumor%20resection%20followed%20by%20chemotherapy%20%28reoperation%20group%2C%20n%20%3D%2059%29%20and%20those%20who%20received%20medical%20treatment%20only%20%28no-reoperation%20group%2C%20n%20%3D%2098%29%20for%20recurrence.%5CnResults%3A%20The%20baseline%20characteristics%20of%20the%20two%20groups%20differed%20in%20terms%20of%20WHO%20performance%20status%20%28better%20in%20the%20reoperation%20group%29%2C%20mean%20age%20%2860%20years%20in%20the%20reoperation%20group%20vs.%2065%20years%20in%20the%20no-reoperation%20group%29%2C%20mean%20interval%20to%20recurrence%20%283%20months%20later%20in%20the%20reoperation%20group%20than%20in%20the%20no-reoperation%20group%29%20and%20more%20gross%20total%20resections%20in%20the%20reoperation%20group.%20Nevertheless%2C%20the%20patients%20in%20the%20reoperation%20group%20had%20a%20higher%20rate%20%5B32.8%25%5D%20of%20sensorimotor%20deficits%20than%20those%20of%20the%20no-reoperation%20group%20%5B14.2%5D.%20There%20was%20no%20significant%20difference%20in%20sex%3B%20tumor%20localization%2C%20side%2C%20or%20extent%3B%20MGMT%20status%3B%20MIB-1%20labeling%20index%3B%20or%20Karnofsky%20Performance%20Status%20%5BKPS%5D%20score.%20After%20adjustment%20for%20age%2C%20the%20WHO%20performance%20status%2C%20interval%20of%20recurrence%2C%20and%20extent%20of%20resection%20at%20the%20first%20operation%2C%20multivariate%20analysis%20showed%20that%20median%20survival%20was%20significantly%20better%20in%20the%20reoperation%20group%20than%20in%20the%20no-reoperation%20group%20%2822.9%20vs.%2014.61%20months%2C%20P%20%3C%200.05%29.%20After%20a%20total%20of%2069%20repeat%20operations%20in%2059%20patients%20%2810%20had%202%20repeat%20surgeries%29%2C%20we%20noted%2013%20temporary%20and%2020%20permanent%20adverse%20postoperative%20events%2C%20yielding%20a%20permanent%20complication%20rate%20of%2028.99%25%20%2820%5C%2F69%29.%20There%20was%20also%20a%20statistically%20significant%20%28P%20%3D%200.029%2C%20Student%27s%20t-test%29%20decrease%20in%20the%20mean%20KPS%20score%20after%20reoperation%20%28mean%20preoperative%20KPS%20score%20of%2089.34%20vs.%20mean%20postoperative%20score%20of%2084.91%29.%5CnConclusion%3A%20Our%20retrospective%20study%20suggests%20that%20repeat%20surgery%20may%20be%20beneficial%20for%20patients%20with%20GBM%20recurrence%20who%20have%20good%20functional%20status%20%28WHO%20performance%20status%200%20and%201%29%2C%20although%20the%20potential%20benefits%20must%20be%20weighed%20against%20the%20risk%20of%20permanent%20complications%2C%20which%20occurred%20in%20almost%2030%25%20of%20the%20patients%20who%20underwent%20repeat%20resection%20in%20this%20series.%22%2C%22date%22%3A%222021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.4103%5C%2Fajns.AJNS_180_20%22%2C%22ISSN%22%3A%221793-5482%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222021-11-10T15%3A58%3A13Z%22%7D%7D%2C%7B%22key%22%3A%22BPPN7ZVC%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Dalmasso%20et%20al.%22%2C%22parsedDate%22%3A%222021%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDalmasso%2C%20C%26%23xE9%3Bline%2C%20C%26%23xE9%3Bcile%20Pag%26%23xE8%3Bs%2C%20L%26%23xE9%3Bonor%20Chaltiel%2C%20Vincent%20Sibaud%2C%20Elisabeth%20Moyal%2C%20Ciprian%20Chira%2C%20Jean%20Christophe%20Sol%2C%20Igor%20Latorzeff%2C%20Nicolas%20Meyer%2C%20and%20Anouchka%20Modesto.%20%26%23x201C%3BIntracranial%20Treatment%20in%20Melanoma%20Patients%20with%20Brain%20Metastasis%20Is%20Associated%20with%20Improved%20Survival%20in%20the%20Era%20of%20Immunotherapy%20and%20Anti-BRAF%20Therapy.%26%23x201D%3B%20%3Ci%3ECancers%3C%5C%2Fi%3E%2013%2C%20no.%2017%20%282021%29%3A%204493.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers13174493%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers13174493%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Intracranial%20Treatment%20in%20Melanoma%20Patients%20with%20Brain%20Metastasis%20Is%20Associated%20with%20Improved%20Survival%20in%20the%20Era%20of%20Immunotherapy%20and%20Anti-BRAF%20Therapy%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Dalmasso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9cile%22%2C%22lastName%22%3A%22Pag%5Cu00e8s%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%5Cu00e9onor%22%2C%22lastName%22%3A%22Chaltiel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Sibaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Moyal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ciprian%22%2C%22lastName%22%3A%22Chira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Christophe%22%2C%22lastName%22%3A%22Sol%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Igor%22%2C%22lastName%22%3A%22Latorzeff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Meyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anouchka%22%2C%22lastName%22%3A%22Modesto%22%7D%5D%2C%22abstractNote%22%3A%22Metastatic%20melanoma%20patients%20are%20at%20high%20risk%20of%20brain%20metastases%20%28BM%29.%20Although%20intracranial%20control%20is%20a%20prognostic%20factor%20for%20survival%2C%20impact%20of%20local%20%28intracranial%29%20treatment%20%28LT%29%2C%20surgery%20and%5C%2For%20radiotherapy%20%28stereotactic%20or%20whole%20brain%29%20in%20the%20era%20of%20novel%20therapies%20remains%20unknown.%20We%20evaluated%20BM%20incidence%20in%20melanoma%20patients%20receiving%20immune%20checkpoint%20inhibitors%20%28ICI%29%20or%20anti-BRAF%20therapy%20and%20identified%20prognostic%20factors%20for%20overall%20survival%20%28OS%29.%20Clinical%20data%20and%20treatment%20patterns%20were%20retrospectively%20collected%20from%20all%20patients%20treated%20for%20newly%20diagnosed%20locally%20advanced%20or%20metastatic%20melanoma%20between%20May%202014%20and%20December%202017%20with%20available%20BRAF%20mutation%20status%20and%20receiving%20systemic%20therapy.%20Prognostic%20factors%20for%20OS%20were%20analyzed%20with%20univariable%20and%20multivariable%20survival%20analyses.%20BMs%20occurred%20in%20106%20of%20250%20eligible%20patients%20%2842.4%25%29%2C%2064%20of%20whom%20received%20LT.%20Median%20OS%20in%20patients%20with%20BM%20was%207.8%20months%20%2895%25%20CI%20%5B5.4-10.4%5D%29.%20In%20multivariable%20analyses%2C%20LT%20was%20significantly%20correlated%20with%20improved%20OS%20%28HR%200.21%2C%20p%20%3C%200.01%29.%20Median%20OS%20was%2017.3%20months%20%2895%25%20CI%20%5B8.3-22.3%5D%29%20versus%203.6%20months%20%2895%25%20CI%20%5B1.4-4.8%5D%29%20in%20patients%20with%20or%20without%20LT.%20LT%20correlates%20with%20improved%20OS%20in%20melanoma%20patients%20with%20BM%20in%20the%20era%20of%20ICI%20and%20anti-BRAF%20therapy.%20The%20use%20of%20LT%20should%20be%20addressed%20at%20diagnosis%20of%20BM%20while%20introducing%20systemic%20treatment.%22%2C%22date%22%3A%222021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3390%5C%2Fcancers13174493%22%2C%22ISSN%22%3A%222072-6694%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222021-11-10T15%3A58%3A06Z%22%7D%7D%2C%7B%22key%22%3A%22DPDZVVBF%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Roth%20et%20al.%22%2C%22parsedDate%22%3A%222021%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ERoth%2C%20P.%2C%20A.%20Pace%2C%20E.%20Le%20Rhun%2C%20M.%20Weller%2C%20C.%20Ay%2C%20E.%20Cohen-Jonathan%20Moyal%2C%20M.%20Coomans%2C%20et%20al.%20%26%23x201C%3BNeurological%20and%20Vascular%20Complications%20of%20Primary%20and%20Secondary%20Brain%20Tumours%3A%20EANO-ESMO%20Clinical%20Practice%20Guidelines%20for%20Prophylaxis%2C%20Diagnosis%2C%20Treatment%20and%20Follow-Up.%26%23x201D%3B%20%3Ci%3EAnnals%20of%20Oncology%3A%20Official%20Journal%20of%20the%20European%20Society%20for%20Medical%20Oncology%3C%5C%2Fi%3E%2032%2C%20no.%202%20%282021%29%3A%20171%26%23x2013%3B82.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.annonc.2020.11.003%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.annonc.2020.11.003%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Neurological%20and%20vascular%20complications%20of%20primary%20and%20secondary%20brain%20tumours%3A%20EANO-ESMO%20Clinical%20Practice%20Guidelines%20for%20prophylaxis%2C%20diagnosis%2C%20treatment%20and%20follow-up%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Roth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Pace%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Le%20Rhun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Weller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Ay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Cohen-Jonathan%20Moyal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Coomans%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Giusti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Jordan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Nishikawa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Winkler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20T.%22%2C%22lastName%22%3A%22Hong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Ruda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Vill%5Cu00e0%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20J.%20B.%22%2C%22lastName%22%3A%22Taphoorn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%22%2C%22lastName%22%3A%22Wick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Preusser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22EANO%20Executive%20Board.%20Electronic%20address%3A%20office%40eano.eu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22ESMO%20Guidelines%20Committee.%20Electronic%20address%3A%20clinicalguidelines%40esmo.org%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.annonc.2020.11.003%22%2C%22ISSN%22%3A%221569-8041%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222021-10-27T09%3A31%3A51Z%22%7D%7D%2C%7B%22key%22%3A%229VMMTWUS%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Esteyrie%20et%20al.%22%2C%22parsedDate%22%3A%222021%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EEsteyrie%2C%20Vincent%2C%20Caroline%20Dehais%2C%20Elodie%20Martin%2C%20Catherine%20Carpentier%2C%20Emmanuelle%20Uro-Coste%2C%20Dominique%20Figarella-Branger%2C%20Charlotte%20Bronniman%2C%20et%20al.%20%26%23x201C%3BRadiotherapy%20Plus%20Procarbazine%2C%20Lomustine%2C%20and%20Vincristine%20Versus%20Radiotherapy%20Plus%20Temozolomide%20for%20IDH-Mutant%20Anaplastic%20Astrocytoma%3A%20A%20Retrospective%20Multicenter%20Analysis%20of%20the%20French%20POLA%20Cohort.%26%23x201D%3B%20%3Ci%3EThe%20Oncologist%3C%5C%2Fi%3E%2026%2C%20no.%205%20%282021%29%3A%20e838%26%23x2013%3B46.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fonco.13701%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fonco.13701%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Radiotherapy%20Plus%20Procarbazine%2C%20Lomustine%2C%20and%20Vincristine%20Versus%20Radiotherapy%20Plus%20Temozolomide%20for%20IDH-Mutant%20Anaplastic%20Astrocytoma%3A%20A%20Retrospective%20Multicenter%20Analysis%20of%20the%20French%20POLA%20Cohort%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Esteyrie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Dehais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elodie%22%2C%22lastName%22%3A%22Martin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Carpentier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Uro-Coste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%22%2C%22lastName%22%3A%22Figarella-Branger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Bronniman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damien%22%2C%22lastName%22%3A%22Pouessel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Delphine%20Larrieu%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Ducray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%20Cohen-Jonathan%22%2C%22lastName%22%3A%22Moyal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pola%22%2C%22lastName%22%3A%22Network%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20IDH-mutant%20anaplastic%20astrocytomas%20%28AAs%29%20are%20chemosensitive%20tumors%20for%20which%20the%20best%20choice%20of%20adjuvant%20chemotherapy%20between%20procarbazine%2C%20lomustine%2C%20and%20vincristine%20%28PCV%29%20or%20temozolomide%20%28TMZ%29%20after%20radiotherapy%20%28RT%29%20remains%20unclear.%5CnMETHODS%3A%20In%20a%20large%20cohort%20of%20patients%20with%20histologically%20proven%202016%20World%20Health%20Organization%20classification%20AA%20with%20IDH1%5C%2F2%20mutations%20included%20in%20the%20French%20national%20POLA%20cohort%20%28n%20%3D%5Cu2009355%29%2C%20the%20primary%20objective%20was%20to%20compare%20progression-free%20survival%20%28PFS%29%20between%20the%20two%20treatment%20regimens%20%28n%20%3D%5Cu2009311%29.%20Secondary%20endpoints%20were%20overall%20survival%20%28OS%29%2C%20progression%20type%2C%20pseudoprogression%20rate%2C%20and%20toxicity.%5CnRESULTS%3A%20The%204-year%20PFS%20in%20the%20RT%20%2B%20PCV%20arm%20was%2070.8%25%20versus%2053.5%25%20in%20the%20RT%20%2B%20TMZ%20arm%2C%20with%20a%20hazard%20ratio%20%28HR%29%20of%200.58%20%2895%25%20confidence%20interval%20%5BCI%5D%2C%200.38-0.87%3B%20p%20%3D%20.0074%29%20in%20univariable%20analysis%20and%200.63%20%2895%25%20CI%2C%200.41-0.97%3B%20p%20%3D%20.0348%29%20in%20multivariable%20analysis.%20The%204-year%20OS%20in%20the%20RT%20%2B%20PCV%20arm%20was%2084.3%25%20versus%2076.6%25%20in%20the%20RT%20%2B%20TMZ%20arm%2C%20with%20an%20HR%20of%200.57%20%2895%25%20CI%2C%200.30-1.05%3B%20p%20%3D%20.0675%29%20in%20univariable%20analysis.%20Toxicity%20was%20significantly%20higher%20in%20the%20RT%20%2B%20PCV%20arm%20with%20more%20grade%20%5Cu22653%20toxicity%20%2846.7%25%20vs.%208.6%25%2C%20p%20%3C%20.0001%29.%5CnCONCLUSION%3A%20RT%20%2B%20PCV%20significantly%20improved%20PFS%20compared%20with%20RT%20%2B%20TMZ%20for%20IDH-mutant%20AA.%20However%2C%20RT%20%2B%20TMZ%20was%20better%20tolerated.%5CnIMPLICATIONS%20FOR%20PRACTICE%3A%20In%20the%20absence%20of%20fully%20conducted%20randomized%20trials%20comparing%20procarbazine%2C%20lomustine%2C%20and%20vincristine%20%28PCV%29%20with%20temozolomide%20%28TMZ%29%20in%20adjuvant%20treatment%20after%20radiotherapy%20%28RT%29%20for%20the%20management%20of%20IDH-mutant%20anaplastic%20astrocytoma%20%28AA%29%20and%20a%20similar%20level%20of%20evidence%2C%20these%20two%20chemotherapies%20are%20both%20equally%20recommended%20in%20international%20guidelines.%20This%20study%20in%20a%20national%20cohort%20of%20IDH-mutant%20AA%20defined%20according%20the%202016%20World%20Health%20Organization%20%28WHO%29%20classification%20shows%20for%20the%20first%20time%20that%20the%20RT%20%2B%20PCV%20regimen%20significantly%20improves%20progression-free%20survival%20in%20comparison%20with%20the%20RT%20%2B%20TMZ%20regimen.%20Even%20if%20at%20the%20time%20of%20analysis%20the%20difference%20in%20overall%20survival%20was%20not%20significant%2C%20this%20result%20provides%20new%20evidence%20for%20the%20debate%20about%20the%20chemotherapy%20regimen%20to%20prescribe%20in%20adjuvant%20treatment%20to%20RT%20for%20WHO%202016%20IDH-mutant%20AA.%22%2C%22date%22%3A%222021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fonco.13701%22%2C%22ISSN%22%3A%221549-490X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222021-10-20T15%3A07%3A55Z%22%7D%7D%2C%7B%22key%22%3A%22MVIPHY8Y%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Peyraga%20et%20al.%22%2C%22parsedDate%22%3A%222021%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EPeyraga%2C%20G.%2C%20A.%20Ducassou%2C%20F.-X.%20Arnaud%2C%20T.%20Liz%26%23xE9%3Be%2C%20J.%20Pou%26%23xE9%3Bdras%2C%20and%20%26%23xC9%3B%20Moyal.%20%26%23x201C%3B%5BRadiotherapy%20and%20spinal%20toxicity%3A%20News%20and%20perspectives%5D.%26%23x201D%3B%20%3Ci%3ECancer%20Radiotherapie%3A%20Journal%20De%20La%20Societe%20Francaise%20De%20Radiotherapie%20Oncologique%3C%5C%2Fi%3E%2025%2C%20no.%201%20%282021%29%3A%2055%26%23x2013%3B61.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.canrad.2020.05.017%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.canrad.2020.05.017%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22%5BRadiotherapy%20and%20spinal%20toxicity%3A%20News%20and%20perspectives%5D%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Peyraga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Ducassou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.-X.%22%2C%22lastName%22%3A%22Arnaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Liz%5Cu00e9e%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Pou%5Cu00e9dras%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%5Cu00c9%22%2C%22lastName%22%3A%22Moyal%22%7D%5D%2C%22abstractNote%22%3A%22Radiation-induced%20myelopathy%20is%20a%20devastating%20late%20effect%20of%20radiotherapy.%20Fortunately%2C%20this%20late%20effect%20is%20exceptional.%20The%20clinical%20presentation%20of%20radiation%20myelopathy%20is%20aspecific%2C%20typically%20occurring%20between%206%20to%2024%20months%20after%20radiotherapy%2C%20and%20radiation-induced%20myelopathy%20remains%20a%20diagnosis%20of%20exclusion.%20Magnetic%20resonance%20imaging%20is%20the%20most%20commonly%20used%20imaging%20tool.%20Radiation%20oncologists%20must%20be%20extremely%20cautious%20to%20the%20spinal%20cord%20dose%2C%20particularly%20in%20stereotactic%20radiotherapy%20and%20reirradiation.%20Conventionally%2C%20a%20maximum%20dose%20of%2050Gy%20is%20tolerated%20in%20normofractionated%20radiotherapy%20%281.8%20to%202Gy%20per%20fraction%29.%20Repeat%20radiotherapies%20lead%20to%20consider%20cumulative%20doses%20above%20this%20recommendation%20to%20offer%20individualized%20reirradiation.%20Several%20factors%20increase%20the%20risk%20of%20radiation-induced%20myelopathy%2C%20such%20as%20concomitant%20or%20neurotoxic%20chemotherapy.%20The%20development%20of%20predictive%20algorithms%20to%20prevent%20the%20risk%20of%20radiation-induced%20myelopathy%20is%20promising.%20However%2C%20radiotherapy%20prescription%20should%20be%20cautious%2C%20regarding%20to%20ALARA%20principle%20%28as%20low%20as%20reasonably%20achievable%29.%20As%20the%20advent%20of%20immunotherapy%20has%20improved%20patient%20survival%20data%20and%20the%20concept%20of%20oligometastatic%20cancer%20is%20increasing%20in%20daily%20practice%2C%20stereotactic%20treatments%20and%20reirradiations%20will%20be%20increasingly%20frequent%20indications.%20Predict%20the%20risk%20of%20radiation-induced%20myelopathy%20is%20therefore%20a%20major%20issue%20in%20the%20following%20years%2C%20and%20remains%20a%20daily%20challenge%20for%20radiation%20oncologists.%22%2C%22date%22%3A%222021%22%2C%22language%22%3A%22fre%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.canrad.2020.05.017%22%2C%22ISSN%22%3A%221769-6658%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222021-10-20T15%3A07%3A44Z%22%7D%7D%2C%7B%22key%22%3A%22LYHAFI5D%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Picart%20et%20al.%22%2C%22parsedDate%22%3A%222021%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EPicart%2C%20Thi%26%23xE9%3Bbaud%2C%20Marc%20Barritault%2C%20Delphine%20Poncet%2C%20Lise-Prune%20Berner%2C%20Cristina%20Izquierdo%2C%20Emeline%20Tabouret%2C%20Dominique%20Figarella-Branger%2C%20et%20al.%20%26%23x201C%3BCharacteristics%20of%20Diffuse%20Hemispheric%20Gliomas%2C%20H3%20G34-Mutant%20in%20Adults%2C%26%23x201D%3B%202021.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Characteristics%20of%20diffuse%20hemispheric%20gliomas%2C%20H3%20G34-mutant%20in%20adults%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thi%5Cu00e9baud%22%2C%22lastName%22%3A%22Picart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Barritault%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Delphine%22%2C%22lastName%22%3A%22Poncet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lise-Prune%22%2C%22lastName%22%3A%22Berner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cristina%22%2C%22lastName%22%3A%22Izquierdo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emeline%22%2C%22lastName%22%3A%22Tabouret%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%22%2C%22lastName%22%3A%22Figarella-Branger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ahmed%22%2C%22lastName%22%3A%22Idba%5Cu00efh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franck%22%2C%22lastName%22%3A%22Bielle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%5Cu00e9ronique%22%2C%22lastName%22%3A%22Bourg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fanny%20Burel%22%2C%22lastName%22%3A%22Vandenbos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%20Cohen-Jonathan%22%2C%22lastName%22%3A%22Moyal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanelle%22%2C%22lastName%22%3A%22Uro-Coste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacques%22%2C%22lastName%22%3A%22Guyotat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Honnorat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathieu%22%2C%22lastName%22%3A%22Gabut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Meyronet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Ducray%22%7D%5D%2C%22abstractNote%22%3A%22Background%3A%20Diffuse%20hemispheric%20gliomas%2C%20H3%20G34-mutant%20%28DHG%20H3G34-mutant%29%20constitute%20a%20distinct%20type%20of%20aggressive%20brain%20tumors.%20Although%20initially%20described%20in%20children%2C%20they%20can%20also%20affect%20adults.%20The%20aims%20of%20this%20study%20were%20to%20describe%20the%20characteristics%20of%20DHG%20H3G34-mutant%20in%20adults%20and%20to%20compare%20them%20to%20those%20of%20established%20types%20of%20adult%20WHO%20grade%20IV%20gliomas.%5CnMethods%3A%20The%20characteristics%20of%2017%20adult%20DHG%20H3G34-mutant%2C%2032%20H3.3%20K27M-mutant%20diffuse%20midline%20gliomas%20%28DMG%29%2C%20100%20IDH-wildtype%2C%20and%2036%20IDH-mutant%20glioblastomas%20were%20retrospectively%20analyzed.%5CnResults%3A%20Median%20age%20at%20diagnosis%20in%20adult%20DHG%20H3G34-mutant%20was%2025%20years%20%28range%3A%2019-33%29.%20All%20tumors%20were%20hemispheric.%20For%209%20patients%20%2856%25%29%2C%20absent%20or%20faint%20contrast%20enhancement%20initially%20suggested%20another%20diagnosis%20than%20a%20high-grade%20glioma%2C%20and%20diffusion-weighted%20imaging%20seemed%20retrospectively%20more%20helpful%20to%20suspect%20an%20aggressive%20tumor%20than%20MR-spectroscopy%20and%20perfusion%20MRI.%20All%20cases%20were%20IDH-wildtype.%20Most%20cases%20were%20immunonegative%20for%20ATRX%20%2893%25%29%20and%20Olig2%20%28100%25%29%20and%20exhibited%20MGMT%20promoter%20methylation%20%2882%25%29.%20The%20clinical%20and%20radiological%20presentations%20of%20adult%20DHG%20H3G34-mutant%20were%20different%20from%20those%20of%20established%20types%20of%20adult%20grade%20IV%20gliomas.%20Median%20overall%20survival%20of%20adult%20DHG%20H3G34-mutant%20was%2012.4%20months%20compared%20to%2019.6%20months%20%28P%20%3D%20.56%29%2C%2011.7%20months%20%28P%20%3D%20.45%29%2C%20and%2050.5%20months%20%28P%20%3D%20.006%29%20in%20H3.3%20K27M-mutant%20DMG%2C%20IDH-wildtype%2C%20and%20IDH-mutant%20glioblastomas%2C%20respectively.%5CnConclusions%3A%20Adult%20DHG%20H3G34-mutant%20are%20associated%20with%20distinct%20characteristics%20compared%20to%20those%20of%20established%20types%20of%20adult%20WHO%20grade%20IV%20gliomas.%20This%20study%20supports%20considering%20these%20tumors%20as%20a%20new%20type%20of%20WHO%20grade%20IV%20glioma%20in%20future%20classifications.%22%2C%22date%22%3A%222021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%22%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222021-10-20T15%3A07%3A24Z%22%7D%7D%2C%7B%22key%22%3A%22YY6EEREE%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Pinto%20et%20al.%22%2C%22parsedDate%22%3A%222021%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EPinto%2C%20Giulia%2C%20In%26%23xE9%3Bs%20Saenz-de-Santa-Maria%2C%20Patricia%20Chastagner%2C%20Emeline%20Perthame%2C%20Caroline%20Delmas%2C%20Christine%20Toulas%2C%20Elizabeth%20Moyal-Jonathan-Cohen%2C%20Christel%20Brou%2C%20and%20Chiara%20Zurzolo.%20%26%23x201C%3BPatient-Derived%20Glioblastoma%20Stem%20Cells%20Transfer%20Mitochondria%20through%20Tunneling%20Nanotubes%20in%20Tumor%20Organoids.%26%23x201D%3B%20%3Ci%3EThe%20Biochemical%20Journal%3C%5C%2Fi%3E%20478%2C%20no.%201%20%282021%29%3A%2021%26%23x2013%3B39.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1042%5C%2FBCJ20200710%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1042%5C%2FBCJ20200710%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Patient-derived%20glioblastoma%20stem%20cells%20transfer%20mitochondria%20through%20tunneling%20nanotubes%20in%20tumor%20organoids%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giulia%22%2C%22lastName%22%3A%22Pinto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22In%5Cu00e9s%22%2C%22lastName%22%3A%22Saenz-de-Santa-Maria%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patricia%22%2C%22lastName%22%3A%22Chastagner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emeline%22%2C%22lastName%22%3A%22Perthame%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Delmas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Toulas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Moyal-Jonathan-Cohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christel%22%2C%22lastName%22%3A%22Brou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chiara%22%2C%22lastName%22%3A%22Zurzolo%22%7D%5D%2C%22abstractNote%22%3A%22Glioblastoma%20%28GBM%29%20is%20the%20most%20aggressive%20brain%20cancer%20and%20its%20relapse%20after%20surgery%2C%20chemo%20and%20radiotherapy%20appears%20to%20be%20led%20by%20GBM%20stem%20cells%20%28GSCs%29.%20Also%2C%20tumor%20networking%20and%20intercellular%20communication%20play%20a%20major%20role%20in%20driving%20GBM%20therapy-resistance.%20Tunneling%20Nanotubes%20%28TNTs%29%2C%20thin%20membranous%20open-ended%20channels%20connecting%20distant%20cells%2C%20have%20been%20observed%20in%20several%20types%20of%20cancer%2C%20where%20they%20emerge%20to%20drive%20a%20more%20malignant%20phenotype.%20Here%2C%20we%20investigated%20whether%20GBM%20cells%20are%20capable%20to%20intercommunicate%20by%20TNTs.%20Two%20GBM%20stem-like%20cells%20%28GSLCs%29%20were%20obtained%20from%20the%20external%20and%20infiltrative%20zone%20of%20one%20GBM%20from%20one%20patient.%20We%20show%2C%20for%20the%20first%20time%2C%20that%20both%20GSLCs%2C%20grown%20in%20classical%202D%20culture%20and%20in%203D-tumor%20organoids%2C%20formed%20functional%20TNTs%20which%20allowed%20mitochondria%20transfer.%20In%20the%20organoid%20model%2C%20recapitulative%20of%20several%20tumor%27s%20features%2C%20we%20observed%20the%20formation%20of%20a%20network%20between%20cells%20constituted%20of%20both%20Tumor%20Microtubes%20%28TMs%29%2C%20previously%20observed%20in%20vivo%2C%20and%20TNTs.%20In%20addition%2C%20the%20two%20GSLCs%20exhibited%20different%20responses%20to%20irradiation%20in%20terms%20of%20TNT%20induction%20and%20mitochondria%20transfer%2C%20although%20the%20correlation%20with%20the%20disease%20progression%20and%20therapy-resistance%20needs%20to%20be%20further%20addressed.%20Thus%2C%20TNT-based%20communication%20is%20active%20in%20different%20GSLCs%20derived%20from%20the%20external%20tumoral%20areas%20associated%20to%20GBM%20relapse%2C%20and%20we%20propose%20that%20they%20participate%20together%20with%20TMs%20in%20tumor%20networking.%22%2C%22date%22%3A%222021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1042%5C%2FBCJ20200710%22%2C%22ISSN%22%3A%221470-8728%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222021-10-20T14%3A57%3A10Z%22%7D%7D%2C%7B%22key%22%3A%22VL2Z9DG4%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Tauzi%5Cu00e8de-Espariat%20et%20al.%22%2C%22parsedDate%22%3A%222021-08-13%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ETauzi%26%23xE8%3Bde-Espariat%2C%20Arnault%2C%20Aurore%20Siegfried%2C%20Yvan%20Nicaise%2C%20Thomas%20Kergrohen%2C%20Philipp%20Sievers%2C%20Alexandre%20Vasiljevic%2C%20Alexandre%20Roux%2C%20et%20al.%20%26%23x201C%3BSupratentorial%20Non-RELA%2C%20ZFTA-Fused%20Ependymomas%3A%20A%20Comprehensive%20Phenotype%20Genotype%20Correlation%20Highlighting%20the%20Number%20of%20Zinc%20Fingers%20in%20ZFTA-NCOA1%5C%2F2%20Fusions.%26%23x201D%3B%20%3Ci%3EActa%20Neuropathologica%20Communications%3C%5C%2Fi%3E%209%2C%20no.%201%20%28August%2013%2C%202021%29%3A%20135.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs40478-021-01238-y%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs40478-021-01238-y%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Supratentorial%20non-RELA%2C%20ZFTA-fused%20ependymomas%3A%20a%20comprehensive%20phenotype%20genotype%20correlation%20highlighting%20the%20number%20of%20zinc%20fingers%20in%20ZFTA-NCOA1%5C%2F2%20fusions%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnault%22%2C%22lastName%22%3A%22Tauzi%5Cu00e8de-Espariat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aurore%22%2C%22lastName%22%3A%22Siegfried%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yvan%22%2C%22lastName%22%3A%22Nicaise%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Kergrohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philipp%22%2C%22lastName%22%3A%22Sievers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandre%22%2C%22lastName%22%3A%22Vasiljevic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandre%22%2C%22lastName%22%3A%22Roux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edouard%22%2C%22lastName%22%3A%22Dezamis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chiara%22%2C%22lastName%22%3A%22Benevello%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Christine%22%2C%22lastName%22%3A%22Machet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Michalak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chloe%22%2C%22lastName%22%3A%22Puiseux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francisco%22%2C%22lastName%22%3A%22Llamas-Gutierrez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Leblond%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franck%22%2C%22lastName%22%3A%22Bourdeaut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacques%22%2C%22lastName%22%3A%22Grill%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christelle%22%2C%22lastName%22%3A%22Dufour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%5Cu00e9a%22%2C%22lastName%22%3A%22Guerrini-Rousseau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samuel%22%2C%22lastName%22%3A%22Abbou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Volodia%22%2C%22lastName%22%3A%22Dangouloff-Ros%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Boddaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rapha%5Cu00ebl%22%2C%22lastName%22%3A%22Saffroy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lauren%22%2C%22lastName%22%3A%22Hasty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ellen%22%2C%22lastName%22%3A%22Wahler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%5Cu00e9lanie%22%2C%22lastName%22%3A%22Pag%5Cu00e8s%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Felipe%22%2C%22lastName%22%3A%22Andreiuolo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanu%5Cu00e8le%22%2C%22lastName%22%3A%22Lechapt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrice%22%2C%22lastName%22%3A%22Chr%5Cu00e9tien%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Blauwblomme%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%5Cu00e9vin%22%2C%22lastName%22%3A%22Beccaria%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Johan%22%2C%22lastName%22%3A%22Pallud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Puget%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Uro-Coste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascale%22%2C%22lastName%22%3A%22Varlet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22RENOCLIP-LOC%2C%20the%20BIOMECA%20%28Biomarkers%20for%20Ependymomas%20in%20Children%2C%20Adolescents%29%20consortium%22%7D%5D%2C%22abstractNote%22%3A%22The%20cIMPACT-NOW%20Update%207%20has%20replaced%20the%20WHO%20nosology%20of%20%5C%22ependymoma%2C%20RELA%20fusion%20positive%5C%22%20by%20%5C%22Supratentorial-ependymoma%2C%20C11orf95-fusion%20positive%5C%22.%20This%20modification%20reinforces%20the%20idea%20that%20supratentorial-ependymomas%20exhibiting%20fusion%20that%20implicates%20the%20C11orf95%20%28now%20called%20ZFTA%29%20gene%20with%20or%20without%20the%20RELA%20gene%2C%20represent%20the%20same%20histomolecular%20entity.%20A%20hot%20off%20the%20press%20molecular%20study%20has%20identified%20distinct%20clusters%20of%20the%20DNA%20methylation%20class%20of%20ZFTA%20fusion-positive%20tumors.%20Interestingly%2C%20clusters%202%20and%204%20comprised%20tumors%20of%20different%20morphologies%2C%20with%20various%20ZFTA%20fusions%20without%20involvement%20of%20RELA.%20In%20this%20paper%2C%20we%20present%20a%20detailed%20series%20of%20thirteen%20cases%20of%20non-RELA%20ZFTA-fused%20supratentorial%20tumors%20with%20extensive%20clinical%2C%20radiological%2C%20histopathological%2C%20immunohistochemical%2C%20genetic%20and%20epigenetic%20%28DNA%20methylation%20profiling%29%20characterization.%20Contrary%20to%20the%20age%20of%20onset%20and%20MRI%20aspects%20similar%20to%20RELA%20fusion-positive%20EPN%2C%20we%20noted%20significant%20histopathological%20heterogeneity%20%28pleomorphic%20xanthoastrocytoma-like%2C%20astroblastoma-like%2C%20ependymoma-like%2C%20and%20even%20sarcoma-like%20patterns%29%20in%20this%20cohort.%20Immunophenotypically%2C%20these%20NF%5Cu03baB%20immunonegative%20tumors%20expressed%20GFAP%20variably%2C%20but%20EMA%20constantly%20and%20L1CAM%20frequently.%20Different%20gene%20partners%20were%20fused%20with%20ZFTA%3A%20NCOA1%5C%2F2%2C%20MAML2%20and%20for%20the%20first%20time%20MN1.%20These%20tumors%20had%20epigenetic%20homologies%20within%20the%20DNA%20methylation%20class%20of%20ependymomas-RELA%20and%20were%20classified%20as%20satellite%20clusters%202%20and%204.%20Cluster%202%20%28n%5Cu2009%3D%5Cu20099%29%20corresponded%20to%20tumors%20with%20classic%20ependymal%20histological%20features%20%28n%5Cu2009%3D%5Cu20094%29%20but%20also%20had%20astroblastic%20features%20%28n%5Cu2009%3D%5Cu20095%29.%20Various%20types%20of%20ZFTA%20fusions%20were%20associated%20with%20cluster%202%2C%20but%20as%20in%20the%20original%20report%2C%20ZFTA%3AMAML2%20fusion%20was%20frequent.%20Cluster%204%20was%20enriched%20with%20sarcoma-like%20tumors.%20Moreover%2C%20we%20reported%20a%20novel%20anatomy%20of%20three%20ZFTA%3ANCOA1%5C%2F2%20fusions%20with%20only%201%20ZFTA%20zinc%20finger%20domain%20in%20the%20putative%20fusion%20protein%2C%20whereas%20all%20previously%20reported%20non-RELA%20ZFTA%20fusions%20have%204%20ZFTA%20zinc%20fingers.%20All%20three%20cases%20presented%20a%20sarcoma-like%20morphology.%20This%20genotype%5C%2Fphenotype%20association%20requires%20further%20studies%20for%20confirmation.%20Our%20series%20is%20the%20first%20to%20extensively%20characterize%20this%20new%20subset%20of%20supratentorial%20ZFTA-fused%20ependymomas%20and%20highlights%20the%20usefulness%20of%20ZFTA%20FISH%20analysis%20to%20confirm%20the%20existence%20of%20a%20rearrangement%20without%20RELA%20abnormality.%22%2C%22date%22%3A%222021-08-13%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs40478-021-01238-y%22%2C%22ISSN%22%3A%222051-5960%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222021-10-12T10%3A58%3A31Z%22%7D%7D%2C%7B%22key%22%3A%22L2ED3PBX%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Leste%20et%20al.%22%2C%22parsedDate%22%3A%222021-07%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELeste%2C%20Jeremy%2C%20Imene%20Medjahed%2C%20Maxime%20Chauvin%2C%20Tony%20Younes%2C%20Laure%20Vieillevigne%2C%20Regis%20Ferrand%2C%20Xavier%20Franceries%2C%20Manuel%20Bardies%2C%20and%20Luc%20Simon.%20%26%23x201C%3BA%20Study%20of%20the%20Interplay%20Effect%20in%20Radiation%20Therapy%20Using%20a%20Monte-Carlo%20Model.%26%23x201D%3B%20%3Ci%3EPhysica%20Medica%3A%20PM%3A%20An%20International%20Journal%20Devoted%20to%20the%20Applications%20of%20Physics%20to%20Medicine%20and%20Biology%3A%20Official%20Journal%20of%20the%20Italian%20Association%20of%20Biomedical%20Physics%20%28AIFB%29%3C%5C%2Fi%3E%2087%20%28July%202021%29%3A%2073%26%23x2013%3B82.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ejmp.2021.05.019%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ejmp.2021.05.019%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22A%20study%20of%20the%20interplay%20effect%20in%20radiation%20therapy%20using%20a%20Monte-Carlo%20model%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeremy%22%2C%22lastName%22%3A%22Leste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Imene%22%2C%22lastName%22%3A%22Medjahed%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Chauvin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tony%22%2C%22lastName%22%3A%22Younes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Vieillevigne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Regis%22%2C%22lastName%22%3A%22Ferrand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Franceries%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manuel%22%2C%22lastName%22%3A%22Bardies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luc%22%2C%22lastName%22%3A%22Simon%22%7D%5D%2C%22abstractNote%22%3A%22PURPOSE%3A%20In%20modulated%20radiotherapy%2C%20breathing%20motion%20can%20lead%20to%20Interplay%20%28IE%29%20and%20Blurring%20%28BE%29%20effects%20that%20can%20modify%20the%20delivered%20dose.%20The%20aim%20of%20this%20work%20is%20to%20present%20the%20implementation%2C%20the%20validation%20and%20the%20use%20of%20an%20open-source%20Monte-Carlo%20%28MC%29%20model%20that%20computes%20the%20delivered%20dose%20including%20these%20motion%20effects.%5CnMETHODS%3A%20The%20MC%20model%20of%20the%20Varian%20TrueBeam%20was%20implemented%20using%20GATE.%20The%20dose%20delivered%20by%20different%20modulated%20plans%20is%20computed%20for%20several%20breathing%20patterns.%20A%20validation%20of%20these%20MC%20predictions%20is%20achieved%20by%20a%20comparison%20with%20measurements%20performed%20using%20a%20dedicated%20programmable%20motion%20platform%2C%20carrying%20a%20quality%20assurance%20phantom.%20A%20specific%20methodology%20was%20used%20to%20separate%20the%20IE%20and%20the%20BE.%20The%20influence%20of%20different%20motion%20parameters%20%28period%2C%20amplitude%2C%20shape%29%20and%20plan%20parameters%20%28volume%20margin%2C%20dose%20per%20fraction%29%20was%20also%20analyzed.%5CnRESULTS%3A%20The%20MC%20model%20was%20validated%20against%20measurement%20performed%20with%20motion%20with%20a%20mean%203D%20global%20gamma%20index%20pass%20rate%20of%2097.5%25%20%283%25%5C%2F3%20mm%29.%20A%20significant%20correlation%20is%20found%20between%20the%20IE%20and%20the%20period%20and%20the%20antero-posterior%20amplitude%20of%20the%20motion%20but%20not%20between%20the%20IE%20and%20the%20CTV%20margin%20or%20the%20shape%20of%20motion.%20The%20results%20showed%20that%20the%20IE%20increases%20D2%25%20and%20decreases%20the%20D98%25%20of%20CTV%20with%20mean%20values%20of%20%2B6.9%25%20and%20-3.3%25%20respectively.%5CnCONCLUSIONS%3A%20We%20validated%20the%20feasibility%20to%20assess%20the%20IE%20using%20a%20MC%20model.%20We%20found%20that%20the%20most%20important%20parameter%20is%20the%20number%20of%20breathing%20cycles%20that%20must%20be%20greater%20than%2020%20for%20one%20arc%20to%20limit%20the%20IE.%22%2C%22date%22%3A%222021-07%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ejmp.2021.05.019%22%2C%22ISSN%22%3A%221724-191X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222021-10-12T10%3A51%3A17Z%22%7D%7D%2C%7B%22key%22%3A%22V9G7SA3Q%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Younes%20et%20al.%22%2C%22parsedDate%22%3A%222021-02-02%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EYounes%2C%20Tony%2C%20Maxime%20Chauvin%2C%20Alexia%20Delbaere%2C%20Joey%20Labour%2C%20Victoria%20Fonteny%2C%20Luc%20Simon%2C%20Georges%20Fares%2C%20and%20Laure%20Vieillevigne.%20%26%23x201C%3BTowards%20the%20Standardization%20of%20the%20Absorbed%20Dose%20Report%20Mode%20in%20High%20Energy%20Photon%20Beams.%26%23x201D%3B%20%3Ci%3EPhysics%20in%20Medicine%20and%20Biology%3C%5C%2Fi%3E%2066%2C%20no.%204%20%28February%202%2C%202021%29%3A%20045009.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1088%5C%2F1361-6560%5C%2Fabd22c%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1088%5C%2F1361-6560%5C%2Fabd22c%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Towards%20the%20standardization%20of%20the%20absorbed%20dose%20report%20mode%20in%20high%20energy%20photon%20beams%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tony%22%2C%22lastName%22%3A%22Younes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Chauvin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexia%22%2C%22lastName%22%3A%22Delbaere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joey%22%2C%22lastName%22%3A%22Labour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Victoria%22%2C%22lastName%22%3A%22Fonteny%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luc%22%2C%22lastName%22%3A%22Simon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Georges%22%2C%22lastName%22%3A%22Fares%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Vieillevigne%22%7D%5D%2C%22abstractNote%22%3A%22The%20benefits%20of%20using%20an%20algorithm%20that%20reports%20absorbed%20dose-to-medium%20have%20been%20jeopardized%20by%20the%20clinical%20experience%20and%20the%20experimental%20protocols%20that%20have%20mainly%20relied%20on%20absorbed%20dose-to-water.%20The%20aim%20of%20the%20present%20work%20was%20to%20investigate%20the%20physical%20aspects%20that%20govern%20the%20dosimetry%20in%20heterogeneous%20media%20using%20Monte%20Carlo%20method%20and%20to%20introduce%20a%20formalism%20for%20the%20experimental%20validation%20of%20absorbed%20dose-to-medium%20reporting%20algorithms.%20Particle%20fluence%20spectra%20computed%20within%20the%20sensitive%20volume%20of%20two%20simulated%20detectors%20%28T31016%20Pinpoint%203D%20ionization%20chamber%20and%20EBT3%20radiochromic%20film%29%20placed%20in%20different%20media%20%28water%2C%20RW3%2C%20lung%20and%20bone%29%20were%20compared%20to%20those%20in%20the%20undisturbed%20media%20for%206%20MV%20photon%20beams.%20A%20heterogeneity%20correction%20factor%20that%20takes%20into%20account%20the%20difference%20between%20the%20detector%20perturbation%20in%20medium%20and%20under%20reference%20conditions%20as%20well%20as%20the%20stopping-power%20ratios%20was%20then%20derived%20for%20all%20media%20using%20cema%20calculations.%20Furthermore%2C%20the%20different%20conversion%20approaches%20and%20Eclipse%20treatment%20planning%20system%20algorithms%20were%20compared%20against%20the%20Monte%20Carlo%20absorbed%20dose%20reports.%20The%20detectors%20electron%20fluence%20perturbation%20in%20RW3%20and%20lung%20media%20were%20close%20to%20that%20in%20water%20%28%5Cu22641.5%25%29.%20However%2C%20the%20perturbation%20was%20greater%20in%20bone%20%28%5Cu223c4%25%29%20and%20impacted%20the%20spectral%20shape.%20It%20was%20emphasized%20that%20detectors%20readings%20should%20be%20corrected%20by%20the%20heterogeneity%20correction%20factor%20that%20ranged%20from%200.932%20in%20bone%20to%200.985%20in%20lung.%20Significant%20discrepancies%20were%20observed%20between%20all%20the%20absorbed%20dose%20reports%20and%20conversions%2C%20especially%20in%20bone%20%28exceeding%2010%25%29%20and%20to%20a%20lesser%20extent%20in%20RW3.%20Given%20the%20ongoing%20advances%20in%20dose%20calculation%20algorithms%2C%20it%20is%20essential%20to%20standardize%20the%20absorbed%20dose%20report%20mode%20with%20absorbed%20dose-to-medium%20as%20a%20favoured%20choice.%20It%20was%20concluded%20that%20a%20retrospective%20conversion%20should%20be%20avoided%20and%20switching%20from%20absorbed%20dose-to-water%20to%20absorbed%20dose-to-medium%20reporting%20algorithm%20should%20be%20carried%20out%20by%20a%20direct%20comparison%20of%20both%20algorithms.%22%2C%22date%22%3A%222021-02-02%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1088%5C%2F1361-6560%5C%2Fabd22c%22%2C%22ISSN%22%3A%221361-6560%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222021-06-16T13%3A54%3A17Z%22%7D%7D%2C%7B%22key%22%3A%22W6US9RSD%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Khalifa%20et%20al.%22%2C%22parsedDate%22%3A%222021%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EKhalifa%2C%20Jonathan%2C%20Julien%20Mazieres%2C%20Carlos%20Gomez-Roca%2C%20Maha%20Ayyoub%2C%20and%20Elizabeth%20Cohen-Jonathan%20Moyal.%20%26%23x201C%3BRadiotherapy%20in%20the%20Era%20of%20Immunotherapy%26%23xA0%3BWith%20a%20Focus%20on%20Non-Small-Cell%20Lung%20Cancer%3A%20Time%20to%20Revisit%20Ancient%20Dogmas%3F%26%23x201D%3B%20%3Ci%3EFrontiers%20in%20Oncology%3C%5C%2Fi%3E%2011%20%282021%29%3A%20662236.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffonc.2021.662236%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffonc.2021.662236%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Radiotherapy%20in%20the%20Era%20of%20Immunotherapy%5Cu00a0With%20a%20Focus%20on%20Non-Small-Cell%20Lung%20Cancer%3A%20Time%20to%20Revisit%20Ancient%20Dogmas%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Khalifa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Mazieres%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlos%22%2C%22lastName%22%3A%22Gomez-Roca%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maha%22%2C%22lastName%22%3A%22Ayyoub%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%20Cohen-Jonathan%22%2C%22lastName%22%3A%22Moyal%22%7D%5D%2C%22abstractNote%22%3A%22Radiation-induced%20immune%20effects%20have%20been%20extensively%20deciphered%20over%20the%20last%20few%20years%2C%20leading%20to%20the%20concept%20of%20the%20dual%20immune%20effect%20of%20radiotherapy%20with%20both%20immunostimulatory%20and%20immunosuppressive%20effects.%20This%20explains%20why%20radiotherapy%20alone%20is%20not%20able%20to%20drive%20a%20strong%20anti-tumor%20immune%20response%20in%20most%20cases%2C%20hence%20underlining%20the%20rationale%20for%20combining%20both%20radiotherapy%20and%20immunotherapy.%20This%20association%20has%20generated%20considerable%20interest%20and%20hundreds%20of%20trials%20are%20currently%20ongoing%20to%20assess%20such%20an%20association%20in%20oncology.%20However%2C%20while%20some%20trials%20have%20provided%20unprecedented%20results%20or%20shown%20much%20promise%2C%20many%20hopes%20have%20been%20dashed.%20Questions%20remain%2C%20therefore%2C%20as%20to%20how%20to%20optimize%20the%20combination%20of%20these%20treatment%20modalities.%20This%20narrative%20review%20aims%20at%20revisiting%20the%20old%2C%20well-established%20concepts%20of%20radiotherapy%20relating%20to%20dose%2C%20fractionation%2C%20target%20volumes%20and%20organs%20at%20risk%20in%20the%20era%20of%20immunotherapy.%20We%20then%20propose%20potential%20innovative%20approaches%20to%20be%20further%20assessed%20when%20considering%20a%20radio-immunotherapy%20association%2C%20especially%20in%20the%20field%20of%20non-small-cell%20lung%20cancer%20%28NSCLC%29.%20We%20finally%20propose%20a%20framework%20to%20optimize%20the%20association%2C%20with%20pragmatic%20approaches%20depending%20on%20the%20stage%20of%20the%20disease.%22%2C%22date%22%3A%222021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3389%5C%2Ffonc.2021.662236%22%2C%22ISSN%22%3A%222234-943X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%2C%22FGRJFWV3%22%5D%2C%22dateModified%22%3A%222021-06-16T11%3A46%3A20Z%22%7D%7D%5D%7D<\/span>\n\n\t\t\t\t
\n
\n
Zanca, F., I. Hernandez-Giron, M. Avanzo, G. Guidi, W. Crijns, O. Diaz, G. C. Kagadis, et al. “Expanding the Medical Physicist Curricular and Professional Programme to Include Artificial Intelligence.” Physica Medica: PM: An International Journal Devoted to the Applications of Physics to Medicine and Biology: Official Journal of the Italian Association of Biomedical Physics (AIFB)<\/i> 83 (March 2021): 174–83. https:\/\/doi.org\/10.1016\/j.ejmp.2021.01.069<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Robert, C., A. Munoz, D. Moreau, J. Mazurier, G. Sidorski, A. Gasnier, G. Beldjoudi, et al. “Clinical Implementation of Deep-Learning Based Auto-Contouring Tools–Experience of Three French Radiotherapy Centers.” Cancer\/Radiothérapie<\/i> 25, no. 6–7 (2021): 607–16. https:\/\/doi.org\/10.1016\/j.canrad.2021.06.023<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Meyer, P., M.-C. Biston, C. Khamphan, T. Marghani, J. Mazurier, V. Bodez, L. Fezzani, et al. “Automation in Radiotherapy Treatment Planning: Examples of Use in Clinical Practice and Future Trends for a Complete Automated Workflow.” Cancer\/Radiothérapie<\/i> 25, no. 6–7 (2021): 617–22. https:\/\/doi.org\/10.1016\/j.canrad.2021.06.006<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Simon, L., C. Robert, and P. Meyer. “Artificial Intelligence for Quality Assurance in Radiotherapy.” Cancer\/Radiothérapie<\/i> 25, no. 6–7 (2021): 623–26. https:\/\/doi.org\/10.1016\/j.canrad.2021.06.012<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Leste, Jeremy, Tony Younes, Maxime Chauvin, Xavier Franceries, Alexia Delbaere, Laure Vieillevigne, Regis Ferrand, Manuel Bardies, and Luc Simon. “Technical Note: GAMMORA, a Free, Open-Source, and Validated GATE-Based Model for Monte-Carlo Simulations of the Varian TrueBeam.” Physica Medica<\/i> 89 (2021): 211–18. https:\/\/doi.org\/10.1016\/j.ejmp.2021.07.037<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Attal, J., B. Cabarrou, T. Valentin, J. P. Nesseler, E. Stoeckle, A. Ducassou, T. Filleron, et al. “Evaluation of Two Modalities of Perioperative Treatment in the Management of Extremity and Truncal Soft Tissue Sarcomas: Neoadjuvant Concurrent Chemoradiotherapy and Sequential Treatment.” Strahlentherapie Und Onkologie: Organ Der Deutschen Rontgengesellschaft ... [et Al]<\/i> 197, no. 12 (December 2021): 1051–62. https:\/\/doi.org\/10.1007\/s00066-021-01847-5<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Alhalabi, Karam T., Damian Stichel, Philipp Sievers, Heike Peterziel, Alexander C. Sommerkamp, Dominik Sturm, Andrea Wittmann, et al. “PATZ1 Fusions Define a Novel Molecularly Distinct Neuroepithelial Tumor Entity with a Broad Histological Spectrum.” Acta Neuropathologica<\/i> 142, no. 5 (November 2021): 841–57. https:\/\/doi.org\/10.1007\/s00401-021-02354-8<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Sacko, Oumar, Alexandra Benouaich-Amiel, Pierre Brandicourt, Mahamadou Niaré, Saloua Charni, Clarissa Cavandoli, David Brauge, et al. “The Impact of Surgery on the Survival of Patients with Recurrent Glioblastoma.” Asian Journal of Neurosurgery<\/i> 16, no. 1 (2021): 1–7. https:\/\/doi.org\/10.4103\/ajns.AJNS_180_20<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Dalmasso, Céline, Cécile Pagès, Léonor Chaltiel, Vincent Sibaud, Elisabeth Moyal, Ciprian Chira, Jean Christophe Sol, Igor Latorzeff, Nicolas Meyer, and Anouchka Modesto. “Intracranial Treatment in Melanoma Patients with Brain Metastasis Is Associated with Improved Survival in the Era of Immunotherapy and Anti-BRAF Therapy.” Cancers<\/i> 13, no. 17 (2021): 4493. https:\/\/doi.org\/10.3390\/cancers13174493<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Roth, P., A. Pace, E. Le Rhun, M. Weller, C. Ay, E. Cohen-Jonathan Moyal, M. Coomans, et al. “Neurological and Vascular Complications of Primary and Secondary Brain Tumours: EANO-ESMO Clinical Practice Guidelines for Prophylaxis, Diagnosis, Treatment and Follow-Up.” Annals of Oncology: Official Journal of the European Society for Medical Oncology<\/i> 32, no. 2 (2021): 171–82. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.003<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Esteyrie, Vincent, Caroline Dehais, Elodie Martin, Catherine Carpentier, Emmanuelle Uro-Coste, Dominique Figarella-Branger, Charlotte Bronniman, et al. “Radiotherapy Plus Procarbazine, Lomustine, and Vincristine Versus Radiotherapy Plus Temozolomide for IDH-Mutant Anaplastic Astrocytoma: A Retrospective Multicenter Analysis of the French POLA Cohort.” The Oncologist<\/i> 26, no. 5 (2021): e838–46. https:\/\/doi.org\/10.1002\/onco.13701<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Peyraga, G., A. Ducassou, F.-X. Arnaud, T. Lizée, J. Pouédras, and É Moyal. “[Radiotherapy and spinal toxicity: News and perspectives].” Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique<\/i> 25, no. 1 (2021): 55–61. https:\/\/doi.org\/10.1016\/j.canrad.2020.05.017<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Picart, Thiébaud, Marc Barritault, Delphine Poncet, Lise-Prune Berner, Cristina Izquierdo, Emeline Tabouret, Dominique Figarella-Branger, et al. “Characteristics of Diffuse Hemispheric Gliomas, H3 G34-Mutant in Adults,” 2021.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Pinto, Giulia, Inés Saenz-de-Santa-Maria, Patricia Chastagner, Emeline Perthame, Caroline Delmas, Christine Toulas, Elizabeth Moyal-Jonathan-Cohen, Christel Brou, and Chiara Zurzolo. “Patient-Derived Glioblastoma Stem Cells Transfer Mitochondria through Tunneling Nanotubes in Tumor Organoids.” The Biochemical Journal<\/i> 478, no. 1 (2021): 21–39. https:\/\/doi.org\/10.1042\/BCJ20200710<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Tauziède-Espariat, Arnault, Aurore Siegfried, Yvan Nicaise, Thomas Kergrohen, Philipp Sievers, Alexandre Vasiljevic, Alexandre Roux, et al. “Supratentorial Non-RELA, ZFTA-Fused Ependymomas: A Comprehensive Phenotype Genotype Correlation Highlighting the Number of Zinc Fingers in ZFTA-NCOA1\/2 Fusions.” Acta Neuropathologica Communications<\/i> 9, no. 1 (August 13, 2021): 135. https:\/\/doi.org\/10.1186\/s40478-021-01238-y<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Leste, Jeremy, Imene Medjahed, Maxime Chauvin, Tony Younes, Laure Vieillevigne, Regis Ferrand, Xavier Franceries, Manuel Bardies, and Luc Simon. “A Study of the Interplay Effect in Radiation Therapy Using a Monte-Carlo Model.” Physica Medica: PM: An International Journal Devoted to the Applications of Physics to Medicine and Biology: Official Journal of the Italian Association of Biomedical Physics (AIFB)<\/i> 87 (July 2021): 73–82. https:\/\/doi.org\/10.1016\/j.ejmp.2021.05.019<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Younes, Tony, Maxime Chauvin, Alexia Delbaere, Joey Labour, Victoria Fonteny, Luc Simon, Georges Fares, and Laure Vieillevigne. “Towards the Standardization of the Absorbed Dose Report Mode in High Energy Photon Beams.” Physics in Medicine and Biology<\/i> 66, no. 4 (February 2, 2021): 045009. https:\/\/doi.org\/10.1088\/1361-6560\/abd22c<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Khalifa, Jonathan, Julien Mazieres, Carlos Gomez-Roca, Maha Ayyoub, and Elizabeth Cohen-Jonathan Moyal. “Radiotherapy in the Era of Immunotherapy With a Focus on Non-Small-Cell Lung Cancer: Time to Revisit Ancient Dogmas?” Frontiers in Oncology<\/i> 11 (2021): 662236. https:\/\/doi.org\/10.3389\/fonc.2021.662236<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n\n\n

[\/et_pb_toggle][et_pb_toggle title=”PUBLICATIONS 2020″ open_toggle_text_color=”#5EC7ED” open_toggle_background_color=”#ffffff” closed_toggle_background_color=”#AEE3F6″ icon_color=”#505659″ open_icon_color=”#505659″ _builder_version=”4.16″ _module_preset=”default” title_text_color=”#505659″ title_font=”|600||on|||||” title_text_align=”center” title_font_size=”22px” closed_title_font=”|600|||||||” closed_title_text_align=”center” closed_title_font_size=”22px” body_text_align=”left” body_text_color=”#505659″ body_font_size=”16px” text_orientation=”center” global_colors_info=”{}”]<\/p>\n

\n\n\t\t7813506<\/span>\n\t\t<\/span>\n\t\tMCWU4QSQ<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t2020<\/span>\n <\/span>\n items<\/span>\n\t\t1<\/span>\n\t\tchicago-fullnote-bibliography<\/span>\n\t\t0<\/span>\n\t\tdate<\/span>\n\t\tdesc<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n <\/span>\n 2027<\/span>\n\t\thttps:\/\/www.crct-inserm.fr\/wp-content\/plugins\/zotpress\/<\/span>\n\n\t\t
\n\t\t\t
\n\t\t\t\t%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-d3903973fe1cb62be4eb57f6f5d468ca%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22UEK4Y2MT%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Kowalski-Chauvel%20et%20al.%22%2C%22parsedDate%22%3A%222020-12-25%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EKowalski-Chauvel%2C%20Aline%2C%20Marie%20G%26%23xE9%3Braldine%20Lacore%2C%20Florent%20Arnauduc%2C%20Caroline%20Delmas%2C%20Christine%20Toulas%2C%20Elizabeth%20Cohen-Jonathan-Moyal%2C%20and%20Catherine%20Seva.%20%26%23x201C%3BThe%20M6A%20RNA%20Demethylase%20ALKBH5%20Promotes%20Radioresistance%20and%20Invasion%20Capability%20of%20Glioma%20Stem%20Cells.%26%23x201D%3B%20%3Ci%3ECancers%3C%5C%2Fi%3E%2013%2C%20no.%201%20%28December%2025%2C%202020%29%3A%2040.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers13010040%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers13010040%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20m6A%20RNA%20Demethylase%20ALKBH5%20Promotes%20Radioresistance%20and%20Invasion%20Capability%20of%20Glioma%20Stem%20Cells%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aline%22%2C%22lastName%22%3A%22Kowalski-Chauvel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%20G%5Cu00e9raldine%22%2C%22lastName%22%3A%22Lacore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florent%22%2C%22lastName%22%3A%22Arnauduc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Delmas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Toulas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Cohen-Jonathan-Moyal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Seva%22%7D%5D%2C%22abstractNote%22%3A%22Recurrence%20of%20GBM%20is%20thought%20to%20be%20due%20to%20GBMSCs%2C%20which%20are%20particularly%20chemo-radioresistant%20and%20characterized%20by%20a%20high%20capacity%20to%20invade%20normal%20brain.%20Evidence%20is%20emerging%20that%20modulation%20of%20m6A%20RNA%20methylation%20plays%20an%20important%20role%20in%20tumor%20progression.%20However%2C%20the%20impact%20of%20this%20mRNA%20modification%20in%20GBM%20is%20poorly%20studied.%20We%20used%20patient-derived%20GBMSCs%20to%20demonstrate%20that%20high%20expression%20of%20the%20RNA%20demethylase%2C%20ALKBH5%2C%20increases%20radioresistance%20by%20regulating%20homologous%20recombination%20%28HR%29.%20In%20cells%20downregulated%20for%20ALKBH5%2C%20we%20observed%20a%20decrease%20in%20GBMSC%20survival%20after%20irradiation%20likely%20due%20to%20a%20defect%20in%20DNA-damage%20repair.%20Indeed%2C%20we%20observed%20a%20decrease%20in%20the%20expression%20of%20several%20genes%20involved%20in%20the%20HR%2C%20including%20CHK1%20and%20RAD51%2C%20as%20well%20as%20a%20persistence%20of%20%5Cu03b3-H2AX%20staining%20after%20IR.%20We%20also%20demonstrated%20in%20this%20study%20that%20ALKBH5%20contributes%20to%20the%20aggressiveness%20of%20GBM%20by%20favoring%20the%20invasion%20of%20GBMSCs.%20Indeed%2C%20GBMSCs%20deficient%20for%20ALKBH5%20exhibited%20a%20significant%20reduced%20invasion%20capability%20relative%20to%20control%20cells.%20Our%20data%20suggest%20that%20ALKBH5%20is%20an%20attractive%20therapeutic%20target%20to%20overcome%20radioresistance%20and%20invasiveness%20of%20GBMSCs.%22%2C%22date%22%3A%222020-12-25%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.3390%5C%2Fcancers13010040%22%2C%22ISSN%22%3A%222072-6694%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.mdpi.com%5C%2F2072-6694%5C%2F13%5C%2F1%5C%2F40%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A22%3A12Z%22%7D%7D%2C%7B%22key%22%3A%2292C7C9FR%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Grossiord%20et%20al.%22%2C%22parsedDate%22%3A%222020-12-08%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGrossiord%2C%20Elo%26%23xEF%3Bse%2C%20Laurent%20Risser%2C%20Salim%20Kanoun%2C%20Richard%20Aziza%2C%20Harold%20Chiron%2C%20Lo%26%23xEF%3Bc%20Ysebaert%2C%20Fran%26%23xE7%3Bois%20Malgouyres%2C%20and%20Sol%26%23xE9%3Bakh%26%23xE9%3Bna%20Ken.%20%26%23x201C%3BSemi-Automatic%20Segmentation%20of%20Whole-Body%20Images%20in%20Longitudinal%20Studies.%26%23x201D%3B%20%3Ci%3EBiomedical%20Physics%20%26amp%3B%20Engineering%20Express%3C%5C%2Fi%3E%207%2C%20no.%201%20%28December%208%2C%202020%29.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1088%5C%2F2057-1976%5C%2Fabce16%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1088%5C%2F2057-1976%5C%2Fabce16%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Semi-automatic%20segmentation%20of%20whole-body%20images%20in%20longitudinal%20studies%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elo%5Cu00efse%22%2C%22lastName%22%3A%22Grossiord%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Risser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Salim%22%2C%22lastName%22%3A%22Kanoun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%22%2C%22lastName%22%3A%22Aziza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harold%22%2C%22lastName%22%3A%22Chiron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lo%5Cu00efc%22%2C%22lastName%22%3A%22Ysebaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Malgouyres%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sol%5Cu00e9akh%5Cu00e9na%22%2C%22lastName%22%3A%22Ken%22%7D%5D%2C%22abstractNote%22%3A%22We%20propose%20a%20semi-automatic%20segmentation%20pipeline%20designed%20for%20longitudinal%20studies%20considering%20structures%20with%20large%20anatomical%20variability%2C%20where%20expert%20interactions%20are%20required%20for%20relevant%20segmentations.%20Our%20pipeline%20builds%20on%20the%20regularized%20Fast%20Marching%20%28rFM%29%20segmentation%20approach%20by%20Risseret%20al%282018%29.%20It%20consists%20in%20transporting%20baseline%20multi-label%20FM%20seeds%20on%20follow-up%20images%2C%20selecting%20the%20relevant%20ones%20and%20finally%20performing%20the%20rFM%20approach.%20It%20showed%20increased%2C%20robust%20and%20faster%20results%20compared%20to%20clinical%20manual%20segmentation.%20Our%20method%20was%20evaluated%20on%203D%20synthetic%20images%20and%20patients%27%20whole-body%20MRI.%20It%20allowed%20a%20robust%20and%20flexible%20handling%20of%20organs%20longitudinal%20deformations%20while%20considerably%20reducing%20manual%20interventions.%22%2C%22date%22%3A%222020-12-08%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1088%5C%2F2057-1976%5C%2Fabce16%22%2C%22ISSN%22%3A%222057-1976%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222023-03-21T12%3A54%3A09Z%22%7D%7D%2C%7B%22key%22%3A%227R2UK5F2%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bertorello%20et%20al.%22%2C%22parsedDate%22%3A%222020-09%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBertorello%2C%20Juliette%2C%20Julie%20Sesen%2C%20Julia%20Gilhodes%2C%20Sol%26%23xE8%3Bne%20Evrard%2C%20Monique%20Courtade-Sa%26%23xEF%3Bdi%2C%20Meera%20Augustus%2C%20Emmanuelle%20Uro-Coste%2C%20et%20al.%20%26%23x201C%3BTranslation%20Reprogramming%20by%20EIF3%20Linked%20to%20Glioblastoma%20Resistance.%26%23x201D%3B%20%3Ci%3ENAR%20Cancer%3C%5C%2Fi%3E%202%2C%20no.%203%20%28September%202020%29%3A%20zcaa020.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fnarcan%5C%2Fzcaa020%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fnarcan%5C%2Fzcaa020%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Translation%20reprogramming%20by%20eIF3%20linked%20to%20glioblastoma%20resistance%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juliette%22%2C%22lastName%22%3A%22Bertorello%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Sesen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julia%22%2C%22lastName%22%3A%22Gilhodes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sol%5Cu00e8ne%22%2C%22lastName%22%3A%22Evrard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Monique%22%2C%22lastName%22%3A%22Courtade-Sa%5Cu00efdi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Meera%22%2C%22lastName%22%3A%22Augustus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Uro-Coste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Toulas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%20Cohen-Jonathan%22%2C%22lastName%22%3A%22Moyal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Seva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erik%22%2C%22lastName%22%3A%22Dassi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Cammas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Skuli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefania%22%2C%22lastName%22%3A%22Millevoi%22%7D%5D%2C%22abstractNote%22%3A%22Intrinsic%20resistance%20to%20current%20therapies%2C%20leading%20to%20dismal%20clinical%20outcomes%2C%20is%20a%20hallmark%20of%20glioblastoma%20multiforme%20%28GBM%29%2C%20the%20most%20common%20and%20aggressive%20brain%20tumor.%20Understanding%20the%20underlying%20mechanisms%20of%20such%20malignancy%20is%2C%20therefore%2C%20an%20urgent%20medical%20need.%20Deregulation%20of%20the%20protein%20translation%20machinery%20has%20been%20shown%20to%20contribute%20to%20cancer%20initiation%20and%20progression%2C%20in%20part%20by%20driving%20selective%20translational%20control%20of%20specific%20mRNA%20transcripts%20involved%20in%20distinct%20cancer%20cell%20behaviors.%20Here%2C%20we%20focus%20on%20eIF3%2C%20a%20multimeric%20complex%20with%20a%20known%20role%20in%20the%20initiation%20of%20translation%20and%20that%20is%20frequently%20deregulated%20in%20cancer.%20Our%20results%20show%20that%20the%20deregulated%20expression%20of%20eIF3e%2C%20the%20e%20subunit%20of%20eIF3%2C%20in%20specific%20GBM%20regions%20could%20impinge%20on%20selective%20protein%20synthesis%20impacting%20the%20GBM%20outcome.%20In%20particular%2C%20eIF3e%20restricts%20the%20expression%20of%20proteins%20involved%20in%20the%20response%20to%20cellular%20stress%20and%20increases%20the%20expression%20of%20key%20functional%20regulators%20of%20cell%20stemness.%20Such%20a%20translation%20program%20can%20therefore%20serve%20as%20a%20double-edged%20sword%20promoting%20GBM%20tumor%20growth%20and%20resistance%20to%20radiation.%22%2C%22date%22%3A%222020-09%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1093%5C%2Fnarcan%5C%2Fzcaa020%22%2C%22ISSN%22%3A%222632-8674%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%2C%22WVCHCN8C%22%5D%2C%22dateModified%22%3A%222021-11-10T16%3A30%3A20Z%22%7D%7D%2C%7B%22key%22%3A%22J394C73J%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Leste%20et%20al.%22%2C%22parsedDate%22%3A%222020-06-23%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELeste%2C%20Jermey%2C%20Imene%20Medjahed%2C%20Fran%26%23xE7%3Bois-Xavier%20Arnaud%2C%20Regis%20Ferrand%2C%20Xavier%20Franceries%2C%20Manuel%20Bardies%2C%20and%20Luc%20Simon.%20%26%23x201C%3BA%20Study%20of%20the%20Interplay%20Effect%20for%20VMAT%20SBRT%20Using%20a%20Four-Axes%20Motion%20Phantom.%26%23x201D%3B%20%3Ci%3EJournal%20of%20Applied%20Clinical%20Medical%20Physics%3C%5C%2Fi%3E%2C%20June%2023%2C%202020.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Facm2.12947%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Facm2.12947%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22A%20study%20of%20the%20interplay%20effect%20for%20VMAT%20SBRT%20using%20a%20four-axes%20motion%20phantom%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jermey%22%2C%22lastName%22%3A%22Leste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Imene%22%2C%22lastName%22%3A%22Medjahed%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois-Xavier%22%2C%22lastName%22%3A%22Arnaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Regis%22%2C%22lastName%22%3A%22Ferrand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Franceries%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manuel%22%2C%22lastName%22%3A%22Bardies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luc%22%2C%22lastName%22%3A%22Simon%22%7D%5D%2C%22abstractNote%22%3A%22PURPOSE%3A%20To%20assess%20the%20accuracy%20of%20volumetric%20modulated%20arc%20therapy%20%28VMAT%29%20stereotactic%20body%20radiation%20therapy%20%28SBRT%29%20when%20treating%20moving%20targets%20%28such%20as%20lung%20or%20liver%20lesions%29%2C%20focusing%20on%20the%20impact%20of%20the%20interplay%20effect%20in%20the%20event%20of%20complex%20breathing%20motion%20and%20when%20a%20gating%20window%20is%20used.%5CnMETHODS%3A%20A%20dedicated%20programmable%20motion%20platform%20was%20implemented.%20This%20platform%20can%20carry%20large%20quality%20assurance%20%28QA%29%20phantoms%20and%20achieve%20complex%20three-dimensional%20%283D%29%20motion.%20Volumetric%20modulated%20arc%20therapy%20SBRT%20plans%20were%20delivered%20with%20TrueBeam%20linac%20to%20this%20moving%20setup%20and%20the%20measured%20dose%20was%20compared%20to%20the%20computed%20one.%20Several%20parameters%20were%20assessed%20such%20as%20breathing%20period%2C%20dose%20rate%2C%20dose%20prescription%2C%20shape%20of%20the%20breathing%20pattern%2C%20the%20use%20of%20a%20planning%20target%20volume%20%28PTV%29%20margin%2C%20and%20the%20use%20of%20a%20gating%20window.%5CnRESULTS%3A%20Loss%20of%20dose%20coverage%20%28D95%25%29%20was%20acceptable%20in%20most%20situations.%20The%20doses%20received%20by%2095%25%20of%20the%20CTV%2C%20D95%25%20%28%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20C%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20T%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20V%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20m%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%29%20ranged%20from%2094%20to%20101%25%20%28mean%2098%25%29%20and%20the%20doses%20received%20by%202%25%20of%20the%20CTV%20D2%25%20%28%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20C%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20T%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20V%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20m%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%29%20ranged%20from%2094%25%20to%20110%25%20of%20the%20prescribed%20dose.%20A%20visible%20interplay%20effect%20was%20observed%20when%20no%20margin%20was%20used%20or%20when%20the%20number%20of%20breathing%20cycles%20during%20the%20treatment%20delivery%20was%20lower%20than%2020.%5CnCONCLUSIONS%3A%20In%20our%20clinical%20context%2C%20treating%20lung%20and%20liver%20lesions%20using%20VMAT%20SBRT%20is%20reasonable.%20The%20interplay%20effect%20was%20moderated%20and%20acceptable%20in%20all%20simulated%20situations.%22%2C%22date%22%3A%22Jun%2023%2C%202020%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Facm2.12947%22%2C%22ISSN%22%3A%221526-9914%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A41Z%22%7D%7D%2C%7B%22key%22%3A%22QEXZHHRV%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ben%20Ahmed%20et%20al.%22%2C%22parsedDate%22%3A%222020-05-04%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBen%20Ahmed%2C%20Yassir%2C%20J%26%23xE9%3Br%26%23xE9%3Bmy%20Coulaud%2C%20Sol%26%23xE9%3Bakhena%20Ken%2C%20and%20Laure%20Parent.%20%26%23x201C%3BDetermination%20of%20Paramagnetic%20Ferrous%20Gel%20Sensitivity%20in%20Low%20Energy%20X-Ray%20Beam%20Produced%20by%20a%20Miniature%20Accelerator.%26%23x201D%3B%20Edited%20by%20Guillem%20Pratx.%20%3Ci%3EPLOS%20ONE%3C%5C%2Fi%3E%2015%2C%20no.%205%20%28May%204%2C%202020%29%3A%20e0232315.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pone.0232315%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pone.0232315%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Determination%20of%20paramagnetic%20ferrous%20gel%20sensitivity%20in%20low%20energy%20x-ray%20beam%20produced%20by%20a%20miniature%20accelerator%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yassir%22%2C%22lastName%22%3A%22Ben%20Ahmed%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00e9my%22%2C%22lastName%22%3A%22Coulaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sol%5Cu00e9akhena%22%2C%22lastName%22%3A%22Ken%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Parent%22%7D%2C%7B%22creatorType%22%3A%22editor%22%2C%22firstName%22%3A%22Guillem%22%2C%22lastName%22%3A%22Pratx%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222020-5-4%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1371%5C%2Fjournal.pone.0232315%22%2C%22ISSN%22%3A%221932-6203%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fdx.plos.org%5C%2F10.1371%5C%2Fjournal.pone.0232315%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A15Z%22%7D%7D%2C%7B%22key%22%3A%227TXYTVQ7%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Gouaz%5Cu00e9-Andersson%20and%20Cohen-Jonathan%20Moyal%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGouaz%26%23xE9%3B-Andersson%2C%20Val%26%23xE9%3Brie%2C%20and%20Elizabeth%20Cohen-Jonathan%20Moyal.%20%26%23x201C%3BNew%20Avenues%20in%20Radiotherapy%20of%20Glioblastoma%3A%20From%20Bench%20to%20Bedside.%26%23x201D%3B%20%3Ci%3ECurrent%20Treatment%20Options%20in%20Neurology%3C%5C%2Fi%3E%2022%2C%20no.%2012%20%282020%29%3A%2045.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs11940-020-00654-0%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs11940-020-00654-0%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22New%20Avenues%20in%20Radiotherapy%20of%20Glioblastoma%3A%20from%20Bench%20to%20Bedside%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Gouaz%5Cu00e9-Andersson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Cohen-Jonathan%20Moyal%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2212%5C%2F2020%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1007%5C%2Fs11940-020-00654-0%22%2C%22ISSN%22%3A%221092-8480%2C%201534-3138%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Flink.springer.com%5C%2F10.1007%5C%2Fs11940-020-00654-0%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A22%3A20Z%22%7D%7D%2C%7B%22key%22%3A%225M2RBCRS%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Dalmasso%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDalmasso%2C%20C%26%23xE9%3Bline%2C%20C%26%23xE9%3Bcile%20Pag%26%23xE8%3Bs%2C%20L%26%23xE9%3Bonor%20Chaltiel%2C%20Aurore%20Brun%2C%20Vincent%20Sibaud%2C%20Serge%20Boulinguez%2C%20Ciprian%20Chira%2C%20et%20al.%20%26%23x201C%3BSurvival%20Estimation%20of%20Melanoma%20Patients%20with%20Brain%20Metastasis%20Using%20the%20Melanoma-MolGPA%20Score%3A%20External%20Validation%20from%20a%20French%20Cohort.%26%23x201D%3B%20%3Ci%3EMelanoma%20Research%3C%5C%2Fi%3E%2030%2C%20no.%205%20%282020%29%3A%20472%26%23x2013%3B76.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FCMR.0000000000000670%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FCMR.0000000000000670%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Survival%20estimation%20of%20melanoma%20patients%20with%20brain%20metastasis%20using%20the%20Melanoma-molGPA%20score%3A%20external%20validation%20from%20a%20French%20cohort%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Dalmasso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9cile%22%2C%22lastName%22%3A%22Pag%5Cu00e8s%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%5Cu00e9onor%22%2C%22lastName%22%3A%22Chaltiel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aurore%22%2C%22lastName%22%3A%22Brun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Sibaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Serge%22%2C%22lastName%22%3A%22Boulinguez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ciprian%22%2C%22lastName%22%3A%22Chira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Moyal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Lubrano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Meyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anouchka%22%2C%22lastName%22%3A%22Modesto%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2210%5C%2F2020%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1097%5C%2FCMR.0000000000000670%22%2C%22ISSN%22%3A%220960-8931%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fjournals.lww.com%5C%2F10.1097%5C%2FCMR.0000000000000670%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A23Z%22%7D%7D%2C%7B%22key%22%3A%22MXDH7DWN%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22De%20Barros%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDe%20Barros%2C%20Amaury%2C%20Justine%20Attal%2C%20Margaux%20Roques%2C%20Julien%20Nicolau%2C%20Jean-Christophe%20Sol%2C%20Saloua%20Charni%2C%20Elizabeth%20Cohen-Jonathan-Moyal%2C%20and%20Franck-Emmanuel%20Roux.%20%26%23x201C%3BGlioblastoma%20Survival%20Is%20Better%20Analyzed%20on%20Preradiotherapy%20MRI%20than%20on%20Postoperative%20MRI%20Residual%20Volumes%3A%20A%20Retrospective%20Observational%20Study.%26%23x201D%3B%20%3Ci%3EClinical%20Neurology%20and%20Neurosurgery%3C%5C%2Fi%3E%20196%20%282020%29%3A%20105972.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.clineuro.2020.105972%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.clineuro.2020.105972%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Glioblastoma%20survival%20is%20better%20analyzed%20on%20preradiotherapy%20MRI%20than%20on%20postoperative%20MRI%20residual%20volumes%3A%20A%20retrospective%20observational%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amaury%22%2C%22lastName%22%3A%22De%20Barros%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Justine%22%2C%22lastName%22%3A%22Attal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Margaux%22%2C%22lastName%22%3A%22Roques%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Nicolau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Christophe%22%2C%22lastName%22%3A%22Sol%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Saloua%22%2C%22lastName%22%3A%22Charni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Cohen-Jonathan-Moyal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franck-Emmanuel%22%2C%22lastName%22%3A%22Roux%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2209%5C%2F2020%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.clineuro.2020.105972%22%2C%22ISSN%22%3A%2203038467%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Flinkinghub.elsevier.com%5C%2Fretrieve%5C%2Fpii%5C%2FS0303846720303152%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A21Z%22%7D%7D%2C%7B%22key%22%3A%22VHP2MAUW%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Cohen-Jonathan-Moyal%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ECohen-Jonathan-Moyal%2C%20%26%23xE9%3B.%2C%20V.%20Vendrely%2C%20L.%20Motte%2C%20J.%20Balosso%2C%20and%20J.%20Thariat.%20%26%23x201C%3BRadioresistant%20Tumours%3A%20From%20Identification%20to%20Targeting.%26%23x201D%3B%20%3Ci%3ECancer%5C%2FRadioth%26%23xE9%3Brapie%3C%5C%2Fi%3E%2C%202020%2C%20S1278321820301669.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.canrad.2020.05.005%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.canrad.2020.05.005%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Radioresistant%20tumours%3A%20From%20identification%20to%20targeting%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%5Cu00e9.%22%2C%22lastName%22%3A%22Cohen-Jonathan-Moyal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Vendrely%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Motte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Balosso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Thariat%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%228%5C%2F2020%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.canrad.2020.05.005%22%2C%22ISSN%22%3A%2212783218%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Flinkinghub.elsevier.com%5C%2Fretrieve%5C%2Fpii%5C%2FS1278321820301669%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A13Z%22%7D%7D%2C%7B%22key%22%3A%22CRVX5MC6%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Modesto%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EModesto%2C%20A.%2C%20C.%20Dalmasso%2C%20A.%20Lusque%2C%20L.%20Vieillevigne%2C%20F.%20Izar%2C%20E.%20Moyal%2C%20N.%20Carr%26%23xE8%3Bre%2C%20R.%20Guimbaud%2C%20and%20M.%20Rives.%20%26%23x201C%3BTolerance%20and%20Efficacy%20of%20Dose%20Escalation%20Using%20IMRT%20Combined%20with%20Chemotherapy%20for%20Unresectable%20Esophageal%20Carcinoma%3A%20Long-Term%20Results%20of%2051%20Patients.%26%23x201D%3B%20%3Ci%3ECancer%5C%2FRadioth%26%23xE9%3Brapie%3C%5C%2Fi%3E%2024%2C%20no.%202%20%282020%29%3A%2088%26%23x2013%3B92.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.canrad.2020.01.006%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.canrad.2020.01.006%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Tolerance%20and%20efficacy%20of%20dose%20escalation%20using%20IMRT%20combined%20with%20chemotherapy%20for%20unresectable%20esophageal%20carcinoma%3A%20Long-term%20results%20of%2051%20patients%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Modesto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Dalmasso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Lusque%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Vieillevigne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Izar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Moyal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Carr%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Guimbaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Rives%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2204%5C%2F2020%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.canrad.2020.01.006%22%2C%22ISSN%22%3A%2212783218%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Flinkinghub.elsevier.com%5C%2Fretrieve%5C%2Fpii%5C%2FS1278321820300524%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A24Z%22%7D%7D%5D%7D<\/span>\n\n\t\t\t\t
\n
\n
Kowalski-Chauvel, Aline, Marie Géraldine Lacore, Florent Arnauduc, Caroline Delmas, Christine Toulas, Elizabeth Cohen-Jonathan-Moyal, and Catherine Seva. “The M6A RNA Demethylase ALKBH5 Promotes Radioresistance and Invasion Capability of Glioma Stem Cells.” Cancers<\/i> 13, no. 1 (December 25, 2020): 40. https:\/\/doi.org\/10.3390\/cancers13010040<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Grossiord, Eloïse, Laurent Risser, Salim Kanoun, Richard Aziza, Harold Chiron, Loïc Ysebaert, François Malgouyres, and Soléakhéna Ken. “Semi-Automatic Segmentation of Whole-Body Images in Longitudinal Studies.” Biomedical Physics & Engineering Express<\/i> 7, no. 1 (December 8, 2020). https:\/\/doi.org\/10.1088\/2057-1976\/abce16<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Bertorello, Juliette, Julie Sesen, Julia Gilhodes, Solène Evrard, Monique Courtade-Saïdi, Meera Augustus, Emmanuelle Uro-Coste, et al. “Translation Reprogramming by EIF3 Linked to Glioblastoma Resistance.” NAR Cancer<\/i> 2, no. 3 (September 2020): zcaa020. https:\/\/doi.org\/10.1093\/narcan\/zcaa020<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Leste, Jermey, Imene Medjahed, François-Xavier Arnaud, Regis Ferrand, Xavier Franceries, Manuel Bardies, and Luc Simon. “A Study of the Interplay Effect for VMAT SBRT Using a Four-Axes Motion Phantom.” Journal of Applied Clinical Medical Physics<\/i>, June 23, 2020. https:\/\/doi.org\/10.1002\/acm2.12947<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Ben Ahmed, Yassir, Jérémy Coulaud, Soléakhena Ken, and Laure Parent. “Determination of Paramagnetic Ferrous Gel Sensitivity in Low Energy X-Ray Beam Produced by a Miniature Accelerator.” Edited by Guillem Pratx. PLOS ONE<\/i> 15, no. 5 (May 4, 2020): e0232315. https:\/\/doi.org\/10.1371\/journal.pone.0232315<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Gouazé-Andersson, Valérie, and Elizabeth Cohen-Jonathan Moyal. “New Avenues in Radiotherapy of Glioblastoma: From Bench to Bedside.” Current Treatment Options in Neurology<\/i> 22, no. 12 (2020): 45. https:\/\/doi.org\/10.1007\/s11940-020-00654-0<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Dalmasso, Céline, Cécile Pagès, Léonor Chaltiel, Aurore Brun, Vincent Sibaud, Serge Boulinguez, Ciprian Chira, et al. “Survival Estimation of Melanoma Patients with Brain Metastasis Using the Melanoma-MolGPA Score: External Validation from a French Cohort.” Melanoma Research<\/i> 30, no. 5 (2020): 472–76. https:\/\/doi.org\/10.1097\/CMR.0000000000000670<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
De Barros, Amaury, Justine Attal, Margaux Roques, Julien Nicolau, Jean-Christophe Sol, Saloua Charni, Elizabeth Cohen-Jonathan-Moyal, and Franck-Emmanuel Roux. “Glioblastoma Survival Is Better Analyzed on Preradiotherapy MRI than on Postoperative MRI Residual Volumes: A Retrospective Observational Study.” Clinical Neurology and Neurosurgery<\/i> 196 (2020): 105972. https:\/\/doi.org\/10.1016\/j.clineuro.2020.105972<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Cohen-Jonathan-Moyal, é., V. Vendrely, L. Motte, J. Balosso, and J. Thariat. “Radioresistant Tumours: From Identification to Targeting.” Cancer\/Radiothérapie<\/i>, 2020, S1278321820301669. https:\/\/doi.org\/10.1016\/j.canrad.2020.05.005<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Modesto, A., C. Dalmasso, A. Lusque, L. Vieillevigne, F. Izar, E. Moyal, N. Carrère, R. Guimbaud, and M. Rives. “Tolerance and Efficacy of Dose Escalation Using IMRT Combined with Chemotherapy for Unresectable Esophageal Carcinoma: Long-Term Results of 51 Patients.” Cancer\/Radiothérapie<\/i> 24, no. 2 (2020): 88–92. https:\/\/doi.org\/10.1016\/j.canrad.2020.01.006<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n\n\n

[\/et_pb_toggle][et_pb_toggle title=”PUBLICATIONS 2019″ open_toggle_text_color=”#5EC7ED” open_toggle_background_color=”#ffffff” closed_toggle_text_color=”#505659″ closed_toggle_background_color=”#AEE3F6″ icon_color=”#505659″ open_icon_color=”#505659″ _builder_version=”4.16″ _module_preset=”default” title_text_color=”#505659″ title_font=”|600||on|||||” title_text_align=”center” title_font_size=”22px” closed_title_text_align=”center” closed_title_font_size=”22px” body_text_align=”left” body_text_color=”#505659″ body_font_size=”16px” text_orientation=”center” global_colors_info=”{}”]<\/p>\n

\n\n\t\t7813506<\/span>\n\t\t<\/span>\n\t\tMCWU4QSQ<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t2019<\/span>\n <\/span>\n items<\/span>\n\t\t1<\/span>\n\t\tchicago-fullnote-bibliography<\/span>\n\t\t0<\/span>\n\t\tdate<\/span>\n\t\tdesc<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n <\/span>\n 2027<\/span>\n\t\thttps:\/\/www.crct-inserm.fr\/wp-content\/plugins\/zotpress\/<\/span>\n\n\t\t
\n\t\t\t
\n\t\t\t\t%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-fc2e0a7dab215e99eb428b7a39b0b3c1%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22AKLSBXUU%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Deshors%20et%20al.%22%2C%22parsedDate%22%3A%222019-10-28%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDeshors%2C%20Pauline%2C%20Christine%20Toulas%2C%20Florent%20Arnauduc%2C%20Laure%20Malric%2C%20Aurore%20Siegfried%2C%20Yvan%20Nicaise%2C%20Anthony%20Lemari%26%23xE9%3B%2C%20et%20al.%20%26%23x201C%3BIonizing%20Radiation%20Induces%20Endothelial%20Transdifferentiation%20of%20Glioblastoma%20Stem-like%20Cells%20through%20the%20Tie2%20Signaling%20Pathway.%26%23x201D%3B%20%3Ci%3ECell%20Death%20%26amp%3B%20Disease%3C%5C%2Fi%3E%2010%2C%20no.%2011%20%28October%2028%2C%202019%29%3A%20816.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41419-019-2055-6%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41419-019-2055-6%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Ionizing%20radiation%20induces%20endothelial%20transdifferentiation%20of%20glioblastoma%20stem-like%20cells%20through%20the%20Tie2%20signaling%20pathway%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pauline%22%2C%22lastName%22%3A%22Deshors%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Toulas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florent%22%2C%22lastName%22%3A%22Arnauduc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Malric%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aurore%22%2C%22lastName%22%3A%22Siegfried%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yvan%22%2C%22lastName%22%3A%22Nicaise%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anthony%22%2C%22lastName%22%3A%22Lemari%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dorian%22%2C%22lastName%22%3A%22Larrieu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Tosolini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Cohen-Jonathan%20Moyal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Monique%22%2C%22lastName%22%3A%22Courtade-Saidi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sol%5Cu00e8ne%20M.%22%2C%22lastName%22%3A%22Evrard%22%7D%5D%2C%22abstractNote%22%3A%22Glioblastomas%20%28GBM%29%20are%20brain%20tumors%20with%20a%20poor%20prognosis%20despite%20treatment%20that%20combines%20surgical%20resection%20and%20radio-chemotherapy.%20These%20tumors%20are%20characterized%20by%20abundant%20vascularization%20and%20significant%20cellular%20heterogeneity%20including%20GBM%20stem-like%20cells%20%28GSC%29%20which%20contribute%20to%20tumor%20aggressiveness%2C%20resistance%2C%20and%20recurrence.%20Recent%20data%20has%20demonstrated%20that%20GSC%20are%20directly%20involved%20in%20the%20formation%20of%20new%20vessels%20via%20their%20transdifferentiation%20into%20Tumor%20Derived%20Endothelial%20Cells%20%28TDEC%29.%20We%20postulate%20that%20cellular%20stress%20such%20as%20ionizing%20radiation%20%28IR%29%20could%20enhance%20the%20transdifferentiation%20of%20GSC%20into%20TDEC.%20GSC%20neurospheres%20isolated%20from%203%20different%20patients%20were%20irradiated%20or%20not%20and%20were%20then%20transdifferentiated%20into%20TDEC.%20In%20fact%2C%20TDEC%20obtained%20from%20irradiated%20GSC%20%28TDEC%20IR%2B%29%20migrate%20more%20towards%20VEGF%2C%20form%20more%20pseudotubes%20in%20MatrigelTM%20in%20vitro%20and%20develop%20more%20functional%20blood%20vessels%20in%20MatrigelTM%20plugs%20implanted%20in%20Nude%20mice%20than%20TDEC%20obtained%20from%20non-irradiated%20GSC.%20Transcriptomic%20analysis%20allows%20us%20to%20highlight%20an%20overexpression%20of%20Tie2%20in%20TDEC%20IR%2B.%20All%20IR-induced%20effects%20on%20TDEC%20were%20abolished%20by%20using%20a%20Tie2%20kinase%20inhibitor%2C%20which%20confirms%20the%20role%20of%20the%20Tie2%20signaling%20pathway%20in%20this%20process.%20Finally%2C%20by%20analyzing%20Tie2%20expression%20in%20patient%20GBMs%20by%20immunohistochemistry%2C%20we%20demonstrated%20that%20the%20number%20of%20Tie2%2B%20vessels%20increases%20in%20recurrent%20GBM%20compared%20with%20matched%20untreated%20tumors.%20In%20conclusion%2C%20we%20demonstrate%20that%20IR%20potentiates%20proangiogenic%20features%20of%20TDEC%20through%20the%20Tie2%20signaling%20pathway%2C%20which%20indicates%20a%20new%20pathway%20of%20treatment-induced%20tumor%20adaptation.%20New%20therapeutic%20strategies%20that%20associate%20standard%20treatment%20and%20a%20Tie2%20signaling%20pathway%20inhibitor%20should%20be%20considered%20for%20future%20trials.%22%2C%22date%22%3A%22Oct%2028%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41419-019-2055-6%22%2C%22ISSN%22%3A%222041-4889%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A42Z%22%7D%7D%2C%7B%22key%22%3A%2237NZ5A3A%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bayart%20et%20al.%22%2C%22parsedDate%22%3A%222019-08-24%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBayart%2C%20E.%2C%20D.%20Azria%2C%20J.%20Balosso%2C%20M.%20Benderitter%2C%20E.%20Cohen-Jonathan%20Moyal%2C%20G.%20Delpon%2C%20E.%20Deutsch%2C%20et%20al.%20%26%23x201C%3B%5BRadioTransNet%2C%20the%20French%20network%20for%20preclinical%20research%20in%20oncological%20radiotherapy%5D.%26%23x201D%3B%20%3Ci%3ECancer%20Radiotherapie%3A%20Journal%20De%20La%20Societe%20Francaise%20De%20Radiotherapie%20Oncologique%3C%5C%2Fi%3E%2C%20August%2024%2C%202019.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.canrad.2019.07.155%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.canrad.2019.07.155%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22%5BRadioTransNet%2C%20the%20French%20network%20for%20preclinical%20research%20in%20oncological%20radiotherapy%5D%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Bayart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Azria%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Balosso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Benderitter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Cohen-Jonathan%20Moyal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Delpon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Deutsch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Dutreix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Lacornerie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20H.%22%2C%22lastName%22%3A%22Romeo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Marchesi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Maingon%22%7D%5D%2C%22abstractNote%22%3A%22The%20ambition%20of%20the%20RADIOTRANSNET%20network%2C%20launched%20by%20the%20INCa%20at%20the%20end%20of%202018%2C%20is%20to%20create%20a%20French%20research%20consortium%20dedicated%20to%20preclinical%20radiotherapy%20to%20foster%20scientific%20and%20clinical%20interactions%20at%20the%20interface%20of%20radiotherapy%20and%20radiobiology%2C%20and%20to%20identify%20research%20priorities%20dedicated%20to%20innovation%20in%20radiotherapy.%20The%20activities%20of%20the%20network%20are%20organized%20around%20four%20major%20axes%20that%20are%20target%20definition%2C%20normal%20tissue%2C%20combined%20treatments%20and%20dose%20modelling.%20Under%20the%20supervision%20of%20the%20Scientific%20Council%2C%20headed%20by%20a%20coordinator%20designated%20by%20the%20SFRO%20and%20a%20co-coordinator%20designated%20by%20the%20SFPM%2C%20three%20leaders%20coordinate%20each%20axis%3A%20a%20radiation-oncologist%2C%20a%20medical%20physicist%20and%20a%20biologist%2C%20who%20are%20responsible%20for%20organizing%20a%20scientific%20meeting%20based%20on%20the%20consensus%20conference%20methodology%20to%20identify%20priority%20issues.%20The%20selected%20themes%20will%20be%20the%20basis%20for%20the%20establishment%20of%20a%20strategic%20research%20agenda%20and%20a%20roadmap%20to%20help%20coordinate%20national%20basic%20and%20translational%20research%20efforts%20in%20oncological%20radiotherapy.%20This%20work%20will%20be%20published%20and%20will%20be%20transmitted%20to%20the%20funding%20institutions%20and%20bodies%20with%20the%20aim%20of%20opening%20dedicated%20calls%20to%20finance%20the%20necessary%20human%20and%20technical%20resources.%20Structuration%20of%20a%20preclinical%20research%20network%20will%20allow%20coordinating%20the%20efforts%20of%20all%20the%20actors%20in%20the%20field%20and%20thus%20promoting%20innovation%20in%20radiotherapy.%22%2C%22date%22%3A%22Aug%2024%2C%202019%22%2C%22language%22%3A%22fre%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.canrad.2019.07.155%22%2C%22ISSN%22%3A%221769-6658%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A34Z%22%7D%7D%2C%7B%22key%22%3A%224VXSW8FM%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Dauzier%20et%20al.%22%2C%22parsedDate%22%3A%222019-08%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDauzier%2C%20Etienne%2C%20Benjamin%20Lacas%2C%20Pierre%20Blanchard%2C%20Quynh-Thu%20Le%2C%20Christian%20Simon%2C%20Gregory%20Wolf%2C%20Fran%26%23xE7%3Bois%20Janot%2C%20et%20al.%20%26%23x201C%3BRole%20of%20Chemotherapy%20in%205000%20Patients%20with%20Head%20and%20Neck%20Cancer%20Treated%20by%20Curative%20Surgery%3A%20A%20Subgroup%20Analysis%20of%20the%20Meta-Analysis%20of%20Chemotherapy%20in%20Head%20and%20Neck%20Cancer.%26%23x201D%3B%20%3Ci%3EOral%20Oncology%3C%5C%2Fi%3E%2095%20%28August%202019%29%3A%20106%26%23x2013%3B14.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.oraloncology.2019.06.001%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.oraloncology.2019.06.001%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Role%20of%20chemotherapy%20in%205000%20patients%20with%20head%20and%20neck%20cancer%20treated%20by%20curative%20surgery%3A%20A%20subgroup%20analysis%20of%20the%20meta-analysis%20of%20chemotherapy%20in%20head%20and%20neck%20cancer%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Dauzier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benjamin%22%2C%22lastName%22%3A%22Lacas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Blanchard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Quynh-Thu%22%2C%22lastName%22%3A%22Le%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Simon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregory%22%2C%22lastName%22%3A%22Wolf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Janot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Masatoshi%22%2C%22lastName%22%3A%22Horiuchi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeffrey%20S.%22%2C%22lastName%22%3A%22Tobias%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%22%2C%22lastName%22%3A%22Moon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%22%2C%22lastName%22%3A%22Simes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vinay%22%2C%22lastName%22%3A%22Deshmane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Jacques%22%2C%22lastName%22%3A%22Mazeron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samir%22%2C%22lastName%22%3A%22Mehta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Branko%22%2C%22lastName%22%3A%22Zaktonik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Minoru%22%2C%22lastName%22%3A%22Tamura%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Moyal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lisa%22%2C%22lastName%22%3A%22Licitra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Fortpied%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruce%20G.%22%2C%22lastName%22%3A%22Haffty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20Grazia%22%2C%22lastName%22%3A%22Ghi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Gregoire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Harris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Bourhis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Aup%5Cu00e9rin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Pierre%22%2C%22lastName%22%3A%22Pignon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22MACH-NC%20Collaborative%20Group%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20To%20evaluate%20the%20effect%20of%20chemotherapy%20added%20to%20a%20surgical%20locoregional%20treatment%20%28LRT%29%20for%20patients%20with%20locally%20advanced%20head%20and%20neck%20squamous%20cell%20carcinoma%20%28HNSCC%29.%5CnMATERIALS%20AND%20METHODS%3A%20We%20studied%20the%20sub-group%20of%20trials%20with%20surgical%20LRT%20included%20in%20the%20meta-analysis%20on%20chemotherapy%20in%20head%20and%20neck%20cancer%20%28MACH-NC%29.%20Data%20from%20published%20and%20unpublished%20randomized%20trials%20comparing%20the%20addition%20of%20chemotherapy%20to%20LRT%20in%20HNSCC%20patients%20were%20sought%20using%20electronic%20database%20searching%20for%20the%20period%201965-2000%2C%20hand%20searching%20and%20by%20contacting%20experts%20in%20the%20field.%20Trials%20with%20less%20than%2060%20patients%2C%20or%20preoperative%20radiotherapy%20or%20where%20the%20type%20of%20LRT%20could%20not%20be%20individually%20determined%20were%20excluded.%20All%20individual%20patient%20data%20were%20checked%20for%20internal%20consistency%2C%20compared%20with%20published%20reports%2C%20and%20validated%20with%20trialists.%20Data%20were%20pooled%20using%20a%20fixed-effect%20model.%20Heterogeneity%20was%20assessed%20using%20Cochrane%20test%20and%20I2%20statistic.%5CnRESULTS%3A%20Twenty-four%20trials%20were%20eligible%20%285000%20patients%29.%20Chemotherapy%20improved%20overall%20survival%20%28HR%5Cu202f%3D%5Cu202f0.92%20%5B95%25CI%3A%200.85-0.99%5D%20p%5Cu202f%3D%5Cu202f0.02%29.%20There%20was%20a%20significant%20interaction%20between%20treatment%20effect%20and%20timing%20of%20chemotherapy%20%28p%5Cu202f%3D%5Cu202f0.08%20at%20pre-specified%20threshold%20of%200.10%29%20with%20a%20greater%20effect%20for%20concomitant%20chemotherapy%20%28HR%5Cu202f%3D%5Cu202f0.79%2C%2095%25CI%3A%200.69-0.92%29.%20The%20benefit%20of%20chemotherapy%20was%20greater%20in%20women%20%28HRwomen%5Cu202f%3D%5Cu202f0.63%2C%2095%25CI%3A%200.50-0.80%29%20compared%20to%20men%20%28HRmen%5Cu202f%3D%5Cu202f0.96%2C%2095%25CI%3A%200.89-1.04%3B%20p%20for%20interaction%5Cu202f%3D%5Cu202f0.001%29.%5CnCONCLUSIONS%3A%20This%20analysis%20confirmed%20the%20benefit%20of%20concomitant%20chemotherapy%20added%20to%20surgical%20LRT.%20The%20role%20of%20induction%20therapy%20as%20yet%20to%20be%20determined%20as%20it%20did%20not%20improve%20OS.%20Women%20may%20benefit%20more%20than%20men%20from%20chemotherapy.%22%2C%22date%22%3A%22Aug%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.oraloncology.2019.06.001%22%2C%22ISSN%22%3A%221879-0593%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A28Z%22%7D%7D%2C%7B%22key%22%3A%22M2CP2J76%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Mouly%20et%20al.%22%2C%22parsedDate%22%3A%222019-07-24%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMouly%2C%20Laetitia%2C%20Julia%20Gilhodes%2C%20Anthony%20Lemari%26%23xE9%3B%2C%20Elizabeth%20Cohen-Jonathan%20Moyal%2C%20Christine%20Toulas%2C%20Gilles%20Favre%2C%20Olivier%20Sordet%2C%20and%20Sylvie%20Monferran.%20%26%23x201C%3BThe%20RND1%20Small%20GTPase%3A%20Main%20Functions%20and%20Emerging%20Role%20in%20Oncogenesis.%26%23x201D%3B%20%3Ci%3EInternational%20Journal%20of%20Molecular%20Sciences%3C%5C%2Fi%3E%2020%2C%20no.%2015%20%28July%2024%2C%202019%29.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fijms20153612%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fijms20153612%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20RND1%20Small%20GTPase%3A%20Main%20Functions%20and%20Emerging%20Role%20in%20Oncogenesis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laetitia%22%2C%22lastName%22%3A%22Mouly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julia%22%2C%22lastName%22%3A%22Gilhodes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anthony%22%2C%22lastName%22%3A%22Lemari%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Cohen-Jonathan%20Moyal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Toulas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Favre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Sordet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvie%22%2C%22lastName%22%3A%22Monferran%22%7D%5D%2C%22abstractNote%22%3A%22The%20Rho%20GTPase%20family%20can%20be%20classified%20into%20classic%20and%20atypical%20members.%20Classic%20members%20cycle%20between%20an%20inactive%20Guanosine%20DiPhosphate%20-bound%20state%20and%20an%20active%20Guanosine%20TriPhosphate-bound%20state.%20Atypical%20Rho%20GTPases%2C%20such%20as%20RND1%2C%20are%20predominantly%20in%20an%20active%20GTP-bound%20conformation.%20The%20role%20of%20classic%20members%20in%20oncogenesis%20has%20been%20the%20subject%20of%20numerous%20studies%2C%20while%20that%20of%20atypical%20members%20has%20been%20less%20explored.%20Besides%20the%20roles%20of%20RND1%20in%20healthy%20tissues%2C%20recent%20data%20suggest%20that%20RND1%20is%20involved%20in%20oncogenesis%20and%20response%20to%20cancer%20therapeutics.%20Here%2C%20we%20present%20the%20current%20knowledge%20on%20RND1%20expression%2C%20subcellular%20localization%2C%20and%20functions%20in%20healthy%20tissues.%20Then%2C%20we%20review%20data%20showing%20that%20RND1%20expression%20is%20dysregulated%20in%20tumors%2C%20the%20molecular%20mechanisms%20involved%20in%20this%20deregulation%2C%20and%20the%20role%20of%20RND1%20in%20oncogenesis.%20For%20several%20aggressive%20tumors%2C%20RND1%20presents%20the%20features%20of%20a%20tumor%20suppressor%20gene.%20In%20these%20tumors%2C%20low%20expression%20of%20RND1%20is%20associated%20with%20a%20bad%20prognosis%20for%20the%20patients.%20Finally%2C%20we%20highlight%20that%20RND1%20expression%20is%20induced%20by%20anticancer%20agents%20and%20modulates%20their%20response.%20Of%20note%2C%20RND1%20mRNA%20levels%20in%20tumors%20could%20be%20used%20as%20a%20predictive%20marker%20of%20both%20patient%20prognosis%20and%20response%20to%20anticancer%20agents.%22%2C%22date%22%3A%22Jul%2024%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3390%5C%2Fijms20153612%22%2C%22ISSN%22%3A%221422-0067%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22W973EZ5X%22%2C%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A31Z%22%7D%7D%2C%7B%22key%22%3A%22X2ZI2Z7Z%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Modesto%20et%20al.%22%2C%22parsedDate%22%3A%222019-04%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EModesto%2C%20A.%2C%20C.%20Chira%2C%20J.-C.%20Sol%2C%20V.%20Lubrano%2C%20S.%20Boulinguez%2C%20C.%20Pag%26%23xE8%3Bs%2C%20V.%20Sibaud%2C%20C.%20Gomez-Roca%2C%20%26%23xC9%3B%20Moyal%2C%20and%20N.%20Meyer.%20%26%23x201C%3B%5BTreatment%20of%20patients%20with%20brain%20metastases%20from%20a%20melanoma%5D.%26%23x201D%3B%20%3Ci%3ECancer%20Radiotherapie%3A%20Journal%20De%20La%20Societe%20Francaise%20De%20Radiotherapie%20Oncologique%3C%5C%2Fi%3E%2023%2C%20no.%202%20%28April%202019%29%3A%20147%26%23x2013%3B50.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.canrad.2018.05.006%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.canrad.2018.05.006%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22%5BTreatment%20of%20patients%20with%20brain%20metastases%20from%20a%20melanoma%5D%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Modesto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Chira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.-C.%22%2C%22lastName%22%3A%22Sol%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Lubrano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Boulinguez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Pag%5Cu00e8s%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Sibaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Gomez-Roca%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%5Cu00c9%22%2C%22lastName%22%3A%22Moyal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Meyer%22%7D%5D%2C%22abstractNote%22%3A%22Whereas%20immune%20checkpoint%20inhibitors%20of%20serine%5C%2Fthreonine%20protein%20kinase%20B-raf%20therapy%20dramatically%20changed%20metastatic%20outcomes%20of%20patients%20with%20melanoma%2C%20they%20remain%20at%20high%20risk%20of%20brain%20extension.%20Additional%20local%20treatment%20can%20be%20offered%20in%20this%20situation%20such%20as%20surgery%20and%20or%20stereotactic%20radiotherapy.%20In%20this%20review%20article%2C%20we%20describe%20the%20different%20options%20with%20published%20data%20and%20their%20optimal%20timing.%22%2C%22date%22%3A%22Apr%202019%22%2C%22language%22%3A%22fre%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.canrad.2018.05.006%22%2C%22ISSN%22%3A%221769-6658%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A12Z%22%7D%7D%2C%7B%22key%22%3A%22QLSPENGT%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Kowalski-Chauvel%20et%20al.%22%2C%22parsedDate%22%3A%222019-03-22%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EKowalski-Chauvel%2C%20Aline%2C%20Valerie%20Gouaze-Andersson%2C%20Laurent%20Baricault%2C%20Elodie%20Martin%2C%20Caroline%20Delmas%2C%20Christine%20Toulas%2C%20Elizabeth%20Cohen-Jonathan-Moyal%2C%20and%20Catherine%20Seva.%20%26%23x201C%3BAlpha6-Integrin%20Regulates%20FGFR1%20Expression%20through%20the%20ZEB1%5C%2FYAP1%20Transcription%20Complex%20in%20Glioblastoma%20Stem%20Cells%20Resulting%20in%20Enhanced%20Proliferation%20and%20Stemness.%26%23x201D%3B%20%3Ci%3ECancers%3C%5C%2Fi%3E%2011%2C%20no.%203%20%28March%2022%2C%202019%29.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers11030406%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers11030406%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Alpha6-Integrin%20Regulates%20FGFR1%20Expression%20through%20the%20ZEB1%5C%2FYAP1%20Transcription%20Complex%20in%20Glioblastoma%20Stem%20Cells%20Resulting%20in%20Enhanced%20Proliferation%20and%20Stemness%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aline%22%2C%22lastName%22%3A%22Kowalski-Chauvel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valerie%22%2C%22lastName%22%3A%22Gouaze-Andersson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Baricault%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elodie%22%2C%22lastName%22%3A%22Martin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Delmas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Toulas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Cohen-Jonathan-Moyal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Seva%22%7D%5D%2C%22abstractNote%22%3A%22Glioblastoma%20%28GBM%29%20is%20the%20most%20lethal%20primary%20brain%20tumor%20in%20adults%20and%20is%20known%20to%20be%20particularly%20aggressive%20and%20resistant%20to%20anti-cancer%20therapies%2C%20mainly%20due%20to%20the%20presence%20of%20GBM%20stem%20cells%20%28GBMSC%29.%20By%20in%20vitro%20approaches%20supported%20by%20analysis%20from%20patients%27%20databases%2C%20we%20determined%20how%20%5Cu03b16-integrin%20and%20Fibroblast%20Growth%20Factor%20Receptor%201%20%28FGFR1%29%20work%20in%20concert%20to%20regulate%20proliferation%20and%20stemness%20of%20GBMSC.%20We%20showed%20that%20%5Cu03b16-integrin%20regulates%20the%20expression%20of%20FGFR1%20and%20its%20target%20gene%20Fokhead%20Box%20M1%20%28FOXM1%29%20via%20the%20ZEB1%5C%2FYAP1%20transcription%20complex.%20These%20results%20were%20in%20accordance%20with%20the%20positive%20correlation%20observed%20in%20GBM%20between%20%5Cu03b16-integrin%20expression%20and%20its%20target%20genes%20ZEB1%5C%2FYAP1%2C%20FGFR1%2C%20and%20FOXM1%20in%20the%20databases%2C%20TCGA%20and%20Rembrandt.%20In%20addition%2C%20the%20clinical%20data%20demonstrate%20that%20GBM%20patients%20with%20high%20levels%20of%20the%20five%20genes%20signature%2C%20including%20%5Cu03b16-integrin%2C%20ZEB1%5C%2FYAP1%2C%20FGFR1%20and%20FOXM1%2C%20have%20a%20significantly%20shorter%20overall%20survival.%20In%20vitro%2C%20we%20observed%20a%20similar%20decrease%20in%20the%20expression%20of%20stemness-related%20factors%2C%20neurospheres%20forming%20capacity%2C%20as%20well%20as%20spheroids%20growth%20when%20%5Cu03b16-integrin%20or%20FGFR1%20was%20blocked%20individually%20with%20specific%20siRNA%2C%20whereas%20the%20combination%20of%20both%20siRNA%20led%20to%20a%20significantly%20higher%20inhibition%20of%20spheres%20formation.%20These%20data%20suggest%20that%20co-administration%20of%20anti-FGFR1%20and%20anti-%5Cu03b16-integrin%20could%20provide%20an%20improved%20therapeutic%20response%20in%20GBMSC.%22%2C%22date%22%3A%22Mar%2022%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3390%5C%2Fcancers11030406%22%2C%22ISSN%22%3A%222072-6694%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A08Z%22%7D%7D%2C%7B%22key%22%3A%2265J87UNG%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Laprie%20et%20al.%22%2C%22parsedDate%22%3A%222019-02-21%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELaprie%2C%20Anne%2C%20Sol%26%23xE9%3Bakh%26%23xE9%3Bna%20Ken%2C%20Thomas%20Filleron%2C%20Vincent%20Lubrano%2C%20Laure%20Vieillevigne%2C%20Fatima%20Tensaouti%2C%20Isabelle%20Catalaa%2C%20et%20al.%20%26%23x201C%3BDose-Painting%20Multicenter%20Phase%20III%20Trial%20in%20Newly%20Diagnosed%20Glioblastoma%3A%20The%20SPECTRO-GLIO%20Trial%20Comparing%20Arm%20A%20Standard%20Radiochemotherapy%20to%20Arm%20B%20Radiochemotherapy%20with%20Simultaneous%20Integrated%20Boost%20Guided%20by%20MR%20Spectroscopic%20Imaging.%26%23x201D%3B%20%3Ci%3EBMC%20Cancer%3C%5C%2Fi%3E%2019%2C%20no.%201%20%28February%2021%2C%202019%29%3A%20167.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12885-019-5317-x%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12885-019-5317-x%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Dose-painting%20multicenter%20phase%20III%20trial%20in%20newly%20diagnosed%20glioblastoma%3A%20the%20SPECTRO-GLIO%20trial%20comparing%20arm%20A%20standard%20radiochemotherapy%20to%20arm%20B%20radiochemotherapy%20with%20simultaneous%20integrated%20boost%20guided%20by%20MR%20spectroscopic%20imaging%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Laprie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sol%5Cu00e9akh%5Cu00e9na%22%2C%22lastName%22%3A%22Ken%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Filleron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Lubrano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Vieillevigne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fatima%22%2C%22lastName%22%3A%22Tensaouti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Catalaa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sergio%22%2C%22lastName%22%3A%22Boetto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Khalifa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Justine%22%2C%22lastName%22%3A%22Attal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Peyraga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlos%22%2C%22lastName%22%3A%22Gomez-Roca%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Uro-Coste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Georges%22%2C%22lastName%22%3A%22Noel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Truc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Pierre%22%2C%22lastName%22%3A%22Sunyach%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Magn%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Charissoux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phane%22%2C%22lastName%22%3A%22Supiot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Bernier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Muriel%22%2C%22lastName%22%3A%22Mounier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Muriel%22%2C%22lastName%22%3A%22Poublanc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amandine%22%2C%22lastName%22%3A%22Fabre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Pierre%22%2C%22lastName%22%3A%22Delord%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Cohen-Jonathan%20Moyal%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Glioblastoma%2C%20a%20high-grade%20glial%20infiltrating%20tumor%2C%20is%20the%20most%20frequent%20malignant%20brain%20tumor%20in%20adults%20and%20carries%20a%20dismal%20prognosis.%20External%20beam%20radiotherapy%20%28EBRT%29%20increases%20overall%20survival%20but%20this%20is%20still%20low%20due%20to%20local%20relapses%2C%20mostly%20occurring%20in%20the%20irradiation%20field.%20As%20the%20ratio%20of%20spectra%20of%20choline%5C%2FN%20acetyl%20aspartate%3E%5Cu20092%20%28CNR2%29%20on%20MR%20spectroscopic%20imaging%20has%20been%20described%20as%20predictive%20for%20the%20site%20of%20local%20relapse%2C%20we%20hypothesized%20that%20dose%20escalation%20on%20these%20regions%20would%20increase%20local%20control%20and%20hence%20global%20survival.%5CnMETHODS%5C%2FDESIGN%3A%20In%20this%20multicenter%20prospective%20phase%20III%20trial%20for%20newly%20diagnosed%20glioblastoma%2C%20220%20patients%20having%20undergone%20biopsy%20or%20surgery%20are%20planned%20for%20randomization%20to%20two%20arms.%20Arm%20A%20is%20the%20Stupp%20protocol%20%28EBRT%2060%5Cu2009Gy%20on%20contrast%20enhancement%20%2B%5Cu20092%5Cu2009cm%20margin%20with%20concomitant%20temozolomide%20%28TMZ%29%20and%206%20months%20of%20TMZ%20maintenance%29%3B%20Arm%20B%20is%20the%20same%20treatment%20with%20an%20additional%20simultaneous%20integrated%20boost%20of%20intensity-modulated%20radiotherapy%20%28IMRT%29%20of%2072Gy%5C%2F2.4Gy%20delivered%20on%20the%20MR%20spectroscopic%20imaging%20metabolic%20volumes%20of%20CHO%5C%2FNAA%5Cu2009%3E%5Cu20092%20and%20contrast-enhancing%20lesions%20or%20resection%20cavity.%20Stratification%20is%20performed%20on%20surgical%20and%20MGMT%20status.%5CnDISCUSSION%3A%20This%20is%20a%20dose-painting%20trial%2C%20i.e.%20delivery%20of%20heterogeneous%20dose%20guided%20by%20metabolic%20imaging.%20The%20principal%20endpoint%20is%20overall%20survival.%20An%20online%20prospective%20quality%20control%20of%20volumes%20and%20dose%20is%20performed%20in%20the%20experimental%20arm.%20The%20study%20will%20yield%20a%20large%20amount%20of%20longitudinal%20multimodal%20MR%20imaging%20data%20including%20planning%20CT%2C%20radiotherapy%20dosimetry%2C%20MR%20spectroscopic%2C%20diffusion%20and%20perfusion%20imaging.%5CnTRIAL%20REGISTRATION%3A%20NCT01507506%20%2C%20registration%20date%20December%2020%2C%202011.%22%2C%22date%22%3A%22Feb%2021%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12885-019-5317-x%22%2C%22ISSN%22%3A%221471-2407%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A03Z%22%7D%7D%2C%7B%22key%22%3A%22SHE8IRRP%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22De%20Barros%20et%20al.%22%2C%22parsedDate%22%3A%222019-02-19%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDe%20Barros%2C%20Amaury%2C%20Justine%20Attal%2C%20Margaux%20Roques%2C%20Julien%20Nicolau%2C%20Jean-Christophe%20Sol%2C%20Elizabeth%20Cohen-Jonathan-Moyal%2C%20and%20Franck-Emmanuel%20Roux.%20%26%23x201C%3BImpact%20on%20Survival%20of%20Early%20Tumor%20Growth%20between%20Surgery%20and%20Radiotherapy%20in%20Patients%20with%20de%20Novo%20Glioblastoma.%26%23x201D%3B%20%3Ci%3EJournal%20of%20Neuro-Oncology%3C%5C%2Fi%3E%2C%20February%2019%2C%202019.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs11060-019-03120-3%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs11060-019-03120-3%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Impact%20on%20survival%20of%20early%20tumor%20growth%20between%20surgery%20and%20radiotherapy%20in%20patients%20with%20de%20novo%20glioblastoma%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amaury%22%2C%22lastName%22%3A%22De%20Barros%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Justine%22%2C%22lastName%22%3A%22Attal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Margaux%22%2C%22lastName%22%3A%22Roques%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Nicolau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Christophe%22%2C%22lastName%22%3A%22Sol%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Cohen-Jonathan-Moyal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franck-Emmanuel%22%2C%22lastName%22%3A%22Roux%22%7D%5D%2C%22abstractNote%22%3A%22PURPOSE%3A%20Systematic%20pre-radiotherapy%20MRI%20in%20patients%20with%20newly%20resected%20glioblastoma%20%28OMS%202016%29%20sometimes%20reveals%20tumor%20growth%20in%20the%20period%20between%20surgery%20and%20radiotherapy.%20We%20evaluated%20the%20relation%20between%20early%20tumor%20growth%20and%20overall%20survival%20%28OS%29%20with%20the%20aim%20of%20finding%20predictors%20of%20regrowth.%5CnMETHODS%3A%20Seventy-five%20patients%20from%2025%20to%2084%5Cu00a0years%20old%20%28Median%20age%2062%5Cu00a0years%29%20with%20preoperative%2C%20immediate%20postoperative%2C%20and%20preradiotherapy%20MRI%20were%20included.%20Volumetric%20measurements%20were%20made%20on%20each%20of%20the%20three%20MRI%20scans%20and%20clinical%20and%20molecular%20parameters%20were%20collected%20for%20each%20case.%5CnRESULTS%3A%20Fifty-four%20patients%20%2872%25%29%20had%20an%20early%20regrowth%20with%20a%20median%20contrast%20enhancement%20volume%20of%203.61%5Cu00a0cm3-range%200.12-71.93%5Cu00a0cm3.%20The%20median%20OS%20was%2024%5Cu00a0months%20in%20patients%20with%20no%20early%20tumor%20growth%20and%2017.1%5Cu00a0months%20in%20those%20with%20early%20tumor%20regrowth%20%28p%5Cu2009%3D%5Cu20090.0024%29.%20In%20the%20population%20with%20initial%20complete%20resection%20%2827%20patients%29%2C%20the%20median%20OS%20was%2025.3%5Cu00a0months%20%2819%20patients%29%20in%20those%20with%20no%20early%20tumor%20growth%20between%20surgery%20and%20radiotherapy%20compared%20to%2016.3%20months%20%288%20patients%29%20in%20those%20with%20tumor%20regrowth.%20In%20multivariate%20analysis%2C%20the%20initial%20extent%20of%20resection%20%28p%5Cu2009%3C%5Cu20090.001%29%20and%20the%20delay%20between%20postoperative%20MRI%20and%20preradiotherapy%20MRI%20%28p%5Cu2009%3C%5Cu20090.001%29%20were%20significant%20independent%20prognostic%20factors%20of%20regrowth%20and%20of%20poorer%20outcome.%5CnCONCLUSIONS%3A%20We%20demonstrated%20that%2C%20in%20addition%20to%20the%20well%20known%20issue%20of%20incomplete%20resection%2C%20longer%20delays%20between%20surgery%20and%20adjuvant%20treatment%20is%20an%20independent%20factors%20of%20tumor%20regrowth%20and%20a%20risk%20factor%20of%20poorer%20outcomes%20for%20the%20patients.%20To%20overcome%20the%20delay%20factor%2C%20we%20suggest%20shortening%20the%20usual%20time%20between%20surgery%20and%20radiotherapy.%22%2C%22date%22%3A%22Feb%2019%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs11060-019-03120-3%22%2C%22ISSN%22%3A%221573-7373%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A03Z%22%7D%7D%2C%7B%22key%22%3A%22N49WT8DA%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Malric%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMalric%2C%20Laure%2C%20Sylvie%20Monferran%2C%20Caroline%20Delmas%2C%20Florent%20Arnauduc%2C%20Perrine%20Dahan%2C%20Sabrina%20Boyrie%2C%20Pauline%20Deshors%2C%20et%20al.%20%26%23x201C%3BInhibiting%20Integrin%20%26%23x392%3B8%20to%20Differentiate%20and%20Radiosensitize%20Glioblastoma-Initiating%20Cells.%26%23x201D%3B%20%3Ci%3EMolecular%20Cancer%20Research%3A%20MCR%3C%5C%2Fi%3E%2017%2C%20no.%202%20%282019%29%3A%20384%26%23x2013%3B97.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F1541-7786.MCR-18-0386%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F1541-7786.MCR-18-0386%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Inhibiting%20Integrin%20%5Cu03b28%20to%20Differentiate%20and%20Radiosensitize%20Glioblastoma-Initiating%20Cells%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Malric%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvie%22%2C%22lastName%22%3A%22Monferran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Delmas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florent%22%2C%22lastName%22%3A%22Arnauduc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Perrine%22%2C%22lastName%22%3A%22Dahan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sabrina%22%2C%22lastName%22%3A%22Boyrie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pauline%22%2C%22lastName%22%3A%22Deshors%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Lubrano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dina%20Ferreira%22%2C%22lastName%22%3A%22Da%20Mota%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julia%22%2C%22lastName%22%3A%22Gilhodes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Filleron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aurore%22%2C%22lastName%22%3A%22Siegfried%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sol%5Cu00e8ne%22%2C%22lastName%22%3A%22Evrard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aline%22%2C%22lastName%22%3A%22Kowalski-Chauvel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%20Cohen-Jonathan%22%2C%22lastName%22%3A%22Moyal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Toulas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anthony%22%2C%22lastName%22%3A%22Lemari%5Cu00e9%22%7D%5D%2C%22abstractNote%22%3A%22Glioblastomas%20%28GB%29%20are%20malignant%20brain%20tumors%20with%20poor%20prognosis%20despite%20treatment%20with%20surgery%20and%20radio%5C%2Fchemotherapy.%20These%20tumors%20are%20defined%20by%20an%20important%20cellular%20heterogeneity%20and%20notably%20contain%20a%20subpopulation%20of%20GB-initiating%20cells%20%28GIC%29%2C%20which%20contribute%20to%20tumor%20aggressiveness%2C%20resistance%2C%20and%20recurrence.%20Some%20integrins%20are%20specifically%20expressed%20by%20GICs%20and%20could%20be%20actionable%20targets%20to%20improve%20GB%20treatment.%20Here%2C%20integrin%20%5Cu03b28%20%28ITGB8%29%20was%20identified%20as%20a%20potential%20selective%20target%20in%20this%20highly%20tumorigenic%20GIC%20subpopulation.%20Using%20several%20patient-derived%20primocultures%2C%20it%20was%20demonstrated%20that%20ITGB8%20is%20overexpressed%20in%20GICs%20compared%20with%20their%20differentiated%20progeny.%20Furthermore%2C%20ITGB8%20is%20also%20overexpressed%20in%20GB%2C%20and%20its%20overexpression%20is%20correlated%20with%20poor%20prognosis%20and%20with%20the%20expression%20of%20several%20other%20classic%20stem%20cell%20markers.%20Moreover%2C%20inhibiting%20ITGB8%20diminished%20several%20main%20GIC%20characteristics%20and%20features%2C%20including%20self-renewal%20ability%2C%20stemness%2C%20migration%20potential%2C%20and%20tumor%20formation%20capacity.%20Blockade%20of%20ITGB8%20significantly%20impaired%20GIC%20cell%20viability%20via%20apoptosis%20induction.%20Finally%2C%20the%20combination%20of%20radiotherapy%20and%20ITGB8%20targeting%20radiosensitized%20GICs%20through%20postmitotic%20cell%20death.%20IMPLICATIONS%3A%20This%20study%20identifies%20ITGB8%20as%20a%20new%20selective%20marker%20for%20GICs%20and%20as%20a%20promising%20therapeutic%20target%20in%20combination%20with%20chemo%5C%2Fradiotherapy%20for%20the%20treatment%20of%20highly%20aggressive%20brain%20tumors.%22%2C%22date%22%3A%2202%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1158%5C%2F1541-7786.MCR-18-0386%22%2C%22ISSN%22%3A%221557-3125%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222021-10-11T11%3A43%3A28Z%22%7D%7D%5D%7D<\/span>\n\n\t\t\t\t
\n
\n
Deshors, Pauline, Christine Toulas, Florent Arnauduc, Laure Malric, Aurore Siegfried, Yvan Nicaise, Anthony Lemarié, et al. “Ionizing Radiation Induces Endothelial Transdifferentiation of Glioblastoma Stem-like Cells through the Tie2 Signaling Pathway.” Cell Death & Disease<\/i> 10, no. 11 (October 28, 2019): 816. https:\/\/doi.org\/10.1038\/s41419-019-2055-6<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Bayart, E., D. Azria, J. Balosso, M. Benderitter, E. Cohen-Jonathan Moyal, G. Delpon, E. Deutsch, et al. “[RadioTransNet, the French network for preclinical research in oncological radiotherapy].” Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique<\/i>, August 24, 2019. https:\/\/doi.org\/10.1016\/j.canrad.2019.07.155<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Dauzier, Etienne, Benjamin Lacas, Pierre Blanchard, Quynh-Thu Le, Christian Simon, Gregory Wolf, François Janot, et al. “Role of Chemotherapy in 5000 Patients with Head and Neck Cancer Treated by Curative Surgery: A Subgroup Analysis of the Meta-Analysis of Chemotherapy in Head and Neck Cancer.” Oral Oncology<\/i> 95 (August 2019): 106–14. https:\/\/doi.org\/10.1016\/j.oraloncology.2019.06.001<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Mouly, Laetitia, Julia Gilhodes, Anthony Lemarié, Elizabeth Cohen-Jonathan Moyal, Christine Toulas, Gilles Favre, Olivier Sordet, and Sylvie Monferran. “The RND1 Small GTPase: Main Functions and Emerging Role in Oncogenesis.” International Journal of Molecular Sciences<\/i> 20, no. 15 (July 24, 2019). https:\/\/doi.org\/10.3390\/ijms20153612<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Modesto, A., C. Chira, J.-C. Sol, V. Lubrano, S. Boulinguez, C. Pagès, V. Sibaud, C. Gomez-Roca, É Moyal, and N. Meyer. “[Treatment of patients with brain metastases from a melanoma].” Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique<\/i> 23, no. 2 (April 2019): 147–50. https:\/\/doi.org\/10.1016\/j.canrad.2018.05.006<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Kowalski-Chauvel, Aline, Valerie Gouaze-Andersson, Laurent Baricault, Elodie Martin, Caroline Delmas, Christine Toulas, Elizabeth Cohen-Jonathan-Moyal, and Catherine Seva. “Alpha6-Integrin Regulates FGFR1 Expression through the ZEB1\/YAP1 Transcription Complex in Glioblastoma Stem Cells Resulting in Enhanced Proliferation and Stemness.” Cancers<\/i> 11, no. 3 (March 22, 2019). https:\/\/doi.org\/10.3390\/cancers11030406<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Laprie, Anne, Soléakhéna Ken, Thomas Filleron, Vincent Lubrano, Laure Vieillevigne, Fatima Tensaouti, Isabelle Catalaa, et al. “Dose-Painting Multicenter Phase III Trial in Newly Diagnosed Glioblastoma: The SPECTRO-GLIO Trial Comparing Arm A Standard Radiochemotherapy to Arm B Radiochemotherapy with Simultaneous Integrated Boost Guided by MR Spectroscopic Imaging.” BMC Cancer<\/i> 19, no. 1 (February 21, 2019): 167. https:\/\/doi.org\/10.1186\/s12885-019-5317-x<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
De Barros, Amaury, Justine Attal, Margaux Roques, Julien Nicolau, Jean-Christophe Sol, Elizabeth Cohen-Jonathan-Moyal, and Franck-Emmanuel Roux. “Impact on Survival of Early Tumor Growth between Surgery and Radiotherapy in Patients with de Novo Glioblastoma.” Journal of Neuro-Oncology<\/i>, February 19, 2019. https:\/\/doi.org\/10.1007\/s11060-019-03120-3<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Malric, Laure, Sylvie Monferran, Caroline Delmas, Florent Arnauduc, Perrine Dahan, Sabrina Boyrie, Pauline Deshors, et al. “Inhibiting Integrin Β8 to Differentiate and Radiosensitize Glioblastoma-Initiating Cells.” Molecular Cancer Research: MCR<\/i> 17, no. 2 (2019): 384–97. https:\/\/doi.org\/10.1158\/1541-7786.MCR-18-0386<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n\n\n

[\/et_pb_toggle][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”448e09ae-9652-4ead-bc5f-152c7adf1202″ global_colors_info=”{}”]<\/p>\n

LES MEMBRES DE L\u2019\u00c9QUIPE<\/strong><\/h2>\n

[\/et_pb_text][et_pb_divider color=”#F19532″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_divider][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.16″ _module_preset=”default” max_width=”none” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

\n
<\/div>\n\n\n
\n
\n
\n
\n
\n
\"\"<\/a><\/div>\n
Gaelle Dormio<\/a><\/div>\n
Ing\u00e9nieur de laboratoire \/ laboratory engineer<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Lucas Robinet<\/a><\/div>\n
Doctorant \/ PhD student<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Ziad Kheil<\/a><\/div>\n
Doctorant \/ PhD student<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Augustin Le Naour<\/a><\/div>\n
Enseignant chercheur \/ University researcher<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Anouchka Modesto<\/a><\/div>\n
Clinicien Chercheur \/ Researcher hospital practitioner<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Emmanuelle Uro-Coste<\/a><\/div>\n
Hospitalo-Universitaire \/ University teacher hospital practitioner<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Luc Simon<\/a><\/div>\n
Clinicien Chercheur \/ Researcher hospital practitioner<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Sol\u00e8ne Evrard<\/a><\/div>\n
Enseignant chercheur \/ University researcher<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Laurent Baricault<\/a><\/div>\n
Enseignant chercheur \/ University researcher<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Anthony Lemari\u00e9<\/a><\/div>\n
Enseignant chercheur \/ University researcher<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Monique Courtade-Sa\u00efdi<\/a><\/div>\n
Hospitalo-Universitaire \/ University teacher hospital practitioner<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Elizabeth Moyal<\/a><\/div>\n
Hospitalo-Universitaire \/ University teacher hospital practitioner<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Laure Vieillevigne<\/a><\/div>\n
Enseignant chercheur \/ University researcher<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Tom Maillet<\/a><\/div>\n
Doctorant \/ PhD student<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Alexia Delbaere<\/a><\/div>\n
Chercheur Post-Doctorant \/ Post-Doc researcher<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Val\u00e9rie Gouaze-Andersson<\/a><\/div>\n
Chercheur statutaire \/ permanent scientist<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Sheraz Blas<\/a><\/div>\n
Doctorant \/ PhD student<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Pauline Deshors<\/a><\/div>\n
Chercheur Post-Doctorant \/ Post-Doc researcher<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Yvan Nicaise<\/a><\/div>\n
Ing\u00e9nieur de laboratoire \/ laboratory engineer<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Florent Arnauduc<\/a><\/div>\n
Technicien de laboratoire \/ Laboratory Technician<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n <\/div>\n<\/div><\/div>\n\n